2010 Annual Scientific Meeting and Exposition 2010 Annual ...

American Society of Hypertension2010 Annual Scientific Meetingand Exposition25th Anniversary, 1986–20102010 Program BookHilton New YorkSaturday, May 1, 2010 – Tuesday, May 4, 2010

in hypertensionMany hypertensive patients could benefit from a more comprehensiveRAAS inhibitor than an ARB to help achieve their BP goals 1-3A SMART VALTURNATIVEVisit Booth #1100to learn more about VALTURNAIndicationVALTURNA is indicated for the treatment of hypertension in adults.VALTURNA may be substituted for the titrated components. VALTURNA may be used inpatients whose blood pressure is not adequately controlled on aliskiren or any ARBmonotherapy and as initial therapy in patients who are likely to need multiplemedications to achieve their blood pressure goals.The choice of VALTURNA as initial therapy should be based on an assessment of potentialbenefits and risks. The decision to use a combination as initial therapy should beindividualized and should be shaped by considerations such as baseline blood pressure,target goal, and the incremental likelihood of achieving goal with a combination productcompared to monotherapy.Important Safety InformationWARNING: AVOID USE IN PREGNANCY: When pregnancy is detected, discontinueVALTURNA as soon as possible. When used in pregnancy during the second and thirdtrimesters, drugs that act directly on the renin-angiotensin-aldosterone system (RAAS)can cause injury and even death to the developing fetus. [See Warnings andPrecautions (5.1)]Angioedema: Angioedema of the face, extremities, lips, tongue, glottis, and/or larynx hasbeen reported in patients treated with aliskiren and has necessitated hospitalization andintubation. This may occur at any time during treatment and has occurred in patients withand without a history of angioedema with ACE inhibitors (ACEIs) or angiotensin receptorantagonists. Discontinue aliskiren immediately in patients who develop angioedema, andprovide appropriate therapy and monitoring until signs and symptoms resolve. Aliskirenshould not be readministered.Hypotension: In clinical trials, an excessive fall in blood pressure (hypotension) was seen rarely(

Valturna offers bothsuperior BP efficacy andmore comprehensive RAASinhibition thanValsartan tablets$15 co-pay for most patients**Valid for those patients with private insurance only.Not valid for patients whose prescription is paid for in part or in full under Medicare, Medicaid or any other federal orstate program, self-paying patients (those without private insurance), or for residents of MA. Limitations apply.This card is the property of Novartis and must be returned upon request.Novartis reserves the right to rescind, revoke, or amend this program without notice.Patient is responsible for reporting receipt of program rewards to any private insurer that pays for or reimburses anyAdvertisementpart of the prescriptions filled with this program.This offer will expire on 12/31/2010.Renal Considerations: Care should be used when dosing VALTURNA in patients with severe renalimpairment. As a consequence of inhibiting the RAAS, changes in renal function may be observedin susceptible individuals (eg, patients with renal artery stenosis or severe heart failure). Patientswith severe renal impairment were excluded from clinical trials with VALTURNA in hypertension.In studies of ACEIs in hypertensive patients with unilateral or bilateral renal artery stenosis,increases in serum creatinine or blood urea nitrogen have been reported. There has been nolong-term use of valsartan in patients with unilateral or bilateral renal artery stenosis, but aneffect similar to that seen with ACEIs should be anticipated.In patients with severe heart failure whose renal function may depend on the activity of the RAAS,treatment with ACEIs and angiotensin receptor antagonists has been associated with oliguria orprogressive azotemia and (rarely) with acute renal failure or death. Similar outcomes have beenreported with valsartan.Hepatic Considerations: As a majority of valsartan is eliminated in the bile, valsartan should beused with care in patients with mild-to-moderate hepatic impairment, including patients withbiliary obstructive disorders, because of lower valsartan clearance.Patients With CHF and Post-MI: Include assessment of renal function when evaluating patientswith heart failure or post-MI. Dosage reduction and/or discontinuation of a diuretic and/orvalsartan may be required.Hyperkalemia: In short-term controlled trials of VALTURNA, the incidence of hyperkalemia(K + >5.5 mEq/L) was about 1%-2% higher than with corresponding monotherapies or placebo.Electrolyte Imbalance: Periodic determinations of serum electrolytes to detect possibleelectrolyte imbalances is advised, particularly in patients at risk for hyperkalemia such as thosewith renal impairment.Cyclosporine: It is not recommended to prescribe VALTURNA for patients who also take cyclosporine.Furosemide: When aliskiren was coadministered with furosemide, the AUC and C max of furosemidewere reduced by about 30% and 50%, respectively. Patients receiving furosemide could find itseffect diminished after starting aliskiren.Common AEs: The most common adverse events (AEs) that occurred more frequentlywith VALTURNA than placebo were fatigue (2.6% vs 1.4%), nasopharyngitis (2.6% vs 2.2%),diarrhea (1.4% vs 0.9%), upper respiratory tract infection (1.4% vs 1.1%), urinary tractinfection (1.4% vs 0.6%), influenza (1.1% vs 0.2%), and vertigo (1.1% vs 0.3%).References: 1. Alderman MH, Cohen HW, Sealey JE,Laragh JH. Plasma renin activity levels in hypertensivepersons: their wide range and lack of suppression indiabetic and in most elderly patients. Am J Hypertens.2004;17(1):1-7. 2. Blumenfeld JD, Laragh JH. Reninsystem analysis: a rational method for the diagnosisand treatment of the individual patient with hypertension.Am J Hypertens. 1998;11(7):894-896. 3. VALTURNA[prescribing information]. East Hanover, NJ: NovartisPharmaceuticals Corporation; 2009.A smart option in BP lowering©2010 Novartis Printed in USA 3/10 C-VAT-100018

Valturna (aliskiren and valsartan, USP) TabletsInitial U.S. Approval: 2009BRIEF SUMMARY: Please see package insert for full prescribing information.WARNING: AVOID USE IN PREGNANCYWhen pregnancy is detected, discontinue Valturna as soon as possible. Whenused in pregnancy during the second and third trimesters, drugs that act directlyon the renin-angiotensin-aldosterone system can cause injury and death to thedeveloping fetus. [See Warnings and Precautions (5.1)].1 INDICATIONS AND USAGEValturna is indicated for the treatment of hypertension.Add-on TherapyA patient whose blood pressure is not adequately controlled with aliskiren aloneor valsartan (or another angiotensin receptor blocker) alone may be switched tocombination therapy with Valturna.Replacement TherapyValturna may be substituted for the titrated components.Initial TherapyValturna may be used as initial therapy in patients who are likely to need multipledrugs to achieve their blood pressure goals.The choice of Valturna as initial therapy should be based on an assessment ofpotential benefits and risks.Patients with Stage 2 hypertension are at a relatively high risk for cardiovascularevents (such as strokes, heart attacks, and heart failure), kidney failure, andvision problems, so prompt treatment is clinically relevant. The decision to use acombination as initial therapy should be individualized and should be shaped byconsiderations such as baseline blood pressure, the target goal, and the incrementallikelihood of achieving goal with a combination compared to monotherapy.Individual blood pressure goals may vary based upon the patient’s risk.Data from the high-dose multifactorial study [see Clinical Studies (14) in the fullprescribing information] provide estimates of the probability of reaching a targetblood pressure with Valturna compared to aliskiren or valsartan monotherapy.The figures below provide estimates of the likelihood of achieving systolic ordiastolic blood pressure control with Valturna 300/320 mg, based upon baselinesystolic or diastolic blood pressure. The curve of each treatment group was estimatedby logistic regression modeling. The estimated likelihood at the right tailof each curve is less reliable because of a small number of subjects with highbaseline blood pressures.Figure 1: Probability of Achieving Systolic Blood Pressure (SBP)

Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP)

4 CONTRAINDICATIONSNone.5 WARNINGS AND PRECAUTIONS5.1 Fetal/Neonatal Morbidity and MortalityValturna can cause fetal harm when administered to a pregnant woman. If thisdrug is used during pregnancy, or if a patient becomes pregnant while takingthis drug, apprise the patient of the potential hazard to the fetus.Drugs that act directly on the renin-angiotensin-aldosterone system can causefetal and neonatal morbidity and death when administered to pregnant women. Ifthis drug is used during pregnancy, or if the patient becomes pregnant whiletaking this drug, apprise the patient of the potential hazard to the fetus [see Usein Specific Populations (8.1)]. In several dozen published cases, use of ACEinhibitors during the second and third trimesters of pregnancy was associatedwith fetal and neonatal injury, including hypotension, neonatal skull hypoplasia,anuria, reversible or irreversible renal failure, and death. In addition, first trimesteruse of ACE inhibitors has been associated with birth defects in retrospective data.5.2 Head and Neck AngioedemaAliskirenAngioedema of the face, extremities, lips, tongue, glottis and/or larynx has beenreported in patients treated with aliskiren and has necessitated hospitalizationand intubation. This may occur at any time during treatment and has occurred inpatients with and without a history of angioedema with ACE inhibitors or angiotensinreceptor antagonists. If angioedema involves the throat, tongue, glottisor larynx, or if the patient has a history of upper respiratory surgery, airwayobstruction may occur and be fatal. Patients who experience these effects, evenwithout respiratory distress, require prolonged observation since treatment withantihistamines and corticosteroids may not be sufficient to prevent respiratoryinvolvement. Prompt administration of subcutaneous epinephrine solution1:1000 (0.3 to 0.5 mL) and measures to ensure a patent airway may be necessary.Discontinue aliskiren immediately in patients who develop angioedema and donot readminister.5.3 HypotensionAn excessive fall in blood pressure (hypotension) was rarely seen (

potential for other drugs acting on the renin-angiotensin-aldosterone system toincrease serum creatinine and blood urea nitrogen are not available.ValsartanIn studies of ACE inhibitors in hypertensive patients with unilateral or bilateralrenal artery stenosis, increases in serum creatinine or blood urea nitrogen havebeen reported. In a 4-day trial of valsartan in 12 hypertensive patients with unilateralrenal artery stenosis, no significant increases in serum creatinine or bloodurea nitrogen were observed. There has been no long-term use of valsartan inpatients with unilateral or bilateral renal artery stenosis, but an effect similar tothat seen with ACE inhibitors should be anticipated.As a consequence of inhibiting the renin-angiotensin-aldosterone system, changesin renal function may occur particularly in volume depleted patients. In patientswith severe heart failure whose renal function may depend on the activity of therenin-angiotensin-aldosterone system, treatment with angiotensin-convertingenzyme inhibitors and angiotensin receptor antagonists has been associatedwith oliguria or progressive azotemia and (rarely) with acute renal failure or death.Similar outcomes have been reported with valsartan.5.5 Patients with Hepatic ImpairmentValsartanAs the majority of valsartan is eliminated in the bile, patients with mild-tomoderatehepatic impairment, including patients with biliary obstructive disorders,showed lower valsartan clearance (higher AUCs).5.6 Patients with Congestive Heart Failure and Post-Myocardial InfarctionValsartanSome patients with heart failure have developed increases in blood urea nitrogen,serum creatinine, and potassium on valsartan. These effects are usually minorand transient, and they are more likely to occur in patients with pre-existingrenal impairment. Dosage reduction and/or discontinuation of the diuretic and/orvalsartan may be required. In the Valsartan Heart Failure Trial, in which 93% ofpatients were on concomitant ACE inhibitors, treatment was discontinued forelevations in creatinine or potassium (total of 1.0% on valsartan vs. 0.2% onplacebo). In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), discontinuationdue to various types of renal dysfunction occurred in 1.1% ofvalsartan-treated patients and 0.8% of captopril-treated patients. Include assessmentof renal function when evaluating patients with heart failure or postmyocardialinfarction.5.7 Serum Electrolyte AbnormalitiesValturnaIn the short-term controlled trials of various doses of Valturna, the incidence ofhyperkalemia (serum potassium >5.5 mEq/L) was about 1%-2% higher in thecombination treatment group compared with the monotherapies aliskiren andvalsartan, or with placebo.In a long-term, uncontrolled study with median treatment duration of about oneyear, about 4% of the patients had at least one serum potassium >5.5 mEq/L atsome time during the study; about 0.8% of patients discontinued study treatmentand had a high serum potassium at some point during the study. Patientswith hyperkalemia were older (median age 65 vs. 55) with slightly lower meanbaseline estimated creatinine clearance compared to patients without hyperkalemia.While about 25% of the hyperkalemic episodes occurred in the first twomonths, other initial episodes were reported throughout the study.Periodic determinations of serum electrolytes to detect possible electrolyteimbalances is advised, particularly in patients at risk for hyperkalemia such asthose with renal impairment.Caution is advised with concomitant use of Valturna with potassium-sparingdiuretics, potassium supplements, salt substitutes containing potassium, orother drugs that increase potassium levels may lead to increases in serumpotassium.5.8 Renal Artery StenosisAliskirenNo data are available on the use of aliskiren in patients with unilateral or bilateralrenal artery stenosis or stenosis of the artery to a solitary kidney.ValsartanIn studies of ACE inhibitors in hypertensive patients with unilateral or bilateralrenal artery stenosis, increases in serum creatinine or blood urea nitrogen have

een reported. In a 4-day trial of valsartan in 12 hypertensive patients with unilateralrenal artery stenosis, no significant increases in serum creatinine or bloodurea nitrogen were observed. There has been no long-term use of valsartan inpatients with unilateral or bilateral renal artery stenosis, but an effect similar tothat seen with ACE inhibitors should be anticipated.5.9 CyclosporineAliskirenWhen aliskiren was given with cyclosporine, the blood concentrations of aliskirenwere significantly increased. Concomitant use of aliskiren with cyclosporine isnot recommended [see Drug Interactions (7)].6 ADVERSE REACTIONS6.1 Clinical Studies ExperienceThe following serious adverse reactions are discussed in greater detail in othersections of the label:• Risk of fetal/neonatal morbidity and mortality [see Warnings and Precautions(5.1)]• Head and neck angioedema [see Warnings and Precautions (5.2)]• Hypotension [see Warnings and Precautions (5.3)]Because clinical trials are conducted under widely varying conditions, adversereaction rates observed in the clinical trials of a drug cannot be directly comparedto rates in clinical trials of another drug and may not reflect the ratesobserved in practice.ValturnaValturna has been evaluated for safety in more than 1,225 patients, includingover 316 patients for over 1 year. In placebo-controlled clinical trials, discontinuationof therapy because of a clinical adverse event (including uncontrolledhypertension) occurred in 1.4% of patients treated with Valturna versus 2.7%of patients given placebo.Adverse events in placebo-controlled trials that occurred in at least 1% of patientstreated with Valturna and at a higher incidence than placebo included fatigue(2.6% vs. 1.4%), nasopharyngitis (2.6% vs. 2.2%), diarrhea (1.4% vs 0.9%),upper respiratory tract infection (1.4% vs. 1.1%), urinary tract infection (1.4%vs. 0.6%), influenza (1.1% vs 0.2%), and vertigo (1.1% vs. 0.3%).Hyperkalemia has been observed as a serum electrolyte abnormality in Valturnaclinical trials [see Warnings and Precautions (5.7)].AliskirenAliskiren has been evaluated for safety in 6,460 patients, including 1,740 treatedfor longer than 6 months, and 1,250 for longer than 1 year. In placebo-controlledclinical trials, discontinuation of therapy because of a clinical adverse event,including uncontrolled hypertension occurred in 2.2% of patients treated withaliskiren, versus 3.5% of patients given placebo.Two cases of angioedema with respiratory symptoms were reported with aliskirenuse in the clinical studies. Two other cases of periorbital edema without respiratorysymptoms were reported as possible angioedema and resulted in discontinuation.The rate of these angioedema cases in the completed studies was 0.06%.In addition, 26 other cases of edema involving the face, hands, or whole bodywere reported with aliskiren use, including 4 leading to discontinuation.In the placebo-controlled studies, however, the incidence of edema involving theface, hands, or whole body was 0.4% with aliskiren compared with 0.5% withplacebo. In a long-term active-controlled study with aliskiren and HCTZ arms,the incidence of edema involving the face, hands, or whole body was 0.4% inboth treatment arms.Aliskiren produces dose-related gastrointestinal (GI) adverse reactions. Diarrheawas reported by 2.3% of patients at 300 mg, compared to 1.2% in placebopatients. In women and the elderly (age ≥65) increases in diarrhea rates wereevident starting at a dose of 150 mg daily, with rates for these subgroups at150 mg similar to those seen at 300 mg for men or younger patients (all ratesabout 2%). Other GI symptoms included abdominal pain, dyspepsia, and gastroesophagealreflux, although increased rates for abdominal pain and dyspepsiawere distinguished from placebo only at 600 mg daily. Diarrhea and other GIsymptoms were typically mild and rarely led to discontinuation.Aliskiren was associated with a slight increase in cough in the placebo-controlledstudies (1.1% for any aliskiren use vs. 0.6% for placebo). In active-controlledtrials with ACE inhibitor (ramipril, lisinopril) arms, the rates of cough for the

aliskiren arms were about one-third to one-half the rates in the ACE inhibitorarms.Other adverse reactions with increased rates for aliskiren compared to placeboincluded rash (1% vs. 0.3%), elevated uric acid (0.4% vs. 0.1%), gout (0.2% vs.0.1%), and renal stones (0.2% vs. 0%).Single episodes of tonic-clonic seizures with loss of consciousness were reportedin two patients treated with aliskiren in the clinical trials. One patient had predisposingcauses for seizures and had a negative electroencephalogram (EEG) andcerebral imaging following the seizures; for the other patient, EEG and imagingresults were not reported. Aliskiren was discontinued and there was no rechallengein either case.The following adverse events occurred in placebo-controlled clinical trials at anincidence of more than 1% of patients treated with aliskiren, but also occurredat about the same or greater incidence in patients receiving placebo: headache,nasopharyngitis, dizziness, fatigue, upper respiratory tract infection, back painand cough.No clinically meaningful changes in vital signs or in ECG (including QTc interval)were observed in patients treated with aliskiren.ValsartanValsartan has been evaluated for safety in more than 4,000 hypertensive patientsin clinical trials, including over 400 treated for over 6 months, and more than160 for over 1 year.In trials in which valsartan was compared to an ACE inhibitor with or withoutplacebo, the incidence of dry cough was significantly greater in the ACE inhibitorgroup (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%).In a 129 patient trial limited to patients who had had dry cough when they hadpreviously received ACE inhibitors, the incidences of cough in patients whoreceived valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively(p0.2% of patients in controlledclinical trials with valsartan are:Body as a Whole: allergic reaction, astheniaMusculoskeletal: muscle crampsNeurologic and Psychiatric: paresthesiaRespiratory: sinusitis, pharyngitisUrogenital: impotenceOther reported events seen less frequently in clinical trials were: angioedema.Adverse reactions reported for valsartan for indications other than hypertensionmay be found in the prescribing information for Diovan.6.2 Clinical Laboratory Test AbnormalitiesRBC count, hemoglobin and hematocrit:Small mean decreases from baseline were seen in RBC count, hemoglobin andhematocrit in both monotherapies and combination therapy. These changeswere small, but changes in hemoglobin were slightly more pronounced with thecombination therapy (-0.26 g/dL) than with monotherapy regimens (-0.04 g/dLin aliskiren or -0.13 g/dL in valsartan) or placebo (+0.07 g/dL).Blood Urea Nitrogen (BUN)/Creatinine:Elevations in BUN (>40 mg/dL) and creatinine (>2.0 mg/dL) in any treatmentgroup were less than 1.0%. For creatinine, 0.5% (3/599) of patients on combinationtreatment had a creatinine level >1.5 mg/dL at the end of the study and a30% increase from baseline compared to none in either monotherapy or placebo.Serum Electrolytes: See Warnings and Precautions (5.7)6.3 Post-Marketing ExperienceThe following adverse reactions have been reported in aliskiren post-marketingexperience. Because these reactions are reported voluntarily from a populationof uncertain size, it is not always possible to reliably estimate their frequency orestablish a causal relationship to drug exposure.Hypersensitivity: angioedema requiring airway management and hospitalizationPeripheral edema

7 DRUG INTERACTIONSNo drug interaction studies have been conducted with Valturna and other drugs,although studies with the individual aliskiren and valsartan components aredescribed below.AliskirenEffects of Other Drugs on AliskirenBased on in vitro studies, aliskiren is metabolized by CYP 3A4.Irbesartan: Coadministration of irbesartan reduced aliskiren C max up to 50% aftermultiple dosing.P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major effluxsystem involved in absorption and disposition of aliskiren in preclinical studies.The potential for drug interactions at the Pgp site will likely depend on the degreeof inhibition of this transporter. Coadministration of aliskiren with Pgp substratesor weak to moderate inhibitors such as atenolol, digoxin, and amlodipine did notresult in clinically relevant interactions.Atorvastatin: Coadministration of atorvastatin, a weak Pgp inhibitor, resulted inabout a 50% increase in aliskiren C max and AUC after multiple dosing.Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole, a moderatePgp inhibitor, with aliskiren resulted in approximate 80% increase in plasma levelsof aliskiren. A 400-mg once-daily dose was not studied but would be expectedto increase aliskiren blood levels further.Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine, a potentPgp inhibitor, with 75 mg aliskiren resulted in an approximately 2.5-fold increasein C max and 5-fold increase in AUC of aliskiren. Concomitant use of aliskiren withcyclosporine is not recommended.Verapamil: Coadministration of 240 mg of verapamil, a moderate Pgp inhibitor,with 300 mg aliskiren resulted in an approximately 2-fold increase in C max andAUC of aliskiren. However, no dosage adjustment is necessary.Drugs with no clinically significant effects: Coadministration of lovastatin,atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,valsartan, metformin and amlodipine did not result in clinically significantincreases in aliskiren exposure.Effects of Aliskiren on Other DrugsAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19,2D6, 2E1, and CYP 3A) or induce CYP 3A4.Furosemide: When aliskiren was coadministered with furosemide, the AUC andC max of furosemide were reduced by about 30% and 50%, respectively. Patientsreceiving furosemide could find its effect diminished after starting aliskiren.Drugs with no clinically significant effects: Coadministration of aliskiren did notsignificantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine,metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not beenevaluated.ValsartanNo clinically significant pharmacokinetic interactions were observed whenvalsartan was coadministered with aliskiren, amlodipine, atenolol, cimetidine,digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. Thevalsartan-atenolol combination was more antihypertensive than either component,but it did not lower the heart rate more than atenolol alone.Warfarin: Coadministration of valsartan and warfarin did not change the pharmacokineticsof valsartan or the time-course of the anticoagulant properties ofwarfarin.CYP 450 Interactions: In vitro metabolism studies have indicated that CYP450mediated drug interactions between valsartan and coadministered drugs areunlikely because of low extent of metabolism [see Pharmacokinetics – Valsartan(12.3) in the full prescribing information].Transporters: The results from an in vitro study with human liver tissue indicatethat valsartan is a substrate of the hepatic uptake transporter OATP1B1 and thehepatic efflux transporter MRP2. Coadministration of inhibitors of the uptaketransporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increasethe systemic exposure to valsartan.

As with other drugs that block angiotensin II or its effects, concomitant use ofpotassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassiumsupplements, or salt substitutes containing potassium may lead to increasesin serum potassium and in heart failure patients to increases in serum creatinine.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Category D [see Warnings and Precautions (5.1)].Valturna contains both aliskiren (a direct renin inhibitor) and valsartan (an angiotensinII receptor blocker). When administered during the second or third trimesterof pregnancy, drugs that act directly on the renin-angiotensin-aldosterone systemcan cause fetal and neonatal morbidity and death. Valturna can cause fetalharm when administered to a pregnant woman. If this drug is used during pregnancy,or if the patient becomes pregnant while taking this drug, apprise thepatient of the potential hazard to the fetus.Angiotensin II receptor antagonists, like valsartan, and angiotensin-convertingenzyme (ACE) inhibitors exert similar effects on the renin-angiotensin-aldosteronesystem. In several dozen published cases, ACE inhibitor use during the secondand third trimesters of pregnancy was associated with fetal and neonatal injury,including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversiblerenal failure, and death. Oligohydramnios was also reported, presumably fromdecreased fetal renal function. In this setting, oligohydramnios was associatedwith fetal limb contractures, craniofacial deformation, and hypoplastic lungdevelopment. Prematurity, intrauterine growth retardation, and patent ductusarteriosus were also reported, although it is not clear whether these occurrenceswere due to exposure to the drug. In addition, first trimester use of ACE inhibitors,a specific class of drugs acting on the renin-angiotensin-aldosterone system,has been associated with a potential risk of birth defects in retrospective data.When pregnancy occurs in a patient using Valturna, discontinue Valturna treatmentas soon as possible. Inform the patient about potential risks to the fetusbased on the time of gestational exposure to Valturna (first trimester only orlater). If exposure occurs beyond the first trimester, perform an ultrasoundexamination.In rare cases when another antihypertensive agent cannot be used to treat thepregnant patient, perform serial ultrasound examinations to assess the intraamnioticenvironment. Routine fetal testing with non-stress tests, biophysicalprofiles, and/or contraction stress tests may be appropriate based on gestationalage and standards of care in the community. If oligohydramnios occurs in thesesituations, individualized decisions about continuing or discontinuing Valturnatreatment and about pregnancy management should be made by the patient, herphysician, and experts in the management of high risk pregnancy. Patients andphysicians should be aware that oligohydramnios may not appear until after thefetus has sustained irreversible injury.Closely observe infants with histories of in utero exposure to Valturna for hypotension,oliguria, and hyperkalemia. If oliguria occurs, these infants may requireblood pressure and renal perfusion support. Exchange transfusion or dialysismay be required to reverse hypotension or support decreased renal function.No reproductive toxicity studies have been conducted with the combination ofaliskiren and valsartan. However, these studies have been conducted foraliskiren as well as valsartan alone [see Nonclinical Toxicology (13) in the fullprescribing information].8.3 Nursing MothersIt is not known whether aliskiren is excreted in human milk, but aliskiren wassecreted in the milk of lactating rats. It is not known whether valsartan is excretedin human milk. Valsartan was excreted into the milk of lactating rats; however,animal breast milk drug levels may not accurately reflect human breast milk levels.Because of the potential for adverse effects on the nursing infant, a decisionshould be made whether to discontinue nursing or discontinue the drug, takinginto account the importance of the drug to the mother.8.4 Pediatric UseSafety and effectiveness of Valturna in pediatric patients have not been established.

8.5 Geriatric UseIn the short-term controlled clinical trials of Valturna, 99 (15.9%) patientstreated with Valturna were ≥65 years and 14 (2.2%) were ≥75 years.No overall differences in safety or effectiveness were observed between thesesubjects and younger subjects, and other reported clinical experience has notidentified differences in responses between the elderly and younger patients, butgreater sensitivity of some older individuals cannot be ruled out.10 OVERDOSAGEAliskirenLimited data are available related to overdosage in humans. The most likelymanifestation of overdosage would be hypotension. If symptomatic hypotensionoccurs, provide supportive treatment.ValsartanLimited data are available related to overdosage in humans. The most likely effectof overdose with valsartan would be hypotension and tachycardia; bradycardiacould occur from parasympathetic (vagal) stimulation. Depressed level of consciousness,circulatory collapse and shock have been reported. If symptomatichypotension occurs, provide supportive treatment.Valsartan is not removed from the plasma by hemodialysis.Valsartan was without grossly observable adverse effects at single oral doses upto 2000 mg/kg in rats and up to 1000 mg/kg in marmosets, except for the salivationand diarrhea in the rat and vomiting in the marmoset at the highest dose(60 and 31 times, respectively, the maximum recommended human dose on amg/m 2 basis). (Calculations assume an oral dose of 320 mg/day and a 60-kgpatient.)16 STORAGEStore at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) in original container.[See USP Controlled Room Temperature.]Protect from moisture.Dispense in tight container (USP).REV: FEBRUARY 2010 T2010-12Manufactured by:Novartis Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Pharmaceuticals CorporationEast Hanover, New Jersey 07936©Novartis

American Society of Hypertension2010 Annual Scientific Meetingand Exposition25th Anniversary, 1986–20102010 Program BookHilton New YorkSaturday, May 1, 2010 – Tuesday, May 4, 2010

Past Presidents of the AmericanSociety of Hypertension, Inc.John H. Laragh, MDFirst PresidentEdward G. Biglieri, MD President 1988 – 1990Jay N. Cohn, MD President 1990 – 1992Louis Tobian, MD President 1992 – 1994Barry M. Brenner, MD President 1994 – 1995Lawrence R. Krakoff, MD President 1995 – 1996Michael H. Alderman, MD President 1996 – 1998Michael A. Weber, MD President 1998 – 2000Theodore W. Kurtz, MD President 2000 – 2002Haralambos Gavras, MD President 2002 – 2004Thomas D. Giles, MD President 2004 – 2006Jean E. Sealey, DSC President May 19, 2006Suzanne Oparil, MD President 2006 – 2008

Program Color KeyThe pages of this Program Book are color-coded to match theProgram at a Glance (pages 43–46) and serve as a quick, identifiablereference of the type of educational activity or event taking place.Scientific Sessions*1 Pathobiology Track 2 Translational Track 3 Therapy TrackHypertension Highlights 2010Special EventMeet the Expert SessionsHypertension for the Primary Care ClinicianClinical Case DiscussionsPoster Sessions*1 Pathobiology Track 2 Translational Track 3 Therapy TrackSatellite SymposiaHypertension Resource Pavilion*The ASH Twenty-Fifth Annual Scientific Meeting isorganized around three (3) concurrent themes:• Pathobiology of Hypertension• Translational Issues in Hypertension• Therapy of HypertensionSessions in each of the three (3) themes (or tracks) are labeledthroughout the Program Book to be easily identifiable. Inaddition, posters are also grouped by category and then bytheme within the category.Future Meeting DatesSaturday, May 21, 2011 to Tuesday, May 24, 2011Hilton New York, New York, NYSaturday, May 18, 2012 to Tuesday, May 22, 2012Hilton New York, New York, NYWednesday, May 15, 2013 to Saturday, May 18, 2013San Francisco Marriott, San Francisco, CA

Letter from the President continued• Plenary Session II – May 3, 2010This session will include the Awards Session as well as state-ofthe-artlectures. The Irvine Page Award will be presented to Dr.Donald Heistad, the Marvin Moser Award will be presented to Dr.Joel Handler and the Young Scholar Award will be presented to Dr.Bina Joe. Dr. S. Ananth Karumanchi will present a lecture on the“Update on Preeclampsia;” Dr. Neil Stone will discuss “Managementand Regression of Atherosclerosis,” and Dr. Jeffrey Friedmanwill discuss “Leptin and the New Biology of Obestiy.”• What the Hypertension Specialist Should Know – May 2 to May4, 2010This series will feature presentations on topics important to theHypertension Specialist. Following many of the presentations willbe a “Meet the Expert” session on the same topic allowing participantsto engage in further dialogue with the speakers.• Young Investigator-in-Training Abstract Competition – May 1,2010Trainees submitting the highest ranking abstracts to the meetingwill present their work orally in a special session and compete forcash prizes. This highlighted session is consistent with ASH’s goalto foster and facilitate the training of young and new investigatorsin hypertension.• Hypertension for the Primary Care Clinician – May 2, 2010This program will address commonplace questions that face cliniciansin day-to-day care of patients with hypertension.• Special Sessions jointly sponsored by Society-related organizationswill enrich the knowledge base and foster new interactionsfor ASH members and other attendees. ASH is partnering withthe International Society on Hypertension in Blacks (ISHIB),the European Society of Hypertension (ESH), the Inter-American Society of Hypertension (IASH), the Association forResearch into Arterial Structure and Physiology (ARTERY), theAHA Council for High Blood Pressure Research (HBPR), theArgentine Society of Hypertension (SAHA), the Consortium forSoutheastern Hypertension Control (COSEHC) and the ChinaSocial Worker’s Association Vascular Protection Committee.The Society will also sponsor industry-supported Satellite Symposiawhich will introduce novel approaches to antihypertensive therapy.The Exposition Pavilion will host many informative scientific, technical,periodical and book exhibits designed to support you in yourmission of providing the latest in care for your hypertensive patients.Come visit the Innovations Theater, a new feature in the HypertensionResource Pavilion.We look forward to seeing you in New York.Sincerely,Henry R. Black, MDPresident, American Society of Hypertension18

General InformationThis program book has been underwritten by Novartis PharmaceuticalsCorporation.EducationProgram ObjectivesIn keeping with the purpose of the American Society of Hypertension,Inc. (ASH), the Twenty-Fifth Annual Scientific Meeting is designed toencourage and promote the development, advancement, and exchangeof fair and balanced and evidence-based information regarding theresearch, diagnosis and treatment of hypertension and related cardiovasculardiseases, with the goal of improved patient care and health.The sessions will:• Present and examine new findings on the physiology, pathophysiology,epidemiology, diagnosis, and management of hypertensionand related conditions.• Review current state-of-the-art advances in managing particulargroups of patients.• Evaluate specific treatment modalities and pharmacologicalagents.The Society has asked each Scientific Session Presenter to include alearning objective at the beginning of their presentation.Target AudiencePhysicians, scientists, pharmacists, physician assistants, nurses andother health care professionals with an interest in the mechanisms ormanagement of hypertension and related diseases will benefit fromattending Scientific Sessions, Satellite Symposia, Meet-the-ExpertSessions, Case Discussions, Poster Sessions and the ScientificExposition.Continuing Education CreditThe American Society of Hypertension, Inc. is accredited by theAccreditation Council for Continuing Medical Education to providecontinuing medical education for physicians. The American Society ofHypertension, Inc. designates this educational activity for a maximumof 32 AMA PRA Category 1 Credits. Each physician should claimcredit commensurate with the extent of their participation in theactivity.Conflict of Interest DisclosureThe American Society of Hypertension, Inc. strives to ensure balance,independence, objectivity, and scientific rigor in all of its educationalprograms. All faculty members participating in this program havebeen required to disclose any real or apparent conflict(s) of interestthat may have a direct bearing on the subject matter of the session inwhich they are participating. This includes relationships in place atthe time of the meeting or in the twelve (12) months preceding themeeting, with pharmaceutical companies, biomedical device manufacturers,or other corporations whose products or services are relatedto the subject matter of the presentation topic.The intent of the policy is to identify openly any conflict of interest sothat the listeners may form their own judgments about the presentationswith the full disclosure of the facts. All Conflict of Interest DisclosureStatements are available to meeting attendees in the program19

General Information continuedbook on pages 160-167 and at the ASH Information/CME/MembershipDesk located on the Third Floor Promenade.Disclosures not available at the time the program book was printedare included as a separate listing in the registrant bags.Dagger (†) denotes that the abstract presenting author has relateddisclosure information. Please reference the full Disclosure Index atthe ASH Information/CME/Membership Desk located on the ThirdFloor Promenade and in the Author Index of The Journal of ClinicalHypertension 2010 Abstract Supplement.20

General Information continuedHilton New York Floor LayoutFor detailed floor plans of Exhibition and Poster Areas, see pages 187 & 188.For detailed floor plans of Hilton New York, see pages 209 – 211.21

General Information continuedMeeting Venue/Headquarters HotelHilton NY1335 Avenue of the AmericasNew York, NY 10019Phone: 1-212-586-7000Fax: 1-212-315-1374Meeting RegistrationRegistration for the Meeting will be held on the Third FloorPromenade.Registration Desk HoursGroupsFriday, April 3012:00 PM to 4:00 PMIndividualsFriday, April 30Saturday, May 1Sunday, May 2Monday, May 3Tuesday, May 44:00 PM to 9:00 PM6:30 AM to 5:30 PM5:30 AM to 8:00 PM5:30 AM to 7:30 PM7:00 AM to 11:00 AMASH Membership BoothThe ASH membership booth will be located on the Third FloorPromenade.Membership Booth HoursSaturday, May 1Sunday, May 2Monday, May 3Tuesday, May 49:00 AM to 5:00 PM9:00 AM to 5:00 PM9:00 AM to 5:00 PM9:00 AM to 12:00 PMProgram InformationHypertension Highlights 2010Hypertension Highlights is a full-day program dedicated to educatingclinicians and scientists about some of the most interesting, controversialand evolving topics in the field. The program includes stateof-the-artpresentations on various aspects of disease mechanisms,management of special populations, and the future of hypertensionpractice guidelines. It is an ideal update for Hypertension Specialistsand those wishing to become specialists in the field.Saturday, May 1, 20108:00 AM to 3:00 PMASH Plenary SessionsPlenary sessions feature engaging lectures by keynote speakers. Thetopics are of broad general interest.Sunday, May 2, 201012:00 PM to 3:10 PMMonday, May 3, 20101:15 PM to 4:15 PM22

General Information continuedASH Scientific SessionsThe Scientific Sessions will address basic and clinical science issuesover a wide range of topics.Sunday, May 2, 20103:30 PM to 4:30 PM6:00 PM to 7:30 PMMonday, May 3, 20108:00 AM to 9:30 AM10:00 AM to 11:30 AMTuesday, May 4, 20107:45 AM to 9:30 AM10:55 AM to 12:15 PMWhat the Hypertension Specialist Should KnowBack by popular demand, this series will feature presentations on topicsimportant to the Hypertension Specialist. Following the presentationswill be a “Meet the Expert” session on the same topic allowingparticipants to engage in further dialogue with the speakers.Sunday, May 2, 20103:30 PM to 4:30 PMMonday, May 3, 201011:00 AM to 11:30 AMTuesday, May 4, 201010:55 AM to 12:15 PMHypertension for the Primary Care ClinicianThe Hypertension for the Primary Care Clinician program will addresscommonplace questions that face clinicians inday-to-day care of patients with hypertension.Sunday, May 2, 20107:30 AM to 11:40 AMSpecial SessionsSpecial Sessions will address timely topics including Physician IndustryRelations; Pathophysiology of Hypertension and Public Healthand Hypertension: Can Population Based Strategies Work?; TheEmerging Role of Aldosterone in Hypertension and ALLHAT: LongtermOutcomes of Drug Treatment in High CHD Risk HypertensivePatients.Saturday, May 1, 2010Sunday, May 2, 20103:30 PM to 5:00 PM8:00 AM to 9:30 AM10:00 AM to 11:30 AMJoint SessionsSpecial Sessions jointly sponsored by Society-related organizationswill enrich the knowledge base and foster new interactions for ASHmembers and other attendees. ASH is partnering with the InternationalSociety on Hypertension in Blacks (ISHIB), the European Societyof Hypertension (ESH), the Inter-American Society of Hypertension(IASH), the Association for Research into Arterial Structure andPhysiology (ARTERY), the AHA Council for High Blood PressureResearch (HBPR), the Argentine Society of Hypertension (SAHA),the Consortium for Southeastern Hypertension Control (COSEHC)and the China Social Worker’s Association Vascular Protection Committee.Saturday, May 1, 2010Sunday, May 2, 2010Monday, May 3, 2010Tuesday, May 4, 20103:30 PM to 5:00 PM8:00 AM to 9:00 AM3:30 PM to 4:30 PM6:00 PM to 7:30 PM10:00 AM to 11:30 AM8:00 AM to 9:30 AM23

General Information continued2010 ASH Hypertension Community OutreachASH is proud to present its 3rd Annual Hypertension CommunityOutreach Initiative in conjunction with the Twenty-Fifth AnniversaryAnnual Scientific Meeting & Exposition. In 2008, ASH began theHypertension Community Outreach Initiative in New Orleans withgreat success. We continued the Outreach Initiative in San Franciscoin 2009.In 2010 the Outreach Initiative will provide hypertension screeningand education targeting local New York underinsured and uninsuredpopulation segments. ASH will educate the residents of the New Yorkcommunity about hypertension and provide them with products andtools to take home. This promises to be an exceptional program.ASH has recently published "Blood Pressure and Your Health" apatient information pamphlet written in Both English and Spanish.Visit the ASH Outreach booth in the Hypertension Resource Pavilionfor copies.Meet the Expert SessionsThese sessions provide an opportunity for interaction and consultationwith professionals who have expertise in a specific area.Attendees will be admitted on a first-come, first-served basis.Sunday, May 2, 201010:00 AM to 11:00 AM4:45 PM to 5:45 PMMonday, May 3, 201011:45 AM to 12:45 PMClinical Case DiscussionsHard-to-treat clinical cases will be presented with ample opportunityfor audience participation.Sunday, May 2, 201010:00 AM to 11:00 AMMonday, May 3, 201011:45 AM to 12:45 PMAbstract PresentationsAuthors will showcase their research in oral or poster format. Posterviewing will take place at the following times:Saturday, May 1, 20105:00 PM to 6:00 PMSunday, May 2, 20104:45 PM to 5:45 PMMonday, May 3, 20104:15 PM to 5:15 PMFeatured Poster DiscussionFaculty members will publicly discuss a select group of posters withconference participants.Sunday, May 2, 20104:45 PM to 5:45 PMSatellite SymposiaThe latest information regarding new concepts, treatments, devicesand techniques will be addressed in industry-supported Satellite Symposiathroughout the meeting.Sunday, May 2, 20106:00 AM to 7:30 AM8:00 PM to 9:30 PMMonday, May 3, 20106:00 AM to 7:30 AM7:30 PM to 9:00 PM24

General Information continuedASH Hypertension Resource Pavilion – Technical ExhibitsThe ASH Hypertension Resource Pavilion located in Americas HallI, will be the center for all Technical Exhibits and the InnovationsTheater. Please come to the Welcome Reception, lunches, and highteas in the Hypertension Resource Pavilion. Innovations Theaters willalso take place in the Pavilion.Saturday, May 1, 20103:00 PM to 7:00 PMOpening Reception5:00 PM to 7:00 PMSunday, May 2, 2010High Tea9:00 AM to 12:00 PMand 3:30 PM to 6:45 PM4:45 PM to 5:45 PMMonday, May 3, 2010High Tea9:00 AM to 1:00 PMand 3:00 PM to 5:15 PM4:15 PM to 5:15 PMASH Hypertension Resource Pavilion – Innovations TheaterSaturday, May 1, 20105:30 PM to 6:30 PM Novartis Pharmaceuticals, Inc.Sunday, May 2, 201010:00 AM to 11:00 AM Novartis Pharmaceuticals, Inc.4:45 PM to 5:45 PM Forest Pharmaceuticals, Inc.Monday, May 3, 201011:45 AM to 12:45 PM Daiichi Sankyo, Inc.ASH Hypertension Resource Pavilion –Hypertension Outreach – Blood Pressure for DocsCome to the Pavilion and check your numbers.Multimedia CD-ROM of Scientific MeetingAudio recordings on CD-ROM including select speaker presentationsin PDF format of the Scientific Sessions and Satellite Symposia will befor sale through AVMG in the Third Flood Promenade. You may alsodownload the individual sessions in MP3 format to your computerpost-conference. Visit our e-commerce store at www.ash-us.org.ASH Policy Regarding Videotaping, Photography andAudio TapingNo individual is permitted to film, videotape, photograph and/oraudiotape meeting symposia, scientific sessions, posters or exhibitswithout prior written approval from the American Society ofHypertension, Inc.25

General Information continuedASH Information/CME DeskThe On-Site ASH Information/CME/Membership Desk will belocated on the Third Floor Promenade near Registration.ASH Staff MembersExecutive OfficeTorry Mark Sansone, Executive DirectorMary Trifault, Executive AssociateScientific Meetings & Professional AffairsMelissa Levine, Associate Executive DirectorAshley Buron, Program CoordinatorEducation ServicesKathleen Sheridan, Director of EducationMeeting and Exhibit Services, Hypertension Community Outreach ServicesGilda C. Caputo-Hansen, DirectorMembership & Marketing ServicesAngel Loayza, ManagerBarbara E. Escobar, Associate ManagerFinancial ServicesKevin Lee, ManagerKereyne A. Bishop, Associate Accounting ManagerJournal of the American Society of Hypertension (JASH)Amy Bittle, Managing Editor26

2010 ASH Corporate MembersBoehringer Ingelheim Pharmaceuticals, Inc.Daiichi Sankyo, Inc.Forest Laboratories, Inc.Gilead Sciences, Inc.GlaxoSmithKline PharmaceuticalsMerck & Co., Inc.NicOx SANovartis Pharmaceuticals CorporationPfizer IncTakeda Pharmaceuticals North America, Inc.27

ASH SponsorsThe American Society of Hypertension, Inc. wishesto acknowledge the following Corporate Sponsorsfor their generous support of the ASH Twenty-FifthAnnual Scientific Meeting.2010 Annual Scientific MeetingSponsorsBoehringer Ingelheim Pharmaceuticals, Inc.Daiichi Sankyo, Inc.NicOx SANovartis Pharmaceuticals CorporationTakeda Pharmaceuticals North America, Inc.28

ASH Leadership2009-2010 Board of DirectorsOfficersPresident: Henry R. Black, MDPresident-Elect: George L. Bakris, MDVice President: C. Venkata S. Ram, MDSecretary: Sandra J. Taler, MDTreasurer: Franz H. Messerli, MDImmediate Past President: Suzanne Oparil, MDDirectors-At-LargeJohn D. Bisognano, MD, PhDKeith C. Ferdinand, MDAlan H. Gradman, MDDaniel T. Lackland, DrPHDaniel Levy, MDRobert A. Phillips, MD, PhDAddison A. Taylor, MD, PhDWilliam B. White, MDEx Officio Non-Voting MembersThomas D. Giles, MD, Chair, ASH Specialists Program Inc.Michael A. Weber, MD, Editor-In-Chief,The Journal of Clinical Hypertension (JCH)Myron H. Weinberger, MD, Editor-In-Chief,Journal of the American Society of Hypertension (JASH)Torry Mark Sansone, Executive Director29

2010 Scientific ProgramCommitteeHenry R. Black, MD, ChairTherapy of HypertensionWilliam B. White, MD, Co-ChairJan N. Basile, MDJohn D. Bisognano, MD, PhDWilliam J. Elliott, MD, PhDMichael E. Ernst, PharmDF. Wilford Germino, MDJohn B. Kostis, MDLouis Kuritzky, MDSamuel J. Mann, MDFranz H. Messerli, MDRobert A. Phillips, MD, PhDPeter P. Toth, MD, PhDRaymond R. Townsend, MDMichael A. Weber, MDSteven A. Yarows, MDPathobiology of HypertensionClive Rosendorff, MD, PhD, Co-ChairOscar A. Carretero, MDWilla A. Hsueh, MDAllyn L. Mark, MDL. Gabriel Navar, PhDRhian M. Touyz, MD, PhDChristopher S. Wilcox, MD, PhDTranslational Issues in HypertensionGeorge L. Bakris, MD, Co-ChairLawrence J. Appel, MD, MPHRoger S. Blumenthal, MDRobert D. Brook, MDDaniel Feig, MD, PhDRichard H. Grimm, Jr., MD, PhDBertram Pitt, MDHenry A. Solomon, MDPeter F. Wilson, MD30

Special LectureMonday, May 3, 2010, 1:15 PM - 4:15 PM • East BallroomIrvine Page Award LectureDonald Heistad, MDDr. Donald Heistad is Zahn Professorof Cardiology and Professor of InternalMedicine and Pharmacology at theUniversity of Iowa Carver College ofMedicine. He is Deputy Director of theCardiovascular Center.Dr. Heistad was born in Chicago, andreceived his MD from the University ofChicago. He has received internationalrecognition for his studies of hypertension,atherosclerosis, and the cerebral circulation.His research has resulted in almost500 original papers and reviews.Dr. Heistad’s research has built the foundation for understanding cerebrovascularadaptive mechanisms and consequences of hypertension.The studies have demonstrated structural changes and endothelialdysfunction in the cerebral circulation during hypertension. His recentstudies have clarified mechanisms by which hypertension leads to intracerebralhemorrhage.Dr. Heistad has received several major research awards, including theResearch Achievement Award of the American Heart Association, theHarry Goldblatt Award and Novartis Award from the Council for HighBlood Pressure Research of the AHA, the Irving S. Wright Award of theStroke Council of the AHA, the Merck International Award of the InternationalSociety of Hypertension, Distinguished Alumni Award from theUniversity of Chicago, the Carl J. Wiggers Award of the American PhysiologicalSociety, and the Eugene M. Landis Award of the MicrocirculatorySociety. He is a member of the Association of American Physicians andthe American Society for Clinical Investigation.Dr. Heistad has given numerous named national and internationallectures, including the Abbott Lecture of the American Society of Hypertension.He is recognized internationally as a leading cardiovascularinvestigator and mentor for biomedical scientists.31

Young Scholar AwardMonday, May 3, 2010, 1:15 PM - 4:15 PM • East BallroomBina Joe, PhDDr. Bina Joe is an Associate Professorin Physiology and Pharmacology at theUniversity of Toledo College of Medicine.Dr. Joe received a national level ResearchFellowship from the Council for Scientificand Industrial Research in India, conductedher graduate studies in the CentralFood Technological Research Instituteunder the guidance of Dr. Belur R. Lokeshand obtained her PhD in Biochemistryfrom the University of Mysore in 1997.After a brief postdoctoral position at theIndian Institute of Science, she workedin AstraZeneca India before moving tothe Intramural Research Division of the National Institutes of Healthas an International Fogarty Research Scholar in Dr. Ronald L. Wilder’sLaboratory. There she began working on the genetics of complex diseasesusing rat models. In 2001, Dr. Joe was appointed as a Research AssistantProfessor in Prof. John P. Rapp’s laboratory at the University of ToledoCollege of Medicine, which was then known as the Medical College ofOhio. Over the years, she rose through the ranks and has held her currentposition of Associate Professor since 2007.Dr. Joe’s research focuses on the genetics of hypertension. Her researchis funded through multiple grants from the National Heart Lung andBlood Institute. She works predominantly with the Dahl Salt-sensitive (S)and Dahl Salt-resistant (R) rats that were inbred at her institution by herpredecessor Prof. Rapp. Through sustained substitution mapping, researchin Dr. Joe’s laboratory has markedly improved resolutions required forthe identification of multiple genomic loci linked to hypertension. Bycombining transcriptomics with substitution mapping, Dr. Joe’s laboratoryhas prioritized candidate genes that were previously not implicatedin hypertension. Her most recent work has identified that variants of agene linked to hypertension in rats is also genetically associated withhuman essential hypertension.Dr. Joe has served as an adhoc member of several NIH study sections since2005. She has also served as an International reviewer for the MedicalResearch Council of UK and the WELLCOME trust. She is a memberof the Editorial Boards of Hypertension and Physiological Genomics. Sheis especially honored to be the sole awardee of the Young Scholar Awardfrom the American Society of Hypertension in 2010, which marks the25th Anniversary of the Society.32

Special LectureMonday, May 3, 2010, 1:15 PM - 4:15 PM • East BallroomMarvin Moser Clinical Hypertension Award LectureJoel Handler, MDCritical Care Committee.Joel Handler has been an attending physicianfor the Southern California KaiserPermanente Medical Group (SCPMG)since 1979. Board certified in internalmedicine, critical care medicine, geriatricmedicine, and an ASH Specialist,he is a full time clinician seeing patientsin an office based practice as well as thehospital and emergency department. In1992 he initiated a hypertension clinicfor difficult to control patients and seesreferrals from throughout the SouthernCalifornia Kaiser system. Since 1992, hehas chaired the Kaiser Orange CountyHe has been section editor of the Journal of Clinical Hypertension since2001 writing a Case Studies in Hypertension series based mostly on difficultto control hypertension patients seen in the clinic and hospital. Hehas given lectures throughout the Southern California Kaiser system aswell as the national Kaiser meetings, and has also participated in ASHand NHLBI sponsored hypertension symposia. Dr. Handler developedan interactive educational module for physicians, which was creditedwith improving hypertension control performance.Since 2003, Dr. Handler has led the Southern California Kaiser hypertensionprogram, and since 2006 has been the national Kaiser PermanenteCare Management Institute clinical hypertension lead. Kaiser has eightnational regions with 8 million members, and the Southern Californiaregion contains 13 hospital based service areas with more than 3 millionmembers. As national clinical lead, he heads the hypertension treatmentguidelines development team. A simple drug treatment algorithm iscredited as an important factor contributing to a hypertension controlrate of 80% for the California regions, compared to 55% five years ago.He is also a member of the national Kaiser Integrated CardiovascularHealth Care Management Institute core group developing national prioritiesand implementation strategies for cardiovascular health initiatives.In 2008, Dr. Handler was appointed to the expert panel of the 8th JointNational Committee on High Blood Pressure (JNC8), and also to theNHLBI Guidelines Implementation Work group. Dr. Handler completedhis undergraduate work at Dickinson College in Carlisle, Pennsylvaniafollowed by medical school at the University of Pittsburgh, and residencyat the University of California, San Diego.33

2010 Abstract ReviewersLawrence J. Appel, MD, MPHBaltimore, MDJordan R. Asher, MDNashville, TNGeorge L. Bakris, MDChicago, ILJan N. Basile, MDCharleston, SCDonald L. Batisky, MDColumbus, OHDan R. Berlowitz, MD, MPHBedford, MAJohn D. Bisognano, MD, PhDRochester, NYHenry R. Black, MDNew York, NYRoger S. Blumenthal, MDBaltimore, MDRobert D. Brook, MDAnn Arbor, MIAngela L. Brown, MDSt. Louis, MODavid A. Calhoun, MDBirmingham, ALOscar A. Carretero, MDDetroit, MIBarry L. Carter, PharmDIowa City, IAJohn R. Cockcroft, MDCardiff, United KingdomDonald J. DiPette, MDColumbia, SCBrent M. Egan, MDCharleston, SCGilbert M. Eisner, MDWashington, DCWilliam J. Elliott, MD, PhDYakima, WAMichael E. Ernst, PharmDIowa City, IABonita Falkner, MDPhiladelphia, PADaniel I. Feig, MD, PhDHouston, TXKeith C. Ferdinand, MDAtlanta, GAJohn M. Flack, MD, MPHDetroit, MIJoseph T. Flynn, MDSeattle, WAF. Wilford Germino, MDOrland Park, ILPhilip B. Gorelick, MD, MPHChicago, ILRichard H. Grimm, Jr., MD, PhDMinneapolis, MNJohn E. Hall, PhDJackson, MSDavid J. Hyman, MD, MPHHouston, TXJohn B. Kostis, MDNew Brunswick, NJTheodore W. Kurtz, MDSan Francisco, CADaniel T. Lackland, DrPHCharleston, SCLewis Landsberg, MDChicago, ILDaniel Levy, MDFramingham, MAGiuseppe Mancia, MDMilan, ItalySamuel J. Mann, MDNew York, NYAllyn L. Mark, MDIowa City, IAGary F. Mitchell, MDNorwood, MAMichael A. Moore, MDWinston-Salem, NCL. Gabriel Navar, PhDNew Orleans, LASuzanne Oparil, MDBirmingham, ALVasilios Papademetriou, MDWashington, DCRobert A. Phillips, MD, PhDWorcester, MALeopoldo Raij, MDMiami, FLC. Venkata S. Ram, MDDallas, TXClive Rosendorff, MD, PhDNew York, NYGary E. Sander, MD, PhDNew Orleans, LA34

2010 Abstract Reviewers continuedErnesto L. Schiffrin, MD, PhDMontreal, CanadaAlan B. Schwartz, MDPhiladelphia, PAJames R. Sowers, MDColumbia, MOJan A. Staessen, MD, PhDLeuven, BelgiumSandra J. Taler, MDRochester, MNAddison A. Taylor, MD, PhDHouston, TXSheldon W. Tobe, MDToronto, CanadaPeter P. Toth, MD, PhDSterling, ILRhian M. Touyz, PhDOttawa, CanadaRaymond R. Townsend, MDPhiladelphia, PAJason G. Umans, MD, PhDWashington, DCAlan B. Weder, MDAnn Arbor, MIMyron H. Weinberger, MDIndianapolis, INHoward Weintraub, MDNew York, NYMatthew R. Weir, MDBaltimore, MDWilliam B. White, MDFarmington, CTSteven A. Yarows, MDChelsea, MI35

GET ON THE BP LINE–See How NY Moves Hypertension @ ASH.IndicationTEKTURNA is indicated for the treatment of hypertension in adults.TEKTURNA may be used alone or in combination with other antihypertensiveagents. The use of TEKTURNA with maximal doses of ACE inhibitorshas not been adequately studied, and it is not known whether additiveeffects are present when TEKTURNA is used with ACE inhibitors orbeta-blockers.Important ConsiderationsWARNING: AVOID USE IN PREGNANCYWhen pregnancy is detected, discontinue TEKTURNA as soon aspossible. Drugs that act directly on the renin-angiotensin system cancause injury and even death to the developing fetus. See WARNINGSAND PRECAUTIONS (5.1).Angioedema of the face, extremities, lips, tongue, glottis and/or larynx has beenreported in patients treated with aliskiren and has necessitated hospitalizationand intubation. This may occur at any time during treatment and has occurredin patients with and without a history of angioedema with ACE inhibitors orangiotensin receptor antagonists. Discontinue TEKTURNA immediately inpatients who develop angioedema, and do not readminister.Excessive hypotension was seen rarely (0.1%) in patients with uncomplicatedhypertension treated with TEKTURNA alone. Hypotension was also infrequentduring combination therapy with other antihypertensive agents (

Visit TEKTURNA at Booth 1100.and/or salt-depletion should be corrected in patients before administeringTEKTURNA or symptomatic hypotension may occur. Patients taking TEKTURNAshould be observed for clinical signs of fluid or electrolyte imbalance.Caution should be exercised when dosing TEKTURNA in patients withsevere renal impairment (GFR

TEKTURNA ® (aliskiren) Tablets, OralInitial U.S. Approval: 2007BRIEF SUMMARY: Please see package insert for full prescribing information.WARNING: AVOID USE IN PREGNANCYWhen pregnancy is detected, discontinue Tekturna as soon as possible.Drugs that act directly on the renin-angiotensin system can cause injury anddeath to the developing fetus. [See Warnings and Precautions (5.1)]1 INDICATIONS AND USAGE1.1 HypertensionTekturna is indicated for the treatment of hypertension. It may be used aloneor in combination with other antihypertensive agents. Use with maximaldoses of ACE inhibitors has not been adequately studied.4 CONTRAINDICATIONSNone.5 WARNINGS AND PRECAUTIONS5.1 Fetal/Neonatal Morbidity and MortalityDrugs that act directly on the renin-angiotensin system can cause fetal andneonatal morbidity and death when administered to pregnant women. If thisdrug is used during pregnancy, or if the patient becomes pregnant while takingthis drug, the patient should be apprised of the potential hazard to thefetus. [See Use in Specific Populations (8.1)] In several dozen publishedcases, ACE inhibitor use during the second and third trimesters of pregnancywas associated with fetal and neonatal injury, including hypotension, neonatalskull hypoplasia, anuria, reversible or irreversible renal failure, and death. Inaddition, first trimester use of ACE inhibitors has been associated with birthdefects in retrospective data.5.2 Head and Neck AngioedemaAngioedema of the face, extremities, lips, tongue, glottis and/or larynx hasbeen reported in patients treated with Tekturna and has necessitated hospitalizationand intubation. This may occur at any time during treatment and hasoccurred in patients with and without a history of angioedema with ACEinhibitors or angiotensin receptor antagonists. If angioedema involves thethroat, tongue, glottis or larynx, or if the patient has a history of upper respiratorysurgery, airway obstruction may occur and be fatal. Patients who experiencethese effects, even without respiratory distress, require prolongedobservation since treatment with antihistamines and corticosteroids may notbe sufficient to prevent respiratory involvement. Prompt administration ofsubcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) and measures toensure a patient airway may be necessary.Discontinue Tekturna immediately in patients who develop angioedema, anddo not readminister.5.3 HypotensionAn excessive fall in blood pressure was rarely seen (0.1%) in patients withuncomplicated hypertension treated with Tekturna alone in controlled trialsand in

5.5 HyperkalemiaIncreases in serum potassium >5.5 mEq/L were infrequent with Tekturnaalone (0.9% compared to 0.6% with placebo). However, when used in combinationwith an ACE inhibitor in a diabetic population, increases in serumpotassium were more frequent (5.5%). Routine monitoring of electrolytesand renal function is indicated in this population. Concomitant use of Tekturnawith potassium-sparing diuretics, potassium supplements, salt substitutescontaining potassium, or other drugs that increase potassium levels may leadto increases in serum potassium. If concomitant use is considered necessary,caution should be exercised.5.6 Renal Artery StenosisNo data are available on the use of Tekturna in patients with unilateral or bilateralrenal artery stenosis or stenosis of the artery to a solitary kidney.6 ADVERSE REACTIONS6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adversereaction rates observed in the clinical trials of a drug cannot be directly comparedto rates in clinical trials of another drug and may not reflect the ratesobserved in practice.Data described below reflect the evaluation of the safety of Tekturna in morethan 6,460 patients, including over 1,740 treated for longer than 6 months,and more than 1,250 patients for longer than 1 year. In placebo controlledclinical trials, discontinuation of therapy due to a clinical adverse event,including uncontrolled hypertension occurred in 2.2% of patients treatedwith Tekturna vs. 3.5% of patients given placebo.Angioedema: Two cases of angioedema with respiratory symptoms werereported with Tekturna use in the clinical studies. Two other cases of periorbitaledema without respiratory symptoms were reported as possibleangioedema and resulted in discontinuation. The rate of these angioedemacases in the completed studies was 0.06%. In addition, 26 other cases ofedema involving the face, hands, or whole body were reported with Tekturnause including 4 leading to discontinuation. In the placebo controlled studies,however, the incidence of edema involved the face, hands or whole body was0.4% with Tekturna compared with 0.5% with placebo. In a long term activecontrol study with Tekturna and HCTZ arms, the incidence of edema involvingthe face, hand or whole body was 0.4% in both treatment arms. [See Warningsand Precautions (5.2)]Gastrointestinal: Tekturna produces dose-related gastrointestinal (GI) adverseeffects. Diarrhea was reported by 2.3% of patients at 300 mg, compared to1.2% in placebo patients. In women and the elderly (age ≥65) increases indiarrhea rates were evident starting at a dose of 150 mg daily, with rates forthese subgroups at 150 mg comparable to those seen at 300 mg for men oryounger patients (all rates about 2.0-2.3%). Other GI symptoms includedabdominal pain, dyspepsia, and gastroesophageal reflux, although increasedrates for abdominal pain and dyspepsia were distinguished from placebo onlyat 600 mg daily. Diarrhea and other GI symptoms were typically mild andrarely led to discontinuation.Cough: Tekturna was associated with a slight increase in cough in theplacebo-controlled studies (1.1% for any Tekturna use vs. 0.6% for placebo).In active-controlled trials with ACE inhibitor (ramipril, lisinopril) arms therates of cough for the Tekturna arms were about one-third to one-half therates in the ACE inhibitor arms.Seizures: Single episodes of tonic-clonic seizures with loss of consciousnesswere reported in two patients treated with Tekturna in the clinical trials.One of these patients did have predisposing causes for seizures and had anegative electroencephalogram (EEG) and cerebral imaging following theseizures (for the other patient EEG and imaging results were not reported).Tekturna was discontinued and there was no re-challenge.The following adverse events occurred in placebo-controlled clinical trials atan incidence of more than 1% of patients treated with Tekturna, but alsooccurred at about the same or greater incidence in patients receiving placebo:headache, nasopharyngitis, dizziness, fatigue, upper respiratory tract infection,back pain and cough.

Other adverse effects with increased rates for Tekturna compared to placeboincluded rash (1% vs. 0.3%), elevated uric acid (0.4% vs. 0.1%), gout (0.2%vs. 0.1%) and renal stones (0.2% vs. 0%).Aliskiren’s effect on ECG intervals was studied in a randomized, double-blind,placebo and active-controlled (moxifloxacin), 7-day repeat dosing study withHolter-monitoring and 12 lead ECGs throughout the interdosing interval. Noeffect of aliskiren on QT interval was seen.6.2 Clinical Laboratory FindingsIn controlled clinical trials, clinically relevant changes in standard laboratoryparameters were rarely associated with the administration of Tekturna. Inmultiple-dose studies in hypertensive patients, Tekturna had no clinicallyimportant effects on total cholesterol, HDL, fasting triglycerides, fasting glucose,or uric acid.Blood Urea Nitrogen, Creatinine: Minor increases in blood urea nitrogen(BUN) or serum creatinine were observed in less than 7% of patients withessential hypertension treated with Tekturna alone vs. 6% on placebo.Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit(mean decreases of approximately 0.08 g/dL and 0.16 volume percent,respectively, for all aliskiren monotherapy) were observed. The decreaseswere dose-related and were 0.24 g/dL and 0.79 volume percent for 600 mgdaily. This effect is also seen with other agents acting on the renin-angiotensinsystem, such as angiotensin inhibitors and angiotensin receptor blockers andmay be mediated by reduction of angiotensin II which stimulates erythropoetinproduction via the AT1 receptor. These decreases led to slight increasesin rates of anemia with aliskiren compared to placebo were observed (0.1%for any aliskiren use, 0.3% for aliskiren 600 mg daily, vs 0% for placebo). Nopatients discontinued therapy due to anemia.Serum Potassium: Increases in serum potassium >5.5 mEq/L were infrequentin patients with essential hypertension treated with Tekturna alone (0.9%compared to 0.6% with placebo). However, when used in combination withan angiotensin-converting enzyme inhibitor (ACEI) in a diabetic populationincreases in serum potassium were more frequent (5.5%) and routine monitoringof electrolytes and renal function is indicated in this population.Serum Uric Acid: Aliskiren monotherapy produced small median increases inserum uric acid levels (about 6 μmol/L) while HCTZ produced larger increases(about 30 μmol/L). The combination of aliskiren with HCTZ appears to beadditive (about 40 μmol/L increase). The increases in uric acid appear to leadto slight increases in uric acid-related AEs: elevated uric acid (0.4% vs. 0.1%),gout (0.2% vs. 0.1%), and renal stones (0.2% vs. 0%).Creatine Kinase: Increases in creatine kinase of >300% were recorded inabout 1% of aliskiren monotherapy patients vs. 0.5% of placebo patients.Five cases of creatine kinase rises, three leading to discontinuation and onediagnosed as subclinical rhabdomyolysis, and another as myositis, werereported as adverse events with aliskiren use in the clinical trials. No caseswere associated with renal dysfunction.6.3 Post-marketing ExperienceThe following adverse reactions have been reported in aliskiren post-marketingexperience. Because these reactions are reported voluntarily from a populationof uncertain size, it is not always possible to reliably estimate their frequencyor establish a causal relationship to drug exposure.Hypersensitivity: angioedema requiring airway management andhospitalizationPeripheral edema7 DRUG INTERACTIONS7.1 Effects of Other Drugs on AliskirenBased on in vitro studies, aliskiren is metabolized by CYP 3A4.Irbesartan: Coadministration of irbesartan reduced aliskiren C max up to 50%after multiple dosing.P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the majorefflux system involved in absorption and disposition of aliskiren in preclinicalstudies. The potential for drug interactions at the Pgp site will likely dependon the degree of inhibition of this transporter. Coadministration of aliskiren

with Pgp substrates or weak to moderate inhibitors such as atenolol, digoxin,and amlodipine did not result in clinically relevant interactions.Atorvastatin: Coadministration of atorvastatin, a weak Pgp inhibitor, resultedin about a 50% increase in aliskiren C max and AUC after multiple dosing.Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole, a moderatePgp inhibitor, with aliskiren resulted in an approximate 80% increase inplasma levels of aliskiren. A 400-mg once-daily dose was not studied butwould be expected to increase aliskiren blood levels further.Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine, a potentPgp inhibitor, with 75 mg aliskiren resulted in an approximately 2.5-foldincrease in C max and 5-fold increase in AUC of aliskiren. Concomitant use ofaliskiren with cyclosporine is not recommended.Verapamil: Coadministration of 240 mg of verapamil, a moderate Pgp inhibitor,with 300 mg aliskiren resulted in an approximately 2-fold increase in C max andAUC of aliskiren. However, no dosage adjustment is necessary.Drugs with no clinically significant effects: Coadministration of lovastatin,atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,ramipril, valsartan, metformin and amlodipine did not result in clinically significantincreases in aliskiren exposure.7.2 Effects of Aliskiren on Other DrugsAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19,2D6, 2E1, and 3A) or induce CYP 3A4.Furosemide: When aliskiren was coadministered with furosemide, the AUCand C max of furosemide were reduced by about 30% and 50%, respectively.Patients receiving furosemide could find its effect diminished after startingaliskiren.Drugs with no clinically significant effects: Coadministration of aliskiren didnot significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan,amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril orhydrochlorothiazide.Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not beenevaluated.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Categories C (first trimester) and D (second and third trimesters)[See Warnings and Precautions (5.1)]There is no clinical experience with the use of Tekturna in pregnant women.Drugs that act directly on the renin-angiotensin system can cause fetal andneonatal morbidity and death when administered to pregnant women. Severaldozen cases have been reported in the world literature in patients who weretaking angiotensin-converting enzyme inhibitors. When pregnancy is detected,Tekturna should be discontinued as soon as possible. The use of drugs thatact directly on the renin-angiotensin system during the second and thirdtrimesters of pregnancy has been associated with fetal and neonatal injury,including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversiblerenal failure, and death. Oligohydramnios has also been reported,presumably resulting from decreased fetal renal function; oligohydramnios inthis setting has been associated with fetal contractures, craniofacial deformation,and hypoplastic lung development. Prematurity, intrauterine growthretardation, and patent ductus arteriosus have also been reported, although itis not clear whether these occurrences were due to exposure to the drug.In addition, first trimester use of ACE inhibitors, a specific class of drugs actingon the renin-angiotensin system, has been associated with a potential riskof birth defects in retrospective data. Healthcare professionals that prescribedrugs acting directly on the renin-angiotensin system should counsel womenof childbearing potential about the potential risks of these agents during pregnancy.Rarely (probably less often than once in every thousand pregnancies),no alternative to a drug acting on the renin-angiotensin system will be found.In these rare cases, the mothers should be apprised of the potential hazardsto their fetuses and serial ultrasound examination should be performed toassess the intra-amniotic environment. If oligohydramnios is observed,Tekturna should be discontinued unless it is considered life-saving for themother. Contraction stress testing (CST), a nonstress test (NST) or biophysical

profiling (BPP) may be appropriate, depending upon the week of pregnancy.Patients and physicians should be aware, however, that oligohydramnios maynot appear until after the fetus has sustained irreversible injury.Infants with histories of in-utero exposure to a renin inhibitor should beclosely observed for hypotension, oliguria, and hyperkalemia. If oliguriaoccurs, attention should be directed toward support of blood pressure andrenal perfusion. Exchange transfusion or dialysis may be required as meansof reversing hypotension and/or substituting for disordered renal function.[See Nonclinical Toxicology (13) in the full prescribing information]8.3 Nursing MothersIt is not known whether aliskiren is excreted in human breast milk. Aliskirenwas secreted in the milk of lactating rats. Because of the potential for adverseeffects on the nursing infant, a decision should be made whether to discontinuenursing or discontinue the drug, taking into account the importance ofthe drug to the mother.8.4 Pediatric UseSafety and effectiveness of aliskiren in pediatric patients

ASH Program at a GlanceSaturday, May 1, 20106:00 AMEastBallroomBeekmanParlorSuttonNorthMercuryBallroomSuttonCenterRendezvousTrianonRhinelanderGalleryAmericasHall I7:00 AM8:00 AMHypertensionHighlights 20109:00 AM10:00 AM11:00 AM12:00 PM1:00 PM2:00 PM3:00 PM4:00 PM5:00 PM6:00 PMSession:Physician Industry RelationsSession:Pathophysiology ofHypertensionSession:Public Health andHypertension: CanPopulation Based StrategiesWork?Session:Molecular Mechanismsof Hypertension: NovelConcepts and ClinicalImplicationsYoung Investigatorin-TrainingAbstractCompetitionPoster HallPosters on Display from3:00 PM to 7:00 PMPoster Viewing from5:00 PM to 6:00 PMAntihypertensive Drugsand Pharmacology; ArterialStructure and Compliance;Cardiac Structure andFunction/Imaging; CoronaryArtery Disease; SecondaryHypertension; StrokeHypertensionResource PavilionOpen from3:00 PM to 7:00 PMOpening Reception from5:00 PM to 7:00 PM7:00 PM8:00 PM9:00 PM9:30 PMScientific SessionsSpecial EventHypertension HighlightsPoster SessionsHypertension Resource Pavillion43

ASH Program at a GlanceSunday, May 2, 20106:00 AM7:00 AMTrianonBallroomSatellite Symposium:The Journey to OptimalTreatment Strategiesfor the OA Patient withHypertensionWestBallroomBeekmanParlorSuttonNorthMercuryBallroomMorganSuiteBryantSuiteClintonSuiteGibsonSuiteRhinelanderGalleryEastBallroomAmericasHall I8:00 AM9:00 AM10:00 AM11:00 AM12:00 PM1:00 PM2:00 PM3:00 PM4:00 PM5:00 PMHypertension for thePrimary Care Clinician2010Session:Overviews in VascularFunction andClinicalPharmacologySession:Improving RegionalCardiovascular OutcomesMeet the Expert:How to Interpret a ClinicalTrial ManuscriptSession:Cardio-MetabolicAbnormalitiesin ArterialHypertensionSession:The Emerging Roleof Aldosterone inHypertensionMeet the Expert:Angiotensin 1-7. Is itRelevant?Session:ALLHAT: Long-termOutcomes of DrugTreatment in High CHD RiskHypertensive PatientsSession:Aging and AtherosclerosisMeet the Expert:Update and Results onWomen’s Health InitiativeMeet the Expert:Pharmacokinetics,PharmacodynamicsMeet the Expert:Management of LowHDL CholesterolMeet the Expert:Vascular FunctionMeet the Expert:Isolated SystolicHypertensionMeet the Expert:Imaging for SecondaryCauses of HypertensionMeet the Expert:Hypertension and AirPollutionMeet the Expert:Peripheral Vascular DiseasePoster HallClinical Cases:Resistant Hypertension:Non-Drug ApproachesPosters on Display from9:00 AM to 6:45 PMPoster Viewing from4:45 PM to 5:45 PMFeatured Posters;Blood PressureMeasurement/Monitoring;Heart Failure/Hypertrophy;Kidney and Hypertension;Metabolic Syndrome;Non-PharmacologicalTherapy;Patient-Provider-HealthcareSystem Issues;Risk Factors;Pregnancy.Cardiovascular Risk in theYoung AthleteSession:Plenary Session I:Hypertension in the21st CenturySession:Secondary Hypertension:Causes and ComplicationsHypertensionResource PavilionOpen from9:00 AM to 12:00 PMHypertensionResource PavilionOpen from 3:30 PM to6:45 PMHigh Tea from 4:45 PM to5:45 PM.6:00 PM7:00 PMSession:Non-Cardiac Drugs thatRaise Blood PressureSession:Cornerstones of theEuropean and AmericanGuidelines –Session:Hypertension andOxidative StressandDrug InteractionSession:Blood Pressure Goals:Novel Approaches8:00 PM9:00 PM9:30 PMSatellite Symposium:Exploring the Futureof CombinationAntihypertensive Therapy:Is There a Limit to theNumber of Drugs in aFixed-Dose Combination?Similarities andDifferencesSatellite SymposiaScientific SessionsSpecial EventPrimary Care SessionClinical Case DiscussionsMeet the Expert SessionsPoster SessionsHypertension Resource Pavillion44

ASH Program at a GlanceMonday, May 3, 20106:00 AM7:00 AMTrianonBallroomSatellite Symposium:Targeting EndothelialDysfunction in HypertensiveCardiovascular Disease:Why, When, and HowMercuryBallroomEastBallroomWestBallroomSuttonNorthBryantSuiteGibsonSuiteMorganSuiteRhinelanderGalleryAmericasHall I8:00 AM9:00 AM10:00 AM11:00 AMSession:The Genetic Basis ofHypertensionSession:Renal Mechanisms ofHypertensionSession:Biomarkers andCardiovascular Risk: NovelMethods of AssessmentSession:Cardiometabolic Syndrome:New Insights about RiskReductionSession:Hypertension as a SilentPrelude to Heart FailureSession:Complications of theHypertensive DiseaseProcessSession:Assessing ArterialStiffness to Improvethe Management ofCardiovascular Disease inthe 21st CenturyPoster HallPosters on Display from9:00 to 5:15 PMPoster Viewing from 4:15PM to 5:15 PMHypertensionResource PavilionOpen from9:00 AM to 1:00 PM12:00 PMMeet the Expert:Metabolic Syndrome andPolycystic Ovary SyndromeMeet the Expert:Renal Sympathetic NervesMeet the Expert:The Treatment of AtrialFibrillation in theMeet the Expert:Exercise TestingClinical Cases:Hypertension Emergenciesand Urgencies1:00 PM2:00 PM3:00 PM4:00 PM5:00 PMSession:Plenary Session II:Awards Presentationsand State-of-the-ArtLecturesHypertensivePatientCellular Mechanisms;Clinical Trials; EndothelialFunction; Epidemiology/Special Populations;Genetics/Gene Therapy/Proteomics; NeuralHormonal Mechanisms;Obesity; PediatricHypertension; PreclinicalModels/ExperimentalHypertension; VascularInjury/Inflammation andRemodeling;Late-Breaking Posters.Etiological Approach toObesity Assessment andManagementHypertensionResource PavilionOpen from3:30 PM to 5:15 PMHigh Tea from4:45 PM to 5:15 PM.6:00 PM7:00 PM8:00 PM9:00 PMSatellite Symposium:A Cross Examination ofContemporary Issues inHypertension: Today’sControversy and Consensus9:30 PMSatellite SymposiaScientific SessionsSpecial EventClinical Case DiscussionsMeet the Expert SessionsPoster SessionsHypertension Resource Pavillion45

ASH Program at a GlanceTuesday, May 4, 20106:00 AMWestBallroomBeekmanParlorSuttonSouthSuttonNorthRendezvousTrianon7:00 AM8:00 AM9:00 AMLate-BreakingClinical TrialsSession:Consensus Update to ISHIBManagement GuidelinesSession:Cardiovascular and KidneyOutcomes in Heart FailureSession:Early Vascular DiseaseDetection andManagement: Experiencefrom China10:00 AMASH MembershipMeeting11:00 AM12:00 PM1:00 PMSession:Essential Pathobiology forthe Hypertension SpecialistSession:UnderstandingUnappreciated Outcomes ofCardiovascular RiskSession:Important Co-morbidDisorders in Patients withHypertension: Evaluationand Treatment2:00 PM3:00 PM4:00 PM5:00 PM6:00 PM7:00 PM8:00 PM9:00 PM9:30 PMScientific Sessions Special Event Clinical Case Discussions46

Poster Category PresentationPosters will be displayed in the Rhinelander Gallery.Saturday, May 1, 2010Posters on Display: 3:00 PM – 7:00 PM • Poster Viewing: 5:00 PM – 6:00 PMAntihypertensive Drugs and Pharmacology......... (PO-009 – PO-077B)Arterial Structure and Compliance........................ (PO-078 – PO-099B)Cardiac Structure and Function/Imaging.................(PO-100 – PO-105)Coronary Artery Disease............................................(PO-106 – PO-107)Secondary Hypertension.............................................(PO-108 – PO-109)Stroke.............................................................................(PO-110 – PO-114)Sunday, May 2, 2010Posters on Display: 9:00 AM – 6:45 PM • Poster Viewing: 4:45 PM – 5:45 PMFeatured Posters...........................................................(PO-001 – PO-008)Blood Pressure Measurement/Monitoring...............(PO-115 – PO-160)Heart Failure/Hypertrophy(Diastolic Dysfunction)...............................................(PO-161 – PO-164)Kidney and Hypertension...........................................(PO-165 – PO-178)Metabolic Syndrome (Diabetes/Glycemic Control;Dysglycemic Drugs; Insulin Resistance)...................(PO-179 – PO-199)Non-Pharmacological Therapy (AlternativeMedicine; Diet; Physical Activity).............................(PO-200 – PO-202)Patient-Provider-Healthcare System Issues..............(PO-203 – PO-209)Risk Factors (Lipids)....................................................(PO-210 – PO-213)Pregnancy......................................................................(PO-214 – PO-216)Monday, May 3, 2010Posters on Display: 9:00 AM – 5:15 PM • Poster Viewing: 4:15 PM – 5:15 PMCellular Mechanisms (Cell Biology;Cell Membrane Transport/Ion Channels;Coagulation/Thrombosis; Growth Factors).............(PO-217 – PO-219)Clinical Trials................................................................(PO-220 – PO-242)Endothelial Function...................................................(PO-243 – PO-255)Epidemiology/Special Populations............................(PO-256 – PO-293)Genetics/Gene Therapy/Proteomics..........................(PO-294 – PO-297)Neural Hormonal Mechanisms (Renin;Neural Control; Vasoactive Autacoids).....................(PO-298 – PO-300)Obesity...........................................................................(PO-301 – PO-306)Pediatric Hypertension...............................................(PO-307 – PO-308)Preclinical Models/ExperimentalHypertension................................................................(PO-309 – PO-311)Vascular Injury/Inflammation andRemodeling...................................................................(PO-312 – PO-318)Late-Breaking Posters........................................(LBPO-001 – LBPO-016)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.47

2010 ASH FacultyGail Adler, MD, PhDBoston, MASonia Y. Angell, MD, MPHNew York, NYLawrence J. Appel, MD, MPHBaltimore, MDBrad C. Astor, PhD, MPHBaltimore, MDGeorge L. Bakris, MDChicago, ILSripal Bangalore, MDBrookline, MAJoshua Barzilay, MDTucker, GAJan N. Basile, MDCharleston, SCClaudio A. Bellido, MD, PhDBuenos Aires, ArgentinaDan R. Berlowitz, MD, MPHBedford, MAJohn D. Bisognano, MD, PhDRochester, NYHenry R. Black, MDNew York, NYMichael J. Bloch, MDReno, NVRoger S. Blumenthal, MDBaltimore, MDEugene Braunwald, MDBoston, MARobert D. Brook, MDAnn Arbor, MIAngela L. Brown, MDSt. Louis, MOJohn C. Burnett, Jr., MDRochester, MNDavid A. Calhoun, MDBirmingham, ALDavid S. Cannom, MDLos Angeles, CAOscar A. Carretero, MDDetroit, MILisa A. Cassis, PhDLexington, KYAihua Chen, MDKunming, ChinaAtul R. Chugh, MDLouisville, KYJohn R. Cockcroft, MDCardiff, United KingdomThomas M. Coffman, MDDurham, NCJay N. Cohn, MDMinneapolis, MNWilliam C. Cushman, MDMemphis, TNJeffrey A. Cutler, MD, MPHWashington, DCMichael A. Davidson, MDChicago, ILBarry R. Davis, MD, PhDHouston, TXGerald F. DiBona, MDIowa City, IAAnna F. Dominiczak, MDGlasgow, United KingdomSteven L. Dubovsky, MDBuffalo, NYBrent M. Egan, MDCharleston, SCDavid A. Ehrmann, MDChicago, ILWilliam J. Elliott, MD, PhDYakima, WAMurray Epstein, MDMiami, FLMichael E. Ernst, PharmDIowa City, IAMark Espeland, PhDWinston-Salem, NCDaniel I. Feig, MD, PhDHouston, TX,Peter U. Feig, MDRahway, NJCarlos M. Ferrario, MDWinston-Salem, NCGregory D. Fink, MDEast Lansing, MIEdward A. Fisher, MD, PhD,MPHNew York, NYJohn M. Flack, MD, MPHDetroit, MICharles K. Francis, MDNeptune, NJJeffrey M. Friedman, MD, PhDNew York, NYToshiro Fujita, MDTokyo, Japan48

2010 ASH Faculty continuedJeffrey R. Garber, MDBoston, MAHaralambos Gavras, MDBoston, MAF. Wilford Germino, MDOrland Park, ILThomas D. Giles, MDNew Orleans, LACelso E. Gomez-Sanchez, MDJackson, MSPhilip B. Gorelick, MD, MPHChicago, ILAlan H. Gradman, MDPittsburgh, PARichard H. Grimm, Jr., MD,PhDMinneapolis, MNEhud Grossman, MDTel Hashomer, IsraelMartha Gulati, MD, MSChicago, ILYuan Guo, MD, MSBeijing, ChinaJoel Handler, MDAnaheim, CADonald D. Heistad, MDIowa City, IAJudith Hochman, MDNew York, NYMichael F. Holick, MD, PhDBoston, MANorman K. Hollenberg, MD,PhDBoston, MAYongqiang Hong, MDFuzhou, ChinaWilla A. Hsueh, MDHouston, TXRoberto A. Ingaramo, MDTrelew Chubut, ArgentinaJoseph L. Izzo, Jr., MDBuffalo, NYBina Joe, PhDToledo, OHLuis Juncos, MDCórdoba, ArgentinaNorman M. Kaplan, MDDallas, TXS. Ananth Karumanchi, MDBoston, MASverre E. Kjeldsen, MDOslo, NorwayMyra Kleinpeter, MD, MPHNew Orleans, LAJohn B. Kostis, MDNew Brunswick, NJDavid S. Kountz, MDNeptune, NJPeter R. Kowey, MDWynnewood, PALawrence R. Krakoff, MDEnglewood, NJLouis Kuritzky, MDGainesville, FLTheodore W. Kurtz, MDSan Francisco, CADaniel T. Lackland, DrPHCharleston, SCEdward G. Lakatta, MDBaltimore, MDLilach O. Lerman, MD, PhDRochester, MNDaniel Levy, MDFramingham, MATianhu Liu, MDChengdu, ChinaThomas E. Lohmeier, PhDJackson, MSJianfang Luo, MDGuangzhou, ChinaGiuseppe Mancia, MDMilan, ItalySamuel J. Mann, MDNew York, NYKaren L. Margolis, MD, MPHMinneapolis, MNAllyn L. Mark, MDIowa City, IAR. Preston Mason, PhDBoston, MATerry Mason, MDChicago, ILBarry M. Massie, MDSan Francisco, CABarry J. Materson, MD, MBAMiami, FLCarmel M. McEniery, PhDCambridge, United KingdomFranz H. Messerli, MDNew York, NY49

2010 ASH Faculty continuedGary F. Mitchell, MDNorwood, MAMichael A. Moore, MDWinston-Salem, NCMarvin Moser, MDNew Haven, CTDominik N. Müller, MDBerlin, GermanyKrzysztof Narkiewicz, MD,PhDGdánsk, PolandL. Gabriel Navar, PhDNew Orleans, LAShawna D. Nesbitt, MD, MSDallas, TXGbenga Ogedegbe, MD, MPHNew York, NYSuzanne Oparil, MDBirmingham, ALEduardo Ortiz, MD, MPHBethesda, MDVasilios Papademetriou, MDWashington, DCAldo J. Peixoto, MDWest Haven, CTRobert A. Phillips, MD, PhDWorcester, MALinda B. Piller, MD, MPHHouston, TXBertram Pitt, MDAnn Arbor, MIMahboob Rahman, MDCleveland, OHLeopoldo Raij, MDMiami, FLC. Venkata S. Ram, MDDallas, TXEfrain Reisin, MDNew Orleans, LAEdward J. Roccella, PhD, MPHVienna, VAMary J. Roman, MDNew York, NYClive Rosendorff, MD, PhDBronx, NYKathryn Sandberg, PhDWashington, DCElijah Saunders, MDBaltimore, MDArya M. Sharma, MD, PhDEdmonton, CanadaDomenic A. Sica, MDRichmond, VAKanwar Singh, MDFarmington, CTHenry A. Solomon, MDNew York, NYScott D. Solomon, MDBoston, MAThomas A. Sos, MDNew York, NYJames R. Sowers, MDColumbia, MOLance K. Stell, PhDDavidson, NCNeil J. Stone, MDChicago, ILThomas P. Stossel, MDBoston, MAPatrick J. Strollo, Jr., MDPittsburgh, PASandra J. Taler, MDRochester, MNAddison A. Taylor, MD, PhDHouston, TXStephen C. Textor, MDRochester, MNRhian M. Touyz, MD, PhDOttawa, CanadaRaymond R. Townsend, MDPhiladelphia, PAP. Roy Vagelos, MDBedminster, NJHector O. Ventura, MDNew Orleans, LACharalambos Vlachopoulos,MDAthens, GreeceHongyu Wang, MD, PhDBeijing, ChinaR. Clinton Webb, PhDAugusta, GAMichael A. Weber, MDNew York, NYMyron H. Weinberger, MDIndianapolis, INHoward Weintraub, MDNew York, NY50

2010 ASH Faculty continuedAndrew Whelton, MDBaltimore, MDWilliam B. White, MDFarmington, CTChristopher S. Wilcox, MD,PhDWashington, DCGordon H. Williams, MDBoston, MAPeter F. Wilson, MDAtlanta, GAClyde W. Yancy, MDDallas, TXSteven A. Yarows, MDChelsea, MI51

Program Color KeyThe pages of this Program Book are color-coded to match theProgram at a Glance (pages 43–46) and serve as a quick, identifiablereference of the type of educational activity or event taking place.Scientific Sessions*1 Pathobiology Track 2 Translational Track 3 Therapy TrackHypertension Highlights 2010Special EventMeet the Expert SessionsHypertension for the Primary Care ClinicianClinical Case DiscussionsPoster Sessions*1 Pathobiology Track 2 Translational Track 3 Therapy TrackSatellite SymposiaHypertension Resource Pavilion*The ASH Twenty-Fifth Annual Scientific Meeting isorganized around three (3) concurrent themes:• Pathobiology of Hypertension• Translational Issues in Hypertension• Therapy of HypertensionSessions in each of the three (3) themes (or tracks) are labeledthroughout the Program Book to be easily identifiable. Inaddition, posters are also grouped by category and then bytheme within the category.

2010American Societyof HypertensionProgram

MAY 1Saturday MorningHypertension Highlights 20108:00 AM – 3:00 PM • East BallroomPart IHeld in Association with theNew York State Chapter, AmericanCollege of CardiologyChairs: Charles K. Francis, MD, Neptune, NJ andShawna D. Nesbitt, MD, MS, Dallas, TX8:00 AM Decreased Activity in Obesity and Hypertension:What’s Behind It and What Can We Do About It?Allyn L. Mark, MD, Iowa City, IA8:30 AM Update on the Evaluation and Treatment of HeartFailureClyde W. Yancy, MD, Dallas, TX9:00 AM The Impact of Sex on Blood Pressure andHypertensionKathryn Sandberg, PhD, Washington, DC9:30 AM Update on Cardiovascular Health in WomenMartha Gulati, MD, MS, Chicago, IL10:00 AM Break10:30 AM Integrated Guidelines: Metabolic Syndrome,Where are We Going?James R. Sowers, MD, Columbia, MOPart IIModerator: Michael A. Weber, MD, New York, NY11:00 AM Panel Discussion: Goals of Blood PressureReductionIntroduction: Michael A. Weber, MDPanelists: Sripal Bangalore, MD, Brookline, MA,Atul R. Chugh, MD, Louisville, KY,William C. Cushman, MD, Memphis, TN andAldo J. Peixoto, MD, West Haven, CT12:15 PM LunchPart IIIChairs: Stephen C. Textor, MD, Rochester, MN andRaymond R. Townsend, MD, Philadelphia, PA1:30 PM Electrolyte Disturbances in HypertensionManagementBertram Pitt, MD, Ann Arbor, MI2:00 PM Update in Pathophysiology and Therapy of RenalVascular HypertensionLilach O. Lerman, MD, PhD, Rochester, MN andStephen C. Textor, MD2:30 PM Update: Bio Markers as a Tool to Assess Renal Riskand Renal InjuryBrad C. Astor, PhD, MPH, Baltimore, MD54

Saturday Afternoon MAY 1PostersPosters will be displayed in the Rhinelander Gallery.Saturday, May 1, 2010Posters on Display: 3:00 PM – 7:00 PM • Poster Viewing: 5:00 PM – 6:00 PMAntihypertensive Drugs and Pharmacology......... (PO-009 – PO-077B)Arterial Structure and Compliance........................ (PO-078 – PO-099B)Cardiac Structure and Function/Imaging.................(PO-100 – PO-105)Coronary Artery Disease............................................(PO-106 – PO-107)Secondary Hypertension.............................................(PO-108 – PO-109)Stroke.............................................................................(PO-110 – PO-114)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.1 Pathobiology Track 2 Translational Track 3 Therapy Track55

MAY 1SessionsSaturday Afternoon3:30 PM – 5:00 PM • Beekman ParlorPhysician Industry RelationsChairs: Henry R. Black, MD, New York, NY andMichael A. Weber, MD, New York, NY3:30 PM The Physician/Industry Relationship:Why is it Under Attack?Thomas P. Stossel, MD, Boston, MA4:00 PM Conflict of Interest: What Does it Really Mean?Lance K. Stell, PhD, Davidson, NC4:30 PM Are Academic Physicians, Individually and asOrganizations, Too Dependent on Industry?Jeffrey R. Garber, MD, Boston, MA56

Saturday Afternoon MAY 1Sessions3:30 PM – 5:00 PM • Sutton NorthPathophysiology of HypertensionChairs: Haralambos Gavras, MD, Boston, MA andBertram Pitt, MD, Ann Arbor, MI3:30 PM New Concepts in AldosteroneGail Adler, MD, PhD, Boston, MA4:00 PM EndothelinGregory D. Fink, MD, East Lansing, MI4:30 PM Insights into the Mechanism of ACE InhibitionOscar A. Carretero, MD, Detroit, MI57

MAY 1SessionsSaturday Afternoon3:30 PM – 5:00 PM • Mercury BallroomPublic Health and Hypertension:Can Population-Based Strategies Work?Chairs: Keith C. Ferdinand, MD, Atlanta, GA andJoseph L. Izzo, Jr., MD, Buffalo, NY3:30 PM Chicago Initiatives to Change the Effects ofExcess Sodium, Saturated Fat Intake, and PhysicalInactivityTerry Mason, MD, Chicago, IL3:50 PM New York City Initiatives to Increase HealthyFood Patterns in Restaurants and the National SaltReduction InitiativeSonia Y. Angell, MD, MPH, New York, NY4:10 PM Developing Community Networks to ImproveHypertension CareGbenga Ogedegbe, MD, MPH, New York, NY4:25 PM Update on the South Carolina Initiatives to ReduceHypertensionBrent M. Egan, MD, Charleston, SC4:40 PM Panel Discussion58

Saturday Afternoon MAY 1Sessions3:30 PM – 5:00 PM • Sutton CenterMolecular Mechanisms of Hypertension: NovelConcepts and Clinical ImplicationsHeld in Partnership with the American Heart Association Council forHigh Blood Pressure Research (HBPR)Chairs: Rhian M. Touyz, MD, PhD, Ottawa, Canada andR. Clinton Webb, PhD, Augusta, GA3:30 PM RAS, Inflammation and Immunity: Implications inHypertensionDominik N. Müller, MD, Berlin, Germany3:52 PM Adipocytes and Vascular Cell Networking: A LinkBetween Obesity and HypertensionLisa A. Cassis, PhD, Lexington, KY4:14 PM Systems Medicine Strategies in CardiovascularPreventionAnna F. Dominiczak, MD, Glasgow, United Kingdom4:36 PM The Kidneys, the Heart and the Vessels in ClinicalHypertension: Lessons from MiceThomas M. Coffman, MD, Durham, NC59

MAY 1SessionsSaturday Afternoon4:00 PM – 5:00 PM • Rendezvous TrianonYoung Investigator-in-Training AbstractCompetitionModerator: Suzanne Oparil, MD, Birmingham, ALJudges: John M. Flack, MD, MPH, Detroit, MI, Alan H.Gradman, MD, Pittsburgh, PA, Daniel T. Lackland,DrPH, Charleston, SC, Sandra J. Taler, MD, Rochester,MN and Myron H. Weinberger, MD, Indianapolis, IN4:00 PM OR-35: Efficacy and Safety of Dual Calcium Channel(CCB) TherapyCarlos L. Alviar, Santhosh Devarapally, Jorge Romero,Hyuensok Kang, Girish N. Nadkarni, Fahad Javed,Alexandre M. Benjo, Franz Messerli. St. Luke’s-Roosevelt Hospital Center, Columbia UniversityCollege of Physicians and Surgeons, New York, NY,US.4:12 PM OR-37: Refractory Hypertension: Definition,Prevalence, and Patient CharacteristicsMaria Czarina Acelajado, David A. Calhoun.University of Alabama at Birmingham, Birmingham,AL, US.4:24 PM OR-38: Abnormal Regulation of the Renin-Angiotensin-Aldosterone System in ObeseHypertensive MenCamilla Asferg, Ulrik B. Andersen, Jørgen Jeppesen.Copenhagen University Hospital Glostrup, Glostrup,DK.4:36 PM OR-39: Mapping a Genetic Determinant of BloodPressure to

Sunday Morning MAY 2Satellite Symposium6:00 AM – 7:30 AM • Trianon BallroomThe Journey to Optimal Treatment Strategies forthe OA Patient with HypertensionChairperson: Michael A. Weber, MD, Brooklyn, NYProgram Agenda:6:00 AM Welcome and IntroductionsMichael A. Weber, MD6:10 AM NSAIDs, Blood Pressure and Cardiovascular Risk:Understanding the Risks for Osteoarthritis PatientsAndrew Whelton, MD, Baltimore, MD6:30 AM Nitric Oxide: The Journey from Basic Biology toTherapeutic PotentialLeopoldo Raij, MD, Miami, FL6:55 AM CINODs: A New Option in the Management ofOsteoarthritis Patients with HypertensionMichael A. Weber, MD7:20 AM Panel Discussion/Questions and AnswersAll FacultyLearning Objectives:• Review the current available options for thetreatment of osteoarthritis (OA) and evaluatetheir potential benefits and risks• Discuss the relationship of backgroundantihypertensive therapy in NSAID-inducedblood pressure destabilization• Summarize the outcomes associated withendothelial dysfunction and decreasedbioavailability of nitric oxide• Evaluate the data and potential utility ofCyclooxygenase-Inhibiting Nitric Oxide Donating(CINOD) drugsBreakfast will be served at 5:45 AM in theTrianon Ballroom.Supported by an educational grant from NicOx, Inc.61

MAY 2SessionsSunday morning7:30 AM – 11:40 AM • West BallroomHypertension for the Primary Care Clinician 2010Moderator:Jan N. Basile, MD, Charleston, SCTheme 1:Blood Pressure Measurement: Which MetricMatters?Chairs: Louis Kuritzky, MD, Gainesville, FL andMarvin Moser, MD, New Haven, CT7:30 AM Case Study: Measurement of Blood PressureF. Wilford Germino, MD, Orland Park, IL7:40 AM White Coat and Masked Hypertension. Does itMatter?Angela L. Brown, MD, St. Louis, MO8:00 AM 24-Hour Ambulatory and Home Blood PressureMeasurement: How to Use in Clinical PracticeWilliam B. White, MD, Farmington, CT8:20 AM Q & ATheme 2:Hypertension in the ElderlyChairs: F. Wilford Germino, MD andEdward G. Lakatta, MD, Baltimore, MD8:30 AM Case PresentationSteven A. Yarows, MD, Chelsea, MI8:35 AM Isolated Systolic HypertensionSteven A. Yarows, MD9:05 AM The Clinical Implications of the HYVET StudyMichael J. Bloch, MD, Reno, NV9:35 AM Q & A9:45 AM BreakTheme 3:Resistant Hypertension: Optimizing Drug TherapyChairs: Jan N. Basile, MD and Angela L. Brown, MD10:00 AM Introduction: Differential Diagnosis of ResistantHypertension. When to Work-Up for SecondaryHypertensionSamuel J. Mann, MD, New York, NY10:10 AM Case PresentationsModerator: Samuel J. Mann, MD, New York, NYWilliam J. Elliott, MD, PhD, Yakima, WA, David A.Calhoun, MD, Birmingham, AL, and Stephen C. Textor,MD, Rochester, MN10:50 AM Q & Acontinued…62

Sunday Morning MAY 2Sessions continuedTheme 4:Evidence vs. Guidelines:What Should Be the Goal Blood Pressure inDiabetics: Results of the ACCORD StudyChairs: Louis Kuritzky, MD and Samuel J. Mann, MD11:00 AM Results of the ACCORD Blood Pressure TrialLouis Kuritzky, MD11:20 AM What These Results Mean to the Primary CareClinicianMyra Kleinpeter, MD, MPH, New Orleans, LA11:30 AM Q & A63

MAY 2PostersSunday MorningPosters will be displayed in the Rhinelander Gallery.Sunday, May 2, 2010Posters on Display: 9:00 AM – 6:45 PM • Poster Viewing: 4:45 PM – 5:45 PMFeatured Posters...........................................................(PO-001 – PO-008)Blood Pressure Measurement/Monitoring...............(PO-115 – PO-160)Heart Failure/Hypertrophy(Diastolic Dysfunction)...............................................(PO-161 – PO-164)Kidney and Hypertension...........................................(PO-165 – PO-178)Metabolic Syndrome (Diabetes/Glycemic Control;Dysglycemic Drugs; Insulin Resistance)...................(PO-179 – PO-199)Non-Pharmacological Therapy (AlternativeMedicine; Diet; Physical Activity).............................(PO-200 – PO-202)Patient-Provider-Healthcare System Issues..............(PO-203 – PO-209)Risk Factors (Lipids)....................................................(PO-210 – PO-213)Pregnancy......................................................................(PO-214 – PO-216)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.1 Pathobiology Track 2 Translational Track 3 Therapy Track64

Sunday Morning MAY 2Sessions8:00 AM – 9:00 AM • Beekman ParlorImproving Regional Cardiovascular OutcomesHeld in Partnership with the Consortium for Southeastern HypertensionControl (COSEHC)Chair: Daniel T. Lackland, DrPH, Charleston, SC,Board of Directors Member, COSEHC8:00 AM The COSEHC Cardiovascular Centers of ExcellenceModel for Improving Cardiovascular Health: TheReality of a DreamMichael A. Moore, MD, Winston-Salem, NC, President,Founder, COSEHC8:20 AM The COSEHC Database: Defining the Need andImprovementsCarlos M. Ferrario, MD, Winston-Salem, NC, VicePresident for Development, Founder, COSEHC8:40 AM The Potential of the COSEHC Model forCardiovascular ImprovementEdward J. Roccella, PhD, MPH, Vienna, VA,Board of Directors Member, COSEHC8:55 AM Closing RemarksMichael A. Moore, MDLearning Objectives:At the end of the activity the learner will be able to:1. Utilize a process improvement approach to assistpatients in reaching recommended cardiovascularrisk factor goals2. Utilize electronic medical record data to improvecardiovascular outcomes3. Develop his/her practice into a COSEHCCardiovascular Center of Excellence4. Describe the utility of the COSEHC database inplanning, developing and testing community CVeducation materials and programs.65

MAY 2SessionsSunday Morning8:00 AM – 9:30 AM • Sutton NorthThe Emerging Role of Aldosterone in HypertensionChairs: Keith C. Ferdinand, MD, Atlanta, GA andLeopoldo Raij, Miami, FL8:00 AM Aldosterone, Hypertension and the MetabolicSyndromeToshiro Fujita, MD, Tokyo, Japan8:30 AM Aldosterone and the Kidney: An UpdateMurray Epstein, MD, Miami, FL9:00 AM Chiral Molecules: A New Approach in the Treatmentof HypertensionC. Venkata S. Ram, MD, Dallas, TXSupported by an educational grant from Emcure Pharmaceuticals.66

Sunday Morning MAY 2Sessions10:00 AM – 11:30 AM • Mercury BallroomALLHAT: Long-term Outcomes of Drug Treatment inHigh CHD Risk Hypertensive PatientsChair: Jeffrey A. Cutler, MD, MPH, Washington, DC10:00 AM Overview of ALLHAT Post-trial Follow-upBarry R. Davis, MD, PhD, Houston, TX10:15 AM Long-term Outcomes in ALLHATWilliam C. Cushman, MD, Memphis, TN10:30 AM Post-incident Heart Failure Mortality in 10 years ofFollow-up in ALLHATLinda B. Piller, MD, MPH, Houston, TX10:45 AM Risk Modification by Diabetes at Baseline andIncident During Randomized Phase of the TrialJoshua Barzilay, MD, Tucker, GA11:00 AM Cardiovascular and Renal Outcomes in Those withCKDMahboob Rahman, MD, Cleveland, OH11:15 PM CommentsMark Espeland, PhD, Winston-Salem, NCLearning Objectives:At the end of this session, the attendees will be ableto describe appropriate treatment for the long-termmanagement of hypertension based on:1. 10-year follow-up of ALLHAT participants,including prespecified subgroups2. post-incident heart failure mortality in ALLHATparticipants who developed heart failure duringthe randomized phase of the trial, overall and byejection fraction3. long-term outcomes in those who developed typeII diabetes during the randomized phase of thetrial by randomized treatment groups4. long-term follow-up of ALLHAT participantswith CKD at baseline.67

MAY 2Special SessionsSunday Morning10:00 AM – 11:00 AMMeet the Expert Brunch SessionsMorgan SuiteUpdates and Results on Women’s Health InitiativeKaren L. Margolis, MD, MPH, Minneapolis, MNBryant SuiteClinton SuiteManagement of Low HDL CholesterolHoward Weintraub, MD, New York, NYIsolated Systolic HypertensionJohn B. Kostis, MD, New Brunswick, NJBeekman ParlorHow to Interpret a Clinical Trial ManuscriptRichard H. Grimm, Jr., MD, PhD, Minneapolis, MNGibson SuiteHypertension and Air PollutionRobert D. Brook, MD, Ann Arbor, MISutton NorthAngiotensin 1-7. Is it Relevant?Carlos M. Ferrario, MD, Winston-Salem, NC68

Sunday Morning MAY 2Sessions10:00 AM – 11:00 AM • Rhinelander GalleryClinical Case DiscussionsModerator:Moderator:John M. Flack, MD, MPH, Detroit, MIResistant Hypertension: Non-Drug ApproachesJohn D. Bisognano, MD, PhD, Rochester, NY andThomas E. Lohmeier, PhD, Jackson, MSThomas D. Giles, MD, New Orleans, LACardiovascular Risk in the Young AthleteDavid S. Cannom, MD, Los Angeles, CA andAlan H. Gradman, MD, Pittsburgh, PA69

MAY 2Plenary Session ISunday Afternoon12:00 PM – 3:10 PM • East BallroomPlenary Session I: Hypertension in the 21st CenturyChairs: Henry R. Black, MD, New York, NY andGeorge L. Bakris, MD, Chicago, IL12:00 PM President’s WelcomeHenry R. Black, MD, New York, NY12:40 PM JNC 8: An Evidence-Based Approach to GuidelineDevelopment at NHLBIEduardo Ortiz, MD, MPH, Bethesda, MD1:00 PM Keynote Lecture: Hypertension: The Past – ThePresent – The FutureEugene Braunwald, MD, Boston, MA1:40 PM Management of Blood Pressure in Patient with anAcute StrokePhilip B. Gorelick, MD, MPH, Chicago, IL2:10 PM An Approach to Global RiskJohn B. Kostis, MD, New Brunswick, NJ2:40 PM New Ways to Interpret Clinical Trials:Non Inferiority Studies and Network Meta-AnalysisWilliam J. Elliott, MD, PhD, Yakima, WA70

Sunday Afternoon MAY 2Sessions3:30 PM – 4:30 PM • Mercury Ballroom1 Aging and AtherosclerosisChairs: C. Venkata S. Ram, MD, Dallas, TX andClive Rosendorff, MD, PhD, New York, NY3:30 PM What the Hypertension Specialist Should KnowAbout the Pathophysiology of Central ArterialAgingEdward G. Lakatta, MD, Baltimore, MD4:00 PM What the Hypertension Specialist Should KnowAbout the Pathobiology of the AtheroscleroticPlaqueEdward A. Fisher, MD, PhD, MPH, New York, NY1 Pathobiology Track 2 Translational Track 3 Therapy Track71

MAY 2SessionsSunday Afternoon3:30 PM – 4:30 PM • East Ballroom2 Secondary Hypertension: Causes andComplicationsChairs: Vasilios Papademetriou, MD, Washington, DC andSandra J. Taler, MD, Rochester, MN3:30 PM What the Hypertension Specialist ShouldKnow About Imaging for Secondary Causes ofHypertension: When to Take ActionThomas A. Sos, MD, New York, NY4:00 PM What the Hypertension Specialist Should KnowAbout Peripheral Vascular DiseaseKanwar Singh, MD, Farmington, CT1 Pathobiology Track 2 Translational Track 3 Therapy Track72

Sunday Afternoon MAY 2Sessions3:30 PM – 4:30 PM • West Ballroom3 Overviews in Vascular Function and ClinicalPharmacologyChairs: Jan N. Cohn, MD, Minneapolis, MN andWilliam B. White, MD, Farmington, CT3:30 PM What the Hypertension Specialist Should KnowAbout Pharmacokinetics, Pharmacodynamics andDrug InteractionDomenic A. Sica, MD, Richmond, VA4:00 PM What the Hypertension Specialist Should KnowAbout Vascular FunctionRaymond R. Townsend, MD, Philadelphia, PA1 Pathobiology Track 2 Translational Track 3 Therapy Track73

MAY 2SessionsSunday Afternoon3:30 PM – 4:30 PM • Beekman ParlorCardio-Metabolic Abnormalities in ArterialHypertensionHeld in Partnership with the Argentine Society of Hypertension(SAHA)Chairs: Roberto A. Ingaramo, MD, Trelew Chubut, Argentina,1st Vice President, Argentine Society of Hypertension,and Claudio A. Bellido, MD, PhD, Buenos Aires,Argentina3:30 PM Diastolic Heart Failure and HypertensionHector O. Ventura, MD, New Orleans, LA3:50 PM Obesity and the Metabolic Syndrome:Cardiovascular and Renal ConsequencesEfrain Reisin, MD, New Orleans, LA4:10 PM Statins and Lipids in Hypertension and RenalDiseaseLuis Juncos, MD, Córdoba, Argentina74

Sunday Afternoon MAY 2Special Sessions4:45 PM – 5:45 PMMeet the Expert SessionsMorgan SuitePharmacokinetics, Pharmacodynamics and DrugInteractionDomenic A. Sica, MD, Richmond, VABryant SuiteClinton SuiteGibson SuiteVascular FunctionRaymond R. Townsend, MD, Philadelphia, PAImaging for Secondary Causes of HypertensionThomas A. Sos, MD, New York, NYPeripheral Vascular DiseaseKanwar Singh, MD, Farmington, CT75

MAY 2SessionsSunday Evening6:00 PM – 7:30 PM • Mercury Ballroom1 Hypertension and Oxidative StressChairs: Gregory D. Fink, MD, East Lansing, MI andRhian M. Touyz, MD, PhD, Ottawa, CanadaOriginal Communications6:00 PM OR-1: Regulation of Renal Inflammation byDopamine D2 ReceptorsInes Armando†, Yanrong Zhang, Yu Yang, XioayanWang, John E. Jones, Laureano D. Asico, CrisantoEscano, Pedro A. Jose. Children’s Research Institute,Washington, DC, US.6:15 PM OR-2: Hyperuricemia Induces Oxidative Stressand Decreased Nitric Oxide Availability via theAngiotensin Type 1 ReceptorDalila Corry, 1 Janake Wijesuriya†, 2 Michael D. Nyby, 2Victoria Smutko, 2 Michael L. Tuck. 2 1 David GeffenSchool of Medicine at UCLA, Sylmar, CA, US and2 David Geffen School of Medicine at UCLA/VAGLAHS, Sepulveda, CA, US.6:30 PM OR-3: Temporal Hemodynamic Changes PostMyocardial Infarction in Relation to CentralAlterations in Angiotensin II and Oxidative StressTarek M. Mousa, 1 Irving H. Zucker. 2 1 The New YorkHospital Medical Center of Queens, Flushing, NY,US and 2 University of Nebraska Medical Center-Cardiovascular Research Center, Omaha, NE, US.6:45 PM OR-4: Novel Angiotensinogen Gene PromoterVariants And Kidney CancerRiccardo Sarzani, 1 Marica Bordicchia, 1 Marcod’Anzeo, 1 Guido Salvetti, 2 Ferruccio Santini, 2 AntonioBarbato, 3 Pasquale Strazzullo, 3 Paolo Dessì-Fulgheri, 1Allessandro Rappelli. 1 1 Dept of Internal Medicine,University of Ancona - Politecnica Marche, Ancona,IT; 2 Endocrinology and Kidney Unit, UniversityHospital, Pisa, IT and 3 Dept. of Clinical andExperimental Medicine-University Naples, Napoli, IT.7:00 PM Oxidative Stress and HypertensionChristopher S. Wilcox, MD, PhD, Washington, DC1 Pathobiology Track 2 Translational Track 3 Therapy Track76

Sunday Evening MAY 2Sessions6:00 PM – 7:15 PM • East Ballroom2 Blood Pressure Goals: Novel ApproachesChairs: Roger S. Blumenthal, MD, Baltimore, MD andMurray Epstein, MD, Miami, FLOriginal Communications6:00 PM OR-5: Triple Combination Therapy withAmlodipine/Valsartan/HCTZ at Maximal DosesIs Safe and Effective for Hypertensive PatientsUncontrolled on ARB Monotherapy: The EXTRAStudyS. Oparil†, 1 T. Giles, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5R. Samuel, 5 R. Hilkert, 5 J. Sowers. 6 1 Univ. Alabama atBirmingham, US; 2 Tulane Univ. SoM, US; 3 MorehouseSoM, US; 4 Univ. Michigan SoM, US; 5 Novartis, US and6 Univ. Missouri SoM, US.6:15 PM OR-6: Trends in Antihypertensive Medication UseAmong Incident Cases Of Hypertension, 2002-2006:The Geisinger Clinic PopulationFrederick J. Bloom, 1 Robert D. Langer, 2 Jove Graham, 1Raymond R. Townsend, 3 Sean Hennessy. 3 1 GeisingerHealth System, Danville, PA, US; 2 Jackson HoleCenter for Preventive Medicine, US and 3 University ofPennsylvania, US.6:30 PM OR-8: Improved Non-Fatal CardiovascularEvents with Chlorthalidone Compared toHydrochlorothiazideMichael P. Dorsch, 1,2 Steven R. Erickson, 1,2 Barry E.Bleske, 1,2 Alan B. Weder. 1,3 1 University of MichiganHospitals, Ann Arbor, MI, US; 2 University of MichiganCollege of Pharmacy, Ann Arbor, MI, US and3 University of Michigan Medical School, Ann Arbor,MI, US.6:45 PM Adherence to TherapyWilliam J. Elliott, MD, PhD, Yakima, WA1 Pathobiology Track 2 Translational Track 3 Therapy Track77

MAY 2SessionsSunday Evening6:00 PM – 7:30 PM • West Ballroom3 Non-Cardiac Drugs that Raise Blood PressureChairs: Franz Messerli, MD, New York, NY andElijah Saunders, MD, Baltimore, MDOriginal Communications6:00 PM OR-9: Hyperuricemia, Cronotherapy withAlopurinol and HypertensionCarlos Calvo, 1 Alvaro Hermida, 1 José Enrique Lopez, 1Marta Pena, 1 Luisa Romero, 1 Gaila Calvo, 1 AntonioCoca. 2 1 Hypertension and Vascular Risk Unit.Complejo Hospitalario Universitario de Santiago,ES and 2 Unit Hypertension, Hospital Clinico deBarcelona, ES.6:15 PM OR-10: The Nitric Oxide Donator Naproxcinod HasBlood Pressure Effects Similar to Placebo in Patientswith OsteoarthritisW. B. White†, 1 T. Schnitzer, 2 J. Dijian, 3 H. Frayssinet, 3B. Duquesroix, 3 M. A. Weber. 4 1 University ofConnecticut School of Medicine, Farmington, CT,US; 2 Northwestern University Feinberg School ofMedicine, Chicago, IL, US; 3 Nicox, S.A., Sophia-Antipolis, FR and 4 SUNY Downstate College ofMedicine, Brooklyn, NY, US.6:30 PM OR-11: Different Effects of Aliskiren/Hydrochlorotiazide and Atenolol/Hydrochlorotiazide Combinations on CentralPressure in Elderly Hypertensive PatientsRoberto Fogari, Amedeo Mugellini, Paola Preti,Maurizio Destro, Luca Corradi, Giuseppe Derosa.Department of Internal Medicine, University of Pavia,Pavia, IT.6:45 PM OR-12: Factors Influencing the Ambulatory BloodPressure Response to Low-Dose Aspirin in Subjectswith Untreated Mild HypertensionDiana E. Ayala, Ramon C. Hermida, Maria J. Fontao,Artemio Mojon, Jose R. Fernandez. University of Vigo,ES.7:00 PM Blood Pressure Increases from Non-cardiacTherapies Including Arthritis Meds, Psychotropics,Neurological Drugs, Angiogenesis BlockersEhud Grossman, MD, Tel Hashomer, Israel1 Pathobiology Track 2 Translational Track 3 Therapy Track78

Sunday Evening MAY 2Sessions6:00 PM – 7:30 PM • Beekman ParlorCornerstones of the European and AmericanGuidelines: Similarities and DifferencesHeld in partnership with the European Society of Hypertension(ESH)Chairs: Henry R. Black, MD, New York, NY andKrzysztof Narkiewicz, MD, PhD, Gdánsk, Poland6:00 PM Antihypertensive Drug Treatment: Threshold andTarget Blood Pressure ValuesGiuseppe Mancia, MD, Milan, Italy6:22 PM Assessment of Organ Damage in HypertensionSverre E. Kjeldsen, MD, Oslo, Norway6:44 PM Combination Treatment in HypertensionSuzanne Oparil, MD, Birmingham, AL7:06 PM Antihypertensive Treatment in Diabetes and OtherSpecial Clinical ConditionsGeorge L. Bakris, MD, Chicago, IL79

MAY 2Satellite SymposiumSunday Evening8:00 PM – 9:30 PM • Trianon BallroomExploring the Future of CombinationAntihypertensive Therapy: Is There a Limit to theNumber of Drugs in a Fixed-Dose Combination?Chairperson: Suzanne Oparil, MD, Birmingham, ALProgram Agenda:8:00 PM Welcome and Introductory RemarksSuzanne Oparil, MD8:05 PM Recent Clinical Trial Evidence on CombinationAntihypertensive TherapySuzanne Oparil, MD8:25 PM Combination Antihypertensive Therapy:What Are the Options and How Do We Use Them?Jan N. Basile, MD, Charleston, SC8:45 PM Triple Combinations and Beyond: What Is theFuture of Fixed-Dose Therapy?C. Venkata Ram, MD, Dallas, TX9:05 PM Optimizing the Use of Combination Therapy:A Case-Study-Illustrated DiscussionPanel Presentation – All Faculty9:25 PM Concluding RemarksSuzanne Oparil, MDLearning Objectives:• Describe hypertensive treatment practices inpatients with uncontrolled BP• Discuss the role of aggressive combinationtherapy to help achieve optimal BP control inpatients with difficult-to-treat hypertension• Describe the pharmacokinetic differences amongantihypertensive combination regimens• Understand the relative benefits of variousantihypertensive combinationsDinner will be served at 7:30 PM in theTrianon Ballroom.Supported by an educational grant from Daiichi Sankyo Inc.80

Monday Morning MAY 3Satellite Symposium6:00 AM - 7:30 AM • Trianon BallroomTargeting Endothelial Dysfunction in HypertensiveCardiovascular Disease: Why, When, and HowChairperson: Thomas D. Giles, MD, New Orleans, LAProgram Agenda:6:00 AM Introduction: New Evidence for Targeting CriticalMechanisms in Hypertensive Heart DiseaseThomas D. Giles, MD6:25 AM Race-Specific Differences in EndothelialDysfunction: Relevance to Management ofHypertensionR. Preston Mason, PhD, Boston, MA6:50 AM Targeting Endothelial Dysfunction in theManagement of Cardiovascular DiseaseAlan H. Gradman, MD, Pittsburgh, PA7:15 AM Panel Discussion and Concluding RemarksThomas D. Giles, MDLearning Objectives:• Describe the role of nitric oxide in endothelialdysfunction and in the pathogenesis ofhypertension, and hypertensive cardiovasculardisease, including LVH and heart failure• Evaluate the relationship between oxidative stressand endothelial function and its relevance to themanagement of hypertensive patients• Identify pre-clinical and clinical evidencesupporting the concept that there are race-baseddifferences in endothelial function which mayhave clinical ramifications• Analyze the pharmacologic differences amongβ-blockers, including those with vasodilatingproperties, and outline the evidence for theclinical impact of these properties, especially ontolerability and efficacyBreakfast will be served at 5:45 AM in theTrianon Ballroom.Supported by an educational grant from Forest Pharmaceuticals, Inc.81

MAY 3SessionsMonday morning8:00 AM – 9:30 AM • Mercury Ballroom1 The Genetic Basis of HypertensionChairs: Willa A. Hsueh, MD, Houston, TX andAllyn L. Mark, MD, Iowa City, IAOriginal Communications8:00 AM OR-13: A

Monday Morning MAY 3Sessions8:00 AM – 9:30 AM • East Ballroom2 Biomarkers and Cardiovascular Risk: NovelMethods of AssessmentChairs: Daniel Levy, MD, Framingham, MA andHenry A. Solomon, MD, New York, NYOriginal Communications8:00 AM OR-17: Early Inflammatoryand Metabolic Changesin Association with AGTR1 Polymorphisms inPrehypertensive SubjectsMaple M. Fung†, 1,2 Fangwen Rao, 1,2 ManjulaMahata, 1,2 Suskil K. Mahata, 1,2 Daniel T. O’Connor. 21 Veterans Affairs San Diego Healthcare System, LaJolla, CA, US and 2 University of California, San Diego,La Jolla, CA, US.8:15 AM OR-18: Assessment of Target-Organ Damage inAdolescent White Coat and Sustained HypertensivesDenes Pall, 1 Maria Juhasz, 1 Eva M. Katona, 1 SzabolcsLengyel, 1 Csilla Molnar, 2 Eva Komonyi, 1 GyorgyParagh, 1 Bela Fulesdi. 2 1 First Department ofMedicine, University of Debrecen, Debrecen, HU and2 Department of Anesthesiology and Intensive Care,University of Debrecen, Debrecen, HU.8:30 AM OR-19: A Cross-Sectional Analysis ofCardiometabolic Risk Factors and Blood PressureControl Among 28 Physician Practices in the USDaniel A. Belletti†, 1 Jennifer Wogen, 2 ChristopherZacker. 1 1 Novartis Pharmaceuticals Corporation, EastHanover, NJ, US and 2 MedMentis Consulting, LLC,Towaco, NJ, US.8:45 AM OR-20: Southeastern Cardiovascular Risk FactorControl Rates In Primary Care ClinicsMichael Moore†, 1 Carlos M. Ferrario, 2 RichardSchuster, 3 Jerry Miller, 4 Bill Bestermann, 5 DebbieSimmons, 6 JaNae Joyner. 7 1 Wake Forest Sch Med,US; 2 Wake Forest Sch Med, US; 3 Med Coll Georgia,US; 4 Holston Med Grp, US; 5 Holston Med Grp, US;6 COSEHC, US and 7 COSEHC, US.9:00 AM Academic Industry RelationsP. Roy Vagelos, MD, Bedminster, NJ1 Pathobiology Track 2 Translational Track 3 Therapy Track83

MAY 3SessionsMonday morning8:00 AM – 9:30 AM • West Ballroom3 Hypertension as a Silent Prelude to HeartFailureChairs: John D. Bisognano, MD, PhD, Rochester, NY andMichael E. Ernst, PharmD, Iowa City, IAOriginal Communications8:00 AM OR-21: Riser Pattern Is Associated with ImpairedCognitive Function in Heart Failure PatientsTakahiro Komori, Kazuo Eguchi, Hidenori Tomizawa,Satoshi Hoshide, Joji Ishikawa, Kazuyuki Shimada,Kazuomi Kario. Division of Cardiovascular Medicine,Department of Medicine, Jichi Medical UniversitySchool of Medicine, Shimotsuke-shi, Tochigi-ken, JP.8:15 AM OR-22: Control of Hypertension in 15 MedicalCenters from the Department of Veterans AffairsRoss D. Fletcher, 1 Vasilios Papademetriou, 1 RichardAmdur, 1 Charles Faselis, 2 Christopher McManus, 1Ronald Jones Jones. 1 1 VAMC and GeorgetownUniversity, Washington, DC, US and 2 VAMC andGeorg Washington University, Washington, DC, US.8:30 AM OR-23: Strong Association of Left VentricularMass with Renal Outcomes in Patients with HighCardiovascular RiskC. Tsioufis, 1 P. Kokkinos, 1 C. MacManus, 1 C.Thomopoulos, 2 C. Stefanadis, 2 V. Papademetriou. 11 Veterans Affairs Medical Center/CardiologyDepartment and Georgetown Medical Centers,Washington, DC, US and 2 First Cardiology Clinic,University of Athens, Hippokration Hospital, Athens,GR.8:45 AM OR-24: Independent Predictive Value of LVH andRenal Dysfunction Changes During Treatment inHypertensive PatientsMaria Lorenza Muiesan, Massimo Salvetti, ClaudiaAgabiti Rosei, Anna Paini, Cristina Monteduro, CarloAggiusti, Enrico Agabiti Rosei. Internal Medicine,University of Brescia, Italy, IT.9:00 AM Heart Failure with Preserved Systolic FunctionBarry M. Massie, MD, San Francisco, CA1 Pathobiology Track 2 Translational Track 3 Therapy Track84

Monday Morning Afternoon MAY 21 3PostersPosters will be displayed in the Rhinelander Gallery.Monday, May 3, 2010Posters on Display: 9:00 AM – 5:15 PM • Poster Viewing: 4:15 PM – 5:15 PMCellular Mechanisms (Cell Biology;Cell Membrane Transport/Ion Channels;Coagulation/Thrombosis; Growth Factors).............(PO-217 – PO-219)Clinical Trials................................................................(PO-220 – PO-242)Endothelial Function...................................................(PO-243 – PO-255)Epidemiology/Special Populations............................(PO-256 – PO-293)Genetics/Gene Therapy/Proteomics..........................(PO-294 – PO-297)Neural Hormonal Mechanisms (Renin;Neural Control; Vasoactive Autacoids).....................(PO-298 – PO-300)Obesity...........................................................................(PO-301 – PO-306)Pediatric Hypertension...............................................(PO-307 – PO-308)Preclinical Models/ExperimentalHypertension................................................................(PO-309 – PO-311)Vascular Injury/Inflammation andRemodeling...................................................................(PO-312 – PO-318)Late-Breaking Posters........................................(LBPO-001 – LBPO-016)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.1 Pathobiology Track 2 Translational Track 3 Therapy Track85

MAY 3SessionsMonday morning10:00 AM – 11:15 AM • Mercury Ballroom1 Renal Mechanisms of HypertensionChairs: Oscar A. Carretero, MD, Detroit, MI andL. Gabriel Navar, PhD, New Orleans, LAOriginal Communications10:00 AM OR-25: Close Relationship between Albuminuriaand Circulating Soluble Receptor for AdvancedGlycation End Products in HypertensionK. Dimitriadis, C. Tsioufis, D. Syrseloudis, C.Thomopoulos, A. Mazaraki, A. Miliou, D. Tousoulis,C. Stefanadis. First Cardiology Clinic, University ofAthens, Hippokration Hospital, Athens, GR.10:15 AM OR-26: A Genetic Variation in Human Salt-Inducible Kinase 1 Increases Cell Sodium Transportand Confers Susceptibility to High Blood Pressureand Increases in Left Ventricular MassSergej Popov, 1 Angela M. Silveira, 2 Kei Kamide, 3Sachiko Matsumoto, 3 Dick Wågsäter, 2 Fabio Sanchez, 1Yoshihiro Kokubo, 4 Tomonori Okamura, 4 YuheiKawano, 3 Ann-Christine Syvänen, 5 ToshiyukiMiyata, 3 Anders Hamsten, 2 Olle Melander, 6 AlejandroM. Bertorello†. 1 1 Membrane Signaling Networks,Atherosclerosis Research Unit, Department ofMedicine, Karolinska Institutet, Stockholm, SE;2 Cardiovascular Genetics, Atherosclerosis ResearchUnit, Department of Medicine, Karolinska Institutet,Stockholm, SE; 3 Department of Hypertension andNephrology, National Cardiovascular Center ResearchInstitute, Osaka, JP; 4 Department of PreventiveCardiology, National Cardiovascular Center ResearchInstitute, Osaka, JP; 5 Molecular Medicine, Departmentof Medical Sciences, Uppsala University, Uppsala, SEand 6 Department of Clinical Sciences, Lund University,Lund, SE.10:30 AM OR-27: A Novel Designer Natriuretic Peptidewith Potent Blood Pressure Lowering and CardiacUnloading Properties in a Model of AcuteHypertensionPaul M. McKie, Alessandro Cataliotti, S. JesonSangaralingham, Horng H. Chen, Guido Boerrigter,John C. Burnett, Jr. Mayo Clinic, Rochester, MN, US.10:45 AM What the Hypertension Specialist Should KnowAbout Renal Sympathetic NervesGerald F. DiBona, MD, Iowa City, IA1 Pathobiology Track 2 Translational Track 3 Therapy Track86

Monday Morning MAY 3Sessions10:00 AM – 11:30 AM • East Ballroom2 Cardiometabolic Syndrome: New Insights AboutRisk ReductionChairs: Lawrence J. Appel, MD, MPH, Baltimore, MD andNeil J. Stone, MD, Chicago, ILOriginal Communications10:00 AM OR-28: Does Prolonged Aldosterone Blockade AffectAdversely Glucose Control and Arterial Propertiesin Type 2 Diabetic Patients?Marina Shargorodsky, 2 Relu Cernes, 2 ReuvenZimlichman. 2 1 Wolfson Medical Center, Holon, IL and2 Sackler School of Medicine, Tel Aviv, IL.10:15 AM OR-29: Patients with Metabolic Syndrome ShowsHigh Salt Consumption and Increased BloodPressure Reactivity to Dietary Salt IntakeJoao Faria, Susana Bertoquini, Jose A. Silva, JorgePolonia. Blood Pressure Unit - Hospital PedroHispano, Matosinhos, PT.10:30 AM OR-30: Metabolic Syndrome and Atrial Fibrillationin Patients with Essential HypertensionG. Vyssoulis, 1 1 E. Karpanou, 2 D. Adamopoulos, 1Stella-Maria Kyvelou, 1 V. Tzamou, 1 P. Pietri, 1 P.Spanos, 1 C. Stefanadis. 1 1 1st Cardiology Clinic AthensUniversity Hippokration Hospital, Athens, GR and2 Cardiology Clinic Onassis Cardiosurgery Center,Athens, GR.10:45 AM OR-31: Apparently Healthy U.S. Adults withCoexisting Prehypertension and Prediabetes Pronefor Early Cardiovascular EventsAlok K. Gupta, Meghan McGlone, William D. Johnson.Pennington Biomedical Research Center, US.11:00 AM What the Hypertension Specialist Should Knowabout Metabolic Syndrome and Polycystic OvarySyndromeDavid A. Ehrmann, MD, Chicago, IL1 Pathobiology Track 2 Translational Track 3 Therapy Track87

MAY 3SessionsMonday morning10:00 AM – 11:30 AM • West Ballroom3 Complications of the Hypertensive DiseaseProcessChairs: Judith Hochman, MD, New York, NY andRobert A. Phillips, MD, PhD, Worcester, MAOriginal Communications10:00 AM OR-32: Coronary Artery Calcification Predicts AllCause Mortality in Hypertensive MalesJoseph Shemesh, 1 Michael Motro, 1 Nira Koren-Morag, 1 Awraham Weiss, 2 Ehud Grossman†. 2 1 CardiacRehabilitation Institute, Tel Hashomer, IL and 2 InternalMedicine D and Hypertension Unit, Tel Hashomer, IL.10:15 AM OR-33: Effects of Pedometer-Based Physical ActivityIntervention on Abdominal Fat and Blood Pressure:Saku Community-Based Randomized CrossoverIntervention StudyMotohiko Miyachi, Yumi Ohmori, Akemi Morita,Naomi Aiba, Shaw Watanabe. National Institute ofHealth and Nutrition, Shinjuku, Tokyo, JP.10:30 AM OR-34: Aliskiren Administration Time andAmbulatory Blood PressureCarlos Calvo, 1 Alvaro Hermida, 1 José Enrique Lopez, 1Marta Pena, 1 Gaila Calvo, 1 María Luisa Romero, 1Antonio Coca. 2 1 Hypertension and Vascular Risk Unit,Complejo Hospitalario Universitario de Santiago,Santiago de Compostela, ES and 2 Hypertension Unit.Hospital Clinico de Barcelona, ES.10:45 AM OR-35: Efficacy and Safety of Dual Calcium ChannelTherapyCarlos L. Alviar, Santhosh Devarapally, Jorge Romero,Hyuensok Kang, Girish N. Nadkarni, Fahad Javed,Alexandre M. Benjo, Franz Messerli. St. Luke’s-Roosevelt Hospital Center, Columbia UniversityCollege of Physicians and Surgeons, New York, NY,US.11:00 AM What the Hypertension Specialist Should KnowAbout the Treatment of Atrial Fibrillation in theHypertension PatientPeter R. Kowey, MD, Wynnewood, PA1 Pathobiology Track 2 Translational Track 3 Therapy Track88

Monday Morning MAY 3Sessions10:00 AM – 11:30 AM • Sutton NorthAssessing Arterial Stiffness to Improve theManagement of Cardiovascular Disease in the 21stCenturyHeld in partnership with the Association for Research into ArterialStructure and Physiology (ARTERY)Chairs:George L. Bakris, MD, Chicago, IL andJohn R. Cockcroft, MD, Cardiff, United KingdomEpidemiological Aspects: The Evidence10:00 AM Pulse Wave Velocity and Outcome Meta AnalysisCarmel M. McEniery, PhD, Cambridge, UnitedKingdom10:17 AM Central Blood Pressure and Outcome Meta AnalysisMary J. Roman, MD, New York, NYMechanistic Aspects10:34 AM Inflammation and Arterial StiffnessCharalambos Vlachopoulos, MD, Athens, Greece10:51 AM Genetics of Arterial StiffnessGary F. Mitchell, MD, Norwood, MANorth American Artery and the Tasks Ahead11:08 AM John R. Cockcroft, MD11:18 AM Raymond R. Townsend, MD, Philadelphia, PA89

MAY 3Special SessionsMonday morning11:45 AM – 12:45 PMMeet the Expert Lunch SessionsBryant SuiteGibson SuiteRenal Sympathetic NervesGerald F. DiBona, MD, Iowa City, IAThe Treatment of Atrial Fibrillation in theHypertensive PatientPeter R. Kowey, MD, Wynnewood, PASutton NorthMetabolic Syndrome and Polycystic OvarySyndromeDavid A. Ehrmann, MD, Chicago, ILMorgan SuiteExercise TestingMartha Gulati, MD, MS, Chicago, IL90

Monday Morning MAY 3Sessions11:45 AM – 12:45 PM • Rhinelander GalleryClinical Case DiscussionsModerator:Moderator:Samuel J. Mann, MD, New York, NYHypertension Emergencies and UrgenciesC. Venkata S. Ram, MD, Dallas, TXDaniel I. Feig, MD, PhD, Houston, TXEtiological Approach to Obesity Assessment andManagementDaniel I. Feig, MD, PhD, Houston, TX andArya M. Sharma, MD, PhD, Edmonton, Canada91

MAY 3Plenary Session IIMonday Afternoon1:15 PM – 4:15 PM • East BallroomAward PresentationsChairs:Henry R. Black, MD, New York, NY andNorman K. Hollenberg, MD, PhD, Boston, MA1:15 PM Welcome and IntroductionIrvine Page Award Lecture1:20 PM How Does Hypertension Produce IntracerebralHemorrhage?Donald D. Heistad, MD, Iowa City, IAYoung Scholar Award Lecture1:50 PM Under Pressure to Identify the GeneticDeterminents of Blood PressureBina Joe, PhD, Toledo, OHMarvin Moser Clinical HypertensionAward Lecture2:10 PM Team Approaches to Integrated CardiovascularHealthJoel Handler, MD, Anaheim, CAAnnouncement of ASH 2010 Young Investigator-in-Training Abstract Competition Award RecipientsState-of-the-Art LecturesChairs: Henry R. Black, MD, New York, NY andBarry J. Materson, MD, MBA, Miami, FL2:45 PM Update on PreeclampsiaS. Ananth Karumanchi, MD, Boston, MA3:15 PM Management and Regression of AtherosclerosisNeil J. Stone, MD, Chicago, IL3:45 PM Leptin and the New Biology of ObesityJeffrey M. Friedman, MD, PhD, New York, NY92

Monday Evening May 3Satellite Symposium7:30 PM – 9:00 PM • Trianon BallroomA Cross Examination of Contemporary Issues inHypertension: Today’s Controversy and ConsensusChairperson: George L. Bakris, MD, Chicago, ILProgram Agenda:7:30 PM Introduction and Opening RemarksGeorge L. Bakris, MD7:35 PM Debate #1:Setting Treatment Goals in Hypertension CareDomenic A. Sica, MD, Richmond, VAWilliam B. White, MD, Farmington, CT8:00 PM Summary Comments/Questions & AnswersModerated by George L. Bakris, MD8:05 PM Case Study Discussion: Combining Blood Pressure-Lowering Agents and Emerging Treatment OptionsWilliam B. White, MDPanel DiscussionAll Faculty8:20 PM Debate #2:Using Biomarkers to Assess Risk in HypertensionPatientsDomenic A. Sica, MDWilliam B. White, MD8:45 PM Summary Comments/Questions & AnswersModerated by George L. Bakris, MDLearning Objectives:• Optimize cardiovascular risk reduction byestablishing appropriate hypertension treatmentgoals and providing blood pressure monitoringthat accurately gauges progress toward treatmentgoals• Improve assessment of individual cardiovascularrisk using biomarkers to guide the developmentand adjustment of blood pressure–loweringregimens• Develop individualized blood pressure–loweringregimens that optimally employ currentlyavailable antihypertensive agents, eitherindividually or in combinationDinner will be served at 7:00 PM in theTrianon Ballroom.Cosponsored with the ASH Specialist Program Inc. andTCL Institute LLC.Supported by an educational grant from Takeda PharmaceuticalsNorth America, Inc.93

May 4SessionsTuesday MORNING7:45 AM – 9:45 AM • West BallroomLate-Breaking Clinical TrialsChairs: Henry R. Black, MD, New York, NY andGeorge L. Bakris, MD, Chicago, IL7:45 AM LB-OR-01: Tachycardia Predicts CardiovascularEvents in the VALUE TrialStevo Julius, 1 Paolo Palatini, 2 Sverre Kjeldsen, 3 AlbertoZanchetti , 4 Michael Weber, 5 Gordon McInnes, 6Tsushung Hua, 7 Bjoern Holzhauer , 7 Dion Zappe. 71 University of Michigan Cardiovascular Center, US;2 University of Padua, IT; 3 University of Oslo, NO;4 University of Milan, IT; 5 State University of NewYork, US; 6 University of Glasgow, GB and 7 NovartisPharmaceuticals, US.7:57 AM LB-OR-02: Once-Daily, Low Dose, Controlled-Release Phentermine/Topiramate Improves BloodPressure snd Result in Weight Loss in Overweight/Obese Patients Through 28 WeeksSuzanne Oparil†, 1 Louis J. Aronne, 2 Thomas Najarian, 3Wesley W. Day. 3 1 University of Alabama, Birmingham,Birmingham, AL, US; 2 Weill Cornell, New York, NY,US and 3 Vivus, Inc., Mountain View, CA, US.8:09 AM LB-OR-03: Results of a Double-BlindRandomized Study Comparing Chlorthalidoneand Hydrochlorothiazide Combined with theNew Angiotensin Receptor Blocker AzilsartanMedoxomil in Primary HypertensionG. Bakris†, 1 W. B. White, 2 M. A. Weber, 3 D. Sica, 4A. Perez, 5 C. Cao, 5 S. Kupfer. 5 1 U of Chicago Schoolof Medicine, US; 2 U of CT Health Center, US;3 SUNY Downstate College of Medicine, US; 4 VCUHealth System, US and 5 Takeda Global Research &Development, US.8:21 AM LB-OR-04: Matrix Metalloproteinase (MMP)-9 Genotype Affects the Responsiveness toAntihypertensive Therapy in GestationalHypertension But Not in PreeclampsiaAna Palei, 1 Valeria Sandrim, 2 Ricardo Cavalli, 2 RaquelGerlach, 2 Jose Tanus-Santos. 2 1 UNICAMP, Campinas,SP, BR and 2 USP, Ribeirao Preto, SP, BR.8:33 AM LB-OR-05: A Genetic Variant of the AtrialNatriuretic Peptide Gene and Its ProteinProduct Are Associated with Reduced Risk forCardiometabolic Disease in the General PopulationValentina Cannone, 1 Alessandro Cataliotti, 1 GuidoBoerrigter, 1 Lisa C. Costello-Boerrigter, 1 Kent R.Bailey, 2 Brian Lahr, 2 Denise M. Heublein, 1 Richard J.Rodeheffer, 1 Timothy M. Olson, 3 John C. Burnett. 11 Mayo Clinic, Rochester, Minnesota, US; 2 MayoClinic, Rochester, Minnesota, US and 3 Mayo Clinic,Rochester, Minnesota, US.94

Tuesday Morning May 48:45 AM LB-OR-06: Incremental Predictive Value ofNoninvasive Vascular Assessments Over TraditionalRisk Factors in Patients with Hypertension, Diabetesand Renal DiseaseOana Sandu, 1 Iulian Natac, 2 Jaime Uribarri. 1 1 MSSM,NY, NY, US and 2 PUB, Bucharest, RO.8:57 AM LB-OR-07: Baseline Levels of Systolic BloodPressure and LDL-C Are Powerful Predictors ofCardiovascular Outcomes Among 12,839 Patients atHigh Risk of Future EventsPrakash Deedwania†, 1 Helen Colhoun. 2 1 VACCHCS/UCSF School of Medicine, Fresno, US and 2 Universityof Dundee, Dundee, GB.9:09 AM LB-OR-08: Rheos® Baroreflex Activation Therapy®Significantly Lowers Blood Pressures in Patientswith Resistant Hypertension: Results from PivotalTrial Roll-In SubjectsGeorge L. Bakris†, 1 John Bisognano, 2 Mitra Nadim, 3Luis Sanchez, 4 Domenic A. Sica. 5 1 University ofChicago, US; 2 University of Rochester School ofMedicine, US; 3 University of Southern CaliforniaKeck School of Medicine, US; 4 Washington UniversitySchool of Medicine, US and 5 Virginia CommonwealthUniversity, US.9:21 AM LB-OR-09: Effects of Intensive Blood PressureControl on Stroke and Other Cardiovascular Eventsin Type 2 Diabetes Mellitus: The Action to ControlCardiovascular Risk in Diabetes (ACCORD) BloodPressure TrialWilliam C. Cushman, 1 Gregory W. Evans, 2 Jeffrey A.Cutler, 3 Richard H. Grimm, Jr., 4 For the ACCORDStudy Group. 1 Preventive Medicine Section, MemphisVeterans Affairs (VA) Medical Center, Memphis,TN, US; 2 Division of Public Health Sciences, WakeForest University School of Medicine, Winston-Salem,NC, US; 3 National Heart, Lung, and Blood Institute,Bethesda, MD, US and 4 Berman Center for Outcomesand Clinical Research, Minneapolis, MN, US.95

MAY 4SessionsTuesday Morning8:00 AM – 9:30 AM • Beekman ParlorConsensus Update to ISHIB ManagementGuidelinesHeld in partnership with the International Society on Hypertension inBlacks (ISHIB)Chair: David S. Kountz, MD, MBA, Neptune, NJ8:00 AM Overview of the Updated ISHIB GuidelinesJohn M. Flack, MD, MPH, Detroit, MI8:25 AM Clinical Trials to Support the Updated ISHIBGuidelinesRichard H. Grimm, MD, PhD, Minneapolis, MN8:50 AM Implementing the Updated ISHIB Guidelines inClinical PracticeBrent M. Egan, MD, Charleston, SC9:15 AM Panel Discussion96

Tuesday Morning May 4Sessions8:00 AM – 9:30 AM • Sutton SouthCardiovascular and Kidney Outcomes in HeartFailureHeld in partnership with the Inter-American Society of Hypertension(IASH)Chairs: John D. Bisognano, MD, PhD, Rochester, NY andL. Gabriel Navar, PhD, New Orleans, LA8:00 AM Pathophysiological/Adaptive Changes in KidneyFunction in the Failing HeartJohn C. Burnett, Jr., MD, Rochester, MN8:30 AM Diastolic vs Systolic Dysfunction: Should BP’s be atDifferent Levels?Scott D. Solomon, MD, Boston, MA9:00 AM Approaches to Blood Pressure Control to OptimizeCardiovascular Outcomes in Heart FailureDomenic A. Sica, MD, Richmond, VA97

MAY 4SessionsTuesday Morning8:00 AM – 9:30 AM • Sutton NorthThe 2nd American Society of Hypertension/ChinaSocial Worker’s Association Vascular ProtectionCommittee Session on Early Vascular DiseaseDetection and Management: Experience from ChinaChairs: Daniel Levy, MD, Framingham, MA andHongyu Wang, MD, PhD, Beijing, China8:00 AM Opening RemarksHongyu Wang, MD, PhD8:05 AM Vascular Disease Control and Early Prevention inChinaHongyu Wang, MD, PhD8:25 AM Expression of Matrix Metalloproteinase-9 in AorticDissection PatientJianfang Luo, MD, Guangzhou, China8:45 AM Inflammatory Factors and AtherosclerosisYuan Guo, MD, Beijing, China9:05 AM A Study on the Correlation between Pulse Pressureand Intima-Media Thickness of Carotid Arteryin Rural She People: Chinese Arterial StiffnessEvaluation Study, CASE-4Yongqiang Hong, MD, Fuzhou, China9:15 AM Early Screening Vasculopathy and StrategyPrevention and Cure with High Risk GroupTianhu Liu, MD, Chengdu, China9:25 AM The Evaluation of Forecasting Coronary ArteryDisease with Flow Mediated Dilation of BrachialArtery by EchocardiographyAihua Chen, MD, Kunming, China98

Tuesday Morning MAY 4ASH Membership Meeting10:00 AM – 10:45 AM • Rendezvous TrianonAnnual ASH Membership Meeting99

MAY 4SessionsTuesday Morning10:55 AM – 12:15 PM • Beekman Parlor1 Essential Pathobiology for the HypertensionSpecialistChairs: Carlos M. Ferrario, MD, Winston-Salem, NC andAddison A. Taylor, MD, PhD, Houston, TX10:55 AM What the Hypertension Specialist Should KnowAbout Vitamin D for HealthMichael F. Holick, MD, PhD, Boston, MA11:15 AM What the Hypertension Specialist Should KnowAbout Vascular RemodelingRhian M. Touyz, MD, PhD, Ottawa, Canada11:35 AM What the Hypertension Specialist Should KnowAbout Angry FatWilla A. Hsueh, MD, Houston, TX11:55 AM What the Hypertension Specialist Should KnowAbout Mineralocorticoid and GlucocorticoidCelso E. Gomez-Sanchez, MD, Jackson, MS1 Pathobiology Track 2 Translational Track 3 Therapy Track100

Tuesday Morning MAY 4Sessions10:55 AM – 12:15 PM • Sutton North2 Understanding Unappreciated Outcomes ofCardiovascular RiskChairs: Karen L. Margolis, MD, MPH, Minneapolis, MN andPeter F. Wilson, MD, Atlanta, GA10:55 AM What the Hypertension Specialist Should KnowAbout Adverse Effects of Statin TherapyMichael H. Davidson, MD, Chicago, IL11:15 AM What the Hypertension Specialist Should KnowAbout Outcomes ResearchDan R. Berlowitz, MD, MPH, Bedford, MA11:35 AM What the Hypertension Specialist Should KnowAbout Masked HypertensionRobert A. Phillips, MD, PhD, Worcester, MA11:55 AM What the Hypertension Specialist Should KnowAbout the Evaluation of Exercise TestingMartha Gulati, MD, Chicago, IL1 Pathobiology Track 2 Translational Track 3 Therapy Track101

MAY 4SessionsTuesday Morning10:55 AM – 12:15 PM • Sutton South3 Important Co-morbid Disorders in Patients withHypertension: Evaluation and TreatmentChairs: Peter U. Feig, MD, Rahway, NJ andHoward Weintraub, MD, New York, NY10:55 AM What the Hypertension Specialist Should KnowAbout the Patient with an Acute Coronary EventJudith Hochman, MD, New York, NY11:15 AM What the Hypertension Specialist Should KnowAbout Management of Endocrine HypertensionGordon H. Williams, MD, Boston, MA11:35 AM What the Hypertension Specialist Should KnowAbout Depression and AnxietySteven L. Dubovsky, MD, Buffalo, NY11:55 AM What the Hypertension Specialist Should KnowAbout Sleep DisordersPatrick J. Strollo, Jr., MD, Pittsburgh, PA1 Pathobiology Track 2 Translational Track 3 Therapy Track102

2010American Societyof HypertensionProgramPosters

MAY 1PostersSaturday AfternoonPosters will be displayed in the Rhinelander Gallery.Saturday, May 1, 2010Posters on Display: 3:00 PM – 7:00 PM • Poster Viewing: 5:00 PM – 6:00 PMAntihypertensive Drugs and Pharmacology......... (PO-009 – PO-077B)Arterial Structure and Compliance........................ (PO-078 – PO-099B)Cardiac Structure and Function/Imaging.................(PO-100 – PO-105)Coronary Artery Disease............................................(PO-106 – PO-107)Secondary Hypertension.............................................(PO-108 – PO-109)Stroke.............................................................................(PO-110 – PO-114)1 Pathobiology Track 2 Translational Track 3 Therapy Track104

Saturday Afternoon MAY 1Posters3:00 PM – 7:00 PM • Rhinelander GalleryAntihypertensive Drugs andPharmacologyPO-9: 1PO-10: 3PO-11: 3PO-12: 3PO-13: 3Gender Differences in the Response toAdrenoreceptor AntagonistsJames M. Coulson†, John R. Cockcroft. CardiffUniversity, Cardiff, Wales, GB.Chronotherapy with a Fixed Valsartan/Hydrochlorothiazide Combination: ImprovedNighttime Blood Pressure Control with BedtimeDosingDiana E. Ayala, Ramon C. Hermida, Artemio Mojon,Jose R. Fernandez. University of Vigo, ES.First-Line Aliskiren/HydrochlorothiazideCombination Treatment Lowers BP More Effectivelythan Hydrochlorothiazide Alone in Older Patientswith Stage 2 Hypertension (Action Study)Jan Basile†, 1 Simon Babazadeh, 2 Michael Lillestol, 3Jaco Botha, 4 Carol Yurkovic, 5 Richard Weitzman. 51 Ralph H Johnson VA Medical Center, Charleston,SC, US; 2 Crest Clinical Trials Inc., Santa Ana, CA,US; 3 Lillestol Research LLC, Fargo, ND, US; 4 NovartisPharma AG, Basel, CH and 5 Novartis PharmaceuticalsCorporation, East Hanover, NJ, US.First-Line Aliskiren/HydrochlorothiazideCombination Treatment Lowers BP More Effectivelythan Hydrochlorothiazide Alone in Older Patientswith Severe Stage 2 Hypertension (Systolic BP180–

MAY 1PostersSaturday AfternoonPO-15: 3PO-16: 3PO-17: 3PO-18: 3PO-19: 3Aliskiren as Monotherapy or in Combinationwith Hydrochlorothiazide Provides Effective BPLowering in Patients with Systolic BP 160–

Saturday Afternoon MAY 1PostersPO-20: 3PO-21: 3PO-22: 3PO-23: 3PO-24: 3PO-25: 3Combination Aliskiren/Amlodipine is MoreEffective than Amlodipine Monotherapy in Maleand Female African American Subjects with Stage 2HypertensionHenry Black†, 1 M. Weinberger, 2 D. Purkayastha, 3J. Lee, 3 M. Israel, 3 R. Hilkert, 3 J. Izzo. 4 1 New YorkUniversity, US; 2 Indiana University Medical Center,US; 3 Novartis Pharmaceuticals, US and 4 StateUniversity of New York at Buffalo, US.Long-Term in Vitro Antiproliferative Action ofPoly(3-Hydroxybutyrate) Microparticles Loadedwith PaclitaxelAnton P. Bonartsev, 1 Elena A. Filatova, 2 Sergey A.Yakovlev, 2 Galina M. Soboleva, 1 Tatiana K. Mahina, 2Vera L. Myshkina, 2 Garina A. Bonartseva. 2 1 Facultyof Biology, M.V.Lomonosov Moscow State University,Moscow, RU and 2 A.N.Bach’s Institute of Biochemistry,Russian Academy of Sciences, Moscow, RU.First-Line Therapy with Aliskiren/AmlodipineCombination Provides Robust Blood PressureReductions in Patients with Moderate to SevereHypertensionRüdiger C. Braun-Dullaeus, 1 Jack Zhang, 2 SashkaHristoskova, 3 Dieter A. Häring, 3 Weichi Liao. 2 1 Ottovon-Guericke-University,Magdeburg, DE; 2 NovartisPharmaceuticals Corporation, East Hanover, NJ, USand 3 Novartis Pharma AG, Basel, CH.Aliskiren has a Better Forgiveness Factor for PoorAdherence than Irbesartan or Ramipril: Effects ofAdherence Level and Duration of Action on ClinicalOutcomesMichel Burnier†, 1 Veronica C. Munk, 2 Yvonne Brede, 2Adam Lowy. 2 1 Centre Hospitalier UniversitaireVaudois, Lausanne, CH and 2 Novartis Pharma AG,Basel, CH.Differences between Manidipine and Amlodipine toReduce Central Blood Pressure in Mild to ModerateHypertensive Patients. Prospective StudyRicardo M. Cabrera Sole, 1 Caridad Turpin Lucas, 1Santiago Garcia Ruiz, 1 Rafael Gil Landa, 1 Santos JulianGonzalez, 1 Ana Maria Galdamez, 1 Manuel AguileraSaldaña. 1 1 University General Hospital of Albacete,Albacete, Albacete, ES and 2 Health Center no 2 ofAlbacete, Albacete, Albacete, ES.Effects of Aliskiren on Total Peripheral Resistance,Augmentation Index and Ambulatory ArterialStiffness Index in Mild to Moderate HypertensivePatientsRicardo M. Cabrera Sole, Caridad Turpin Lucas,Manuel Aguilera Saldaña, Santiago Garcia Ruiz,Santos Julian Gonzalez. University General Hospital ofAlbacete, Albacete, Albacete, ES.1 Pathobiology Track 2 Translational Track 3 Therapy Track107

MAY 1PostersSaturday AfternoonPO-26: 3PO-27: 3PO-28: 3PO-29: 3PO-30: 3Differences between Two Fixed-Dose ofCombinations: Enalaprilo Plus Lercanidipine orFelodipine Plus Metoprolol on Central Pressure andAugmentation IndexRicardo M. Cabrera Sole, 1 Santiago Garcia Ruiz, 1Caridad Turpin Lucas, 1 Rafael Gil Landa, 1 JuanCañas, 2 Manuel Aguilera Saldaña. 1 1 University GeneralHospital of Albacete, Albacete, Albacete, ES and2 Health Center no 2 of Albacete, Albacete, Albacete,ES.A Fixed-Dose Combination of OlmesartanMedoxomil (OM), Amlodipine (AML), andHydrochlorothiazide (HCTZ): Use of Modeling andSimulation to Support an Understanding of theDose Response of Intermediate Dose CombinationsNot Included in the Pivotal Phase 3 StudyTimothy J. Carrothers†, 1 Michelle Green, 1 HelenMoore, 1 Shashank Rohatagi, 2 SaeHeum Song, 2 JamesLee, 2 Antonia Wang, 2 Reinilde Heyrman, 2 Daniel E.Salazar. 2 1 Pharsight, US and 2 Daiichi Sankyo PharmaDevelopment, US.Pharmacokinetic Interaction between Simvastatinand Diltiazem in RatsDong-Hyun Choi, Sung-Il Ha, Young-Youp Koh,Kyoung-sig Chang, Soon-Pyo Hong, Joong-WhaChung. College of Medicine, Chosun University,Gwangju, KR.Incidence of Hyperkalemia with Aliskiren/ValsartanCombination in Hypertensive Patients with Mildto Moderate Renal Impairment and Patients withNormal Renal Function: A 54 Week RetrospectiveAnalysisSteven G. Chrysant†, 1 Alexander Murray, 2 UtaHoppe, 3 Dan Dattani, 4 Samir Patel, 5 AnastasiaLesogor, 6 Melanie Wright, 6 Jack Zhang. 5 1 Universityof Oklahoma, US; 2 PharmQuest, US; 3 Universityof Cologne, DE; 4 Prairie Clinical Research Groupand University of Saskatchewan, CA; 5 NovartisPharmaceuticals Corporation, US and 6 NovartisPharma AG, CH.Efficacy and Safety of Combination OlmesartanMedoxomil (OM)+Amlodipine Besylate(AML)+Hydrochlorothiazide (HCTZ) in Patientswith Hypertension: Analysis by Age and GenderSteven G. Chrysant†, 1 Michael Melino, 2 VictorFernandez, 2 James Lee, 2 Reinilde Heyrman. 21 Oklahoma Cardiovascular and Hypertension Centerand University of Oklahoma College of Medicine, USand 2 Daiichi Sankyo, Inc, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track108

Saturday Afternoon MAY 1PostersPO-31: 3PO-32: 3PO-33: 3PO-34: 3PO-35: 3PO-36: 3PO-37: 3Safety and Tolerability of Combination OlmesartanMedoxomil (OM)+Amlodipine Besylate(AML)+Hydrochlorothiazide (HCTZ) in Patientswith HypertensionSteven G. Chrysant†, 1 Suzanne Oparil, 2 MichaelMelino, 3 Victor Fernandez, 3 James Lee, 3 ReinildeHeyrman. 3 1 Oklahoma Cardiovascular andHypertension Center and University of OklahomaCollege of Medicine, US; 2 University of Alabama atBirmingham, US and 3 Daiichi Sankyo, Inc, US.Effect of Combined Use of Candesartan andVery-Low-Dose Hydrochlorothiazide on Clinicand Ambulatory Blood Pressure in UncontrolledHypertensive PatientsKazuo Eguchi, Satoshi Hoshide, Tomoyuki Kabutoya,Kazuyuki Shimada, Kazuomi Kario. Jichi MedicalUniversity School of Medicine, Shimotsuke, Tochigi,JP.Anthropometric Factors and Hypertensive Status inPatients with “Aspirin Resistance”Rosa Fabregate, Asuncion Guerri, Martin Fabregate,Ana Alonso, Arantxa Rodriguez, Olivia Sanchez,Susana Tello, Nuria de la Torre, Jose Saban-Ruiz.Endothelial Pathology Unit, Madrid, ES.Difference in Incidence of Cough Induced byImidapril and Ramipril: Role of ProstaglandinSynthesis InhibitionRoberto Fogari, Amedeo Mugellini, Paola Preti,Maurizio Destro, Luca Corradi, Giuseppe Derosa.Department of Internal Medicine, University of Pavia,Pavia, IT.Diuretics Reduce Sitaxsentan (SIT) InducedPlasma Volume (PV) Expansion and MaintainAntihypertensive Effect in Normal Salt (NS) FedDahl S (DS) RatsLufei Hu, Mykolai Zerebeckyj, Tom Maslanik, LuizBelardinelli, Craig Plato. Gilead Sciences, CA, US.Variation in 24-Hour Ambulatory Blood PressureResponses to Angiotensin Receptor Blockade:Predictive Aspects of Monotherapy Responses onSubsequent Effects of Dose Titration and Additionof Hydrochlorothiazide (HCTZ)J. L. Izzo†, 1 N. A. Crikelair, 2 D. H. Zappe. 2 1 StateUniversity of New York at Buffalo, Buffalo, NY, US and2 Novartis Pharmaceuticals Corporation, East Hanover,NJ, US.Response to Angiotensin Receptor BlockerMonotherapy and Add-On Hydrochlorothiazide:Influence of Age and Race Using Ambulatory BloodPressure MonitoringJoseph Izzo†, 1 Nora Crikelair, 2 Dion Zappe. 2 1 StateUniversity of New York at Buffalo, Erie CountyMedical Center, Buffalo, NY, US and 2 NovartisPharmaceuticals Corporation, East Hanover, NJ, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track109

MAY 1PostersSaturday AfternoonPO-38: 3PO-39: 3PO-40: 3PO-41: 3PO-42: 3PO-43: 3Aliskiren/Amlodipine Combination ReducesCentral Blood Pressure More than AmlodipineAlone in African Americans with Stage 2HypertensionJoseph Izzo†, 1 M. Weinberger, 2 M. Israel, 3 R. Hilkert, 3D. Purkayastha, 3 J. Lee, 3 H. Black. 4 1 State University ofNew York at Buffalo, US; 2 Indiana University MedicalCenter, US; 3 Novartis Pharmaceuticals, US and 4 NewYork University, US.24-Hour Efficacy and Safety of Full-Dose, TriplecombinationTherapy with Olmesartan, Amlodipine,and HydrochlorothiazideJoseph Izzo†, 1 Michael Melino, 2 Victor Fernandez, 2James Lee, 2 Reinilde Heyrman. 2 1 State University ofNew York at Buffalo, Buffalo, NY, US and 2 DaiichiSankyo, Inc, Parsippany, NJ, US.Initial Combined Valsartan/HCTZ Therapy vs EitherComponent as Monotherapy in Elderly Individualswith Systolic Hypertension: Age-Stratified Analysisof the Valvet StudyJ. L. Izzo, Jr.†, 1 D. Duprez, 2 H. Weintraub, 3 R. Samuel, 4D. Purkayastha, 4 D. Zappe, 4 W. Cushman. 5 1 StateUniv. of New York at Buffalo, US; 2 Univ. Minnesota,US; 3 NYU School of Medicine, US; 4 Novartis, US and5 Univ. Tennessee, US.Efficacy and Tolerability of Combined AngiotensinReceptor Blocker+Diuretic Therapy vs Monotherapywith Either Component in Elderly Individuals withSystolic Hypertension: Results from ValvetJ. L. Izzo, Jr.†, 1 H. Weintraub, 2 D. Duprez, 3 R. Samuel, 4D. Purkayastha, 4 D. Zappe, 4 W. Cushman. 5 1 SUNYBuffalo, US; 2 NYU School of Medicine, US; 3 Univ.Minnesota, US; 4 Novartis, US and 5 Univ. Tennessee,US.Effects of Thiazide Diuretics on Bone MineralDensity in Hypertensive Elderly African AmericanWomenFahad Javed, Emad F. Aziz, Shahzeb Khan, RamyaSuryadevara, Iffat Shaheen, Carlos Alviar, JorgeRomero, Alexandre Benjo, Eyal Herzog, Franz H.Messerli. St Lukes Roosevelt Hosp Ctr/Univ Hospitalfor Coll of Physicians & Surgeons of Columbia Univ,New York, US.Immunoreactive Active Renin Alone Does NotPredict Antihypertensive Efficacy of Direct ReninInhibitorsCharlotte Jones-Burton†, 1 Yabing Mai, 1 JosephRubino, 1 Marc Bellet, 2 Jasper Dingemanse, 2 MichaelStepanavage, 1 Peter Feig. 1 1 Merck, US and 2 Actelion,CH.1 Pathobiology Track 2 Translational Track 3 Therapy Track110

Saturday Afternoon MAY 1PostersPO-44: 3PO-45: 3PO-46: 3PO-47: 3PO-48: 3PO-49: 3PO-50: 3An Assessment of Adherence and Persistence toSingle Pill vs Free Combination ARB/CCB Therapyin Patients with Hypertension in a Real-worldSettingSiddhesh Kamat†, 1 L. A. Andrews, 2 Christy Fang, 1Mark Cziraky, 1 Kristijan Kahler. 2 1 HealthCore Inc.,Wilmington, DE, US and 2 Novartis PharmaceuticalsCorporation, East Hanover, NJ, US.Efficacy and Safety of Combination OlmesartanMedoxomil (OM)+Amlodipine Besylate(AML)+Hydrochlorothiazide (HCTZ) Based onSeverity of Hypertension: The Trinity StudyDean Kereiakes†, 1 Steven G. Chrysant, 2 MichaelMelino, 3 Victor Fernandez, 3 James Lee, 3 ReinildeHeyrman. 3 1 The Christ Hospital Heart and VascularCenter/The Lindner Research Center, US; 2 Universityof Oklahoma College of Medicine, US and 3 DaiichiSankyo, Inc, US.Comparative Efficacy of Lercanidipine andAmlodipine in Uzbek Patients with Mild-To-Moderate Essential HypertensionAmayak Kevorkov. Republican Specialized Center ofCardiology, Tashkent, UZ.Effects of Nebivolol in Obese African-Americanswith Hypertension (The Noaah Study): Markers ofInflammation and Obesity in Response to Exercise-Induced StressBobby V. Khan†, 2 Nadya Merchant, 1 Tahir Haque, 1Jessica E. Wahi, 1 Guillermo E. Umpierrez, 2 Keith C.Ferdinand. 2 1 Atlanta Vascular Research Foundation,Atlanta, GA, US and 2 Emory University School ofMedicine, Atlanta, GA, US.Amlodipine and Atorvastatin Combination in theTreatment of the High-Risk Hypertensive PatientJosé Enrique López-Paz, 1 Alvaro Hermida, 1 MartaPena, 1 Gaila Calvo, 1 Luisa Romero, 1 Cristina Sierra, 2Antonio Coca, 2 Carlos Calvo. 1 1 Hypertensionand Vascular Risk Unit. Complejo HospitalarioUniversitario de Santiago, ES and 2 Hypertension Unit,Hospital Clinico de Barcelona, ES.Change in Framingham Risk Score Associated withAliskiren-Mediated Blood Pressure ReductionsDrew Levy†, Deborah Keefe, Ricardo Rocha. NovartisPharmaceutical Corporation, US.Efficacy and Safety of Combination OlmesartanMedoxomil (OM)+Amlodipine Besylate(AML)+Hydrochlorothiazide (HCTZ)—The TrinityStudy: A Subgroup Analysis by RaceThomas Littlejohn, 1 Phillip Toth, 2 Michael Melino, 3Victor Fernandez, 3 James Lee, 3 Reinilde Heyrman. 31 Piedmont Medical Research Associates, US; 2 MidwestInstitute for Clinical Research, US and 3 DaiichiSankyo, Inc, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track111

MAY 1PostersSaturday AfternoonPO-51: 3PO-52: 3PO-53: 3PO-54: 3PO-55: 3PO-56: 3Resistant Hypertension in Elderly Patients: Non-Dipper Pattern and ChronotherapyJose Enrique Lopez, 1 Alvaro Hermida, 1 Marta Pena, 1Luisa Romero, 1 Gaila Calvo, 1 Antonio Coca, 2 CarlosCalvo. 1 1 Hypertension and Vascular Unit, ComplejoHospitalario Universitario de Santiago, Santiago deCompostela, ES and 2 Hypertension Unit. HospitalClinico de Barcelona, ES.Olmesartan and Amlodipine Combination inAntihipertensive ChronotherapyJosé Enrique Lopez-Paz, 1 Alvaro Hermida, 1 MartaPena, 1 Luisa Romero, 1 Gaila Calvo, 1 Cristina Sierra, 2Antonio Coca, 2 Carlos Calvo. 1 1 Hypertensionand Vascular Risk Unit. Complejo HospitalarioUniversitario de Santiago, ES and 2 Hypertension Unit,Hospital Clinico de Barcelona, ES.Tolerability of Thiazides Compared to OtherAntihypertensive Drug ClassesHarikrishna J. Makani, 1 Sripal Bangalore, 2 SanthoshDevarapally, 1 Kuntal Pujara, 1 Jorge Silva Enciso, 1Franz H. Messerli. 1 1 St. Luke’s Roosevelt Hospitaland Columbia University College of Physicians andSurgeons, New York, NY, US and 2 Brigham andWomen’s Hospital, Harvard Medical School, Boston,MA, US.Long-Term Therapy with Aliskiren/Amlodipine/Hydrochlorothiazide Combination ProvidesEffective Blood Pressure Reduction with GoodTolerability in Patients with Moderate-To-SevereHypertensionAlexander Murray†, 1 Wolfgang Koenig, 2 Juan Garcia-Puig, 3 Samir Patel, 4 Molla Uddin, 4 Jack Zhang. 41 PharmQuest, US; 2 University of Ulm Medical Centre,DE; 3 Hospital Universitario La Paz, ES and 4 NovartisPharmaceuticals Corporation, US.Influence of Salt Intake on Target Organ Damages inTreated Hypertensive PatientsYuko Ohta, Takuya Tsuchihashi, Eri Hasegawa.National Kyushu Medical Center, Fukuoka, JP.Intensive Treatment with Combination Amlodipine/Valsartan Provides Greater AntihypertensiveEfficacy vs Moderate Treatment for HypertensivePatients Uncontrolled on ARB Monotherapy: TheExtra StudySuzanne Oparil†, 1 T. Giles, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5R. Samuel, 5 R. Hilkert, 5 J. Sowers. 6 1 Univ. Alabamaat Birmingham, US; 2 Tulane Univ., US; 3 MorehouseSoM, US; 4 Univ. Michigan SoM, US; 5 Novartis, US and6 Univ. Missouri SoM, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track112

Saturday Afternoon MAY 1PostersPO-57: 3PO-58: 3PO-59: 3PO-60: 3PO-61: 3PO-62: 3PO-63: 3Efficacy and Safety of Combination OlmesartanMedoxomil (OM)+Amlodipine Besylate(AML)+Hydrochlorothiazide (HCTZ) in Patientswith Hypertension: The Trinity StudySuzanne Oparil†, 1 Michael Melino, 2 Victor Fernandez, 2James Lee, 2 Reinilde Heyrman. 2 1 University ofAlabama at Birmingham, US and 2 Daiichi Sankyo, Inc,US.Diabetic Patient: Treatment with Amlodipine andAtorvastatin in ChronotherapyMarta Pena Seijo, 1 José Enrique López, 1 AlvaroHermida, 1 Gaila Calvo, 1 Luisa Romero, 1 CristinaSierra, 2 Antonio Coca, 2 Carlos Calvo. 1 1 Hypertensionand Vascular Risk Unit, Complejo HospitalarioUniversitario de Santiago, ES and 2 Hypertension Unit,Hospital Clinico de Barcelona, ES.Efficacy of Aliskiren as an Additive Anti-Hypertensive DrugErdal Sarac†, Muneer AlZoby, Nanette Chua, DavidGemmel. Saint Elizabeth Hospital Medical Center,Youngstown, OH, US.Comparative Effectiveness of Angiotensin IIReceptor BlockersRob Simons, 1 Venkata Ram, 2 Krishnan Ramaswamy, 3Joe Biskupiak, 4 Ed Reiner. 5 1 Global HEOR, Inc,Summit, NJ, US; 2 TX Blood Pres Inst, Dallas, TX, US;3 Daiichi Sankyo, Parsippany, NJ, US; 4 U of Utah, SaltLake City, UT, US and 5 GE Healthcare, Pound Ridge,NY, US.Treatment Respiratory Syndrome in HypertensivePatientsVolodymyra I. Sovtus. Ivano-Frankivsk NationalMedical University, Ivano-Frankivsk, UA.Intensive Treatment with Combination Amlodipine/Valsartan Provides Greater AntihypertensiveEfficacy vs Moderate Treatment for HypertensivePatients with Cardiometabolic SyndromeUncontrolled on ARB MonotherapyJames Sowers†, 1 T. Giles, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5R. Samuel, 5 R. Hilkert, 5 S. Oparil. 6 1 Univ. MissouriSchool of Med, US; 2 Tulane Univ. School of med, US;3 Morehouse SoM, US; 4 Univ. Michigan SoM, US;5 Novartis, US and 6 Univ. Alabama, US.Intensive Treatment with Combination Amlodipine/Valsartan vs Moderate Therapy for HypertensivePatients with Diabetes or CKD Uncontrolled onARB MonotherapyJames Sowers†, 1 T. Giles, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5 R.Samuel, 5 R. Hilkert, 5 S. Oparil. 6 1 Univ. Missouri SoM,US; 2 Tulane Univ. SoM, US; 3 Morehouse SoM, US;4 Univ. Michigan SoM, US; 5 Novartis, US and 6 Univ.Alabama at Birmingham, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track113

MAY 1PostersSaturday AfternoonPO-64: 3PO-65: 3PO-66: 3PO-67: 3PO-68: 3PO-69: 3Combination Aliskiren/Amlodipine ProvidesGreater Blood Pressure Reduction than AmlodipineMonotherapy in African American Subjects withStage 2 Hypertension and Obesity or MetabolicSyndromeMyron Weinberger†, 1 J. Izzo, 2 D. Purkayastha, 3 J. Lee, 3M. Israel, 3 R. Hilkert, 3 H. Black. 4 1 Indiana UniversityMedical Center, US; 2 State University of New York atBuffalo, US; 3 Novartis Pharmaceuticals, US and 4 NewYork University, US.Aliskiren and HCTZ in Combination ProvidesImproved Blood Pressure Control Comparedwith Ramipril in Obese Patients with Stage 2Hypertension Regardless of Baseline Systolic BloodPressureAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.Combination Therapy with Aliskiren and HCTZDecreases Plasma Renin Activity and OxidativeStress vs Ramipril While Reducing Blood Pressurein Obese Patients with Stage 2 HypertensionAdam Whaley-Connell†, 1 J. Sowers, 1 D. Purkayastha, 2Z. Ricks, 2 A. Yadao. 2 1 University of Missouri Schoolof Medicine, US and 2 Novartis PharmaceuticalsCorporation, US.Ethnic Differences in Response to CombinationAliskiren/HCTZ vs Ramipril Monotherapy in ObesePatients with Stage 2 HypertensionAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.Antihypertensive Efficacy of Combination Aliskiren/HCTZ Compared to Ramipril Monotherapy inObese Stage 2 Hypertensive Patients Stratified byAgeAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.Combination Therapy with Aliskiren+HCTZReduces 24h Ambulatory Blood Pressure MoreEffectively than Ramipril in Obese Patients withStage 2 HypertensionAdam Whaley-Connell†, 1 D. Purkayastha, 2 Z. Ricks, 2A. Yadao, 2 J. Sowers. 1 1 University of Missouri-Columbia, US and 2 Novartis PharmaceuticalsCorporation, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track114

Saturday Afternoon MAY 1PostersPO-70: 3PO-71: 3PO-72: 3PO-73: 3PO-74: 3PO-75: 3PO-76: 2Attenuation of Exercise-Induced Rise in SystolicBlood Pressure by the Direct Renin InhibitorAliskirenBryan Williams†, 1 Fabio Baschiera, 2 Peter S. Lacy, 1Jaco Botha, 2 Patrick Brunel. 2 1 Department ofCardiovascular Sciences, University of Leicester,Leicester, GB and 2 Novartis Pharma AG, Basel, CH.Initial Use of Combination Aliskiren/Valsartanis More Effective than Either ComponentMonotherapy in Elderly and Non-elderlyHypertensive PatientsSteven A. Yarows†, 1 S. Oparil, 2 S. Patel, 3 M. Wright, 4A. Yadao, 3 J. Zhang. 3 1 Chelsea Internal Medicine/IHA,MI, US; 2 UAB Vascular Biology and HypertensionProgram, AL, US; 3 Novartis PharmaceuticalsCorporation, NJ, US and 4 Novartis Pharma AG, CH.Initial Use of the Aliskiren/Valsartan Combinationis More Effective than Either ComponentMonotherapy in Hypertensive Patients with DiabetesSteven A. Yarows†, 1 S. Oparil, 2 S. Patel, 3 M. Wright, 4A. Yadao, 3 J. Zhang. 3 1 Chelsea Internal Medicine/IHA,MI, US; 2 UAB Vascular Biology and HypertensionProgram, AL, US; 3 Novartis PharmaceuticalsCorporation, NJ, US and 4 Novartis Pharma AG, CH.Initial Use of the Aliskiren/Valsartan Combinationis More Effective than Either ComponentMonotherapy in Obese and Non-Obese HypertensivePatientsSteven A. Yarows†, 1 S. Oparil, 2 S. Patel, 3 M. Wright, 4A. Yadao, 3 J. Zhang. 3 1 Chelsea Internal Medicine/IHA,MI, US; 2 UAB Vascular Biology and HypertensionProgram, AL, US; 3 Novartis PharmaceuticalsCorporation, NJ, US and 4 Novartis Pharma AG, CH.The Treatment of Renal Endothelium Dysfunctionin Scleroderma: Telmisartan Effects vs RamiprilRoman I. Yatsyshyn, Natalya G. Yatsyshyn, Yevgen M.Neyko. Ivano-Frankivsk National Medical University,Ivano-Frankivsk, UA.Telmisartan Brain Protection in CRDH Ratsas Revealed by Magnetic Resonance Imaging isBestowed to Adiponectin IncreaseFiras M. Younis, 1 Tamar Blumenfeld-Katzir, 2 TalmaRosenthal. 1 1 Tel Aviv University, Ramat Aviv, Tel Aviv,IL and 2 Tel Aviv University, Ramat Aviv, Tel Aviv, IL.Plasma Renin Efficiency, a Derived Metric ofBiomarker Response, and Its Relation to BPLowering in Hypertensive Patients on AliskirenTreatment: A Pooled Analysis Using Data from NineClinical TrialsRamesh Sarangapani†, 1 William Ebling, 2 Deborah L.Keefe. 1 1 Novartis Pharmaceuticals Corporation, EastHanover, NJ, US and 2 Emergent Insights, Newark, DE,US.1 Pathobiology Track 2 Translational Track 3 Therapy Track115

MAY 1PostersSaturday AfternoonPO-77: 2 Nebivolol Induces Lipolysis, Uncoupling Protein 1Expression and Size Reduction in Human VisceralAdipocytes and Differentiated PreadipocytesRiccardo Sarzani, Marica Bordicchia, PierfrancescoMarcucci, Marco d’Anzeo, Antonella Pocognoli, SaraGaleazzi, Paolo Dessì Fulgheri, Alessandro Rappelli.Dept of Internal Medicine, University of Ancona -Politecnica Marche, Ancona, IT.PO-77A: 2 Level of Blood Pressure Above Goal and ClinicalInertia in a Medicaid PopulationAnthony J. Viera, 1 Dorothee Schmid, 2 Susan Bostrom, 3Angie Yow, 3 William Lawrence, 3,4 Annette DuBard. 1,3,51 University of North Carolina at Chapel Hill, ChapelHill, NC, US; 2 North Carolina State Center for HealthStatistics, US; 3 North Carolina Division of MedicalAssistance, US; 4 Duke University Health Systems,Durham, NC, US and 5 Cecil G. Sheps Center forHealth Services Research, Chapel Hill, NC, US.PO-77B: 3 Does Glomerular Filtration Rate Affect theBP Response to Angiotensin Receptor Blocker(ARB) Monotherapy or to Combined ARB +Hydrochlorothiazide (HCTZ) Therapy?Domenic A. Sica†, 1 Crikelair A. Nora, 2 S. Li, 2 ZappeH. Dion. 2 1 Virginia Commonwealth UniversityHealth System, Richmond, VA, US and 2 NovartisPharmaceuticals Corporation, East Hanover, NJ, US.Arterial Structure and CompliancePO-78: 1PO-79: 1PO-80: 1PO-81: 1Arterial Stiffness Methods. Correlation vs LeftVentricular MassMarcos A. Baroni, Mariana A. Cruz, AlfredoDellamora, Jose P. Sala, Mario Bendersky. InstitutoModelo de Cardiologia Privado SRL, Cordoba, AR.High Level of Cardiorespiratory Fitness isAssociated with Reduced Age-Related CarotidArtery RemodelingYuko Gando†, 1 Kenta Yamamoto, 2 Hiroshi Kawano, 1Haruka Murakami, 2 Yumi Ohmori, 2 RyokoKawakami, 2 Kiyoshi Sanada, 3 Mitsuru Higuchi, 1 IzumiTabata, 2 Motohiko Miyachi. 2 1 Waseda University,Tokorozawa, Saitama, JP; 2 National Institute of Healthand Nutrition, JP and 3 Ritsumeikan University, JP.Can Blood Pressure Variability Determine Changesin Arterial Stiffness?Alvaro Hermida-Ameijeiras, Jose E. López-Paz, MariaL. Romero-Miguez, Gaila Calvo-González, CarlosCalvo-Gomez. Clinic Hospital of Santiago, Santiago deCompostela, La Coruña, ES.Age Related Changes in Arterial Wave RefectionIndices Mediate Central Systolic Blood Pressure(CSBP) in African-Americans (AA)Haroon Kamran, Louis Salciccioli, Parag Kumar,Muhammed Umer, Bhuvaneshwasi Venkalesan, JasonLazar. Downstate Medical Center/State University ofNY, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track116

Saturday Afternoon MAY 1PostersPO-82: 1PO-83: 1PO-84: 1PO-85: 1PO-86: 1PO-87: 1Determinants of the Carotid-Radial Pulse WaveVelocity Response to HyperemiaHaroon Kamran, Vinod Namana, BhuvaneshwasiVenkatesan, Priyank Khandelwal, Louis Salciccioli,Jason Lazar. Downstate Medical Center/StateUniversity of NY, US.Effect of Chronic Aortic Regurgitation on Indices ofArterial Wave ReflectionHaroon Kamran, Louis Salciccioli, Parag Kumar,Bhuvaneshwasi Venkatesan, Muhammed Umer, RobinZakariaei, Jason Lazar. Downstate Medical Center, US.The Effect of Acute Changes in Heart Rate onCentral Blood PressureSuresh Krishnamoorthy†, Chee Wah Khoo, GregoryY. H. Lip, Hoong Sern Lim. University Departmentof Medicine Centre for Cardiovascular Sciences, CityHospital, Birmingham, West Midlands, GB.Determinants of Arterial Properties in ChineseType-2 Diabetic Patients Compared withPopulation-Based ControlsYan-Ping Liu, 1,2 Yan Li, 3 Tom Richart, 2,4 Ying Zhu, 1Lutgarde Thijs, 2 Yu Jin, 2 Yi-Fei Zhang, 5 Chang-ShengSheng, 3 Yu-Hong Chen, 5 Ji-Guang Wang, 3 Wei-Wei Zhan, 1 Jan A. Staessen. 2,4 1 The Department ofUltrasonography, Ruijin Hospital, Shanghai JiaotongUniversity School of Medicine, Shanghai, CN;2 University of Leuven, BE; 3 Center for EpidemiologicStudies and Clinical Trials and Center for VascularEvaluation, Ruijin Hospital, Shanghai JiaotongUniversity School of Medicine, Shanghai, CN; 4 theDepartment of Epidemiology, Maastricht University,Maastricht, NL and 5 Shanghai Clinical Center forEndocrine and Metabolic Diseases; Shanghai Instituteof Endocrine and Metabolic Diseases, Ruijin Hospital,Shanghai Jiaotong University School of Medicine,Shanghai, CN.Arterial Stiffness is an Independent Determinant ofHeart Rate Recovery After Exercise in HypertensivePatientsSatoru Sakuragi, Hideyuki Suzuki, Tsuyoshi Miyaji,Kenji Kawamoto, Yusuke Katayama, Jun Iwasaki.Department of Cardiology, Iwakuni Clinical Hospital,Iwakuni, JP.Significant Relationship between Arterial Stiffnessand Retinal Arterioles Abnormality in Patients withAtherosclerotic DiseaseSatoru Sakuragi, 1 Hideyuki Suzuki, 1 MasahiroShinoda, 2 Tsuyoshi Miyaji, 1 Yusuke Katayama, 1 ReijiKawata, 2 Yuji Hirai, 2 Daisuke Sakamoto. 2 1 Departmentof Cardiology, Iwakuni Clinical Hospital, Iwakuni, JPand 2 Institute of Retina Research, Inc, Iwakuni, JP.1 Pathobiology Track 2 Translational Track 3 Therapy Track117

MAY 1PostersSaturday AfternoonPO-88: 1PO-89: 1PO-90: 1PO-91: 1PO-92: 1PO-93: 3Impaired Glucose Regulation and Arterial Stiffness:Evidence for the Importance of Strict GlycemicControlMarina Shargorodsky, 2 Mona Boaz, 2 Zipora Matas, 2Reuven Zimlichman. 2 1 Wolfson Medical Center,Holon, IL and 2 Sackler School of Medicine, Tel AvivUniversity, Tel Aviv, IL.Effect of Weight Loss Maintenance on ArterialCompliance, Metabolic and InflammatoryParameters: A Three Year Follow Up StudyMarina Shargorodsky, 2 Mona Boaz, 2 Ninel Wolfson, 2Zipora Matas, 2 Reuven Zimlichman. 2 1 Wolfson MedicalCenter, Holon, IL and 2 Sackler School of Medicine, TelAviv University, IL.Arterial Stiffness Evaluation in Greek HealthyChildren Going to Elementary SchoolHelen Triantafyllidi, Chrysa Arvaniti, ParaskeviTrivilou, Christos Varounis, Konstantinos Kontsas,Vasilios Souridis, Stavros Tzortzis, GerasimosGasparinatos, John Lekakis, Maria Anastasiou-Nana.University of Athens, ATTIKON Hospital, Athens, GR.Prostate Specific Antigen Levles within NormalRange are Associated with Arterial Stiffness inEssential Hypertensive PatientsV. Tzamou, 1 G. Vyssoulis, 1 E. Karpanou, 2 Stella-MariaKyvelou, 1 C. Vlachopoulos, 1 C. Stefanadis. 1 1 1stCardiology Clinic Athens University HippokrationHospital, GR and 2 Cardiology Clinic OnassisCardiosurgery Center, GR.Large Artery Stiffness and Thyroid Function inEssential Hypertensive Patients and Patients withIsolated Office HypertensionG. Vyssoulis, 1 E. Karpanou, 2 Stella-Maria Kyvelou, 1T. Gialernios, 1 V. Tzamou, 1 C. Vlachopoulos, 1 C.Stefanadis. 1 1 1st Cardiology Clinic Athens UniversityHippokration Hospital, GR and 2 Cardiology ClinicOnassis Cardiosurgery Center, GR.Amlodipine-Valsartan Combination DecreasesCentral Systolic Blood Pressure More Effectivelythan the Amlodipine-Atenolol Combination: TheExplor StudyPierre Boutouyrie†, 1 Stéphane Laurent, 1 AssyaAchouba. 2 1 Hospital European G.Pompidou, Paris, FRand 2 Novartis Pharma S.A.S, Rueil-Malmaison, FR.1 Pathobiology Track 2 Translational Track 3 Therapy Track118

Saturday Afternoon MAY 1PostersPO-94: 3PO-95: 2PO-96: 2PO-97: 2PO-98: 2Changes in Aortic Pulse Wave Velocity inHypertensive Post-Menopausal Women:Comparison between Calcium Channel Blocker(CCB) vs Angiotensin Receptor Blocker (ARB)RegimenDaniel Hayoz†, 1,4 Dion H. Zappe, 2 InYoung Baek, 3Albert Kandra, 3 M. A. Rey-Meier, 4 M. P. Joly, 4 E.Haesler, 4 L. Mazzolai, 4 D. Periard. 4 1 Department ofMedicine, Hopital Cantonal Fribourg, Fribourg, CH,CH; 2 Novartis Pharmaceuticals Corporation, EastHanover, NJ, US; 3 Novartis Pharma AG, Basel, CH and4 Department of Vascular Medicine, CHUV, Lausanne,CH, CH.Comparison of Different Markers of ArterialElasticity in Prediction of Incident CardiovascularDisease Events: The Multi-Ethnic Study ofAtherosclerosisDaniel A. Duprez, 1 David Jacobs, Jr., 1 Pamela L.Lutsey, 1 David A. Bluemke, 2 Joseph Polak, 3 LyndiaBrumback, 4 Philip Greenland, 5 Richard Kronmal. 41 University of Minnesota, Minneapolis, MN, US;2 National Institute of Health, Bethesda, MD, US;3 Tufts University, Boston, MA, US; 4 University ofWashington, Seattle, WA, US and 5 NorthwesternUniversity, Chicago, IL, US.The Relationship between Large Artery Stiffness,Wave Reflection and Pulsatility in the Microcirculation:New Insights into the Management ofBoth Hypertension and DiabetesBarry J. McDonnell, 1 James Coulson, 2 MargaretMunnery, 2 Nichola Gale, 2 Ian Munnery, 2 Carmel M.McEniery, 3 Ian B. Wilkinson, 3 John R. Cockcroft. 21 Cardiff School of Health Sciences, University ofWales Institute, Cardiff, Cardiff, Wales, GB; 2 WalesHeart Research Institute, Cardiff University, Cardiff,Wales, GB and 3 Department of Clinical Pharmacology,Vascular Research Unit, University of Cambridge,Cambridge, GB.Comparison of a Novel Piezoelectric Devicefor Measuring Arterial Pulse Wave Velocitywith a Validated Device in a Normotensive andHypertensive PopulationJohn C. Murphy, 1 Kathy Morrison, 1 Jim McLaughlin, 2Ganesh Manoharan, 1 Jennifer Adgey. 1 1 The HeartCentre, Royal Group of Hospitals, Belfast, NorthernIreland, GB and 2 Northern Ireland BioMedicalEngineering Centre, Belfast, Northern Ireland, GB.Relationship between Arterial Stiffness and LeftVentricular Geometry in a General Population inNorthern ItalyAnna Paini, Maria Lorenza Muiesan, Massimo Salvetti,Cristina Monteduro, Claudia Agabiti Rosei, CarloAggiusti, Deborah Stassaldi, Fabio Bertacchini, FabioBeschi, Maurizio Castellano, Enrico Agabiti Rosei.Internal Medicine, University of Brescia, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track119

MAY 1PostersSaturday AfternoonPO-99: 2 Alterations in Aortic Wave Reflection withVasodilation and Vasoconstriction in AnesthetizedDogsJohn V. Tyberg, 1 Nigel G. Shrive, 1 Jiun-Jr Wang. 21 University of Calgary, Calgary, AB, CA and 2 Fu-JenUniversity Medical School, TW.PO-99A: 1 Effect of β-Blockers on Central Systolic Pressureand Pulse Pressure Amplification in HypertensiveAfrican-Americans (AA)Jason Lazar, Haroon Kamran, Vinod Namana, SergeiPushilin, Vyacheslav Mikheyev, Parag Kumar, LouisSalciccioli. Downstate Medical Center/State Universityof NY, Brooklyn, NY, US.PO-99B: 1 Brachial Artery Diameter and Pulse Wave VelocityResponses to Consonant vs Dissonant MusicListeningMarcellus Merritt, 2 Haroon Kamran, 1 LouisSalciccioli, 1 Vinod Namana, 1 Sergei Pushilin, 1Vyacheslav Mikheyev, 1 Jason Lazar. 1 1 DownstateMedical Center/State University of NY, US and2 University of Wisconsin Milwaukee, US.Cardiac Structure and Function/ImagingPO-100: 1PO-101: 1PO-102: 1PO-103: 1PO-104: 1Left Ventricular Dysfunction and the Intima-MediaThickness: A Tissue-Doppler StudyCristiana Catena, GianLuca Colussi, Alessandro DiFabio, Cristina Petri, Marica Valeri, Luigi Marzano,Leonardo A. Sechi. Hypertension Unit, Department ofInternal Medicine, University of Udine, Udine, IT.Cardiorenal Syndrome in Old Patients with MildChronic Kidney Disease (CKD)Marcos Alvinair Gomes, Sebastiao RodriguesFerreira-Filho. Universidade Federal de Uberlandia,Uberlandia, Minas Gerais, BR.Central Aortic Blood Pressure Measurement andCorrelation with Left Ventricular Mass in Pre-HypertensionTarek M. Mousa, Mark Balek, Sofya Kostanyan, OlaAkinboboye. The New York Hospital Medcial Centerof Queens, Flushing, NY, US.Mortality Risk in Patients with Severe and VerySevere Left Ventricular HypertrophyVasilios Papademetriou, 1 Michael Doumas, 2 CharlesFaselis, 2 Costas Tsioufis, 1 Peter Kokkinos. 1 1 VAMCand Georgetown University, Washington, DC, US and2 VAMC and George Washington University, US.Impairment of Coronary Microcirculation isAccompanied by Left Ventricular DiastolicDysfunction in Essential HypertensivesD. Tsiachris, C. Tsioufis, D. Roussos, K. Dimitriadis, H.Tatsis, E. Tsiamis, I. Kallikazaros, C. Stefanadis. FirstCardiology Clinic, University of Athens, HippokrationHospital, Athens, GR.1 Pathobiology Track 2 Translational Track 3 Therapy Track120

Saturday Afternoon MAY 1PostersPO-105: 2Mortality Risk and Left Ventricular Mass inIndividuals with Type 2 Diabetes MellitusCharles Faselis, 1,3 Fiorina Kyritsi, 1 Eric Nylen, 1,3Vasilios Papademetriou, 1,2 Ross Fletcher, 1,3 AndreasPittaras, 1 Michalis Doumas, 1 Athanasios Manolis, 1Peter Kokkinos. 1,2,3 1 Veterans Affairs Medical Center,Washington, DC, US; 2 Georgetown University Schoolof Medicine, US and 3 George Washington UniversitySchool of Medicine, US.Coronary Artery DiseasePO-106: 1PO-107: 2Influence of Arterial Stiffness on the Incidenceof Peripheral Complications After CardiacCatheterizationJun Iwasaki. Iwakuni Clinical Center, Iwakuni City,Yamaguchi Prefecture, JP.Differences in Coronary Plaque Composition byCoronary Computed Tomography AngiographyAccordingly to HypertensionAldo Martinez Fleites, 1 Juan Rivera, 2 Michael BlahaBlaha, 3 Arthur Agatston, 2 Sang-il Choi, 5 Eun-JuChun, 5 Hyuk-Jae Chang, 4 Roger Blumenthal, 3Khurram Nasir. 3 1 Mount Sinai Medical Center, Miami,FL, US; 2 University of Miami, US; 3 Johns HopkinsCiccarone Center for the Prevention of Heart Disease,US; 4 Yonsei University Severance Hospital, KR and5 Seoul National University Hospital, Seongnam-si,Gyeonggi-do, KR.Secondary HypertensionPO-108: 3PO-109: 2Sleep Quality of Hypertensive Older Individualswith Overweight and Obstructive Sleep ApneaIara F. Anunciato, Romulo R. Lobo, Eduardo B.Coelho, Fernando Nobre, Julio C. Moriguti, EduardoFerriolli, Nereida K. C. Lima. Internal MedicineDepartment - Ribeirao Preto School of Medicine - SaoPauilo University, Ribeirao Preto, Sao Paulo, BR.Renal Resistive Index Fails to Detect CorticalPerfusion Asymmetry in Patients withHaemodynamic Renal Artery StenosisSergio Franco Castellani, 1 Fabrizio D’Abate, 1 MariaBoddi, 1 Andrea Ungar, 1 Manlio Acquafresca, 2 IlarioMenchi, 2 Gian Franco Gensini. 1 1 Department ofCritical Care Medicine and Surgery,Clinica Medica eCardiologia, IT and 2 Radiodiagnostic Section, IT.StrokePO-110: 1Working Memory Deficits in Untreated and TreatedHypertensionJeremy J. Murphy†, 1 Ahmet Fuat, 3 ElizabethLittlewood, 2 Barbara Conway, 4 Susan E. Gathercole. 21 County Durham & Darlington Acute Hospitals,Darlington, GB; 2 University of York, GB; 3 DurhamUniversity, GB and 4 NHS Darlington, GB.1 Pathobiology Track 2 Translational Track 3 Therapy Track121

MAY 1PostersSaturday AfternoonPO-111: 1PO-112: 2PO-113: 2PO-114: 2Relationship of Cognitive Dysfunction with Non-Invasive Indices of Arterial Stiffness in Patients withNever-Treated Essential HypertensionHelen Triantafyllidi, Chrysa Arvaniti, ParaskeviTrivilou, Stavros Tzortzis, Konstantinos Kontsas, JohnLekakis, Maria Anastasiou-Nana. University of Athens,Attikon Hospital, GR.Hypertension, Diabetes and HypercholesterolemiaAssociated with Secondary Stroke AmongCaucasians and African AmericansAndrea D. Boan, David L. Bachman, Robert J. Adams,Daniel T. Lackland. Medical University of SouthCarolina, Charleston, SC, US.Profile of Incidental Thyroid Nodules on CarotidUltrasoundNaveen Saxena, 1 Vinita Srivastava, 1 William Bridges, 2Craft Chanda, 1 Nomita Joshi, 1 Govind Rughani, 1Ricardo Abaunza. 1 1 Internal Medicine and CardiologyCenter, Greenville, SC, US and 2 Clemson University,Clemson, SC, US.The Progression of White Matter Disease ofthe Brain and Decline in Cognitive Function isPredicted Best by 24-Hour Systolic Blood Pressurein the Very ElderlyW. B. White†, 1 N. Moscufo, 1,2 C. Guttmann, 2 D.Wakefield, 1 R. Kaplan, 1 G. Pearlson, 3 L. Wolfson. 11 University of Connecticut School of Medicine, US;2 Harvard Medical School, US and 3 Yale UniversitySchool of Medicine, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track122

Sunday Morning MAY 2PostersPosters will be displayed in the Rhinelander Gallery.Sunday, May 2, 2010Posters on Display: 9:00 AM – 6:45 PM • Poster Viewing: 4:45 PM – 5:45 PMFeatured Posters...........................................................(PO-001 – PO-008)Blood Pressure Measurement/Monitoring...............(PO-115 – PO-160)Heart Failure/Hypertrophy(Diastolic Dysfunction)...............................................(PO-161 – PO-164)Kidney and Hypertension...........................................(PO-165 – PO-178)Metabolic Syndrome (Diabetes/Glycemic Control;Dysglycemic Drugs; Insulin Resistance)...................(PO-179 – PO-199)Non-Pharmacological Therapy (AlternativeMedicine; Diet; Physical Activity).............................(PO-200 – PO-202)Patient-Provider-Healthcare System Issues..............(PO-203 – PO-209)Risk Factors (Lipids)....................................................(PO-210 – PO-213)Pregnancy......................................................................(PO-214 – PO-216)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.1 Pathobiology Track 2 Translational Track 3 Therapy Track123

MAY 2PostersSunday Morning9:00 AM – 6:45 PM • Rhinelander GalleryFeatured Posters – Group 1Discussants:PO-1: 3PO-2: 3PO-3: 1PO-4: 2Lawrence R. Krakoff, MD, Englewood, NJ andDaniel Levy, MD, Framingham, MAThe Cyclooxygenase Inhibiting Nitric Oxide Donator(CINOD) Naproxcinod Induces Less Increases inthe 24-Hour Systolic Blood Pressure than Naproxenand Ibuprofen in Patients with Osteoarthritis andHypertensionWilliam B. White†, 1 Thomas Schnitzer, 2 PascalLonglade, 3 Rosanna Fleming, 3 Jacques Dijian. 31 University of Connecticut School of Medicine,Farmington, CT, US; 2 Northwestern UniversityFeinberg School of Medicine, Chicago, IL, US and3 Nicox, S.A., Sophia-Antipolis, FR.Administration-Time-Dependent Effects ofRamipril on Morning Blood Pressure in Subjectswith Essential HypertensionDiana E. Ayala, Ramon C. Hermida, Artemio Mojon,Jose R. Fernandez. University of Vigo, ES.Short Sleep Duration is an Independent Predictor ofStroke Events in Elderly Hypertensive PatientsKazuo Eguchi, Satoshi Hoshide, Yoshio Matsui,Kazuyuki Shimada, Kazuomi Kario. Jichi MedicalUniversity School of Medicine, Shimotsuke, Tochigi,JP.Indicators of Masked Hypertension in Children andAdolescentsJackeline Karoline Brito Viana, Cláudia M. Salgado†,Paulo César B. V. Jardim, Thiago S. V. Jardim. FederalUniversity of Goiás, Goiânia, Goiás, BR.1 Pathobiology Track 2 Translational Track 3 Therapy Track124

Sunday Morning MAY 2Posters9:00 AM – 6:45 PM • Rhinelander GalleryFeatured Posters – Group 2Discussants:PO-5: 2PO-6: 3PO-7: 2PO-8: 2Norman M. Kaplan, MD, Dallas, TX andSuzanne Oparil, MD, Birmingham, ALDepressed Cardiac Mechanics in Patients withChronic Renal Insufficiency: A Speckle-Strain StudyMarcello Chinali†, Gerard P. Aurigemma, DyutiTrivedi, Arumugam Narayanan, Jeffrey C. Hill, GlennKershaw, Pang-Yen Fan, Dennis A. Tighe, Robert A.Phillips. University of Massachusetts Medical School,Worcester, MA, US.Incident Diabetes with Antihypertensive Drugs:Updated Network and Bayesian Meta-Analyses ofClinical Trial DataWilliam J. Elliott†, 1 Sanjib Basu, 2 Peter M. Meyer. 21 Pacific Northwest University, Yakima, WA, US and2 RUSH Medical College, Chicago, IL, US.Differential Impact of Blood Pressure on LeftVentricular Geometry in Black and White YoungAdults: The Bogalusa Heart StudyJian Wang, 1,2 Wei Chen, 1 Litao Ruan, 1,3 AhmetToprak, 1 Sathanur R. Srinivasan, 1 Gerald S. Berenson†. 11 Center for Cardiovascular Health, Tulane University,US; 2 Department of Ultrasound, The First AffiliatedHospital, Shanxi Medical University, CN and3 Department of Ultrasound Diagnostics, the FirstAffiliated Hospital, School of Medicine, Xi’an JiaotongUniversity, CN.Heart Failure Trend Over Ten Years in a SouthernState: An Analysis by Race, Gender & AgeBaqar Husaini†, 1 Zahid Samad, 2 Pamela Hull, 1 VanCain, 1 U. Sampson, 3,4 Robert Levine. 3 1 Tennessee StateUniversity, US; 2 CDC, Atlanta, US; 3 Meharry MedicalCollege, US and 4 Vanderbilt University, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track125

MAY 2PostersSunday Morning9:00 AM – 6:45 PM • Rhinelander GalleryBlood Pressure Measurement/MonitoringPO-115: 1PO-116: 1PO-117: 1PO-118: 1PO-119: 1PO-120: 1PO-121: 1PO-122: 1Arterial Stiffness and Antihypertensive ControlMarcos A. Baroni, Mariana A. Cruz, AlfredoDellamora, Jose P. Sala, Mario Bendersky. InstitutoModelo de Cardiologia Privado SRL, Cordoba, AR.Weight and Arterial Stiffness in NormotensivePatientsMariana A. Cruz, Marcos A. Baroni, Jose P. Sala, MarioBendersky. Instituto Modelo de Cardiología PrivadoSRL, Cordoba, AR.Arterial Stiffness and Bood Pressure CircadianRhythm in Diabetics Normotensive PatientsMariana A. Cruz, Marcos A. Baroni, Jose P. Sala, MarioBendersky. Instituto Modelo de Cardiologia PrivadoSRL, Cordoba, AR.The Effect of a Single Standardized Blood PressureTraining and Certification on Terminal Digit Bias inHuman Observers in an Internal Medicine ClinicAhmed Dalmar, 1 Anthony Caceres, 2 Clarence E.Grim, 3 Carlene M. Grim. 3 1 Aurora Health Care,Milwaukee, WI, US; 2 University of Wisconsin,Milwaukee, WI, US and 3 Medical College ofWisconsin, Milwaukee, WI, US.Simple Determination of a Vascular Property FromBlood Pressure Measurements Taken at DifferentArm HeightsBenjamin Gavish, Leah Gavish. InterCure Ltd., Lod, IL.Accurate Blood Pressure Measurement: ACollaborative Call to Action Within the MainehealthSystemCassandra C. Grantham, Ann Cannon, Jacquelyn B.Cawley. MaineHealth, Portland, ME, US.Can Changes in the Circadian Variability of BloodPressure be Determined by Anemia?Alvaro Hermida, José Enrique Lopez, Marta Pena,Gaila Calvo, María Luisa Romero, Carlos Calvo.Hypertension and Vascular Risk Unit, ComplejoHospitalario Universitario de Santiago, Santiago deCompostela, ES.Estimation of Seated Central Blood Pressure;Its Theoretical Basis and Validation of TwoCommercially Available MethodsKozo Hirata, 1 Iwao Kojima, 2 Mutsuo Yamazaki, 2Yoshinori Miyawaki, 2 Shin-ichi Momomura. 1 1 JichiMedical University, Saitama Medical Center, SaitamaCity, Saitama, JP and 2 Omron Healthcare, Kyoto City,Kyoto, JP.1 Pathobiology Track 2 Translational Track 3 Therapy Track126

Sunday Morning MAY 2PostersPO-123: 1PO-124: 1PO-126: 1PO-127: 1PO-128: 1PO-129: 1PO-130: 1The Association of the Friesinger Score andPulse Pressure in an Urban South Asian PatientPopulationFahad Javed, 1 Girish Nadkarni, 1 Shahzeb A. Khan, 2Rishi Malhan, 1 Alexandre Benjo, 1 Emad F. Aziz, 1Eyal Herzog. 1 1 St. Luke’s-Roosevelt Hospital Center/University Hospital of Columbia University College ofPhysician and Surgeons, US and 2 Wayne State MedicalUniversity, MI, USA, US.Ambulatory Blood Pressure Profile in HypertensivePatients with β-Thalassemia MinorStella-Maria Kyvelou, 1 G. Vyssoulis, 1 E. Karpanou, 2V. Tzamou, 1 G. Theodosiadis, 1 C. Stefanadis. 1 1 1stCardiology Clinic Athens University HippokrationHospital, Athens, GR and 2 Cardiology Clinic OnassisCardiosurgery Center, Athens, GR.In Treated Hypertensives the Long TermCardiovascular Prognostic Value of AmbulatoryBlood Pressures is Greater in Women than in MenJose Mesquita Bastos, 1 Susana Bertoquini, 2 JorgePolonia. 3 1 Hospital Infante D.Pedro, EPE, Aveiro,PT; 2 Faculdade Psicologia, Porto, PT and 3 FaculdadeMedicina Porto, Porto, PT.The Hypertensive Status is a PrediabeticDeterminant, Unlike the Non-Dipper Phenomenomand Blood Pressure ControlOlivia Sanchez, Arantxa Rodriguez, AngelicaFernandez, Gloria Rodriguez, Asuncion Guerri,Susana Tello, Rosa Fabregate, Martin Fabregate, JoseSabán-Ruiz. Endothelial Pathology Unit. Ramon yCajal Hospital, Madrid, ES.Obesity and PrehypertensionGabor Simonyi, 1 Laszlo Halmy, 2 Robert J. Bedros, 1Tamas Csatay, 3 Mihaly Medvegy. 1 1 Flor FerencTeaching Hospital of County Pest, CardiometabolicCenter, Kistarcsa, HU; 2 Platon Health Center,Budapest, HU and 3 Police Health Center, Budapest,HU.Dipping Sub-Classification Carries No AdditionalPrognostic Importance Among Subjects withNocturnal HypertensionD. Syrseloudis, C. Tsioufis, I. Andrikou, A. Mazaraki,E. Andrikou, T. Papaioannou, D. Soulis, D. Tsiachris,C. Stefanadis. First Cardiology Clinic, University ofAthens, Hippokration Hospital, Athens, GR.24-Hour and Awake Blood Pressure VariabilityAre Associated with HS-CRP in Pre-HypertensiveAfrican AmericansPraveen Veerabhadrappa, Keith M. Diaz, KathleenM. Sturgeon, Deborah L. Feairheller, Sheara T.Williamson, Deborah Crabbe, Abul Kashem, DebraAhrensfield, Michael D. Brown. Temple University, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track127

MAY 2PostersSunday MorningPO-131: 3PO-132: 3PO-133: 3PO-134: 3PO-135: 3PO-136: 3Efficacy of Morning and Evening Dosing ofAmlodipine/Valsartan Combination in HypertensivePatients Uncontrolled by Amlodipine 5 MgRoland Asmar†, 1 Philippe Gosse, 2 Stéphane Quere, 3Assya Achouba. 3 1 Cardiovascular Medical Center,Paris, FR; 2 Saint - André Hospital, Bordeaux, FR and3 Novartis Pharma S.A.S, Rueil-Malmaison, FR.Arterial Stiffness: Impact of the Treatment withEprosartan or Enalaprilo in Mild to ModerateHypertensive Patients with Similar Peripheral BloodPressureRicardo M. Cabrera Sole, 1 Erik Luepke, 1 Juan Cañas, 2Caridad Turpin Lucas, 1 Jesualdo Masia Perez, 1 ManuelAguilera Saldaña. 1 1 University General Hospital ofAlbacete, Albacete, Albacete, ES and 2 Health Centerno 2 of Albacete, Albacete, Albacete, ES.Home BP and Clinic BP Responses in ElderlyIndividuals with Systolic Hypertension DuringInitial Treatment with Combined AngiotensinReceptor Blocker and Diuretic Compared toMonotherapy with Either ComponentW. Cushman†, 1 D. Duprez, 2 H. Weintraub, 3 R.Samuel, 4 D. Purkayastha, 4 D. Zappe, 4 J. L. Izzo, Jr. 51 Univ. Tennessee, US; 2 Univ. Minnesota, US; 3 NYUSchool of Medicine, US; 4 Novartis, US and 5 SUNYBuffalo, US.Comparison of Automated Sphygmomanometer(BPTRU) Measurements Performed in a 5 MinuteCycle with Mean Awake Ambulatory Blood PressureTarick Doleh, Marc A. Pohl, Robert Butler, Martin J.Schreiber, Jr., Mohammed A. Rafey. Cleveland ClinicFoundation, Cleveland, OH, US.Effect of Valsartan, Hydrochlorothiazide, andIts Combination on 24-Hour Ambulatory BloodPressure Response in Elderly Individuals withSystolic Hypertension: A Valvet SubstudyD. Duprez†, 1 H. Weintraub, 2 R. Samuel, 3 D.Purkayastha, 3 D. Zappe, 3 W. Cushman, 4 J. L. Izzo. 51 Univ. Minnesota, US; 2 NYU School of Medicine,US; 3 Novartis, US; 4 Univ. Tennessee, US and 5 SUNYBuffalo, US.Initiating Therapy with Intensive Dose ofCombination Amlodipine/Valsartan ProvidesImproved 24-H BP Response Compared to ModerateDose in Hypertensive Patients Uncontrolled on ARBMonotherapyThomas Giles†, 1 S. Oparil, 2 E. Ofili, 3 B. Pitt, 4 Y. Seifu, 5R. Samuel, 5 R. Hilkert, 5 J. Sowers. 6 1 Tulane Univ. SoM,US; 2 Univ. Alabama at Birmingham, US; 3 MorehouseSoM, US; 4 Univ. Michigan SoM, US; 5 Novartis, US and6 Univ. Missouri SoM, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track128

Sunday Morning MAY 2PostersPO-137: 3PO-138: 3PO-139: 3PO-140: 3PO-141: 3PO-142: 3The OMRON HEM-7113(BP710) Self BloodPressure Monitor Passes Both the ESH and AAMIValidation ProtocolsCarlene M. Grim†, 1 Clarence E. Grim. 2 1 Shared CareResearch and Education Consulting, Inc., Milwaukee,WI, US and 2 High Blood Pressure Consulting,Milwaukee, WI, US.Prognostic Value of Awake and Asleep AmbulatoryBlood Pressure for Prediction of CardiovascularMorbidity: Results of the MAPEC StudyRamon C. Hermida, 1 Diana E. Ayala, 1 ArtemioMojon, 1 Maria J. Fontao, 1 Rita Soler, 1 Luisa Chayan, 2Ignacio Alonso, 1 Jose R. Fernandez. 1 1 University ofVigo, ES and 2 Urgencias Sanitarias 061 Galicia, ES.Evaluation of the Wrist Type Ambulatory BloodPressure Monitoring Device – The ComparativeStudy with Brachial Type Ambulatory BloodPressure Monitoring DeviceTakahiro Komori, Kazuo Eguchi, Satoshi Hoshide,Joji Ishikawa, Kazuyuki Shimada, Kazuomi Kario.Division of Cardiovascular Medicine, Department ofMedicine, Jichi Medical University School of Medicine,Shimotsuke-shi, Tochigi-ken, JP.Prevalence and Risk Factors of MaskedHypertension Identified by Multiple Self BloodPressure Measurement (SBPM)Hae-Young Lee, 1 Jung-Bae Park. 2 1 Seoul NationalUniversity Hospital, KR and 2 Cheil General Hospital,Kwandong University College of Medicine, KR.Blood Pressure Fall After Exercise: The Influenceof Different ABPM Awakefulness and Sleep TimePatterns in the ElderlyLeandra G. Lima, 1 Paulo R. Padovan, 2 Iara F.Anunciato, 1 Fernanda G. Jatte, 1 Julio C. Moriguti, 1Eduardo Ferrioli, 1 Nereida K. C. Lima. 1 1 InternalMedicine Department - Ribeirao Preto School ofMedicine - Sao Paulo University, Ribeirao Preto, SaoPaulo, BR and 2 Victor Franckel School, Ribeirao Preto,Sao Paulo, BR.The Importance of Ambulatory Pulse Pressurewith Left Ventricular Hypertrophy in Patients withHypertensionDragan D. L. Lovic, 1 Branko B. L. Lovic, 1 DraganD. D. J. Djordjevic, 2 Milan M. L. Lovic, 2 Vesna V. S.Stojanov, 3 Branko B. J. Jakovljevic. 3 1 Clinic for InternalDisease Intermedica-Dr Lovic, Nis, Serbia, YU;2 Instiute Niska Banja, Nis, Serbia, YU and 3 ClinicalCenter Serbia, Beograd, Serbia, YU.1 Pathobiology Track 2 Translational Track 3 Therapy Track129

MAY 2PostersSunday MorningPO-143: 3PO-144: 2PO-145: 2PO-146: 2PO-147: 2PO-148: 2PO-149: 2Efficacy of an Amlodipine- and OlmesartanMedoxomil-Based Titration Regimen During theDaytime, Nighttime, Last 6, 4, and 2 Hours ofDosing Interval, and Dipper Status in Patients withHypertension and Type 2 DiabetesJoel M. Neutel†, 1 Thomas W. Littlejohn III, 2 ChunlinQian, 3 Ali Shojaee. 3 1 Orange County Research Center,US; 2 Piedmont Medical Research Associates, US and3 Daiichi Sankyo, Inc., US.Long-Term Reproducibility of Ambulatory BloodPressure is Superior to Office Blood Pressure in theVery ElderlyPatrick T. Campbell†, Nimrta Ghuman, DorothyWakefield, Leslie Wolfson, William B. White.University of Connecticut, Farmington, CT, US.Centralized Arterial Compliance Monitoring &PWV – Establishing Waveform Quality ControlCriteria for Clinical TrialsRaghu Chintala, Aaron Martin. MedifactsInternational, Rockville, MD, US.Education Program for Blood PressureMeasurement Using a DVD and CD-ROM ImprovesNursing Knowledge and Practice: A Study with 206NursesLyne Cloutier, 1 Marie-Ève Leblanc, 1 Isabelle Savary. 21 Université du Québec à Trois-Rivières, Québec, CAand 2 CSSS du Haut-Richelieu Rouville, Québec, CA.Changes in the Awake/Asleep Ratio of BloodPressure and Heart Rate with Aging in EssentialHypertension: The Hygia ProjectJuan J. Crespo, 1 Alfonso Otero, 2 Jesus Perez deLis, 1 Francisco J. Iglesias, 1 Artemio Mojon, 3 DianaE. Ayala, 3 Ramon C. Hermida, 3 Hygia ProjectInvestigators. 3 1 Gerencia Atención Primaria de Vigo,ES; 2 Complejo Hospitalario Universitario, Orense, ESand 3 University of Vigo, ES.Usefulness of Multiple Blood PressureMeasurements Using an Automated OscillometricMonitor (BPTRU) During a Campaign forCardiovascular PreventionGiuseppe Crippa, Giorgio Taroni, Maria Luisa Fares,Antonino Cassi, Pietro Cavallotti. Hypertension Unit,G. da Saliceto Hospital, Piacenza, IT.Comparison between Home Blood PressureMonitoring and Multiple In-Office Blood PressureMeasurements with BPTRU for the Diagnosis ofMasked HypertensionGiuseppe Crippa, Antonino Cassi, Maria Luisa Fares,Elena Bravi, Pietro Cavallotti. Hypertension Unit, G.da Saliceto Hospital, Piacenza, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track130

Sunday Morning MAY 2PostersPO-150: 2PO-151: 2PO-152: 2PO-153: 2PO-154: 2PO-155: 2PO-156: 2Effects of Time of Antihypertensive Treatment onthe Ambulatory Blood Pressure Pattern of Subjectswith Resistant Hypertension: The Hygia ProjectManuel Dominguez, 1 Maria T. Rios, 1 Jose L. Salgado, 1Pedro A. Callejas, 1 Peregrina Eiroa, 1 AlfonsoOtero, 2 Artemio Mojon, 3 Jose R. Fernandez, 3Ramon C. Hermida, 3 Hygia Project Investigators. 31 Gerencia Atención Primaria de Vigo, ES; 2 ComplejoHospitalario Universitario, Orense, ES and 3 Universityof Vigo, ES.Validation of OMRON HEM-6111 (BP629)Wrist Blood Pressure Monitor According to theInternational Protocol of the European Society ofHypertension (ESH) and Further Testing in Armswith a Circumference ≥36 cmClarence E. Grim†, 2 Carlene M. Grim. 1 1 Shared CareResearch and Education Consulting, Inc., Milwaukee,WI, US and 2 High Blood Pressure Consulting,Milwaukee, WI, US.Relative Influence of Nighttime Blood PressureDecline and Ambulatory Blood Pressure Level asPredictors for Cardiovascular Risk: Results of theMAPEC StudyRamon C. Hermida, 1 Diana E. Ayala, 1 ArtemioMojon, 1 Maria J. Fontao, 1 Rita Soler, 1 Luisa Chayan, 2Ignacio Alonso, 1 Jose R. Fernandez. 1 1 University ofVigo, ES and 2 Urgencias Sanitarias 061 Galicia, ES.Oscillometric Determination of the Ankle-BrachialIndex vs DopplerAnastasios Kollias, Athanase Protogerou, George S.Stergiou†. Hypertension Center, Third UniversityDepartment of Medicine, Sotiria Hospital, Athens, GR.Home Blood Pressure Telemonitoring and CaseManagement to Control Hypertension: HyperlinkDesign, Baseline Characteristics, and InterventionAdherenceKaren L. Margolis, Tessa J. Kerby, Stephen E. Asche,Michael V. Maciosek, Peter J. Meyers, JoAnn M. Sperl-Hillen, Simrandeep K. Tiwana, Patrick J. O’Connor.HealthPartners Research Foundation, Minneapolis,MN, US.Prevalence of an Altered Circadian Blood PressurePattern in Hypertensive Subjects with and withoutDiabetes: The Hygia ProjectAna Moya, 1 Maria C. Castiñeira, 2 Sonia M. Gomara, 1Elvira Sineiro, 1 Artemio Mojon, 3 Maria J. Fontao, 3Ramon C. Hermida, 3 Hygia Project Investigators. 31 Gerencia Atención Primaria de Pontevedra, ES;2 Gerencia Atención Primaria de Lugo, ES and3 University of Vigo, ES.Accurate Automatic Measurement of Systolic BloodPressureMeir Nitzan, 1 Zehava Glik. 2 1 Jerusalem College ofTechnology, Jerusalem, IL and 2 Barzilay MedicalCenter, Ashkelon, IL.1 Pathobiology Track 2 Translational Track 3 Therapy Track131

MAY 2PostersSunday MorningPO-157: 2PO-158: 2PO-159: 2PO-160: 2Ambulatory Blood Pressure Pattern in Subjects withand without Chronic Kidney Disease: The HygiaProjectAlfonso Otero, 1 Ana Moya, 2 Manuel Dominguez, 3 JuanJ. Crespo, 3 Artemio Mojon, 4 Diana E. Ayala, 4 RamonC. Hermida, 4 Hygia Project Investigators. 4 1 ComplejoHospitalario Universitario, Orense, ES; 2 GerenciaAtención Primaria de Pontevedra, ES; 3 GerenciaAtención Primaria de Vigo, ES and 4 University of Vigo,ES.Ambulatory Blood Pressure Monitoring (ABPM) inElderly and Very Elderly Patients: A ComparativeStudy on 3718 PatientsRiccardo Sarzani, Federico Guerra, MassimilianoFedecostante, Emma Espinosa, Paolo LorenzoDessì-Fulgheri, Alessandro Rappelli. Dept. InternalMedicine, University Ancona - Politecnica Marche,Ancona, IT.Assessment of Arterial Stiffness Indices in Childrenand AdolescentsGeorge S. Stergiou, 1 Anastasios Kollias, 1 PeriklisGiovas, 1 John Papagiannis, 2 Leonidas Roussias. 11 Hypertension Center, Third University Department ofMedicine, Sotiria Hospital, Athens, GR and 2 Divisionof Pediatric Cardiology, Onassis Cardiac SurgeryCenter, Athens, GR.Differences in Blood Pressure Measurement in aClinical Office between Medical Assistants andPhysician – Is it Time to Change the WorkflowStandard?Steven A. Yarows†. Michigan Hypertension Center,Chelsea, MI, US.Heart Failure/Hypertrophy (DiastolicDysfunction)PO-161: 1PO-162: 1Relationship between Increasing Blood Pressure andDiastolic Function by RaceGaston K. Kapuku†, Shanita Tolbert, Harry Davis,Gwen Bullock, James Halbert, Lashonda Bell, GregoryHarshfield. Medical College of Georgia/ GeorgiaPrevention Institute, Augusta, GA, US.Hypertension in Heart Failure with Normal LVEFis Characterized by LVH, Decreased Atrial EjectionFunction and Two Distinct Patterns of Abnormal LVFillingM. Rizwan Khalid, 1 Zaruhi V. Babayan, 2 EdwardS. Bennett, 3 Muhammad Raza Khalid, 4 Frank C.Messineo, 5 Icilma V. Fergus. 6 1 PSHC, KFMC, Riyadh,SA; 2 Montefiore Medical Center, NY, US; 3 New YorkHospital Queens, NY, US; 4 Al Tawam Johns HopkinsHospital, Al Ain, AE; 5 Lenox Hill Hospital, NY, US and6 Harlem Hospital Center, NY, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track132

Sunday Morning MAY 2PostersPO-163: 1PO-164: 3Orphan Nuclear Receptor Nur77 is a NovelRegulator of Cardiac Myocytes Hypertrophy andCardiac Fibroblast ProliferationJun Pu†, Lisheng Jiang, Ancai Yuan, Peiren Shan, NingZhou, Ben He. Department of Cardiology, ShanghaiRenji Hospital, School of Medicine, Shanghai JiaotongUniversity, CN.Changes of Hemodynamics of the Left Ventricle inPatients with Level II Arterial Hypertension andHeart Failure and Recurents Myocardial InfarctionsNestor Myckolayovych Seredyuk, Ruslana ValentunivnaDenina. Ivano-Frankivsk National Medical University,Ivano-Frankivsk, UA.Kidney and HypertensionPO-165: 1PO-166: 1PO-167: 1PO-168: 1PO-169: 1Glomerular Filtration Rate by Creatinine andCystatin C Measurements in Hypertensive PatientsSantina Cottone, Rosalia Arsena, Marco Guarneri,Chiara Altieri, Francesca Tornese, Gaia Giammarresi,Antonio Previti, Giovanni Cerasola. University ofPalermo - Policlinico Paolo Giaccone, PA, Palermo, IT.Relationship between Blood Pressure Variabilityand Renal Function in Pre-Renal Disease, Pre-Hypertensive African AmericansKeith M. Diaz, Deborah L. Feairheller, KathleenM. Sturgeon, Praveen Veerabhadrappa, ShearaWilliamson, Michael D. Brown. Temple University, US.Relationship between Circadian Blood PressureProfile, Arterial Stiffness and Renal FunctionAlvaro Hermida-Ameijeiras, Jose E. López-Paz, CarlosCalvo-Gomez. Clinic Hospital of Santiago, Santiago deCompostela, La Coruña, ES.Sex Differences in the Augmented Excretion ofUrinary Angiotensinogen (UAGT) in AngiotensinII (ANG II)-Infused Sprague-Dawley Rats DuringHigh Salt DietVicky F. Rands, 1 Hiroyuki Kobori, 1,2 Minolfa C.Prieto†. 1,2,3 1 Tulane University School of MedicineDepartment of Physiology, US; 2 Renal HypertensionCenter of Excellence, US and 3 Tulane-BIRCWHProgram, US.Functional Angiotensinogen -20c Promoter Variantis Associated with Different Renal Tubular SodiumHandling in Normotensive and Hypertensive MenRiccardo Sarzani, 1 Marica Bordicchia, 1 Marcod’Anzeo, 1 Antonio Barbato, 2 Paolo Dessì-Fulgheri, 1Alessandro Rappelli, 1 Pasquale Strazzullo. 2 1 Deptof Internal Medicine, University of Ancona -Politecnica Marche, Ancona, IT and 2 Dept.Clinical &Experimental Medicine-University Naples, Napoli, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track133

MAY 2PostersSunday MorningPO-170: 3PO-171: 3PO-172: 3PO-173: 3PO-174: 3PO-176: 2PO-177: 2Morphology and Cardiac Functions in ChronicKidney Failure Patients (CKF) on Dialysis with andwithout Renal Residual Function (RRF)Salustiano Pereira Araujo†, Sebastiao RodriguesFerreira Filho, Helton Pereira Lemes. UniversidadeFederal de Uberlandia - UFU, Uberlandia, MinasGerais, BR.Effect of Mineralocorticoid Blockade on COXPathway in Aldosterone/Salt Treated RatsDanita Eatman†, Aisha Rollins-Hairston, JefferyAdiyiah, Deborah Lyn, Mohamed A. Bayorh.Morehouse School of Medicine, Atlanta, GA, US.Residual Renal Function and the Long-Term Use ofFurosemide in Hemodialysis PatientsSebastião Rodrigues Ferreira-Filho, 2 Helton PereiraLemes, 1 Salustiano Pereira Araújo, 2 Daniella DinizNascimento, 2 César Bertoldo Garcia, 2 Vinícius deSouza Queiroz, 2 Danny Alves Cunha. 2 1 Nefroclinicade Uberlandia, Uberlandia, MG, BR and 2 FederalUniversity of Uberlandia, Uberlandia, Minas Gerais,BR.Bilateral Lower Extremity Sequential CompressionDevices (SCDS) for the Management of Intra-Dialytic Hypotension – A New Approach to an OldProblemMacaulay A. Onuigbo. 1,2 1 College of Medicine, MayoClinic, Rochester, MN, US and 2 Midelfort Clinic,Mayo Health System, Eau Claire, WI, US.To Stent or Not to Stent in Renal Artery Stenosis – AMayo Health System Hypertension Clinic 82-monthPBRN-Based Patient-Level Prospective DataAnalysis of 26 High-Risk CKD Patients with RenalArtery Stenosis Presenting with Acute Kidney InjuryMacaulay A. Onuigbo, 1,2 Vinay Nijhawan, 2 NnonyelumT. Onuigbo. 3 1 College of Medicine, Mayo Clinic,Rochester, MN, US; 2 Midelfort Clinic, Mayo HealthSystem, Eau Claire, WI, US and 3 NTEC Solutions,LLC, Eau Claire, WI, US.Nondilated Obstructive Uropathy – AnUnrecognized Cause of Acute Renal Failure inHospitalized US Patients: Three Case Reports SeenOver Six Months in a North-Western WisconsinNephrology PracticeMacaulay A. Onuigbo, 1,2 Kayode Lawrence. 3 1 Collegeof Medicine, Mayo Clinic, Rochester, MN, US;2 Midelfort Clinic, Mayo Health System, Eau Claire,WI, US and 3 Mount Sinai School of Medicine, NewYork, NY, US.Single Nucleotide Polymorphism in Enos GeneAssociated with Resting Blood Pressure in HealthyAfrican-AmericansMildred A. Pointer†, Domonique Brunson, MarilynK. McClelland. North Carolina Central University,Durham, NC, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track134

Sunday Morning MAY 2PostersPO-178: 2Differential Protein Expression of Collectrin in SaltSensitive and Salt Resistant Mouse StrainsXiaoyan Wang†, Crisanto S. Escano, Laureano Asico,Ines Armando, Pedro A. Jose. Children’s NationalMedical Center, Washington, DC, US.Metabolic Syndrome (Diabetes/GlycemicControl; Dysglycemic Drugs; InsulinResistance)PO-179: 1PO-180: 1PO-181: 1PO-182: 1PO-183: 1PO-184: 1PO-185: 1Oral Glucose Tolerance Test and New Diagnoses ofMetabolic DisordersMarcos A. Baroni, Mariana A. Cruz, AlfredoDellamora, Jose P. Sala, Mario Bendersky. InstitutoModelo de Cardiologia Privado SRL, Cordoba, AR.The Metabolic Syndrome and Carotid Intima-MediaThickness in Relation to the Parathyroid Hormoneto 25-OH-D3 Ratio in a General PopulationTom Richart, 1,2 Lutgarde Thijs, 2 Tim Nawrot, 3 JinYu, 2 Patrick Segers, 4 Tatiana Kuznetsova, 2 ElisabethJ. Balkestein, 1 Harry A. Struijker-Boudier, 1 Jan A.Staessen. 1,2 1 Maastricht University, NL; 2 Universityof Leuven, BE; 3 Universiteit Hasselt, BE and 4 GhentUniversity, BE.Association between Plasma Transforming GrowthFactor-β Levels and Components of MetabolicSyndrome for Patients with Heart FailureOleg M. Sheremeta, Mariya A. Orynchak. Ivano-Frankivsk National Medical University, Ivano-Frankivsk, UA.Role of Glucose Metabolism Disorders in theDevelopment of Cardiovascular Risk in Patientswith Metabolic SyndromeNigora Zaynutdinovna Srojidinova. Republic Centre ofCardiology, Tashkent, UZ.The Insulin Sensitivity Improving Effect of SelectivePPARγ Modulating Angiotensin II Receptor Blockerin Skeletal MuscleKen Sugimoto, 1 Tomomi Fujisawa, 1 Nobuyasu Shindo, 1Theodore W. Kurtz, 2 Hiromi Rakugi. 1 1 GeriatricMedicine, Osaka University Graduate School ofMedicine, Suita, Osaka, JP and 2 Laboratory Medicine,UCSF Medical Center, San Francisco, CA, US.“Hypertriglyceridemic Waist” Syndrome as aPrehypertensive Status. Correlation with BiomarkersSusana Tello, Asuncion Guerri, Martin Fabregate, RosaFabregate, Arturo Ugalde, Nuria de la Torre, ArantxaRodriguez, Jose Saban-Ruiz. Endothelial PathologyUnit. Ramon y Cajal Hospital, Madrid, ES.Hyperleptinemia as a New Component of MetabolicSyndrome in Hypertensives with PostinfarctionCardiosclerosisIryna Igorivna Vakalyuk, Mariya Andriivna Orynchak,Igor Petrovich Vakaliuk. Ivano-Frankivsk NationalMedical University, Ivano-Frankivsk, UA.1 Pathobiology Track 2 Translational Track 3 Therapy Track135

MAY 2PostersSunday MorningPO-186: 3PO-187: 3PO-188: 3PO-189: 3PO-190: 3PO-191: 3PO-192: 3Long-Term Beneficial Effects on DiabeticRetinopathy of a Therapeutic Regimen Based onUltrahigh Doses of CandesartanPedro Aranda, 1 Angel Cilvetti, 2 Jose Carlos Fernandez-Garcia, 3 Margarita Lapeira, 2 Cristina Jironda, 1Carmen Cobelo, 1 Domingo Hernandez. 1 1 NephrologyDepartment, Carlos Haya University General Hospital,Malaga, ES; 2 Ophthalmology Department, HospitalVirgen de la Victoria, Malaga, ES and 3 EndocrinologyDepartment, Carlos Haya University General Hospital,Malaga, ES.Antiproteinuric Effects of a Switched TherapeuticRegimen Based on Irbesartan Alone or inCombination with Aliskiren in Overt DiabeticNephropathyPedro Aranda, 1 Carmen Cobelo, 1 Cristina Jironda, 1Jose Carlos Fernandez-Garcia, 2 Miguel Angel Frutos, 1Domingo Hernandez. 1 1 Nephrology Department,Carlos Haya University General Hospital, Malaga,ES and 2 Endocrinology Department, Carlos HayaUniversity General Hospital, Malaga, ES.Prevalence, Management and Control of DiabetesMellitus and Associated Risk Factors in the PrimaryHealth Care in PortugalNuno Cortez-Dias, 1 Suzana R. Martins, 1 Adriana Belo, 2Manuela Fiuza. 1 1 University Hospital Santa Maria,Lisbon, PT and 2 Portuguese Society of Cardiology,Lisbon, PT.The Relationship between Blood Pressure Controland Serum Cholesterol Levels in Type 2 DiabeticPatientsJose Diaz-Benito, Luisa Muñoz-Garde. ServicioNavarro de Salud, Pamplona, Navarra, ES.Different Effects of Aliskiren and Losartan onFibrinolysis and Insulin Sensitivity in HypertensivePatients with Metabolic SyndromeRoberto Fogari, Ilaria Ferrari, Amedeo Mugellini,Sibilla Salvadeo, Annalisa Zoppi, Paola Preti, GiuseppeDerosa. Department of Internal Medicine, Universityof Pavia, Pavia, IT.Hypertension and Diabetes BurdenWallace Johnson, 1 Gabriel E. Shaya. 2 1 University ofMaryland School of Medicine, Baltimore, MD, US and2 Georgetown University, Washington, DC, US.Poor Antihypertensive Control of Diabetics inFinnish General Practice Seems Not to be Associatedwith Diabetic Control But Insufficient Medicationand ComplianceIlkka M. Kantola†, 1 Juha Varis, 1 Lassi Nelimarkka, 1Heljä Savola, 1 Risto Vesalainen. 2 1 Turku UniversityHospital, Turku, FI and 2 Medical Centre Pulssi, Turku,FI.1 Pathobiology Track 2 Translational Track 3 Therapy Track136

Sunday Morning MAY 2PostersPO-193: 3PO-194: 3PO-195: 3PO-196: 3PO-197: 2PO-198: 2PO-199: 2Effects of an Amlodipine-and OlmesartanMedoxomil-Based Titration Regimen in Patientswith Hypertension, Type 2 Diabetes and MetabolicSyndromeVenkata S. Ram†, 1 Richard A. Sachson, 2 ChunlinQian, 3 Maninee Patel, 3 Kathy A. Stoakes. 3 1 Universityof Texas Southwestern Medical Center, US; 2 EndocrineAssociates of Dallas, US and 3 Daiichi Sankyo, Inc., US.The Influence of Simvastatin and Tiotriazolin onPlasma Resistin Levels in Patients with DiabetesMellitus and Metabolic Syndrome and Heart FailureNadia V. Skrypnik, Mariya A. Orynchak. Ivano-Frankivsk National Medical University, Ivano-Frankivsk, UA.The Metabolic Syndrome is a Risk Factor forResistant HypertensionKonstantinos Tziomalos, Maria Baltatzi, EliasEfthymiou, Konstantia Psianou, Natalia Papastergiou,Dimitria Magkou, Georgios Zervopoulos, GiannisKagelidis, Evangelia Karlafti, Christos Savopoulos,Apostolos I. Hatzitolios. First Propedeutic Departmentof Internal Medicine, Medical School, AristotleUniversity of Thessaloniki, AHEPA Hospital, GR.Global Cardiovascular Risk Control in Patients withDiabetes of Long DurationJose F. Varona, 1,2 Pedro Pablo, 3 L. Cabrerizo, 4 J. M.Miralles, 5 MELODY Study Group Investigators. 61 University Hospital Madrid Monteprincipe, Madrid,ES; 2 Medical Department, Pfizer, ES; 3 Hospital GeneralGran Canaria, ES; 4 Hospital Clinico, Madrid, ES;5 University Hospital Salamanca, ES and 6 MelodyStudy, ES.Differences in the Impact of Metabolic SyndromeComponents Among Hypertensives Attended inVarious Medical SpecialitiesAlejandro de la Sierra†, 1 Eduardo Alegría, 2 AlbertoMartinez-Castelao, 3 Carlos Morillas, 4 Diego Gonzalez-Segura. 5 1 Hospital Mutua Terrassa, University ofBarcelona, Terrassa, ES; 2 Clinica Universitaria Navarra,Pamplona, ES; 3 Hospital Universitario Bellvitge,Barcelona, ES; 4 Hospital Universitario Dr. Pesset,Valencia, ES and 5 Almirall, Barcelona, ES.Prediabetes is Associated with Functional andStructural Cardiovascular AbnormalitiesDaniel A. Duprez, Natalia Florea, Wei Zhong, GregoryGrandits, Lynn Hoke, Jay N. Cohn. University ofMinnesota, Minneapolis, MN, US.Left Ventricular Mass and the Role of MetabolicSyndrome in Overweight/Obese HypertensivePatientsFederico Guerra, Luca Angelini, Lucia Mancinelli,Marco Fortunati, Paolo Lorenzo Dessì-Fulgheri,Alessandro Rappelli, Riccardo Sarzani. Dept. InternalMedicine, University Ancona - Politecnica Marche,Ancona, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track137

MAY 2PostersSunday MorningNon-Pharmacological Therapy(Alternative Medicine; Diet; PhysicalActivity)PO-200: 3PO-201: 3PO-202: 3Blood Pressure Lowering with a Non-InvasiveDevice in Patients with Uncontrolled ArterialHypertension: Placebo-Controlled StudyYulia Kotovskaya†, 1 Nazilya Bagmanova, 1 GalinaSvintsova, 1 Marina Umnikova, 2 Zhanna Kobalava. 11 Russian Peoples’Friendship University, Moscow, RUand 2 Denas Ms Corporation, Ekaterinburg, RU.Non-Pharmacological Treatment on Changes inLifestyle in a Population of Hypertensive Patientswith ObesityRosa M. Santos, 1 Joao P. Freitas, 2 Mario E. Macedo, 2Irene J. Rebelo. 3 1 Hospital S. Joao, Porto, PT; 2 Facultyof Medicine, Porto, PT and 3 Faculty of Pharmacy,Porto, PT.Effect of Allicin on Metabolic Parameters inSpontaneously Hypertension RatsYehonatan Sharabi, 1,2 Amitay Elkayam, 1,2 Edna Peleg, 1Zehava Shabtay, 1 Ehud Grossman. 1,2 1 HypertensionUnit and Medicine D, Tel Hashomer, IL and 2 SacklerFaculty of Medicine, Tel Aviv, IL.Patient-Provider-Healthcare SystemIssuesPO-203: 3PO-204: 3PO-205: 3Evaluation of Resistant Hypertension in anAcademic Internal Medicine ClinicJiwanjot K. Chhatwal, 1 Susan Steigerwalt†, 1,2 SusannaSzpuner, 2 Micheal Marshall. 1 1 Providence Hospital,Southfield, MI, US and 2 St John Hospital and MedicalCenter, Detroit, MI, US.The Safety and Tolerability Profile of anAmlodipine- and Olmesartan Medoxomil-BasedTitration Regimen in Patients with Hypertensionand Type 2 DiabetesSteven G. Chrysant†, 1 Joel M. Neutel, 2 Chunlin Qian, 3Kathy A. Stoakes. 3 1 Oklahoma Cardiovascular andHypertension Center and the University of OklahomaSchool of Medicine, US; 2 Orange County ResearchCenter, US and 3 Daiichi Sankyo, Inc., US.Validation of Blood Pressure Devices by Combiningthe ESH and AAMI Protocols Saves Time and Moneyand Will Likely Lead to More Device ValidationTesting Before MarketingClarence E. Grim, 2 Carlene M. Grim. 1 1 Shared CareResearch and Education Consulting, Inc., Milwaukee,WI, US and 2 High Blood Pressure Consulting,Milwaukee, WI, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track138

Sunday Morning MAY 2PostersPO-206: 3PO-207: 3PO-208: 3PO-209: 2Clinical Inertia in Hypertension: Factors Associatedwith Failure to ActPhilip B. Mellen, 1 William Smith, 2 Bryan Batson. 11 Hypertension Center of the Hattiesburg Clinic,Hattiesburg, MS, US and 2 University of SouthernMississippi, Hattiesburg, MS, US.Why Are We Treating Hypertension in the Hospital?Kyle William Pfahl, Alan Weder. University ofMichigan Health Systems, Ann Arbor, MI, US.Appropriateness for Referral of the Hypertensives toHypertension UnitElisa Testa, 1 Silvia Totaro, 1 Franco Rabbia, 1 LauraAngelici, 2 Elena Berra, 1 Valeria Milazzo, 1 AndreaIannaccone, 1 Sara Abram, 1 Alberto Milan, 1 FrancoVeglio. 1 1 Hypertension Unit Turin, Turin, IT and2 University of Milan, Milan, IT.What Availability of Resources Have theHypertension Units in Spain? Results From PerfilesSurveyPedro Aranda Lara, 1 Juan Antonio Divisón, 2 PatricioGarrido, 3 Carlos Sanchís, 4 Enrique Godoy, 5 Alfredodel Campo. 6 1 H. Carlos Haya, Malaga, ES; 2 CSCasas Ibáñez, Albacete, ES; 3 Facultad de Medicina,Barcelona, ES; 4 CS de Algemesí, Valencia, ES; 5 Daiichi-Sankyo, Madrid, ES and 6 Sociología y Comunicación,Madrid, ES.Risk Factors (Lipids)PO-210: 3PO-212: 3PO-213: 2Serial Changes in Low-Positive Extra-SensitiveTroponin I Levels in Patients with Acute SevereHypertension and Hypertensive Emergencies AreAssociated with Increased Cardiovascular EventsAtul R. Chugh, 1 Arka Chatterjee, 1 Julius B. Elmore, 1Sofya Kuznetsov, 1 John H. Loughran, 1 James J.Miller, 1 Buddhadeb Dawn. 2 1 University of Louisville,Louisville, KY, US and 2 University of Kansas, KansasCity, KS, US.Impact of Atorvastatin Tratment on MultipleCardiovascular Risk Factors in HypertensivePatientsTakuya Tsuchihashi, Yuko Ohta, Eri Hasegawa.National Kyushu Medical Center, Fukuoka City, JP.Community-Based Analysis of Genetic FactorsAssociated with Gender-Specific Hypertension inJapanMasahiko Eto†, 1 Takanori Aonuma, 1 MasanobuOkayama, 2 Maki Kumada, 2 Ritei Uehara, 2 YoshikazuNakamura, 2 Eiji Kajii. 2 1 Wakuya Medical and WelfareCenter, Wakuya, Miyagi, JP and 2 Jichi MedicalUniversity, Shimotsuke, Tochigi, JP.1 Pathobiology Track 2 Translational Track 3 Therapy Track139

MAY 2PostersSunday MorningPregnancyPO-214: 1PO-215: 1PO-216: 2Women with Previous Preeclampsia are at IncreasedRisk for Developping Hypertension After CombinedOral ContraceptivesJorge Polonia, 1 Filomena Cardoso, 3 Jose A. Silva, 1Helena Belchior, 2 Pedro Tiago, 2 Joao Silva-Carvalho. 31 Blood Pressure Unit, Matosinhos, PT; 2 Obstetricia& Ginecologia, Matosinhos, PT and 3 Obstetriia &Ginecologia, Porto, PT.Low Potassium and Uric Acid Level During the FirstHalf of Pregnancy is Associated with Lower Risk forthe Development of Gestational Diabetes Mellitusand PreeclampsiaTalya Wolak, 1 Esther Paran, 1 Ruslan Sergienco, 3Arnon Wiznitzer, 2 Lior Ben-Shlush, 2 Eyal Sheiner. 21 Hypertension Unit, Soroka University Hospital, Beer-Sheba, IL; 2 Department of Obstetrics and GynecologySoroka University Hospital, Beer-Sheba, IL and3 Epidemiology and Health Services Evaluation Facultyof Health Sciences, Ben Gurion University of theNegev, Beer-Sheba, IL.Evaluation of Left Ventricular Structure andFunction and Carotid Artery Morphology in Womenwith Previous PreeclampsiaMassimo Salvetti, 1 Federico Perfumo, 2 Anna Paini, 1Giorgia Gatti, 2 Claudia Agabiti Rosei, 1 Carlo Aggiusti, 1Enrico Agabiti Rosei, 1 Tiziana Frusca, 2 Maria LorenzaMuiesan. 1 1 Internal Medicine, University of Brescia,IT and 2 Obstetrics and Gynaecology, University ofBrescia, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track140

Monday Morning Afternoon MAY 21 3PostersPosters will be displayed in the Rhinelander Gallery.Monday, May 3, 2010Posters on Display: 9:00 AM – 5:15 PM • Poster Viewing: 4:15 PM – 5:15 PMCellular Mechanisms (Cell Biology;Cell Membrane Transport/Ion Channels;Coagulation/Thrombosis; Growth Factors).............(PO-217 – PO-219)Clinical Trials................................................................(PO-220 – PO-242)Endothelial Function...................................................(PO-243 – PO-255)Epidemiology/Special Populations............................(PO-256 – PO-293)Genetics/Gene Therapy/Proteomics..........................(PO-294 – PO-297)Neural Hormonal Mechanisms (Renin;Neural Control; Vasoactive Autacoids).....................(PO-298 – PO-300)Obesity...........................................................................(PO-301 – PO-306)Pediatric Hypertension...............................................(PO-307 – PO-308)Preclinical Models/ExperimentalHypertension................................................................(PO-309 – PO-311)Vascular Injury/Inflammation andRemodeling...................................................................(PO-312 – PO-318)Late-Breaking Posters........................................(LBPO-001 – LBPO-016)Dagger (†) denotes that the presenting author has related disclosureinformation. Please see page 161 for more details.1 Pathobiology Track 2 Translational Track 3 Therapy Track141

MAY 21 3PostersMonday AfternoonMorning9:00 AM – 5:15 PM • Rhinelander GalleryCellular Mechanisms (Cell Biology;Cell Membrane Transport/Ion Channels;Coagulation/Thrombosis; GrowthFactors)PO-217: 1PO-218: 1PO-219: 2Transforming Growth Factor-β (TGF-β)-mediatedthe Down-Regulation of Peroxisome Proliferator-Activated Receptorγ (PPARγ) in the PressureOverloaded HeartKaizheng Gong, Peng Li, Jason Lucas, Dongqi Xing,Baran Aksut, Fadi Hage, Qinglin Yang, Susan E. Nozell,Suzanne Oparil, Yiu-Fai Chen. Vascular Biology andHypertension Program, University of Alabama atBirmingham, US.Serum Phosphate in White Coat HypertensivePatients: Focus on Dipping Status and MetabolicSynromeV. Tzamou, 1 G. Vyssoulis, 1 E. Karpanou, 2 Stella-Maria Kyvelou, 1 T. Gialernios, 1 C. Stefanadis. 1 1 1stCardiology Clinic Athens University HippokrationHospital, GR and 2 Cardiology Clinic OnassisCardiosurgery Center, GR.Regulation of Manganese Superoxide DismutaseExpression in Cardiac Fibroblasts by Angiotensin IIPaul J. Lijnen, Robert H. Fagard. University of Leuven(KULeuven), Leuven, BE.Clinical TrialsPO-220: 1PO-221: 3Optimal Blood Pressure Control and All CauseMortality in a Clinical Practice SettingVasilios Papademetriou, 1 Richard Amdur, 1 MichaelDoumas, 2 Costas Tsioufis, 1 Peter Kokkinos, 1 CharlesFaselis, 2 Ross D. Fletcher. 1 1 VAMC and GeorgetownUniversity, Washington, DC, US; 2 VAMC and GeorgeWasgington University, US; 3 VAMC and GeorgetownUniversity, US; 4 VAMC and Georgetown University,US and 5 VAMC and Georgetown University, US.Effects of the Novel Angiotensin Receptor BlockerAzilsartan Medoxomil in Patients with PrimaryHypertensionGeorge Bakris†, 1 Domenic Sica, 2 Michael Weber, 3William B. White, 4 Alfonso Perez, 5 Charlie Cao, 5Stuart Kupfer. 5 1 University of Chicago, PritzkerSchool of Medicine, Chicago, IL, US; 2 VirginiaCommonwealth University Health System, Richmond,VA, US; 3 SUNY Downstate College of Medicine,New York, NY, US; 4 Univ. of Connecticut School ofMedicine, Farmington, CT, US and 5 Takeda GlobalResearch & Development, Deerfield, IL, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track142

Monday Morning Afternoon MAY 21 3PostersPO-222: 3PO-223: 3PO-224: 3PO-225: 3PO-226: 3PO-227: 3PO-228: 3PO-229: 3PO-230: 3Efficacy and Safety of Nebivolol in Patients withStage II Hypertension: Pooled Results From ThreePhase III TrialsLynn Denekamp†, Phillip Jennings. Forest ResearchInstitute, Jersey City, NJ, US.Aliskiren: Will a Novel Mechanism Improve ClinicalOutcomes?MariaLeonarda DeRosa. Dept.of Cardiology Universityof Naples Federico II, Naples, Na, IT.Human Blood Pressure Readings are More Accurateand Show Less Variation than Oscillometric DeviceReadingsClarence E. Grim, 2 Carlene M. Grim. 1 1 Shared CareResearch and Education Consulting, Inc., Milwaukee,WI, US and 2 High Blood Pressure Consulting,Milwaukee, WI, US.A Phase IV, Prospective, Randomized, Double-Blind, Placebo-Controlled Study of NebivololWithdrawal in Patients with Stage I-II HypertensionKati Gutierrez†, 1 Fang Dong, 1 Cristian F. Breton. 21 Forest Research Institute, Jersey City, NJ, US and2 International Research Associates, Miami, FL, US.Improved Renal Function Associated with theNormalization of the Circadian Blood PressurePattern by Angiotensin Receptor BlockadeRamon C. Hermida, Diana E. Ayala, Artemio Mojon,Jose R. Fernandez. University of Vigo, ES.Improved Ambulatory Pulse Pressure Reductionwith Bedtime as Compared to MorningAdministration of Nifedipine GITS in EssentialHypertensionRamon C. Hermida, 1 Diana E. Ayala, 1 Luisa Chayan, 2Maria J. Fontao, 1 Artemio Mojon, 1 Jose R. Fernandez. 11 University of Vigo, ES and 2 Urgencias Sanitarias 061Galicia, ES.Treatment of Non-Dipper Essential Hypertension byBedtime Administration of Angiotensin ReceptorBlockersRamon C. Hermida, Diana E. Ayala, Maria J. Fontao,Artemio Mojon, Jose R. Fernandez. University of Vigo,ES.Increasing the Awake/Asleep Blood PressureRatio Towards a More Dipping Pattern ReducesCardiovascular Risk: Results of the MAPEC StudyRamon C. Hermida, 1 Diana E. Ayala, 1 ArtemioMojon, 1 Maria J. Fontao, 1 Rita Soler, 1 Luisa Chayan, 2Ignacio Alonso, 1 Jose R. Fernandez. 1 1 University ofVigo, ES and 2 Urgencias Sanitarias 061 Galicia, ES.Influence of Circadian Time of AntihypertensiveTreatment on Cardiovascular Risk: Results of theMAPEC StudyRamon C. Hermida, 1 Diana E. Ayala, 1 ArtemioMojon, 1 Maria J. Fontao, 1 Rita Soler, 1 Luisa Chayan, 2Ignacio Alonso, 1 Jose R. Fernandez. 1 1 University ofVigo, ES and 2 Urgencias Sanitarias 061 Galicia, ES.1 Pathobiology Track 2 Translational Track 3 Therapy Track143

MAY 21 3PostersMonday AfternoonMorningPO-231: 3PO-232: 3PO-233: 3PO-234: 3PO-235: 3PO-236: 3Mindfulness-Based Stress Reduction Reduces ClinicBP in PrehypertensionJoel W. Hughes†, 1 David M. Fresco, 1 Manfred vanDulmen, 1 Linda E. Carlson, 3 Richard Josephson, 4Rodney Myerscough. 2 1 Kent State University, Kent,OH, US; 2 Summa Health Center, Akron, OH, US;3 University of Calgary, Calgary, AB, CA and 4 CaseWestern Reserve University, Cleveland, OH, US.Efficacy and Safety of Azilsartan Medoxomil, aNovel Angiotensin II Receptor Blocker, in African-Americans with HypertensionW. Johnson†, 1 W. B. White, 2 D. Sica, 3 G. L., 4 M. A.Weber, 5 A. Perez, 6 C. Cao, 6 S. Kupfer, 6 E. Saunders. 11 University of Maryland School of Medicine,Baltimore, MD, US; 2 University of ConnecticutSchool of Medicine, Farmington, CT, US; 3 VirginiaCommonwealth University Health System, Richmond,VA, US; 4 University of Chicago, Pritzker School ofMedicine, Chicago, IL, US; 5 SUNY Downstate Collegeof Medicine, New York, NY, US and 6 Takeda GlobalResearch & Development, Deerfield, IL, US.Efficacy and Onset of Antihypertensive Effects ofan Amlodipine- and Olmesartan Medoxomil-BasedTitration Regimen in Patients with Hypertensionand Type 2 DiabetesDean J. Kereiakes, 1 Richard A. Sachson, 2 ChunlinQian, 3 Maninee Patel. 3 1 The Christ Hospital Heartand Vascular Center and The Carl and Edyth LindnerCenter for Research and Education at The ChristHospital, US; 2 Endocrine Associates of Dallas, US and3 Daiichi Sankyo, Inc., US.High Dose Candesartan Cilexetil in Combinationwith Hydrochlorothiazide for Second StageHypertension: CAESAR (Candesartan Effect inSecond Stage Arterial Hypertension) StudyHae-Young Lee†, 1 Dong Woon Jeon, 1 Chang-KyuPark, 1 Dong Hoon Choi, 2 Bum Ki Hong. 2 1 SeoulNational University Hospital, KR and 2 Yonseiuniversity Severance hospital, KR.Pharmacist Interventions to Enhance PatientAdherence to Antihypertensive Medication: ASystematic ReviewManuel Morgado, Liliana Castanheira, Ignácio Verde,Miguel Castelo-Branco. Health Sciences ResearchCentre, University of Beira Interior, Covilhã, PT.Effects of Nebivolol Added to OngoingAntihypertensive Therapy on Heart Rate in Patientswith Stage I-II Hypertension: Post hoc Analysis of aPhase III TrialJoel M. Neutel†, 1 David H. G. Smith. 2 1 Orange CountyResearch Center, Tustin, CA, US and 2 University ofCalifornia, Irvine, CA, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track144

Monday Morning Afternoon MAY 21 3PostersPO-237: 3PO-238: 3PO-239: 3PO-240: 3PO-241: 3Effects of an Amlodipine- and OlmesartanMedoxomil-Based Titration Regimen on 24-HourBP Profiles in Patients with Hypertension and Type2 DiabetesVenkata S. Ram, 1 Richard A. Sachson, 2 Thomas W.Littlejohn III, 3 Ali Shojaee, 4 Kathy A. Stoakes, 4 Joel M.Neutel. 5 1 University of Texas Southwestern MedicalCenter, US; 2 Endocrine Associates of Dallas, US;3 Piedmont Medical Research Associates, US; 4 DaiichiSankyo, Inc., US and 5 Orange County Research Center,US.New Angiotensin II Receptor Blocker AzilsartanMedoxomil Coadministered with ChlorthalidoneProvides Potent Blood Pressure Reduction in Stage 2HypertensionD. Sica†, 1 G. L. Bakris, 2 W. B. White, 3 M. A. Weber, 4 A.Perez, 5 C. Cao, 5 S. Kupfer. 5 1 Virginia CommonwealthUniversity Health System, Richmond, VA, US;2 University of Chicago, Pritzker School of Medicine,Chicago, IL, US; 3 University of Connecticut Schoolof Medicine, Farmington, CT, US; 4 SUNY DownstateCollege of Medicine, New York, IL, US and 5 TakedaGlobal Research & Development, Deerfield, IL, US.A Phase III Trial of Baroreflex Activation Therapyfor Resistant Hypertension: Trial Design andBaseline Characteristics in the Rheos Pivotal TrialDomenic A. Sica†, 1 George Bakris, 2 JohnBisognano, 3 Mitra Nadim, 4 Luis Sanchez. 5 1 VirginiaCommonwealth University Health System, Richmond,VA, US; 2 University of Chicago, US; 3 University ofRochester Medical Center, US; 4 University of SouthernCalifornia, US and 5 Washington University School ofMedicine, US.Morbidity and Mortality on Combination vsMonotherapy in the Systolic Hypertension in EuropeTrialLutgarde Thijs, 1 Tom Richart, 1,2 Peter W. de Leeuw, 2Tatiana Kuznetsova, 1 Tomasz Grodzicki, 3 KalinaKawecka-Jaszcz, 3 Eoin O’Brien, 4 Josep Redón, 5 WillemH. Birkenhäger, 6 Robert Fagard, 1 Jan A. Staessen†. 1,21 University of Leuven, BE; 2 Maastricht University,NL; 3 Jagiellonian University, PL; 4 University CollegeDublin, IE; 5 University of Valencia, ES and 6 ErasmusUniversity, NL.Antihypertensive Efficacy of the New AngiotensinReceptor Blocker Azilsartan Medoxomil inCombination with AmlodipineM. A. Weber†, 1 W. B. White, 2 D. Sica, 3 G. L. Bakris, 4A. Perez, 5 C. Cao, 5 S. Kupfer. 5 1 SUNY DownstateCollege of Medicine, New York, NY, US; 2 University ofConnecticut School of Medicine, Farmington, CT, US;3 Virginia Commonwealth University Health System,Richmond, VA, US; 4 University of Chicago, PritzkerSchool of Medicine, Chicago, IL, US and 5 TakedaGlobal Research & Development, Deerfield, IL, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track145

MAY 21 3PostersMonday AfternoonMorningPO-242: 3The New Angiotensin Receptor Blocker AzilsartanMedoxomil Has Superior 24-Hour Blood PressureLowering Efficacy to Both Olmesartan and ValsartanW. B. White†, 1 M. A. Weber, 2 D. Sica, 3 G. L. Bakris, 4 A.Perez, 5 C. Cao, 5 S. Kupfer. 5 1 University of ConnecticutSchool of Medicine, US; 2 SUNY Downstate College ofMedicine, US; 3 Virginia Commonwealth UniversityHealth System, US; 4 University of Chicago Schoolof Medicine, US and 5 Takeda Global Research andDevelopment, US.Endothelial FunctionPO-243: 1PO-244: 1PO-245: 1PO-246: 1PO-247: 1PO-248: 1Expression and Function of B1 Receptor in Kidneyof Diabetic RatsRocio Bautista†, Ricardo Mendioza, Said Arellano,Martha Franco. Instituto Nacional de Cardiología“Ignacio Chávez”, México, D.F., MX.Assessment of Endothelial Function by Means ofFlow Mediated Dilation Using Carotid-Radial PulseWave Velocity in Type II DiabeticsClaudio A. Bellido, Eduardo J. Rusak, Oscar R. Iavicoli,Jose D. Braver, Mariano Duarte, Sonia T. Vazquez,Jorge Lerman. University of Buenos Aires, BuenosAires, Capital Federal, AR.Evaluation of Endothelial Function in Patients withNon-Alcoholic Fatty Liver DiseaseGianLuca Colussi, 1 Debora Donnini, 2 CristianaCatena, 1 Lorenzo Iogna Prat, 1 Alessia Carnelutti, 2Alessandro Di Fabio, 1 Giorgio Soardo, 2 Leonardo A.Sechi. 1 1 Hypertension Unit, Department of InternalMedicine, University of Udine, Udine, IT and 2 LiverUnit, Department of Internal Medicine, University ofUdine, Udine, Italy, Udine, IT.Relationship between Plasma Hemoglobin andOxidative Stress in 2-5 CKD PatientsSantina Cottone, Raffaella Riccobene, Giuseppe Mulè,Rosalia Arsena, Francesco Vaccaro, Marco Guarneri,Alessandra Ocello, Giovanni Cerasola. Università diPalermo - Policlinico P.Giaccone, Palermo, PA, IT.Habitual Flavonoid Intake and Vascular Responsesto Flavonoid-Rich Cocoa in Healthy HumansNaomi D. Fisher†, Norman K. Hollenberg. Brighamand Women’s Hospital, Boston, MA, US.Arterial Stiffness in Paroxysmal Atrial Fibrillation:Relationship with Micro and MacrovascularEndothelial Dysfunction and CardiovascularDiseaseSuresh Krishnamoorthy†, Chee Wah Khoo, HoongSern Lim, Gregory Y. H. Lip. University Departmentof Medicine Centre for Cardiovascular Sciences, CityHospital, Birmingham, West Midlands, GB.1 Pathobiology Track 2 Translational Track 3 Therapy Track146

Monday Morning Afternoon MAY 21 3PostersPO-250: 1PO-251: 1PO-252: 1PO-253: 1PO-254: 3PO-255: 2sFlt-1 and P1GF Levels in Patients with Thalassemiaand Sickle Cell DiseaseIoannis Papassotiriou, 1 Alexandra Kouraklis-Symeonidis, 2 Filia Apostolakou, 1 Vassilios Ladis, 3Antonios Kattamis. 3 1 Department of ClinicalBiochemistry, “Aghia Sophia” Children’s Hospital,Athens, GR; 2 Thalassemia Unit, Hematology Division,Department of Internal Medicine, Patras UniversityHospital, Patras, GR and 3 First Department ofPediatrics, Athens University Medical School, Athens,GR.The Association of Plasma Adiponectin Levels andForearm Vascular Endothelial Function in HealthyVolunteers and Patients with Coronary ArteryDiseaseYehonatan Sharabi, 1,2 Michael Shechter, 2 IbrahimMarai, 2 Edna Peleg, 1 Ehud Grossman. 1,2 1 HypertensionUnit and Medicine D, Tel Hashomer, IL and 2 SacklerFaculty of Medicine, Tel Aviv, IL.Associations of Obstructive Sleep Apnea withVascular Damage and Endothelial Dysfunction inHypertensivesC. Thomopoulos, C. Tsioufis, A. Kasiakogias, E.Andrikou, I. Andrikou, A. Mazaraki, D. Roussos,T. Makris, C. Stefanadis. First Cardiology Clinic,University of Athens, Hippokration Hospital, Athens,GR.Aerobic Capacity Correlates with UrinaryThromboxane Concentration in Pre-HypertensiveAfrican AmericansSheara T. Williamson, Deborah L. Feairheller, KeithM. Diaz, Kathleen Sturgeon, Praveen Veerabhadrappa,Deepti Varma, Michael Brown, Susan Jansen. TempleUniversity, Philadelphia, PA, US.Influence of ESA Therapy on Endothelial Functionand Pulse Wave Velocity in Renal TransplantRecipientsStefanie Reiermann, 1 Katrin Kliche, 1 Valerie Bartels, 1Lena Trappe, 1 Viola Malyar, 1 Uta Hillebrand, 1 BarbaraSuwelack, 1 Hermann Pavenstädt, 1 Martin Hausberg. 1,21 Internal Medicine D, University Hospital of Muenster,Muenster, DE and 2 Internal Medicine I, StädtischesKlinikum Karlsruhe, Karlsruhe, DE.Naproxcinod Produces Relaxation in HumanMammary Arteries Showing EndothelialDysfunctionDaniela Miglietta, 1 Alessandra Poggi, 1 BarbaraVergani, 2 Guido Gelpi, 3 Julio Padron, 1 Manlio Bolla†. 11 NicOx Research, Bresso, IT; 2 MIA Consortium,Monza, IT and 3 Sacco Hospital, Milan, IT.1 Pathobiology Track 2 Translational Track 3 Therapy Track147

MAY 21 3PostersMonday AfternoonMorningEpidemiology/Special PopulationsPO-256: 1PO-257: 1PO-258: 1PO-259: 1PO-260: 1PO-261: 1PO-262: 1PO-263: 1Early Stages of Human Hypertension is a DeficiencyState of the Cardiorenal Protective Hormone BNPAlessandro Cataliotti†, Fima Macheret, Paul M. McKie,Richard J. Rodeheffer, Lorenzo S. Malatino, Kent R.Bailey, John C. Burnett. Mayo Clinic, Rochester, MN,US.Sodium (Na) Intake Varies Across the AfricanDiaspora and is Associated with BMIAlexander R. Chang, Holly Kramer, Amy Luke,Guichan Gao, Richard Cooper, Ramon Durazo-Arvizu, David Shoham. Loyola University MedicalCenter, Maywood, IL, US.Plasma 25-Hydroxyvitamin D and Regulation of theRenin Angiotensin System in HumansJohn P. Forman, Jonathan S. Williams, Naomi D. L.Fisher. Brigham and Women’s Hospital, Boston, MA,US.Blood Pressuure Phenotypes in Young MenYulia Kotovskaya, Ruslan Kobzev, Zhanna Kobalava.Russian Peoples’ Friendship University, RU.Determinants of Cardiovascular Disease inHypertensive WomenJuan Pablo López Ramírez, 1 Pablo López Alonso, 2Salvador Ruiz de la Fuente, 2 Francisco J. Giménez. 21 Cardiology Department, Hospital La Fe, Valencia, ESand 2 University of Valencia, Valencia, ES.Tobacco Smoke: A Friend-enemy of Blood PressureAurelio Leone, 2 Alberto Balbarini. 2 1 Cardiac andThoracic, Angiology, Pisa, Pi, IT and 2 Cardiac andThoracic Department University of Pisa, Pisa, Pi, IT.C-Reactive Protein and Soluble UrokinasePlasminogen Activator Receptor are DifferentlyRelated to HypertensionStig Lyngbæk, 1 Steen Haugaard, 2 Jesper Eugen-Olsen, 2Michael Hecht Olsen, 3 Jørgen Jeppesen. 3 1 Departmentof Cardiology, Copenhagen University HospitalGentofte, Gentofte, DK; 2 Copenhagen UniversityHospital Hvidovre, Hvidovre, DK and 3 CopenhagenUniversity Hospital Glostrup, Glostrup, DK.Impact of Coronary Artery Calcification on AllCause Mortality in Asymptomatic IndividualsAccording to Presence or Absence of HypertensionKhurram Nasir, 1,3 Garth Graham, 1 Juan Rivera, 1Michael Blaha, 1 John Rumberger, 5 Paolo Raggi, 4Leslee Shaw, 4 Roger Blumenthal, 1 Matthew Budoff. 21 Ciccarone Preventive Cardiology Center, JohnsHopkins University, School of Medicine, Baltimore,MD, US; 2 Los Angeles Biomedical Research Institute atHarbor-UCLA, Torrance, CA USA, US; 3 Departmentof Internal Medicine, Boston Medical Center, Boston,Massachusetts, US; 4 Division of Cardiology, EmoryUniversity, Atlanta, GA, US and 5 Princeton LongevityCenter, NJ, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track148

Monday Morning Afternoon MAY 21 3PostersPO-264: 1 Left Ventricular Hypertrophy Increases Long TermMortality in Hypertensive African-Americans withCoronary Artery DiseaseAndreas Pittaras, 1,2 Mihail Doumas, 1 AthanasiosManolis, 1 Ioannis Athanasiadis, 2 LeonidasPoulimenos, 1 Konstantinos Kifnidis, 1 Charles Faselis, 1Peter Kokkinos, 1 Vasilios Papademetriou. 1 1 VA &Georgetown University Medical Centers, Washington,DC, US and 2 MEDITON, Athens, GR.PO-265: 1 Chronic Kidney Dysfunction by Occupations in theSpanish Working PopulationLuis Miguel Ruilope, 1 Miguel Ángel Sánchez Chaparro, 2Eva Calvo Bonacho, 2 Arturo González Quintela, 4Martha Cabrera Sierra, 2 Juan Carlos Sainz Gutiérrez, 2Carlos Fernández-Labandera, 2 Jose Ramón Banegas, 5Javier Román García, 2 Alberto Zanchetti. 3 1 Hospital12 de Octubre, ES; 2 Ibermutuamur, ES; 3 IstitutoAuxologico Italiano, IT; 4 Department of InternalMedicine, University of Santiago de Compostela, ESand 5 Department of Preventive Medicine and PublicHealth, School of Medicine, Universidad Autónoma deMadrid, ES.PO-266: 1 Microalbuminuria in Hypertensive Patients: APicture of Clinical PractiseMafalda Santos†, Rodrigues Teresa, Manuel JoãoGomes. Hospital de Santarém, Santarém, PT.PO-267: 1 Prevalence of Target Organ Damage andCardiovascular Disease in Hypertensive andPrehypertensive Patients with AssociatedCardiovascular Risk Factors: Identcare StudyJulian Segura, 1 Alejandro de la Sierra, 2 SandraFernandez, 3 Luis M. Ruilope. 1 1 Hypertension Unit,Nephrology Department, Hospital Universitario 12 deOctubre, ES; 2 Internal Medicine Department. HospitalUniversitario Mutua de Terrassa, ES and 3 MedicalDepartment, Boehringer Ingelheim España, S.A., ES.PO-269: 3 Prevalence of Hypertension in US Adult FemalePopulation: A Sister to Sister Health ScreeningProjectFarhan Aslam, JoAnne Foody, Yun Wang, Irene Pollin.Brigham and Women Hospital, Boston, US.PO-270: 3 Physical Activity Patterns Among Hypertensive U.S.AdultsJames R. Churilla, 1 Earl S. Ford. 2 1 University of NorthFlorida, Jacksonville, FL, US and 2 Centers for DiseaseControl and Prevention, Atlanta, GA, US.PO-271: 3 Uncontrolled Hypertension in the U.S. 1988–2006:Implications for Healthcare Research, Policy andDeliveryBrent M. Egan, Yumin Zhao, R. Neal Axon, RobertF. Woolson. Medical University of South Carolina,Charleston, SC, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track149

MAY 21 3PostersMonday AfternoonMorningPO-272: 3PO-273: 3PO-274: 3PO-275: 3PO-276: 3PO-277: 3PO-278: 3Hypertension in the U.S. 1988–2008: Pursuit of theHealthy People 2010 Blood Pressure Control GoalBrent M. Egan, Yumin Zhao, R. Neal Axon, RobertF. Woolson. Medical University of South Carolina,Charleston, SC, US.Carotid Intima Medial Thickness (CIMT)Measurement for Cardiovascular Disease(CVD) Risk Stratification in Newly DiagnosedAsymptomatic Hypertensive PatientsMahfouz El Shahawy, 1 Miglena Entcheva, 1 Jay Cohn. 21 Sarasota Memorial Hospital, Sarasota, FL, US and2 University of Minnesota, US.Exercise Capacity Lowers Mortality Risk inHypertensive Individuals with Type 2 DiabetesMellitusCharles Faselis, 1,3 Fiorina Kyritsi, 1 Michalis Doumas, 1Puneet Narayan, 1 Andreas Pittaras, 1 AthanasiosManolis, 1 Vasilios Papademetriou, 1,2 Ross Fletcher, 1,2Eric Nylen, 1,3 Peter Kokkinos. 1,2 1 Veterans AffairsMedical Center, Washington, DC, US; 2 GeorgetownUniversity School of Medicine, Washington, DC,US and 3 George Washington University School ofMedicine, Washington, DC, US.Observations by a Hypertensionologist in aGeriatrics Clinic: Measurement, Management and aNew “Retirement Home Hypertension Syndrome”Clarence E. Grim. High Blood Pressure Consulting,Milwaukee, WI, US.Antihypertensive Treatment in Non-Elderly Patientswith or without Coronary Heart Disease and/orDiabetes Mellitus: What Happens in Real-Life?Niki Katsiki, Maria Baltatzi, Christos Savopoulos,Kostas Tziomalos, Andreas Kounanis, Eleni Karlafti,Apostolos Hatzitolios. 1st Propedeutic Department ofInternal Medicine, Department of Vascular Diseases,AHEPA University Hospital, Thessaloniki, GR.Prevalence of Metabolic Syndrome and Its Effect onResponse to Amlodipine Besylate in Primary CareHypertensive PatientsHae-Young Lee†, 1 Cheol-Ho Kim. 2 1 Seoul NationalUniversity Hospital, KR and 2 Bundang Seoul NationalUniversity Hospital, KR.Race/ethnic Differences in AntihypertensiveResponse to Moderate vs Intensive Dose ofCombination Amlodipine/Valsartan in PatientsUncontrolled on ARB MonotherapyE. Ofili†, 1 S. Oparil, 2 T. Giles, 3 B. Pitt, 4 Y. Seifu, 5 R.Samuel, 5 R. Hilkert, 5 J. Sowers. 6 1 Morehouse SoM, US;2 Univ. Alabama at Birmingham, US; 3 Tulane Univ.SoM, US; 4 Univ. Michigan SoM, US; 5 Novartis, US and6 Univ.Missouri SoM, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track150

Monday Morning Afternoon MAY 21 3PostersPO-279: 3PO-280: 3PO-281: 3PO-282: 2PO-283: 2PO-284: 2PO-285: 2Antihypertensive Treatment and Control in aPrimary Care Population of 21,167 PatientsMiriam Qvarnström, 1 Björn Wettermark, 1 CharlottaLjungman, 2 Ramin Zarrinkoub, 3 Jan Hasselstrøm, 4Karin Manhem, 2 Anders Sundström, 1 Thomas Kahan. 51 Karolinska Institutet, Department of Medicine,Centre for Pharmacoepidemiology, Stockholm, SE;2 Institute of Medicine, Department of Emergencyand Cardiovascular Medicine, SU/Östra, SahlgrenskaAcademy, Gothenburg, SE; 3 Southwest Drug andTherapeutics Committee, Stockholm County Council,Stockholm, SE; 4 Karolinska Institutet, Centre forFamily and Community Medicine, Stockholm, SEand 5 Karolinska Institutet, Department of ClinicalSciences, Danderyd Hospital, Stockholm, SE.Plamsa Renin Activity as a Risk for Cardiovascularand Cerebrovascular DiseaseJohn J. Sim†, 1 Jiaxiao M. Shi, 1 Federico B. Calara, 2Scott A. Rasgon. 1 1 Kaiser Permanente Los AngelesMedical Center, Los Angeles, CA, US and 2 NovartisPharmaceutical Inc, US.Characteristics of Antihypertensive Medication andChange of Prescription Over One Year of Followupin Japan; Fukushima Research of Hypertension(FRESH)Hirohide Yokokawa†, 1 Hironobu Sanada, 2 AyaGoto, 1 Tsuyoshi Watanabe, 1 Robin A. Felder, 3Pedro A. Jose, 4 Gilbert M. Eisner, 5 Seiji Yasumura. 11 Fukushima Medical University School of Medicine,Fukushima City, JP; 2 Fukushima Welfare Federation ofAgricultural Cooperatives, JP; 3 University of VirginiaHealth System, US; 4 George Washington UniversitySchool of Medicine and Health Sciences, US and5 Georgetown University Medical Center, US.Prevalence of CVD Among Firefighters and Police:A Population-Based StudyJoseph Finkelstein, Eunme Cha. Johns HopkinsUniversity School of Medicine, Baltimore, MD, US.Hypertension and Glaucoma: A Population-BasedStudyJoseph Finkelstein, Eunme Cha. Johns HopkinsUniversity School of Medicine, Baltimore, MD, US.Development of a Model to Estimate 24-HourUrinary Creatinine ExcretionLinda M. Gerber†, Samuel J. Mann. Weill CornellMedical Center, New York, NY, US.Prevalence of Cardiovacular Risk Factors in NativeAmericans of Chubut (Argentine Patagonia)Roberto A. Ingaramo, David Williams, SergioZambianchi, Mario Del Popolo, Ana Daroca, FernandoSuárez, Gabriela Guevara, María Inés Carletti, LidiaCarrizo. Centro de Hipertensión y EnfermedadesCardiovasculares (CEHTA), Trelew, Chubut, AR.1 Pathobiology Track 2 Translational Track 3 Therapy Track151

MAY 21 3PostersMonday AfternoonMorningPO-286: 2PO-287: 2PO-288: 2PO-289: 2PO-290: 2PO-291: 2PO-292: 2Prevalence and Characteristics of High BloodPressure in Native Americans of Chubut (ArgentinePatagonia)Roberto A. Ingaramo, David Williams, SergioZambianchi, Mario Del Popolo, Ana Daroca, FernandoSuárez, Gabriela Guevara, María Inés Carletti, LidiaCarrizo. Centro de Hipertensión y EnfermedadesCardiovasculares (CEHTA), Trelew, Chubut, AR.Prevalence of Hypertension in an Iranian PopulationPatricia Khashayar, Hamid Reza Aghaei Meybodi,Mohsen Rezai Homami, Mohammad RezaMohajeri Tehrani, Ramin Heshmat, Bagher Larijani.Endocrinology & Metabolism Research Center(EMRC), Tehran, IR.Estimation of Sodium Excretion from a Spot Urine,Using Chloride or Sodium to Creatinine Ratio andEstimated 24-Hr Creatinine ExcretionSamuel J. Mann†, Linda M. Gerber. NY Presbyter.Hosp.- Weill Cornell Med Ctr, NY, NY, US.Chronic Kidney Disease Progression to ESRD:Smooth and Progressive vs Uneven and StaccatoPatterns? – A Mayo Clinic PBRN-Based Patient-Level Data 82-Month Analysis of 100 High-RiskCKD Patients – Implications for a PotentialParadigm Shift in Current Concepts of Reno-ProtectionMacaulay A. Onuigbo, 1,2 Nnonyelum T. Onuigbo. 31 College of Medicine, Mayo Clinic, Rochester, MN,US; 2 Midelfort Clinic, Mayo Health System, EauClaire, WI, US and 3 NTEC Solutions, LLC, Eau Claire,WI, US.Hypertension Control through Social NetworksFadia T. Shaya†, 1,2 Xia Yan, 1 Nicole Norman, 1 ClydeFoster, 1 DeLeonardo Howard, 1 Confidence Gbarayor, 1Wallace Johnson, 2 Elijah Saunders. 2 1 University ofMaryland School of Pharmacy, Baltimore, MD, USand 2 University of Maryland School of Medicine,Baltimore, MD, US.Risk Factors for Pre-Hypertension in AdultPopulationEgle R. Silva, Jose J. Villasmil, Emilio S. Clavell,Gustavo E. Calmon, Alicex C. Gonzalez, Mayela J.Bracho. Instituto de Enfermedades Cardiovasculares.Facultad de Medicina. Universidad del Zulia,Maracaibo, Zulia, VE.Distribution of Global Cardiovascular DiseaseRisk, Treatment and Control in U.S. Adults withHypertension in 2005-2006Nathan D. Wong†, 1 Jennifer Dede, 1 Vincent H. Chow, 1Ken Wong, 2 Greg Brunson, 2 Stanley S. Franklin. 11 University of California, Irvine, Irvine, CA, US and2 Novartis Pharmaceutical Corporation, East Hanover,NJ, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track152

Monday Morning Afternoon MAY 21 3PostersPO-293: 2Cardiac and Arterial Calcifications and All-CauseMortality in the Elderly: The PROTEGER StudyYi Zhang, 1 Michel E. Safar, 1 Pierre Iaria, 1 Ari Lieber, 1Julie Peroz, 1 Athanase Protogerou, 2 Gerald Rajzbaum, 3Jacques Blacher†. 1 1 Diagnosis and Therapeutic Center,Hospital Hôtel-Dieu, Paris Descartes University,Paris, FR; 2 Hypertension Center, Third Departmentof Medicine, Sotiria Hospital, University of Athens,Athens, GR and 3 Hôpital St. Joseph, Paris, FR.Genetics/Gene Therapy/ProteomicsPO-294: 1PO-295: 1PO-296: 1PO-297: 3Temptation of the Hitherto Hidden Treasure inthe RAAS Archives: The Haplotype and EpistasisExploration Seems WorthRahul Kumar†. 1,3 1 Functional Genomics Unit,Institute of Genomics and Integrative Biology, Delhi,IN; 2 Department of Cardiology, G.B. Pant hospital,New Delhi, IN and 3 Department of Biotechnology,Hamdard University, New Delhi, IN.Variants in Genes Involved in Functional PathwaysAssociated with Hypertension in Black AmericansMaria P. Martinez Cantarin, 1 Stephanie Deloach, 1Paolo Fortina, 2 Kathryn Scott, 2 Adam Ertel, 2 TrudyL. Burns, 3 Bonita Falkner. 1 1 Department of Medicine,Thomas Jefferson University, Philadelphia, PA,US; 2 Kimmel Cancer Center, Thomas JeffersonUniversity, Philadelphia, PA, US and 3 Department ofEpidemiology, College of Public Health, University ofIowa, Iowa City, IA, US.Haptoglobin Genotype and the Incidence of Pre-Eclampsia in IsraelFarid Nakhoul, 1 Rachel Miller-Lotan, 2 RamiSammour, 3 Ron Gonen, 3 Ohel Gonen, 3 Andy P.Levy. 2 1 Rambam Health Care Campus, Haifa, IL;2 Laboratory of Vascular Medicine, Haifa, IL; 3 Bni-ZionMedical Center-Gynecology, Haifa, IL and 4 RappaportInstitute-Technion, Haifa, IL.Antihypertensive and Cardioprotective Efficacy ofEnalapril and Eprosartan in Hypertensive Patientsin Account with RAAS Genes PolymorphismsMarietta Eliseyeva, Dilorom Kurbanova, BarnoKarimova. Republican Specialiazed Center ofCardiology, UZ.1 Pathobiology Track 2 Translational Track 3 Therapy Track153

MAY 21 3PostersMonday AfternoonMorningNeural Hormonal Mechanisms (Renin;Neural Control; Vasoactive Autacoids)PO-298: 1PO-299: 1PO-300: 2Correlation of Neuropeptide Y (NPY) Serrum Levelsand Ankle Branchial Index (ABI) as an Index ofAtherosclerosisMaria Baltatzi, 1 Christos Savopoulos, 1 KonstantinosTziomalos, 1 Niki Katsiki, 1 George Koliakos, 2 ApostolosHatzitolios†. 1 1 1st Propedeutic Medical Department,AXEPA Hospital, Aristotles University of Thessaloniki,Thessaloniki, GR and 2 Department of BiologicalChemistry, Aristotles University of Thessaloniki,Thessaloniki, GR.Cerebrovascular Evaluation with TranscranialDoppler in Patients with Neuro-Mediated Syncope.Is Autoregulation Impaired?Joao P. Freitas, 1 Elsa Azevedo, 2 Rosa M. Santos, 2Pedro Castro, 1 Maria Julia Maciel, 2 FranciscoRocha Goncalves. 2 1 Centro de Estudos da FuncaoAutonomica, Hospital de Sao Joao, Porto, PT and2 Faculdade de Medicina do Porto, Porto, PT.Aldosterone/Renin Ratio is a Predictor ofCardiovascular Events in Patients with EssentialHypertensionTomohiko Kisaka, Ryoji Ozono, Yasuki Kihara.Department of Cardiovascular Medicine, HiroshimaUniversity Graduate School of Biomedical Science,Hiroshima, JP.ObesityPO-301: 1PO-302: 1Aldosterone Breakthrough Despite ACE Inhibitorsor ARBS in Overweight/Obese HypertensivePatients: Body Mass Index as a Predictor of PlasmaAldosterone LevelsRiccardo Sarzani, Federico Guerra, Lucia Mancinelli,Laura Roberti, Marica Bordicchia, Paolo LorenzoDessì-Fulgheri, Alessandro Rappelli. Dept. InternalMedicine, University Ancona - Politecnica Marche,Ancona, IT.Vitamin D Deficiency Blunts Vascular Sensitivity toAngiotensin II in ObesityAnand Vaidya, 1 John P. Forman, 2 Naomi D. Fisher, 1Jonathan S. Williams. 1 1 Brigham and Women’sHospital: Division of Endocrinology, Diabetes, andHypertension, Boston, US and 2 Brigham and Women’sHospital: Channing Laboratory Renal Division, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track154

Monday Morning Afternoon MAY 21 3PostersPO-303: 3PO-304: 3PO-305: 3PO-306: 2Antihypertensive Efficacy of Amlodipine/Valsartan/Hydrochlorothiazide Triple Combination in Patientswith Obesity: A Subgroup AnalysisDavid A. Calhoun†, 1 Yves Lacourciere, 2 Nora A.Crikelair, 3 Joseph Yen, 3 Robert Glazer. 3 1 VascularBiology and Hypertension Program, University ofAlabama at Birmingham, Birmingham, AL, US;2 Hypertension Research Unit, Centre Hospitalier del’Université Laval, Ste-Foy, Quebec, CA and 3 NovartisPharmaceuticals Corporation, East Hanover, NJ, US.Anthropometric Predictors of Left VentricularHypertrophy in Hypertensive WomenBranko Jakovljevic†, 1 Vesna Stojanov, 2 Dragan Lovic, 3Katarina Paunovic, 1 Goran Belojevic. 1 1 Institute ofHygiene and Medical Ecology, School of Medicine,Belgrade, YU; 2 Clinical Centre of Serbia, Belgrade, YUand 3 Private Internal Medicine Clinic “Lovic”, Nis, YU.Effect of High-Fat Diet on Oxidative Stress andMetabolic Syndrome in C57BI/mice and PreventiveEffect of Antioxidant SupplementationHilda Vargas-Robles, 1 Monica Arellano-Mendoza, 2Ana Gamez-Mendez, 1 Amelia Rios, 3 Bruno Escalante. 31 CINVESTAV-IPN, Distrito Federal, MX; 2 EscuelaSuperior de Medcina, Distrito Federal, MX and3 CINVESTAV-IPN, Apodaca, Nuevo Leon, MX.The Role of Obesity Variables in DetectingHypertension in an Iranian PopulationPatricia Khashayar, Hamid Reza Aghaei Meybodi,Mohsen Rezai Homami, Mohammad RezaMohajeri Tehrani, Ramin Heshmat, Bagher Larijani.Endocrinology & Metabolism Research Center(EMRC), Tehran, IR.Pediatric HypertensionPO-307: 1PO-308: 1Brachyal Pulsatility Index in Treated AorticCoarctationAntonio J. Marinho-da-Silva, 1 Dina T. Rodrigues, 2Helena M. Andrade, 3 Guilherme M. Pêgo, 4 Luis A.Providência. 5 1 University Hospital, Coimbra, PT;2 University Hospital, PT; 3 University Hospital, PT;4 University Hospital, PT and 5 University Hospital, PT.Presence of Target Organ Damage in Pre-Hypertensive YouthElaine Urbina†, 1 Philip Khoury, 1 Connie McCoy, 1Stephen Daniels, 2 Thomas Kimball, 1 Larry Dolan. 11 Cincinnati Children’s Hosp, Cincinnati, OH, US and2 Children’s Hosp, Aurora, CO, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track155

MAY 21 3PostersMonday AfternoonMorningPreclinical Models/ExperimentalHypertensionPO-309: 1PO-310: 1PO-311: 2Mitochondrial Polymorphisms in Rat GeneticModels of HypertensionSivarajan Kumarasamy†, Kathirvel Gopalakrishnan,Asher Shafton, Jeremy S. Nixon, Phyllis K. Farms, BinaJoe. University of Toledo College of Medicine, Toledo,OH, US.Protective Effects in NaCl-Induced Hypertensionand Centralized Injuries in DOCA-InducedHypertensive Hydrocephalic Sprague Dawley RatsJong Y. Lee†, Louis Tobian. University of MinnesotaSchool of Medicine, Minneapolis, MN, US.Combined AT1 Receptor Blocker and NeprilysinInhibitor Treatment Produces Omapatrilat LikeAntihypertensive Effects without Angioedema in theRatLaxminarayan G. Hegde†, Cecile Yu, Travis Renner,Madhavi Cheruvu, Rachael Olsufka, TimothyPark, Harold Thibodeaux, Carrie Richardson, ScottArmstrong, Lenka Barrettova, Uwe Klein, Sharath S.Hegde. Theravance Inc, South San Francisco, CA, US.Vascular Injury/Inflammation andRemodelingPO-312: 1PO-313: 1PO-314: 1PO-315: 1Impact of Metabolic Factors, Hypertensive Statusand Oxidative Stress in Superoxide DismutaseCirculating LevelsMartin Fabregate, 1 Rosa Fabregate, 1 Asuncion Guerri, 1Susana Tello, 1 Arantxa Rodriguez, 1 Elena Marín, 2Nuria de la Torre, 1 Jose Sabán-Ruiz. 1 1 EndothelialPathology Unit, Madrid, ES and 2 Angiology andVascular Surgery Service, ES.C-Reactive Protein Driven Vascular Inflammation isRegulated by Macrophage FcγR ReceptorsFadi G. Hage, Corey Coleman, Dongqi Xing, MarkMcCrory, Yiu-Fai Chen, Suzanne Oparil, Alexander J.Szalai. University of Alabama at Birmingham, US.Secretory Phospholipase A(2) [SPLA(2)] in aModerate-High Cardiovascular Risk Populationwith/without HypertensionJose Saban-Ruiz, Rosa Fabregate, Susana Tello, MartinFabregate, Asuncion Guerri, Angelica Fernández,Arantxa Rodriguez, Arturo Ugalde, Gloria Rodriguez,Vicente Gomez. Endothelial Pathology Unit, Madrid,ES.Plasma Levels of Pancreatitis-Associated Proteinin African-American and White Hypertensives andNormotensivesRalph E. Watson, Cristiane N. Pereira, Kumar Gaurav,Asad K. Mohmand, Stephanie W. Watts, Gregory D.Fink. Michigan State University, East Lansing, MI, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track156

Monday Morning Afternoon MAY 21 3PostersPO-316: 1PO-317: 3PO-318: 2Plasma Levels of Interleukin-6 and Tumor NecrosisFactor-Alpha in African American and WhiteHypertensives and NormotensivesRalph E. Watson, Cristiane N. Periera, Kumar Gaurav,Asad K. Mohmand, Gregory D. Fink. Michigan StateUniversity, East Lansing, MI, US.The Role of Quinapril and Lipoic Acid: Biomarkersof Vascular Inflammation in the Presence ofDiabetes Mellitus with Stage I Hypertension (ResultsFrom the Quality Study)Bobby V. Khan†, 1 Syed T. Rahman, 1 Nadya Merchant, 1Tahir Haque, 1 Sanjay Rajagopalan, 2 DesikanRajagopal, 2 Sampath Parthasarathy. 2 1 Atlanta VascularResearch Foundation, Atlanta, GA, US and 2 InVascTherapeutics, Atlanta, GA, US.Restoring the Anticontractile Properties of AdiposeTissue Following Hypoxia Using ErythropoietinSarah Withers†, 1 Neha Passi, 1 Declan de Freitas, 2Anthony M. Heagerty. 1 1 University of Manchester,Manchester, Greater Manchester, GB and 2 ManchesterRoyal Infirmary, Manchester, Greater Manchester, GB.1 Pathobiology Track 2 Translational Track 3 Therapy Track157

May 21 3Posters Late-Breaking PostersMonday AfternoonMorningLB-PO-01:LB-PO-02:LB-PO-03:LB-PO-04:LB-PO-05:LB-PO-06:LB-PO-07:Blood Pressure Control of Fixed Dose,Perindopril/Amlodipine Combination Treatmentin Hypertensive Patients Uncontrolled onMonotherapy or on Two Drug Combination TherapyM. P. Girish, 1 Vinay Bahl, 2 Uday Jadhav, 3 HemantThacker, 4 Soumitra Kumar. 5 1 G. B. Pant Hospital, NewDelhi, IN; 2 AIIMS, New Delhi, IN; 3 M.G.M. Hospital,Navi Mumbai, IN; 4 Jaslok Hospital, Mumbai, IN and5 VIMS, Kolkata, IN.A Valsartan-Based Antihypertensive Regimen IsMore Effective than a Losartan-Based Regimen inPatients with Stage 2 Hypertension: The EXALTStudyRichard Wright†, 1 D. Duprez, 2 A. Yadao, 3 D.Purkayastha, 3 R. Samuel, 3 K. Ferdinand. 4 1 Pacific HeartInstitute, CA, US; 2 University of Minnesota, MN, US;3 Novartis Pharmaceuticals Corporation, NJ, US and4 Emory University, GA, US.Initial Combination Therapy with Aliskiren/Hydrochlorothiazide Is More Effective thanAmlodipine in Patients with Stage 2 SystolicHypertension and Diabetes MellitusRaymond R. Townsend†, 1 Alan Forker, 2 PatriciaRumpelt, 3 Cheraz Cherif Papst, 4 Anthony Yadao. 31 University of Pennsylvania Medical Center,Philadelphia, PA, US; 2 Mid-America Heart Institute,Kansas, MO, US; 3 Novartis PharmaceuticalsCorporation, East Hanover, NJ, US and 4 NovartisPharma AG, Basel, CH.Relationships of the Metabolic Syndrome and ItsComponents with Pulse Pressure in ApparentlyHealthy PeopleDaniel H. Suarez, Antonio J. Paragano, RogelioMachado, Ricardo J. Esper, Diego J. Cordero, Pablo M.Merlo, Antonio D. Abdala. Hospital Militar Central,Ciudad Autonoma de Buenos Aires, Buenos Aires, AR.Reproducibility of Blood Pressure Measurements inAtrial Fibrillation Using a Microlife Blood PressureMonitor Designed to Detect Atrial FibrillationJoseph Wiesel†, 1 Lorenzo Fitzig. 2 1 Lenox Hill Hospital,New York, NY, US and 2 New York Hospital Queens,Flushing, NY, US.Prevalence and Association of Hypertensionwith the Different Components of the MetabolicSyndromeDaniel H Suarez, Antonio J. Paragano, RogelioMachado, Ricardo J. Esper, Diego J. Cordero, Pablo M.Merlo, Antonio D. Abdala. Hospital Militar Central,Ciudad Autonoma de Buenos Aires, Buenos Aires, AR.Long-Term Projections of Home Use of a MicrolifeBlood Pressure Monitor Designed to Detect AtrialFibrillationJoseph Wiesel†, Saji Abraham, Frank C. Messineo.Lenox Hill Hospital, New York, NY, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track158

Monday Morning Afternoon May 213Posters Late-Breaking PostersLB-PO-08:LB-PO-09:LB-PO-10:LB-PO-12:LB-PO-13:LB-PO-14:Effects on BP Control Of Amlodipine (AML)/Olmesartan Medoxomil (OM), with or withoutHydrochlorothiazide (HCTZ), in Patients NotControlled by Prior Antihypertensive MonotherapyM. Weir†, 1 W. Hseuh, 2 S. Nesbitt, 3 M. Weber, 4 T.Littlejohn, 5 A. Graff, 6 A. Shojaee, 7 W. Waverczak, 7 C.Qian, 7 C. Jones, 8 J. Neutel. 9 1 University of MarylandSchool of Medicine, US; 2 The Methodist HospitalResearch Institute, US; 3 UT Southwestern MedicalCenter, US; 4 SUNY Downstate Medical CenterCollege of Medicine, US; 5 Piedmont Medical ResearchAssociates, US; 6 Private Practice, US; 7 Daiichi Sankyo,Inc., US; 8 Wolters Kluwer, US and 9 Orange CountyResearch Center, US.Efficacy and Safety of Nebivolol Monotherapy inHispanics with Stage I-II HypertensionHenry A. Punzi, 1 Andrew J. Lewin, 2 Tanya Lukic, 3Thomas Goodin, 3 Wei Chen. 3 1 Trinity HypertensionResearch Institute, Carrollton, TX, US; 2 NationalResearch Institute, Los Angeles, CA, US and 3 ForestResearch Institute, Jersey City, NJ, US.Single-Pill Combination of Telmisartan 80 Mg/Amlodipine 10 Mg Provides Superior Blood-Pressure Reductions in Patients with SevereHypertension: TEAMSTA Severe Htn StudyJoel M. Neutel†, 1 Giuseppe Mancia, 2 Henry R. Black, 3Björn Dahlöf, 4 Holly Defeo, 5 Ludwin Ley, 6 RichardVinisko. 5 1 Orange County Research Center, US;2 University of Milano-Bicocca, San Gerardo Hospital,IT; 3 New York University School of Medicine,US; 4 Sahlgrenska University Hospital/Östra, SE;5 Boehringer Ingelheim Pharmaceuticals Inc, US and6 Boehringer Ingelheim GmbH & Co. KG, DE.ISHIB IMPACT CV RISK Reduction ToolkitResearch Study: Study DesignElijah Saunders, 1 Bessie M. B. Weaver, 1 Keith C.Ferdinand, 2 Kenneth A. Jamerson. 3 1 University ofMaryland School of Medicine, Baltimore, MD, US;2 Association Black Cardiologists, Inc, Atlanta, GA,US and 3 University of Michigan Health System, AnnArbor, MI, US.Differential Changes in RAS Genes and BloodPressure by High Na-Intake in Lean and ObeseZucker RatsPreethi Samuel, Quaisar Ali, Rifat Sabuhi, TahirHussain. University of Houston, Houston, TX, US.Chronic Treatment with AT2 Receptor AgonistCGP42112A Lowers Renal Renin Expression andDecreases Blood Pressure in Obese Zucker RatsQuaisar Ali†, Preethi Samuel, Rifat Sabuhi, TahirHussain. Heart and Kidney Institute, College ofPharmacy, Houston, TX, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track159

May 21 3Posters Late-Breaking PostersMonday AfternoonMorningLB-PO-15:LB-PO-16:Pericardial Fat Inflammation in Patientswith Acute Coronary Syndrome Assessed by18F-Fluorodeoxyglucose Positron EmissionTomographySungeun Kim, 1 Eun Ju Kim, 2 Jin Won Kim, 2 Hong SeogSeog. 2 1 Korea University Guro Hospital, Guro-Gu,Seoul, KR and 2 Cardiovascular Center, Gur0Gu, Seoul,KR.Angiotensin Converting Enzyme InhibitorAssociated Cough: How Reliable is the Informationfrom the Physicians Desk Reference (PDR)?Sripal Bangalore, 1 Sunil Kumar, 2 Franz H. Messerli. 21 Brigham and Women’s Hospital, US and 2 St. Luke’sRoosevelt Hospital and Columbia University, US.1 Pathobiology Track 2 Translational Track 3 Therapy Track160

Faculty Disclosure ListingGail Adler, MD, PhDGrant/Research Support: Novartis.Sonia Y. Angell, MD, MPHI have no relationships or affiliations to disclose.Lawrence J. Appel, MD, MPHI have no relationships or affiliations to disclose.Brad C. Astor, PhD, MPHI have no relationships or affiliations to disclose.George L. Bakris, MDAdvisor/Consultant: Abbott, Merck, Gilead, Forest, Novartis, Walgreens(formulary committee), Takeda, CVRx, Boehringer-Ingelheim,Servier, FDA. Grant/Research Support: GlaxoSmithKline, Forest-Investigator-Initiated. Speakers’ Bureau/Speaking/Teaching: Novartis,Forest. President Elect, ASH Board of Directors.Sripal Bangalore, MDI have no relationships or affiliations to disclose.Joshua Barzilay, MDGrant/Research Support: NIDDK.Jan N. Basile, MDAdvisor/Consultant: Forest, Novartis, Takeda. Grant/Research Support:Novartis, ACCOMPLISH. Speakers’ Bureau/Speaking/Teaching:Boehringer-Ingelheim, Forest, Daiichi-Sankyo, Novartis.Claudio A. Bellido, MD, PhDGrant/Research Support: Bayer, AstraZeneca, Servier, Sanofi-Aventis.Speakers’ Bureau/Speaking/Teaching: Bayer.Dan R. Berlowitz, MD, MPHI have no relationships or affiliations to disclose.John D. Bisognano, MD, PhDAdvisor/Consultant: CVRx. Grant/Research Support: CVRx. Speakers’Bureau/Speaking/Teaching: CVRx. Member, ASH Board ofDirectors.Henry R. Black, MDAdvisor/Consultant: Gilead, NicOx, Novartis, Daiichi-Sankyo,Boehringer-Ingelheim, Mitsubishi, Servier, Xoma, MSD, Biosante.Grant/Research Support: Novartis. Speakers’ Bureau/Speaking/Teaching:Pfizer, Daiichi-Sankyo. President, ASH Board of Directors.Michael J. Bloch, MDAdvisor/Consultant: AstraZeneca. Grant/Research Support: Novartis.Speakers’ Bureau/Speaking/Teaching: Novartis, AstraZeneca, Pfizer,Forest, Daiichi-Sankyo.Roger S. Blumenthal, MDI have no relationships or affiliations to disclose.Eugene Braunwald, MDI have no relationships or affiliations to disclose.Robert D. Brook, MDI have no relationships or affiliations to disclose.Angela L. Brown, MDSpeakers’ Bureau/Speaking/Teaching: Forest, Boehringer-Ingelheim,Novartis, Pfizer.161

Faculty Disclosure Listing continuedJohn C. Burnett, Jr., MDEmployment Income/Salary: Mayo Foundation MGSM. Royalties:NILE Therapeutics, Anexon. Advisor/Consultant: NILE Therapeutics,Otsuka, Medtronics, Anexon, Novartis. Grants/ Research Support:Bayer, Merck, NILE, BioRad, Trevena, Anexon.David A. Calhoun, MDAdvisor/Consultant: Novartis. Grant/Research Support: Novartis.David S. Cannom, MDAdvisor/Consultant: Medtronic Physician Adv Bd. Trustee BoardMember, Committee Member: Minnesota Medical Fdn. Speakers’ Bureau/Speaking/Teaching:Boston Scientific, Medtronic, Sanofi Aventis.Lisa A. Cassis, PhDI have no relationships or affiliations to disclose.Aihua Chen, MDI have no relationships or affiliations to disclose.Atul R. Chugh, MDI have no relationships or affiliations to disclose.John R. Cockcroft, MDAdvisor/Consultant: Merck, Forest, Genzyme. Speakers’ Bureau/Speaking/Teaching: Genzyme, Solvay.Thomas M. Coffman, MDAdvisor/Consultant: Lilly, Novartis, Abbott, Daiichi-Sankyo. Speakers’Bureau/Speaking/Teaching: Merck.Jay N. Cohn, MDI have no relationships or affiliations to disclose.William C. Cushman, MDAdvisor/Consultant: Novartis, Takeda, Daiichi-Sankyo, Gilead, Theravance.Grant/Research Support: Novartis, GlaxoSmithKline.Jeffrey A. Cutler, MD, MPHI have no relationships or affiliations to disclose.Michael H. Davidson, MDAdvisor/Consultant: Abbott, Aegerion, Amgen, AstraZeneca, Daiichi-Sankyo, DTC MD, Esperion, GlaxoSmithKline, iMD, Kinemed, LipoScience,Merck, Merck/Schering-Plough, Novo Nordisk, Omthera,Professional Evaluation, Inc., Roche, Sanofi-Aventis, Sonogene,Synarc, Takeda, Vindico. Grant/Research Support: Abbott, Astra-Zeneca, Merck, Roche. Speakers’ Bureau/Speaking/Teaching: Abbott,AstraZeneca, GlaxoSmithKline, Merck/Schering-Plough. Trustee,Board Member, Committeee Member: Omthera, Profesional Evaluation,Inc., Medical Education Company, Sonogene.Barry R. Davis, MD, PhDTrustee, Board Member, Committee Member: Takeda DSMB member,Amgen DSMB member.Gerald DiBona, MDAdvisor/Consultant: Ardian, Rheos.Anna F. Dominiczak, MDI have no relationships or affiliations to disclose.Brent M. Egan, MDAdvisor/Consultant: Takeda, Novartis, AstraZeneca. Grant/ResearchSupport: Takeda, Novartis, AstraZeneca. Speakers’ Bureau/Speaking/Teaching: Novartis.162

Faculty Disclosure Listing continuedDavid A. Ehrmann, MDI have no relationships or affiliations to disclose.William J. Elliott, MD, PhDRoyalties: Elsevier. Advisor/Consultant: Gilead Sciences. Grant/Research Support: Forest (pending). Speakers’ Bureau/Speaking/Teaching: Forest. Consultant/Scientific Advisory Committee Member/Lecturer: Pfizer, Novartis.Murray Epstein, MDI have no relationships or affiliations to disclose.Michael Ernst, PharmDI have no relationships or affiliations to disclose.Mark Espeland, PhDI have no relationships or affiliations to disclose.Daniel I. Feig, MD, PhDSpeakers’ Bureau/Speaking/Teaching: Fallon Medica, Takeda.Peter Feig, MDEmployment Income/Salary: Merck.Keith C. Ferdinand, MDAdvisor/Consultant: Forest, AstraZeneca, Novartis, Roche, NicOx,Daiichi-Sankyo. Grant/Research Support: Daiichi-Sankyo. Speakers’Bureau/Speaking/Teaching: Forest, AstraZeneca, Novartis. Member,ASH Board of Directors.Carlos M. Ferrario, MDAdvisor/Consultant: Forest, Daiichi-Sankyo. Grant/Research Support:Novartis, Forest. Speakers’ Bureau/Speaking/Teaching: Merck,Daiichi-Sankyo.Gregory D. Fink, MDAdvisor/Consultant: Merck.Edward A. Fisher, MD, PhD, MPHAdvisor/Consultant: GlaxoSmithKline, Takeda, Merck. Speakers’Bureau/Speaking/Teaching: Merck.John M. Flack, MD, MPHAdvisor/Consultant: GlaxoSmithKline, Novartis, NIH, Cardiodynamics,Daiichi-Sankyo. Grants/Research Support: COVANCE, NIH,Cardiodynamics, Daiichi-Sankyo, Sanofi Aventis, PPD Development,Novartis. Speaker Bureau/Speaking/Teaching: Novartis, Pfizer,Daiichi-Sankyo.Charles K. Francis, MDI have no relationships or affiliations to disclose.Toshiro Fujita, MDGrant/Research Support: Novartis, Pfizer, Boehringer-Ingelheim.Jeffrey R. Garber, MDI have no relationships or affiliations to disclose.Haralambos Gavras, MDSpeakers’ Bureau/Speaking/Teaching: Merck, Novartis, Boehringer-Ingelheim.F. Wilford Germino, MDAdvisor/Consultant: Forest, Bristol-Myers Squibb/Sanofi. Grant/ResearchSupport: Daiichi-Sankyo. Speakers’ Bureau/Speaking/Teaching:Bristol-Myers Squibb/Sanofi, Novo Nordisk.163

Faculty Disclosure Listing continuedThomas D. Giles, MDAdvisor/Consultant: Forest, Daiichi-Sankyo, NicOx, Novartis. Grant/Research Support: Forest, Novartis, NIH (Columbia Univ.). Member,ASH Board of Directors. President, ASH Hypertension Specialists.Celso E. Gomez-Sanchez, MDAdvisor/Consultant: Boehringer-Ingelheim.Philip B. Gorelick, MD, MPHAdvisor/Consultant: Boehringer-Ingelheim., Pfizer. Speakers’ Bureau/Speaking/Teaching: Boehringer-Ingelheim.Alan H. Gradman, MDMember, ASH Board of Directors.Richard H. Grimm, Jr., MD, PhDAdvisor/Consultant: Pfizer. Speakers’ Bureau, Speaking, Teaching:Merck, Takeda, Boehringer-Ingelheim.Ehud Grossman, MDAdvisor/Consultant: Intercure. Speakers’ Bureau/Speaking/Teaching:Novartis, AstraZeneca, Dexon.Martha Gulati, MD, MSI have no relationships or affiliations to disclose.Yuan Guo, MDI have no relationships or affiliations to disclose.Joel Handler, MDI have no relationships or affiliations to disclose.Donald D. Heistad, MDOwnership Interest: Merck.Judith Hochman, MDAdvisor/Consultant: Eli Lilly & Co., Bristol-Myers Squibb/Sanofi-Aventis.Norman K. Hollenberg, MD, PhDAdvisor/Consultant: Novartis. Trustee, Board Member, CommitteeMember: Vitae Pharmaceuticals. Grant/Research Support: MasterFoods, Inc.Roberto A. Ingaramo, MDI have no relationships or affiliations to disclose.Joseph L. Izzo, Jr., MDAdvisor/Consultant: Novartis, NicOx, Boehringer-Ingelheim, Glaxo-SmithKline, Daiichi-Sankyo, TheHeart.org. Grant/Research Support:GlaxoSmithKline, Novartis, Daiichi-Sankyo.Speakers’ Bureau/Speaking/Teaching:Novartis, ASH, Daiichi-Sankyo, TheHeart.org.Bina Joe, PhDGrant/Research Support: NHLBI/NIH.Luis Juncos, MDI have no relationships or affiliations to disclose.Norman M. Kaplan, MDSpeakers’ Bureau/Speaking/Teaching: Boehringer-Ingelheim, Forest.S. Ananth Karumanchi, MDRoyalties: Beth Israel Deaconess Medical Center. Advisor/Consultant:Roche, Beckman Coulter.164

Faculty Disclosure Listing continuedSverre E. Kjeldsen, MDAdvisor/Consultant: AstraZeneca, Bayer, Sanofi, Takeda. Speaker’sBureau/Speaking/Teaching: Boehringer-Ingelheim, Menarini, Merck,Novartis, Daiichi-Sankyo.Myra Kleinpeter, MD, MPHSpeakers’ Bureau/Speaking/Teaching: Boehringer-Ingelheim, GlaxoSmithKline.Lawrence R. Krakoff, MDAdvisor/Consultant: NicOx, Takeda.John B. Kostis, MDAdvisor/Consultant: Schering-Plough, Sanofi-Aventis, Phrixus.Grant/Research Support: Abbott, Medtronic, Schering-Plough Foundation.Speakers’ Bureau/Speaking/Teaching: Forest, Takeda, Pfizer.David S. Kountz, MDAdvisor/Consultant: NicOx, Inc.Peter R. Kowey, MDEmployment Income/Salary: Main Line Health Care. Advisor/Consultant:Sanofi-Aventis, Merck, Pfizer, Johnson & Johnson, GlaxoSmoth-Kline, AstraZeneca, Astellas. Ownership Interest: Cardionet. Speakers’Bureau/Speaking/Teaching: Sanofi-Aventis, GlaxoSmithKline.Louis Kuritzky, MDAdvisor/Consultant: Forest, Takeda, Daiichi-Sankyo. Speakers’Bureau/Speaking/Teaching: Forest, Takeda, Daiichi-Sankyo.Theodore W. Kurtz, MDI have no relationships or affiliations to disclose.Daniel T. Lackland, DrPHAdvisor/Consultant: Pfizer. Speakers’ Bureau/Speaking/Teaching:Novartis, Sanofi-Aventis. Member, ASH Board of Directors.Edward G. Lakatta, MDI have no relationships or affiliations to disclose.Lilach O. Lerman, MD, PhDI have no relationships or affiliations to disclose.Daniel Levy, MDMember, ASH Board of Directors.Tianhu Liu, MDEmployment Income/Salary: Pi County People’s Hospital.Thomas Lohmeier, PhDAdvisor/Consultant: CVRx, Inc.Jianfang Luo, MDI have no relationships or affiliations to disclose.Samuel J. Mann, MDAdvisor/Consultant: NicOx. Grant/Research Support: Forest. Speakers’Bureau/Speaking/Teaching: Forest.Karen L. Margolis, MD, MPHGrant/Research Support: Bristol-Myers Squibb.Allyn L. Mark, MDI have no relationships or affiliations to disclose.165

Faculty Disclosure Listing continuedBarry M. Massie, MDExpert Witness: Pfizer. Advisor/Consultant: Merck, Forest, Boehringer-Ingelheim,Novartis. Data Monitoring Committee Chair: Takeda.Barry J. Materson, MD, MBAAdvisor/Consultant: Takeda, NicOx. Grant/Research Support: Forest,Takeda, Merck. Stocks/Bonds: Accu-Break Pharmaceuticals.Carmel M. McEniery, PhDI have no relationships or affiliations to disclose.Franz H. Messerli, MDAdvisor/Consultant: GlaxoSmithKline, Novartis, Forest, Daiichi-Sankyo,Boehringer-Ingelheim, Takeda. Grant/Research Support: Forest,Daiichi-Sankyo, Boehringer-Ingelheim. Speakers’ Bureau/Speaking/Teaching: GlaxoSmithKline, Novartis, Boehringer-Ingelheim, Forest,Daiichi-Sankyo, Takeda, Aphorium, ASH. Treasurer, ASH Board ofDirectors.Gary F. Mitchell, MDOfficer/Trustee/Board Member/Committee Member: CardiovascularEngineering, Inc. Advisor/Consultant: Bristol-Myers Squibb. Stocks/Bonds: Cardiovascular Engineering, Inc. Ownership/Partnership:Cardiovascular Engineering, Inc. Grant/Research Support: NIH.Michael Moore, MDAdvisor/Consultant: Daiichi-Sankyo, NicOx. Speakers’ Bureau/Speaking/Teaching:Daiichi-Sankyo, Forest.Marvin Moser, MDAdvisor/Consultant: Takeda.Krzysztof Narkiewicz, MD, PhDSpeakers’ Bureau/Speaking/Teaching: Abbott, AstraZeneca, BerlinChemie Menarini, Boehringer-Ingelheim, Daiichi-Sankyo, Krka,Novartis, Servier.L. Gabriel Navar, PhDAdvisor/Consultant: Merck, Novartis, Forest, NicOx, Boehringer-Ingelhiem.Trustee/Board Member/Committee Member: AHA, ASH.Grant/Research Support: Merck, Forest , NHLBI, NCRR. OwnershipInterest: Abbott, AstraZeneca, Baxter, Merck, Pfizer. Speakers’ Bureau/Speaking/Teaching: Merck, Forest.Shawna D. Nesbitt, MD, MSAdvisor/Consultant: Novartis, Daiichi-Sankyo. Speakers’ Bureau/Speaking/Teaching: Novartis, Forest, Boehringer-Ingelheim.Gbenga Ogedegbe, MD, MPH, MSI have no relationships or affiliations to disclose.Suzanne Oparil, MDAdvisor/Consultant: Forest, Daiichi-Sankyo, Bristol-Myers Squibb,Novartis, Sanofi-Aventis, The Salt Institute, NicOx, Boehringer-Ingelheim.Grant/Research Support: Daiichi-Sankyo, Novartis, Gilead,Forest, Takeda. Speaker’s Bureau/Speaking/Teaching: Daiichi-Sankyo,Forest, Merck. Member, ASH Board of Directors.Eduardo Ortiz, MD, MPHI have no relationships or affiliations to disclose.Vasilios Papademetriou, MDSpeakers’ Bureau/Speaking/Teaching: Abbott, AstraZeneca.166

Faculty Disclosure Listing continuedAldo J. Peixoto, MDAdvisor/Consultant: Abbott, Sanofi-Aventis. Speakers’ Bureau/Speaking/Teaching:Boehringer-Ingelheim.Robert A. Phillips, MD, PhDAdvisor/Consultant: NicOx. Member, ASH Board of Directors.Linda B. Piller, MD, MPHI have no relationships or affiliations to disclose.Bertram Pitt, MDAdvisor/Consultant: Relypsa, Pfizer, Novartis, Merck, Takeda, Bayer.Ownership Interest: Relypsa.Mahboob Rahman, MDSpeakers’ Bureau/Speaking/Teaching: Boehringer-Ingelheim.Leopoldo Raij, MDI have no relationships or affiliations to disclose.C. Venkata S. Ram, MDAdvisor/Consultant: Genesis, AHM, Peer Group, Cogenix, MedKnowledge and MEDCON. Speakers’ Bureau/Speaking/Teaching:Genesis, AHM, Peer Group, Cogenix, Med Knowledge and MED-CON. Vice-President, ASH Board of Directors.Efrain Reisin, MDI have no relationships or affiliations to disclose.Edward J. Roccella, PhD, MPHI have no relationships or affiliations to disclose.Mary J. Roman, MDI have no relationships or affiliations to disclose.Clive Rosendorff, MD, PhDI have no relationships or affiliations to discloseKathryn Sandberg, PhDI have no relationships or affiliations to disclose.Elijah Saunders, MDAdvisor/Consultant: Boehringer-Ingelheim, Bristol-Myers Squibb, EliLilly, Forest, Novartis, Pfizer, Sanofi-Aventis. Grant/Research Support:Forest, Novartis, Pfizer, Sanofi-Aventis. Speakers’ Bureau/Speaking/Teaching: Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly, Forest,Novartis, Pfizer, Sanofi-Aventis.Arya M. Sharma, MD, PhDI have no relationships or affiliations to disclose.Domenic A. Sica, MDAdvisor/Consultant: Novartis, CVRx, Diiachi-Sankyo, Takeda, BayerPharmaceuticals. Grant/Research Support: CVRx, Novartis, Takeda.Kanwar Singh, MDSpeakers’ Bureau/Speaking/Teaching: Medicines Company.Scott D. Solomon, MDAdvisor/Consultant: Novartis, Abbott. Grant/Research Support:Novartis, Abbott, Amgen.James R. Sowers, MDAdvisor/Consultant: Forest, Novartis. Grant/Research Support: Forest,Novartis, National Institutes of Health, VA Merit Grants.167

Faculty Disclosure Listing continuedLance K. Stell, PhDAdvisor/Consultant: MedImpact.Neil J. Stone, MDOther: Educational Committee for The National Lipid Association.Thomas P. Stossel, MDRoyalties: Velico, Inc. Advisor/Consultant: Pfizer. Trustee, BoardMember, Committee Member: Velico, Inc., Critical Biologics.Patrick J. Strollo, Jr., MDGrant/Research Support: ResMed. Philips Respironics.Sandra J. Taler, MDSecretary, ASH Board of Directors.Addison A. Taylor, MD, PhDGrant/Research Support: Merck, Novartis, Forest, Abbott, Sanofi-Aventis, Bristol-Meyers-Squibb, Pfizer, NIH. Member, ASH Board ofDirectors.Stephen C. Textor, MDTrustee, Board Member, Committee Member: American Society ofNephrology Associate Editor.Rhian M. Touyz, MD, PhDGrant/Research Support: Pfizer, AstraZeneca.Raymond R. Townsend, MDAdvisor/Consultant: NicOx, Novartis, Roche, GlaxoSmithKline.Speakers’ Bureau/Speaking/Teaching: ASN, ASH, NKF. Grant/ResearchSupport: National Institutes of Health/NIDDK.P. Roy Vagelos, MDEmployment Income/Salary: Regeneron Pharma., Theravance.Trustee, Board Member, Committee Member: Regeneron Pharma.,Theravance. Ownership Interest: Regeneron, Theravance.Hector O. Ventura, MDSpeakers’ Bureau/Speaking/Teaching: Actelion, Gilead.Charalambos Vlachopoulos, MDI have no relationships or affiliations to disclose.Hongyu Wang, MD, PhDI have no relationships or affiliations to disclose.Michael A. Weber, MDAdvisor/Consultant: Bistol-Myers Squibb, Forest, Gilead, Novartis,Daiichi-Sankyo, Boehringer-Ingelheim, Takeda. Speakers’ Bureau/Speaking/Teaching: Sanofi-Aventis, Novartis, Daiichi-Sankyo, Boehringer-Ingelheim,GlaxoSmithKline, Forest. Member, ASH Board ofDirectors. Editor-in-Chief, JCH.Myron H. Weinberger, MDEmployment Income/Salary: Editor-in-Chief, JASH. Advisor/Consultant:DSI, Merck, Novartis. Speakers’ Bureau/Speaking/Teaching: SCS,IntraMed. Member, ASH Board of Directors.Howard Weintraub, MDSpeakers’ Bureau/Speaking/Teaching: Takeda, AstraZeneca, Gilead,Daiichi-Sankyo, Novartis.William B. White, MDAdvisor/Consultant: Astellas, Novartis, Takeda, NicOx. Grant/ResearchSupport: Novartis, NIH. Member, ASH Board of Directors.168

Faculty Disclosure Listing continuedChristopher S. Wilcox, MD, PhDAdvisor/Consultant: Mitos.Peter F. Wilson, MDI have no relationships or affiliations to disclose.Gordon H. Williams, MDAdvisor/Consultant: Pfizer.Clyde W. Yancy, MDI have no relationships or affiliations to disclose.Steven A. Yarows, MDAdvisor/Consultant: HoMedics, Inc. Grant/Research Support: Daiichi-Sankyo,Forest, Novartis. Speakers’ Bureau/Speaking/Teaching:Boehringer-Ingelheim, Novartis, Forest, Pfizer, Bristol-Myers Squibb.169

Novartis cordially invitesfollowing programs atTEKTURNA ExploringDirect Renin InhibitionHoward Weintraub, MD, FACCClinical Associate ProfessorDept. of Medicine/CardiologyNew York School of MedicineClinical DirectorNew York University Center for thePrevention of Cardiovascular DiseaseNew York, NYLawrence Byrd, MDClinical Assistant Professor of MedicineUniversity of Medicine and DentistryNewark, NJChief, Hypertension SectionSt. Barnabas Medical CenterLivingston, NJMay 1, 2010 • 5:30–6:30 PMSpace is limited. Register at Booth 1100 in the Hypertension Resource Pavilion (Americas Hall 1,3rd Floor) or register on-site at the Innovations Theater (Americas Hall 1, 3rd Floor).IndicationTEKTURNA and VALTURNA are indicated for the treatment of hypertensionin adults.TEKTURNA may be used alone or in combination with other antihypertensiveagents. VALTURNA may be substituted for the titrated components.VALTURNA may be used in patients whose blood pressure is notadequately controlled on aliskiren or any ARB monotherapy. VALTURNAis also indicated as initial therapy in patients who are likely to needmultiple drugs to achieve their blood pressure goals. It is not knownwhether additive effects are present when TEKTURNA is used withACE inhibitors or beta-blockers. Use with maximal doses of ACE inhibitorshas not been adequately studied.The choice of VALTURNA as initial therapy should be based on anassessment of potential benefits and risks. The decision to use acombination as initial therapy should be individualized and shouldbe shaped by considerations such as baseline blood pressure, target BPgoal, and the incremental likelihood of achieving goal with a combinationproduct compared to monotherapy.Sponsored by:© 2010 Novartis 3/10 CVF-900422

you to attend thethe Innovations TheaterTEKTURNA and VALTURNAfor the Treatment of HypertensionEmma Meagher, MDAssociate Professor of Medicineand PharmacologyAssociate Director, CardiovascularRisk ProgramUniversity of Pennsylvania Health SystemPhiladelphia, PAGeorge Aronoff, MDProfessor of Medicine and PharmacologyChief, Division of NephrologyUniversity of Louisville Schoolof MedicineLouisville, KYMay 2, 2010 • 10:00–11:00 AMThe Innovations Theater’s content and the views expressed therein are those of the presentingcorporate entity and not of the American Society of Hypertension, Inc. The content is not partof the ASH Annual Scientific Meeting as approved by the Annual Scientific Program Committee.Important Safety InformationWARNING: AVOID USE IN PREGNANCYWhen pregnancy is detected, discontinue TEKTURNA or VALTURNA assoon as possible. When used in pregnancy during the second and thirdtrimesters, drugs that act directly on the renin-angiotensin-aldosteronesystem (RAAS) can cause injury and even death to the developing fetus.See WARNINGS AND PRECAUTIONS (5.1).Please see brief summary of Prescribing Information, includingBoxed WARNING, for TEKTURNA and VALTURNA on adjacent pages.

TEKTURNA ® (aliskiren) Tablets, OralInitial U.S. Approval: 2007BRIEF SUMMARY: Please see package insert for full prescribing information.WARNING: AVOID USE IN PREGNANCYWhen pregnancy is detected, discontinue Tekturna as soon as possible.Drugs that act directly on the renin-angiotensin system can cause injury anddeath to the developing fetus. [See Warnings and Precautions (5.1)]1 INDICATIONS AND USAGE1.1 HypertensionTekturna is indicated for the treatment of hypertension. It may be used aloneor in combination with other antihypertensive agents. Use with maximaldoses of ACE inhibitors has not been adequately studied.4 CONTRAINDICATIONSNone.5 WARNINGS AND PRECAUTIONS5.1 Fetal/Neonatal Morbidity and MortalityDrugs that act directly on the renin-angiotensin system can cause fetal andneonatal morbidity and death when administered to pregnant women. If thisdrug is used during pregnancy, or if the patient becomes pregnant while takingthis drug, the patient should be apprised of the potential hazard to thefetus. [See Use in Specific Populations (8.1)] In several dozen publishedcases, ACE inhibitor use during the second and third trimesters of pregnancywas associated with fetal and neonatal injury, including hypotension, neonatalskull hypoplasia, anuria, reversible or irreversible renal failure, and death. Inaddition, first trimester use of ACE inhibitors has been associated with birthdefects in retrospective data.5.2 Head and Neck AngioedemaAngioedema of the face, extremities, lips, tongue, glottis and/or larynx hasbeen reported in patients treated with Tekturna and has necessitated hospitalizationand intubation. This may occur at any time during treatment and hasoccurred in patients with and without a history of angioedema with ACEinhibitors or angiotensin receptor antagonists. If angioedema involves thethroat, tongue, glottis or larynx, or if the patient has a history of upper respiratorysurgery, airway obstruction may occur and be fatal. Patients who experiencethese effects, even without respiratory distress, require prolongedobservation since treatment with antihistamines and corticosteroids may notbe sufficient to prevent respiratory involvement. Prompt administration ofsubcutaneous epinephrine solution 1:1000 (0.3 to 0.5 mL) and measures toensure a patient airway may be necessary.Discontinue Tekturna immediately in patients who develop angioedema, anddo not readminister.5.3 HypotensionAn excessive fall in blood pressure was rarely seen (0.1%) in patients withuncomplicated hypertension treated with Tekturna alone in controlled trialsand in

5.5 HyperkalemiaIncreases in serum potassium >5.5 mEq/L were infrequent with Tekturnaalone (0.9% compared to 0.6% with placebo). However, when used in combinationwith an ACE inhibitor in a diabetic population, increases in serumpotassium were more frequent (5.5%). Routine monitoring of electrolytesand renal function is indicated in this population. Concomitant use of Tekturnawith potassium-sparing diuretics, potassium supplements, salt substitutescontaining potassium, or other drugs that increase potassium levels may leadto increases in serum potassium. If concomitant use is considered necessary,caution should be exercised.5.6 Renal Artery StenosisNo data are available on the use of Tekturna in patients with unilateral or bilateralrenal artery stenosis or stenosis of the artery to a solitary kidney.6 ADVERSE REACTIONS6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adversereaction rates observed in the clinical trials of a drug cannot be directly comparedto rates in clinical trials of another drug and may not reflect the ratesobserved in practice.Data described below reflect the evaluation of the safety of Tekturna in morethan 6,460 patients, including over 1,740 treated for longer than 6 months,and more than 1,250 patients for longer than 1 year. In placebo controlledclinical trials, discontinuation of therapy due to a clinical adverse event,including uncontrolled hypertension occurred in 2.2% of patients treatedwith Tekturna vs. 3.5% of patients given placebo.Angioedema: Two cases of angioedema with respiratory symptoms werereported with Tekturna use in the clinical studies. Two other cases of periorbitaledema without respiratory symptoms were reported as possibleangioedema and resulted in discontinuation. The rate of these angioedemacases in the completed studies was 0.06%. In addition, 26 other cases ofedema involving the face, hands, or whole body were reported with Tekturnause including 4 leading to discontinuation. In the placebo controlled studies,however, the incidence of edema involved the face, hands or whole body was0.4% with Tekturna compared with 0.5% with placebo. In a long term activecontrol study with Tekturna and HCTZ arms, the incidence of edema involvingthe face, hand or whole body was 0.4% in both treatment arms. [See Warningsand Precautions (5.2)]Gastrointestinal: Tekturna produces dose-related gastrointestinal (GI) adverseeffects. Diarrhea was reported by 2.3% of patients at 300 mg, compared to1.2% in placebo patients. In women and the elderly (age ≥65) increases indiarrhea rates were evident starting at a dose of 150 mg daily, with rates forthese subgroups at 150 mg comparable to those seen at 300 mg for men oryounger patients (all rates about 2.0-2.3%). Other GI symptoms includedabdominal pain, dyspepsia, and gastroesophageal reflux, although increasedrates for abdominal pain and dyspepsia were distinguished from placebo onlyat 600 mg daily. Diarrhea and other GI symptoms were typically mild andrarely led to discontinuation.Cough: Tekturna was associated with a slight increase in cough in theplacebo-controlled studies (1.1% for any Tekturna use vs. 0.6% for placebo).In active-controlled trials with ACE inhibitor (ramipril, lisinopril) arms therates of cough for the Tekturna arms were about one-third to one-half therates in the ACE inhibitor arms.Seizures: Single episodes of tonic-clonic seizures with loss of consciousnesswere reported in two patients treated with Tekturna in the clinical trials.One of these patients did have predisposing causes for seizures and had anegative electroencephalogram (EEG) and cerebral imaging following theseizures (for the other patient EEG and imaging results were not reported).Tekturna was discontinued and there was no re-challenge.The following adverse events occurred in placebo-controlled clinical trials atan incidence of more than 1% of patients treated with Tekturna, but alsooccurred at about the same or greater incidence in patients receiving placebo:headache, nasopharyngitis, dizziness, fatigue, upper respiratory tract infection,back pain and cough.

Other adverse effects with increased rates for Tekturna compared to placeboincluded rash (1% vs. 0.3%), elevated uric acid (0.4% vs. 0.1%), gout (0.2%vs. 0.1%) and renal stones (0.2% vs. 0%).Aliskiren’s effect on ECG intervals was studied in a randomized, double-blind,placebo and active-controlled (moxifloxacin), 7-day repeat dosing study withHolter-monitoring and 12 lead ECGs throughout the interdosing interval. Noeffect of aliskiren on QT interval was seen.6.2 Clinical Laboratory FindingsIn controlled clinical trials, clinically relevant changes in standard laboratoryparameters were rarely associated with the administration of Tekturna. Inmultiple-dose studies in hypertensive patients, Tekturna had no clinicallyimportant effects on total cholesterol, HDL, fasting triglycerides, fasting glucose,or uric acid.Blood Urea Nitrogen, Creatinine: Minor increases in blood urea nitrogen(BUN) or serum creatinine were observed in less than 7% of patients withessential hypertension treated with Tekturna alone vs. 6% on placebo.Hemoglobin and Hematocrit: Small decreases in hemoglobin and hematocrit(mean decreases of approximately 0.08 g/dL and 0.16 volume percent,respectively, for all aliskiren monotherapy) were observed. The decreaseswere dose-related and were 0.24 g/dL and 0.79 volume percent for 600 mgdaily. This effect is also seen with other agents acting on the renin-angiotensinsystem, such as angiotensin inhibitors and angiotensin receptor blockers andmay be mediated by reduction of angiotensin II which stimulates erythropoetinproduction via the AT1 receptor. These decreases led to slight increasesin rates of anemia with aliskiren compared to placebo were observed (0.1%for any aliskiren use, 0.3% for aliskiren 600 mg daily, vs 0% for placebo). Nopatients discontinued therapy due to anemia.Serum Potassium: Increases in serum potassium >5.5 mEq/L were infrequentin patients with essential hypertension treated with Tekturna alone (0.9%compared to 0.6% with placebo). However, when used in combination withan angiotensin-converting enzyme inhibitor (ACEI) in a diabetic populationincreases in serum potassium were more frequent (5.5%) and routine monitoringof electrolytes and renal function is indicated in this population.Serum Uric Acid: Aliskiren monotherapy produced small median increases inserum uric acid levels (about 6 µmol/L) while HCTZ produced larger increases(about 30 µmol/L). The combination of aliskiren with HCTZ appears to beadditive (about 40 µmol/L increase). The increases in uric acid appear to leadto slight increases in uric acid-related AEs: elevated uric acid (0.4% vs. 0.1%),gout (0.2% vs. 0.1%), and renal stones (0.2% vs. 0%).Creatine Kinase: Increases in creatine kinase of >300% were recorded inabout 1% of aliskiren monotherapy patients vs. 0.5% of placebo patients.Five cases of creatine kinase rises, three leading to discontinuation and onediagnosed as subclinical rhabdomyolysis, and another as myositis, werereported as adverse events with aliskiren use in the clinical trials. No caseswere associated with renal dysfunction.6.3 Post-marketing ExperienceThe following adverse reactions have been reported in aliskiren post-marketingexperience. Because these reactions are reported voluntarily from a populationof uncertain size, it is not always possible to reliably estimate their frequencyor establish a causal relationship to drug exposure.Hypersensitivity: angioedema requiring airway management andhospitalizationPeripheral edema7 DRUG INTERACTIONS7.1 Effects of Other Drugs on AliskirenBased on in vitro studies, aliskiren is metabolized by CYP 3A4.Irbesartan: Coadministration of irbesartan reduced aliskiren C max up to 50%after multiple dosing.P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the majorefflux system involved in absorption and disposition of aliskiren in preclinicalstudies. The potential for drug interactions at the Pgp site will likely dependon the degree of inhibition of this transporter. Coadministration of aliskiren

with Pgp substrates or weak to moderate inhibitors such as atenolol, digoxin,and amlodipine did not result in clinically relevant interactions.Atorvastatin: Coadministration of atorvastatin, a weak Pgp inhibitor, resultedin about a 50% increase in aliskiren C max and AUC after multiple dosing.Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole, a moderatePgp inhibitor, with aliskiren resulted in an approximate 80% increase inplasma levels of aliskiren. A 400-mg once-daily dose was not studied butwould be expected to increase aliskiren blood levels further.Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine, a potentPgp inhibitor, with 75 mg aliskiren resulted in an approximately 2.5-foldincrease in C max and 5-fold increase in AUC of aliskiren. Concomitant use ofaliskiren with cyclosporine is not recommended.Verapamil: Coadministration of 240 mg of verapamil, a moderate Pgp inhibitor,with 300 mg aliskiren resulted in an approximately 2-fold increase in C max andAUC of aliskiren. However, no dosage adjustment is necessary.Drugs with no clinically significant effects: Coadministration of lovastatin,atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide,ramipril, valsartan, metformin and amlodipine did not result in clinically significantincreases in aliskiren exposure.7.2 Effects of Aliskiren on Other DrugsAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19,2D6, 2E1, and 3A) or induce CYP 3A4.Furosemide: When aliskiren was coadministered with furosemide, the AUCand C max of furosemide were reduced by about 30% and 50%, respectively.Patients receiving furosemide could find its effect diminished after startingaliskiren.Drugs with no clinically significant effects: Coadministration of aliskiren didnot significantly affect the pharmacokinetics of lovastatin, digoxin, valsartan,amlodipine, metformin, celecoxib, atenolol, atorvastatin, ramipril orhydrochlorothiazide.Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not beenevaluated.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Categories C (first trimester) and D (second and third trimesters)[See Warnings and Precautions (5.1)]There is no clinical experience with the use of Tekturna in pregnant women.Drugs that act directly on the renin-angiotensin system can cause fetal andneonatal morbidity and death when administered to pregnant women. Severaldozen cases have been reported in the world literature in patients who weretaking angiotensin-converting enzyme inhibitors. When pregnancy is detected,Tekturna should be discontinued as soon as possible. The use of drugs thatact directly on the renin-angiotensin system during the second and thirdtrimesters of pregnancy has been associated with fetal and neonatal injury,including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversiblerenal failure, and death. Oligohydramnios has also been reported,presumably resulting from decreased fetal renal function; oligohydramnios inthis setting has been associated with fetal contractures, craniofacial deformation,and hypoplastic lung development. Prematurity, intrauterine growthretardation, and patent ductus arteriosus have also been reported, although itis not clear whether these occurrences were due to exposure to the drug.In addition, first trimester use of ACE inhibitors, a specific class of drugs actingon the renin-angiotensin system, has been associated with a potential riskof birth defects in retrospective data. Healthcare professionals that prescribedrugs acting directly on the renin-angiotensin system should counsel womenof childbearing potential about the potential risks of these agents during pregnancy.Rarely (probably less often than once in every thousand pregnancies),no alternative to a drug acting on the renin-angiotensin system will be found.In these rare cases, the mothers should be apprised of the potential hazardsto their fetuses and serial ultrasound examination should be performed toassess the intra-amniotic environment. If oligohydramnios is observed,Tekturna should be discontinued unless it is considered life-saving for themother. Contraction stress testing (CST), a nonstress test (NST) or biophysical

profiling (BPP) may be appropriate, depending upon the week of pregnancy.Patients and physicians should be aware, however, that oligohydramnios maynot appear until after the fetus has sustained irreversible injury.Infants with histories of in-utero exposure to a renin inhibitor should beclosely observed for hypotension, oliguria, and hyperkalemia. If oliguriaoccurs, attention should be directed toward support of blood pressure andrenal perfusion. Exchange transfusion or dialysis may be required as meansof reversing hypotension and/or substituting for disordered renal function.[See Nonclinical Toxicology (13) in the full prescribing information]8.3 Nursing MothersIt is not known whether aliskiren is excreted in human breast milk. Aliskirenwas secreted in the milk of lactating rats. Because of the potential for adverseeffects on the nursing infant, a decision should be made whether to discontinuenursing or discontinue the drug, taking into account the importance ofthe drug to the mother.8.4 Pediatric UseSafety and effectiveness of aliskiren in pediatric patients

Valturna (aliskiren and valsartan, USP) TabletsInitial U.S. Approval: 2009BRIEF SUMMARY: Please see package insert for full prescribing information.WARNING: AVOID USE IN PREGNANCYWhen pregnancy is detected, discontinue Valturna as soon as possible. Whenused in pregnancy during the second and third trimesters, drugs that act directlyon the renin-angiotensin-aldosterone system can cause injury and death to thedeveloping fetus. [See Warnings and Precautions (5.1)].1 INDICATIONS AND USAGEValturna is indicated for the treatment of hypertension.Add-on TherapyA patient whose blood pressure is not adequately controlled with aliskiren aloneor valsartan (or another angiotensin receptor blocker) alone may be switched tocombination therapy with Valturna.Replacement TherapyValturna may be substituted for the titrated components.Initial TherapyValturna may be used as initial therapy in patients who are likely to need multipledrugs to achieve their blood pressure goals.The choice of Valturna as initial therapy should be based on an assessment ofpotential benefits and risks.Patients with Stage 2 hypertension are at a relatively high risk for cardiovascularevents (such as strokes, heart attacks, and heart failure), kidney failure, andvision problems, so prompt treatment is clinically relevant. The decision to use acombination as initial therapy should be individualized and should be shaped byconsiderations such as baseline blood pressure, the target goal, and the incrementallikelihood of achieving goal with a combination compared to monotherapy.Individual blood pressure goals may vary based upon the patient’s risk.Data from the high-dose multifactorial study [see Clinical Studies (14) in the fullprescribing information] provide estimates of the probability of reaching a targetblood pressure with Valturna compared to aliskiren or valsartan monotherapy.The figures below provide estimates of the likelihood of achieving systolic ordiastolic blood pressure control with Valturna 300/320 mg, based upon baselinesystolic or diastolic blood pressure. The curve of each treatment group was estimatedby logistic regression modeling. The estimated likelihood at the right tailof each curve is less reliable because of a small number of subjects with highbaseline blood pressures.Figure 1: Probability of Achieving Systolic Blood Pressure (SBP)

Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP)

4 CONTRAINDICATIONSNone.5 WARNINGS AND PRECAUTIONS5.1 Fetal/Neonatal Morbidity and MortalityValturna can cause fetal harm when administered to a pregnant woman. If thisdrug is used during pregnancy, or if a patient becomes pregnant while takingthis drug, apprise the patient of the potential hazard to the fetus.Drugs that act directly on the renin-angiotensin-aldosterone system can causefetal and neonatal morbidity and death when administered to pregnant women. Ifthis drug is used during pregnancy, or if the patient becomes pregnant whiletaking this drug, apprise the patient of the potential hazard to the fetus [see Usein Specific Populations (8.1)]. In several dozen published cases, use of ACEinhibitors during the second and third trimesters of pregnancy was associatedwith fetal and neonatal injury, including hypotension, neonatal skull hypoplasia,anuria, reversible or irreversible renal failure, and death. In addition, first trimesteruse of ACE inhibitors has been associated with birth defects in retrospective data.5.2 Head and Neck AngioedemaAliskirenAngioedema of the face, extremities, lips, tongue, glottis and/or larynx has beenreported in patients treated with aliskiren and has necessitated hospitalizationand intubation. This may occur at any time during treatment and has occurred inpatients with and without a history of angioedema with ACE inhibitors or angiotensinreceptor antagonists. If angioedema involves the throat, tongue, glottisor larynx, or if the patient has a history of upper respiratory surgery, airwayobstruction may occur and be fatal. Patients who experience these effects, evenwithout respiratory distress, require prolonged observation since treatment withantihistamines and corticosteroids may not be sufficient to prevent respiratoryinvolvement. Prompt administration of subcutaneous epinephrine solution1:1000 (0.3 to 0.5 mL) and measures to ensure a patent airway may be necessary.Discontinue aliskiren immediately in patients who develop angioedema and donot readminister.5.3 HypotensionAn excessive fall in blood pressure (hypotension) was rarely seen (

potential for other drugs acting on the renin-angiotensin-aldosterone system toincrease serum creatinine and blood urea nitrogen are not available.ValsartanIn studies of ACE inhibitors in hypertensive patients with unilateral or bilateralrenal artery stenosis, increases in serum creatinine or blood urea nitrogen havebeen reported. In a 4-day trial of valsartan in 12 hypertensive patients with unilateralrenal artery stenosis, no significant increases in serum creatinine or bloodurea nitrogen were observed. There has been no long-term use of valsartan inpatients with unilateral or bilateral renal artery stenosis, but an effect similar tothat seen with ACE inhibitors should be anticipated.As a consequence of inhibiting the renin-angiotensin-aldosterone system, changesin renal function may occur particularly in volume depleted patients. In patientswith severe heart failure whose renal function may depend on the activity of therenin-angiotensin-aldosterone system, treatment with angiotensin-convertingenzyme inhibitors and angiotensin receptor antagonists has been associatedwith oliguria or progressive azotemia and (rarely) with acute renal failure or death.Similar outcomes have been reported with valsartan.5.5 Patients with Hepatic ImpairmentValsartanAs the majority of valsartan is eliminated in the bile, patients with mild-tomoderatehepatic impairment, including patients with biliary obstructive disorders,showed lower valsartan clearance (higher AUCs).5.6 Patients with Congestive Heart Failure and Post-Myocardial InfarctionValsartanSome patients with heart failure have developed increases in blood urea nitrogen,serum creatinine, and potassium on valsartan. These effects are usually minorand transient, and they are more likely to occur in patients with pre-existingrenal impairment. Dosage reduction and/or discontinuation of the diuretic and/orvalsartan may be required. In the Valsartan Heart Failure Trial, in which 93% ofpatients were on concomitant ACE inhibitors, treatment was discontinued forelevations in creatinine or potassium (total of 1.0% on valsartan vs. 0.2% onplacebo). In the Valsartan in Acute Myocardial Infarction Trial (VALIANT), discontinuationdue to various types of renal dysfunction occurred in 1.1% ofvalsartan-treated patients and 0.8% of captopril-treated patients. Include assessmentof renal function when evaluating patients with heart failure or postmyocardialinfarction.5.7 Serum Electrolyte AbnormalitiesValturnaIn the short-term controlled trials of various doses of Valturna, the incidence ofhyperkalemia (serum potassium >5.5 mEq/L) was about 1%-2% higher in thecombination treatment group compared with the monotherapies aliskiren andvalsartan, or with placebo.In a long-term, uncontrolled study with median treatment duration of about oneyear, about 4% of the patients had at least one serum potassium >5.5 mEq/L atsome time during the study; about 0.8% of patients discontinued study treatmentand had a high serum potassium at some point during the study. Patientswith hyperkalemia were older (median age 65 vs. 55) with slightly lower meanbaseline estimated creatinine clearance compared to patients without hyperkalemia.While about 25% of the hyperkalemic episodes occurred in the first twomonths, other initial episodes were reported throughout the study.Periodic determinations of serum electrolytes to detect possible electrolyteimbalances is advised, particularly in patients at risk for hyperkalemia such asthose with renal impairment.Caution is advised with concomitant use of Valturna with potassium-sparingdiuretics, potassium supplements, salt substitutes containing potassium, orother drugs that increase potassium levels may lead to increases in serumpotassium.5.8 Renal Artery StenosisAliskirenNo data are available on the use of aliskiren in patients with unilateral or bilateralrenal artery stenosis or stenosis of the artery to a solitary kidney.ValsartanIn studies of ACE inhibitors in hypertensive patients with unilateral or bilateralrenal artery stenosis, increases in serum creatinine or blood urea nitrogen have

een reported. In a 4-day trial of valsartan in 12 hypertensive patients with unilateralrenal artery stenosis, no significant increases in serum creatinine or bloodurea nitrogen were observed. There has been no long-term use of valsartan inpatients with unilateral or bilateral renal artery stenosis, but an effect similar tothat seen with ACE inhibitors should be anticipated.5.9 CyclosporineAliskirenWhen aliskiren was given with cyclosporine, the blood concentrations of aliskirenwere significantly increased. Concomitant use of aliskiren with cyclosporine isnot recommended [see Drug Interactions (7)].6 ADVERSE REACTIONS6.1 Clinical Studies ExperienceThe following serious adverse reactions are discussed in greater detail in othersections of the label:• Risk of fetal/neonatal morbidity and mortality [see Warnings and Precautions(5.1)]• Head and neck angioedema [see Warnings and Precautions (5.2)]• Hypotension [see Warnings and Precautions (5.3)]Because clinical trials are conducted under widely varying conditions, adversereaction rates observed in the clinical trials of a drug cannot be directly comparedto rates in clinical trials of another drug and may not reflect the ratesobserved in practice.ValturnaValturna has been evaluated for safety in more than 1,225 patients, includingover 316 patients for over 1 year. In placebo-controlled clinical trials, discontinuationof therapy because of a clinical adverse event (including uncontrolledhypertension) occurred in 1.4% of patients treated with Valturna versus 2.7%of patients given placebo.Adverse events in placebo-controlled trials that occurred in at least 1% of patientstreated with Valturna and at a higher incidence than placebo included fatigue(2.6% vs. 1.4%), nasopharyngitis (2.6% vs. 2.2%), diarrhea (1.4% vs 0.9%),upper respiratory tract infection (1.4% vs. 1.1%), urinary tract infection (1.4%vs. 0.6%), influenza (1.1% vs 0.2%), and vertigo (1.1% vs. 0.3%).Hyperkalemia has been observed as a serum electrolyte abnormality in Valturnaclinical trials [see Warnings and Precautions (5.7)].AliskirenAliskiren has been evaluated for safety in 6,460 patients, including 1,740 treatedfor longer than 6 months, and 1,250 for longer than 1 year. In placebo-controlledclinical trials, discontinuation of therapy because of a clinical adverse event,including uncontrolled hypertension occurred in 2.2% of patients treated withaliskiren, versus 3.5% of patients given placebo.Two cases of angioedema with respiratory symptoms were reported with aliskirenuse in the clinical studies. Two other cases of periorbital edema without respiratorysymptoms were reported as possible angioedema and resulted in discontinuation.The rate of these angioedema cases in the completed studies was 0.06%.In addition, 26 other cases of edema involving the face, hands, or whole bodywere reported with aliskiren use, including 4 leading to discontinuation.In the placebo-controlled studies, however, the incidence of edema involving theface, hands, or whole body was 0.4% with aliskiren compared with 0.5% withplacebo. In a long-term active-controlled study with aliskiren and HCTZ arms,the incidence of edema involving the face, hands, or whole body was 0.4% inboth treatment arms.Aliskiren produces dose-related gastrointestinal (GI) adverse reactions. Diarrheawas reported by 2.3% of patients at 300 mg, compared to 1.2% in placebopatients. In women and the elderly (age ≥65) increases in diarrhea rates wereevident starting at a dose of 150 mg daily, with rates for these subgroups at150 mg similar to those seen at 300 mg for men or younger patients (all ratesabout 2%). Other GI symptoms included abdominal pain, dyspepsia, and gastroesophagealreflux, although increased rates for abdominal pain and dyspepsiawere distinguished from placebo only at 600 mg daily. Diarrhea and other GIsymptoms were typically mild and rarely led to discontinuation.Aliskiren was associated with a slight increase in cough in the placebo-controlledstudies (1.1% for any aliskiren use vs. 0.6% for placebo). In active-controlledtrials with ACE inhibitor (ramipril, lisinopril) arms, the rates of cough for the

aliskiren arms were about one-third to one-half the rates in the ACE inhibitorarms.Other adverse reactions with increased rates for aliskiren compared to placeboincluded rash (1% vs. 0.3%), elevated uric acid (0.4% vs. 0.1%), gout (0.2% vs.0.1%), and renal stones (0.2% vs. 0%).Single episodes of tonic-clonic seizures with loss of consciousness were reportedin two patients treated with aliskiren in the clinical trials. One patient had predisposingcauses for seizures and had a negative electroencephalogram (EEG) andcerebral imaging following the seizures; for the other patient, EEG and imagingresults were not reported. Aliskiren was discontinued and there was no rechallengein either case.The following adverse events occurred in placebo-controlled clinical trials at anincidence of more than 1% of patients treated with aliskiren, but also occurredat about the same or greater incidence in patients receiving placebo: headache,nasopharyngitis, dizziness, fatigue, upper respiratory tract infection, back painand cough.No clinically meaningful changes in vital signs or in ECG (including QTc interval)were observed in patients treated with aliskiren.ValsartanValsartan has been evaluated for safety in more than 4,000 hypertensive patientsin clinical trials, including over 400 treated for over 6 months, and more than160 for over 1 year.In trials in which valsartan was compared to an ACE inhibitor with or withoutplacebo, the incidence of dry cough was significantly greater in the ACE inhibitorgroup (7.9%) than in the groups who received valsartan (2.6%) or placebo (1.5%).In a 129 patient trial limited to patients who had had dry cough when they hadpreviously received ACE inhibitors, the incidences of cough in patients whoreceived valsartan, HCTZ, or lisinopril were 20%, 19%, and 69% respectively(p0.2% of patients in controlledclinical trials with valsartan are:Body as a Whole: allergic reaction, astheniaMusculoskeletal: muscle crampsNeurologic and Psychiatric: paresthesiaRespiratory: sinusitis, pharyngitisUrogenital: impotenceOther reported events seen less frequently in clinical trials were: angioedema.Adverse reactions reported for valsartan for indications other than hypertensionmay be found in the prescribing information for Diovan.6.2 Clinical Laboratory Test AbnormalitiesRBC count, hemoglobin and hematocrit:Small mean decreases from baseline were seen in RBC count, hemoglobin andhematocrit in both monotherapies and combination therapy. These changeswere small, but changes in hemoglobin were slightly more pronounced with thecombination therapy (-0.26 g/dL) than with monotherapy regimens (-0.04 g/dLin aliskiren or -0.13 g/dL in valsartan) or placebo (+0.07 g/dL).Blood Urea Nitrogen (BUN)/Creatinine:Elevations in BUN (>40 mg/dL) and creatinine (>2.0 mg/dL) in any treatmentgroup were less than 1.0%. For creatinine, 0.5% (3/599) of patients on combinationtreatment had a creatinine level >1.5 mg/dL at the end of the study and a30% increase from baseline compared to none in either monotherapy or placebo.Serum Electrolytes: See Warnings and Precautions (5.7)6.3 Post-Marketing ExperienceThe following adverse reactions have been reported in aliskiren post-marketingexperience. Because these reactions are reported voluntarily from a populationof uncertain size, it is not always possible to reliably estimate their frequency orestablish a causal relationship to drug exposure.Hypersensitivity: angioedema requiring airway management and hospitalizationPeripheral edema

7 DRUG INTERACTIONSNo drug interaction studies have been conducted with Valturna and other drugs,although studies with the individual aliskiren and valsartan components aredescribed below.AliskirenEffects of Other Drugs on AliskirenBased on in vitro studies, aliskiren is metabolized by CYP 3A4.Irbesartan: Coadministration of irbesartan reduced aliskiren C max up to 50% aftermultiple dosing.P-glycoprotein Effects: Pgp (MDR1/Mdr1a/1b) was found to be the major effluxsystem involved in absorption and disposition of aliskiren in preclinical studies.The potential for drug interactions at the Pgp site will likely depend on the degreeof inhibition of this transporter. Coadministration of aliskiren with Pgp substratesor weak to moderate inhibitors such as atenolol, digoxin, and amlodipine did notresult in clinically relevant interactions.Atorvastatin: Coadministration of atorvastatin, a weak Pgp inhibitor, resulted inabout a 50% increase in aliskiren C max and AUC after multiple dosing.Ketoconazole: Coadministration of 200 mg twice-daily ketoconazole, a moderatePgp inhibitor, with aliskiren resulted in approximate 80% increase in plasma levelsof aliskiren. A 400-mg once-daily dose was not studied but would be expectedto increase aliskiren blood levels further.Cyclosporine: Coadministration of 200 mg and 600 mg cyclosporine, a potentPgp inhibitor, with 75 mg aliskiren resulted in an approximately 2.5-fold increasein C max and 5-fold increase in AUC of aliskiren. Concomitant use of aliskiren withcyclosporine is not recommended.Verapamil: Coadministration of 240 mg of verapamil, a moderate Pgp inhibitor,with 300 mg aliskiren resulted in an approximately 2-fold increase in C max andAUC of aliskiren. However, no dosage adjustment is necessary.Drugs with no clinically significant effects: Coadministration of lovastatin,atenolol, warfarin, furosemide, digoxin, celecoxib, hydrochlorothiazide, ramipril,valsartan, metformin and amlodipine did not result in clinically significantincreases in aliskiren exposure.Effects of Aliskiren on Other DrugsAliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19,2D6, 2E1, and CYP 3A) or induce CYP 3A4.Furosemide: When aliskiren was coadministered with furosemide, the AUC andC max of furosemide were reduced by about 30% and 50%, respectively. Patientsreceiving furosemide could find its effect diminished after starting aliskiren.Drugs with no clinically significant effects: Coadministration of aliskiren did notsignificantly affect the pharmacokinetics of lovastatin, digoxin, valsartan, amlodipine,metformin, celecoxib, atenolol, atorvastatin, ramipril or hydrochlorothiazide.Warfarin: The effects of aliskiren on warfarin pharmacokinetics have not beenevaluated.ValsartanNo clinically significant pharmacokinetic interactions were observed whenvalsartan was coadministered with aliskiren, amlodipine, atenolol, cimetidine,digoxin, furosemide, glyburide, hydrochlorothiazide, or indomethacin. Thevalsartan-atenolol combination was more antihypertensive than either component,but it did not lower the heart rate more than atenolol alone.Warfarin: Coadministration of valsartan and warfarin did not change the pharmacokineticsof valsartan or the time-course of the anticoagulant properties ofwarfarin.CYP 450 Interactions: In vitro metabolism studies have indicated that CYP450mediated drug interactions between valsartan and coadministered drugs areunlikely because of low extent of metabolism [see Pharmacokinetics – Valsartan(12.3) in the full prescribing information].Transporters: The results from an in vitro study with human liver tissue indicatethat valsartan is a substrate of the hepatic uptake transporter OATP1B1 and thehepatic efflux transporter MRP2. Coadministration of inhibitors of the uptaketransporter (rifampin, cyclosporine) or efflux transporter (ritonavir) may increasethe systemic exposure to valsartan.

As with other drugs that block angiotensin II or its effects, concomitant use ofpotassium sparing diuretics (e.g., spironolactone, triamterene, amiloride), potassiumsupplements, or salt substitutes containing potassium may lead to increasesin serum potassium and in heart failure patients to increases in serum creatinine.8 USE IN SPECIFIC POPULATIONS8.1 PregnancyPregnancy Category D [see Warnings and Precautions (5.1)].Valturna contains both aliskiren (a direct renin inhibitor) and valsartan (an angiotensinII receptor blocker). When administered during the second or third trimesterof pregnancy, drugs that act directly on the renin-angiotensin-aldosterone systemcan cause fetal and neonatal morbidity and death. Valturna can cause fetalharm when administered to a pregnant woman. If this drug is used during pregnancy,or if the patient becomes pregnant while taking this drug, apprise thepatient of the potential hazard to the fetus.Angiotensin II receptor antagonists, like valsartan, and angiotensin-convertingenzyme (ACE) inhibitors exert similar effects on the renin-angiotensin-aldosteronesystem. In several dozen published cases, ACE inhibitor use during the secondand third trimesters of pregnancy was associated with fetal and neonatal injury,including hypotension, neonatal skull hypoplasia, anuria, reversible or irreversiblerenal failure, and death. Oligohydramnios was also reported, presumably fromdecreased fetal renal function. In this setting, oligohydramnios was associatedwith fetal limb contractures, craniofacial deformation, and hypoplastic lungdevelopment. Prematurity, intrauterine growth retardation, and patent ductusarteriosus were also reported, although it is not clear whether these occurrenceswere due to exposure to the drug. In addition, first trimester use of ACE inhibitors,a specific class of drugs acting on the renin-angiotensin-aldosterone system,has been associated with a potential risk of birth defects in retrospective data.When pregnancy occurs in a patient using Valturna, discontinue Valturna treatmentas soon as possible. Inform the patient about potential risks to the fetusbased on the time of gestational exposure to Valturna (first trimester only orlater). If exposure occurs beyond the first trimester, perform an ultrasoundexamination.In rare cases when another antihypertensive agent cannot be used to treat thepregnant patient, perform serial ultrasound examinations to assess the intraamnioticenvironment. Routine fetal testing with non-stress tests, biophysicalprofiles, and/or contraction stress tests may be appropriate based on gestationalage and standards of care in the community. If oligohydramnios occurs in thesesituations, individualized decisions about continuing or discontinuing Valturnatreatment and about pregnancy management should be made by the patient, herphysician, and experts in the management of high risk pregnancy. Patients andphysicians should be aware that oligohydramnios may not appear until after thefetus has sustained irreversible injury.Closely observe infants with histories of in utero exposure to Valturna for hypotension,oliguria, and hyperkalemia. If oliguria occurs, these infants may requireblood pressure and renal perfusion support. Exchange transfusion or dialysismay be required to reverse hypotension or support decreased renal function.No reproductive toxicity studies have been conducted with the combination ofaliskiren and valsartan. However, these studies have been conducted foraliskiren as well as valsartan alone [see Nonclinical Toxicology (13) in the fullprescribing information].8.3 Nursing MothersIt is not known whether aliskiren is excreted in human milk, but aliskiren wassecreted in the milk of lactating rats. It is not known whether valsartan is excretedin human milk. Valsartan was excreted into the milk of lactating rats; however,animal breast milk drug levels may not accurately reflect human breast milk levels.Because of the potential for adverse effects on the nursing infant, a decisionshould be made whether to discontinue nursing or discontinue the drug, takinginto account the importance of the drug to the mother.8.4 Pediatric UseSafety and effectiveness of Valturna in pediatric patients have not been established.

8.5 Geriatric UseIn 8.5the Geriatric short-term Usecontrolled clinical trials of Valturna, 99 (15.9%) patientstreated In the short-term with Valturna controlled were ≥65 clinical yearstrials andof 14 Valturna, (2.2%) were 99 (15.9%) ≥75 years. patientstreated with Valturna were ≥65 years and 14 (2.2%) were ≥75 years.No overall differences in safety or effectiveness were observed between thesesubjects No overall and differences younger subjects, in safety or andeffectiveness other reported were clinical observed experience between has these notidentified subjects and differences youngerinsubjects, responses andbetween other reported the elderly clinical and younger experience patients, has not butgreater identified sensitivity differences of some in responses older individuals between the cannot elderly beand ruled younger out. patients, butgreater sensitivity of some older individuals cannot be ruled out.10 OVERDOSAGE10 Aliskiren OVERDOSAGELimited Aliskirendata are available related to overdosage in humans. The most likelyLimited manifestation data are of available overdosage related would to be overdosage hypotension. in humans. If symptomatic The most hypotension likelymanifestation occurs, provide ofsupportive overdosagetreatment.would be hypotension. If symptomatic hypotensionoccurs, provide supportive treatment.ValsartanLimited Valsartan data are available related to overdosage in humans. The most likely effectLimited of overdose datawith are available valsartanrelated wouldtobeoverdosage hypotension inand humans. tachycardia; The most bradycardia likely effectof could overdose occur with fromvalsartan parasympathetic would be(vagal) hypotension stimulation. and tachycardia; Depressed level bradycardia of consciousness,occur from circulatory parasympathetic collapse and(vagal) shockstimulation. have been reported. Depressed If symptomatic level of con-couldsciousness, hypotensioncirculatory occurs, provide collapse supportive and shock treatment. have been reported. If symptomatichypotension occurs, provide supportive treatment.Valsartan is not removed from the plasma by hemodialysis.Valsartan is not removed from the plasma by hemodialysis.Valsartan was without grossly observable adverse effects at single oral doses upValsartan to 2000 mg/kg was without in rats and grossly up toobservable 1000 mg/kg adverse in marmosets, effects at except single oral for the doses sali-uvation2000and mg/kg diarrhea in rats in and the rat upand to 1000 vomiting mg/kg in in themarmosets, at except the highest for the dose sali-tovation (60 and and 31diarrhea times, respectively, in the rat and thevomiting maximum in the recommended marmoset at human the highest dose on dose(60 mg/mand 2 basis). 31 times, (Calculations respectively, assume the maximum an oral dose recommended of 320 mg/day human anddose 60-kg on apatient.) mg/m 2 basis). (Calculations assume an oral dose of 320 mg/day and a 60-kgpatient.)16 STORAGE16 Store STORAGE at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) in original container.Store at [See 25°C USP (77°F); Controlled excursions Roompermitted Temperature.] to 15-30°C (59-86°F) in original container.[See USP Controlled Room Temperature.]Protect from moisture.Protect from moisture.Dispense in tight container (USP).Dispense in tight container (USP).REV: FEBRUARY 2010 T2010-12REV: FEBRUARY 2010 T2010-12Manufactured by:Novartis Manufactured Pharma by: Stein AGStein, Novartis Switzerland Pharma Stein AGStein, SwitzerlandDistributed by:Novartis Distributed Pharmaceuticals by: CorporationEast Novartis Hanover, Pharmaceuticals New JerseyCorporation07936East Hanover, New Jersey 07936©Novartis©Novartis

2010 ASH Innovations TheaterASH Hypertension Resource Pavilion • America’s Hall I – 3rd FloorSaturday, May 1, 2010 • 5:30 PM – 6:30 PM • Innovations TheaterExploring Direct Renin InhibitionNovartis Pharmaceuticals, Inc.“The Innovations Theater’s content and the views expressedtherein are those of the presenting corporate entity and not ofthe American Society of Hypertension, Inc. The content is notpart of the ASH Annual Scientific Meeting as approved by theAnnual Scientific Program Committee.”Sunday, May 2, 2010 • 10:00 AM – 11:00 AM • Innovations TheaterComprehensive RAAS BlockadeNovartis Pharmaceuticals, Inc.“The Innovations Theater’s content and the views expressedtherein are those of the presenting corporate entity and not ofthe American Society of Hypertension, Inc. The content is notpart of the ASH Annual Scientific Meeting as approved by theAnnual Scientific Program Committee.”Sunday, May 2, 2010 • 4:45 PM – 5:45 PM • Innovations TheaterBystolic ® (nebivolol): For the Treatment of HypertensionForest Pharmaceut icals, Inc.“The Innovations Theater’s content and the views expressedtherein are those of the presenting corporate entity and not ofthe American Society of Hypertension, Inc. The content is notpart of the ASH Annual Scientific Meeting as approved by theAnnual Scientific Program Committee.”Monday, May 3, 2010 • 11:45 AM – 12:45 AM • Innovations TheaterThe Hypertension SyndromeDaiichi Sankyo, Inc..“The Innovations Theater’s content and the views expressedtherein are those of the presenting corporate entity and not ofthe American Society of Hypertension, Inc. The content is notpart of the ASH Annual Scientific Meeting as approved by theAnnual Scientific Program Committee.”186

2010 ASH ExhibitorsASH Hypertension Resource Pavilion • America’s Hall I – 3rd FloorA & D MedicalContact: Brandon Katz, Product Manager1756 Automation ParkwaySan Jose, CA 95131Phone: 408-263-5333Fax: 408-263-0119E-mail: support@lifesourceonline.comWebsite: www.andmedical.comBooth Number: 1820A&D Medical manufactures and distributes a full line ofadvanced electronic blood pressure monitoring equipment andhealth care products for home and professional use. All of thecompany’s consumer home care products are marketed underthe LifeSource brand name in North America. Over the past 25years, we have received praise from the health care communityfor our products, service and innovation.A C Cossor & Son (Surgical) Ltd.Contact: Adrian CossorAccoson WorksParkwayHarlow Business ParkEssexCM19 5QPUnited KingdomPhone: 44 (0)1279 433456Fax: 44 (0)1279 444018Email: adrian @accoson.comWebsite: www.greenlight300.comBooth Number: 1400We are showing our manual sphygmomanometer the Accosongreenlight 300 which is the solution to the problem ofreplacing mercury and aneroid models and which doesn’t needfrequent calibration checks. The device features automatic selfcalibration, cuff deflation rate indicators and is now establishedas the accurate manual device of choice. We also plan to showour new innovative linear cuff deflator.187

2010 ASH Exhibitors continuedAtCor Medical, Inc. (USA)Contact: Beth BoyerOne Pierce Place, Suite 295EItasca, IL 60143Phone: 630-228-8871Fax: 630-228-8872Email: b.boyer@atcormedical.comWebsite: www.atcormedical.comBooth Number: 1106AtCor Medical developed and markets the SphygmoCor®system, the global gold standard for noninvasive central bloodpulse wave analysis and pulse wave velocity assessment. .SphygmoCor systems, featured in over 600 published clinicalstudies, are used by leading institutions and physician practicesworldwide and in major pharmaceutical clinical trials.Boehringer Ingelheim Pharmaceuticals, Inc.Contact: Amy Lyddy900 Ridgebury RoadRidgefield, CT 06877Phone: 203-798-9988Email: amy.lyddy@boehringer-ingleheim.comWebsite: us.boehringer-ingelheim.comBooth Number: 1112Boehringer Ingelheim Pharmaceuticals, Inc., the US subsidiaryof Boehringer Ingelheim, headquartered in Germany, operatesglobally in 47 countries with approximately 39,800 employees.The company is committed to researching, developing,manufacturing and marketing novel products of hightherapeutic value for human and veterinary medicine.Cardiology Career NetworkContact: Jennifer Arocha9100 E. Panorama Dr., Ste. 200Englewood, CO 80112Phone: 888-884-8242Fax: 800-595-2929Email: info@healthecareers.comWebsite: www.healthecareers.com/ccnBooth Number: 1013The Cardiology Career Network is only for cardiology. It’salso part of the HEALTHeCAREERS Network, so you canfill and search jobs across the entire Cardiology Care teamfromnurses and NPs to PAs and other cardiology-specializedprofessions. This online community also offers cardiologycareer tips, industry relevant news and more! Visit us at booth1013 or online at www.healthecareers.com/ccn!188

ASH Hypertension Resource CenterHilton New York • Americas Hall I & RhinelanderAmericas Hall I (third floor)Rhinelander – ASH Posters (second floor)Innovations Theater131 130 999849 48132 129 100 9750 47Homedics1126A&DMedical1820133 128 101 96134 127 102 9574 7375 7251 4652 45TakedaPharmaceuticalsNorthAC Cossor& SonTibaMedicalINCResearch1400 1402 1406NaturePublishing1818CDR- 216'135 126 103 94136 125 104 9376 7177 7053 4454 436'112010'137 124 105 9278 6955 42BoehringerIngelheimCDR- 116'138 123 106 916'139 122 107 9079 6856 4157 406'ROLLUP DOOR10'140 121 108 8958 391112141 120 109 8880 6759 38DOWNTO AMERICAS HALL IIESCALATORUPPhilipsRespironics LippincoftWilliams1110AtCorMedical11061211NationalKidney1306MicrofileMedical Home1207NovartisPharmaceuticals1100Wiley-Blackwell ASH Elsevier10111005NicOx1308Sanofi-AventisUS LLC1301CardiologyCareer Net1013ForestPharmaceuticals1307CVRx1305ENTRANCE142 119 110 87 60 376' 6'143 118 111 86144 117 112 85145 116 113 8481 66 61 3662 3582 65 63 346' 6' 6' 6'146 115 114 83 64 33ENTRANCEDalichi SankyoSunTechMedicalISHIBOmronHealthcareIntercure1000 1004 1006 1008 1012ELEC.ROOMINDICATED FIRE ALARMSINDICATED FIRE EXITSFIRE ALARMS MUST BE VISIBLEAT ALL TIMES.INDICATED FIRE EXITSFE - FIRE EXTINGUISHER189

ASH Exposition GuideHilton New York • Americas Hall I • Third FloorSaturday, May 1, 20105:30 PM – 6:30 PM • Innovations TheaterExploring Direct Renin InhibitionNovartis Pharmaceuticals, Inc.“The Innovations Theater’s content andthe views expressed therein are thoseof the presenting corporate entity andnot of the American Society of Hypertension,Inc. The content is not partof the ASH Annual Scientific Meetingas approved by the Annual ScientificProgram Committee.”Sunday, May 2, 201010:00 AM – 11:00 AM • Innovations TheaterComprehensive RAAS BlockadeNovartis Pharmaceuticals, Inc.“The Innovations Theater’s content andthe views expressed therein are thoseof the presenting corporate entity andnot of the American Society of Hypertension,Inc. The content is not partof the ASH Annual Scientific Meetingas approved by the Annual ScientificProgram Committee.”Sunday, May 2, 20104:45 PM – 5:45 PM • Innovations TheaterBystolic® (nebivolol): For theTreatment of HypertensionForest Pharmaceuticals, Inc.“The Innovations Theater’s content andthe views expressed therein are thoseof the presenting corporate entity andnot of the American Society of Hypertension,Inc. The content is not partof the ASH Annual Scientific Meetingas approved by the Annual ScientificProgram Committee.”Monday, May 3, 201011:45 AM – 12:45 AM • Innovations TheaterThe Hypertension SyndromeDaiichi Sankyo, Inc..“The Innovations Theater’s content andthe views expressed therein are thoseof the presenting corporate entity andnot of the American Society of Hypertension,Inc. The content is not partof the ASH Annual Scientific Meetingas approved by the Annual ScientificProgram Committee.”A & D MedicalBooth Number: 1820A&D Medical manufactures anddistributes a full line of advancedelectronic blood pressure monitoringequipment and health care productsfor home and professional use. Allof the company’s consumer homecare products are marketed underthe LifeSource brand name in NorthAmerica. Over the past 25 years, wehave received praise from the healthcare community for our products,service and innovation.A C Cossor & Son (Surgical) Ltd.Booth Number: 1400We are showing our manual sphygmomanometerthe Accoson greenlight300 which is the solution to theproblem of replacing mercury andaneroid models and which doesn’tneed frequent calibration checks. Thedevice features automatic self calibration,cuff deflation rate indicatorsand is now established as the accuratemanual device of choice. We also planto show our new innovative linear cuffdeflator.AtCor Medical, Inc. (USA)Booth Number: 1106AtCor Medical developed and marketsthe SphygmoCor® system, the globalgold standard for noninvasive centralblood pulse wave analysis and pulsewave velocity assessment. . SphygmoCorsystems, featured in over 600published clinical studies, are usedby leading institutions and physicianpractices worldwide and in majorpharmaceutical clinical trials.Boehringer IngelheimPharmaceuticals, IncBooth Number: 1112Boehringer Ingelheim Pharmaceuticals,Inc., the US subsidiary ofBoehringer Ingelheim, headquarteredin Germany, operates globally in 47countries with approximately 39,800employees. The company is committedto researching, developing,manufacturing and marketing novelproducts of high therapeutic value forhuman and veterinary medicine.Cardiology Career NetworkBooth Number: 1013The Cardiology Career Network isonly for cardiology. It’s also part ofthe HEALTHeCAREERS Network,so you can fill and search jobs acrossthe entire Cardiology Care team-fromnurses and NPs to PAs and othercardiology-specialized professions.This online community also offers cardiologycareer tips, industry relevantnews and more! Visit us at booth1013 or online at www.healthcareers.com/ccn!CVRx Inc.Booth Number: 1305CVRx, Inc. has developed for the treatmentof hyper Rheos® System for thetreatment of hypertension and heartfailure. It is the first and only implantabledevice that provides baroreflex activationtherapy for these conditions. The RheosSystem is an investigational device and iscurrently in clinical trials in the UnitedStates and Europe.Daiichi Sankyo, Inc.Booth Number: 1000Daiichi Sankyo, Inc., is the U.S. subsidiaryof Daiichi Sankyo Co. Ltd., a globalleader in pharmaceutical innovation since1899. The U.S. organization, includingcommercial operations and global clinicaldevelopment, is headquartered in NJ. Afocus of R& D is cardiovascular disease,hypertension, diabetes and acute coronarysyndrome. www.dsi.comElsevierBooth Number: 1308ELSEVIER, proud publisher of theJournal of the AMERICAN SOCIETY OFHYPERTENSION, is dedicated to beingyour integral partner in delivering exceptionalhealthcare. Trust ELSEVIER tooffer superior resources that expand yourknowledge, foster communication, buildinsights, enable individual and collectiveadvancement in the healthcare field.Forest Pharmaceuticals, Inc.Booth Number: 1307Forest Pharmaceuticals, Inc welcomesyou to New York! We invite you to visitour exhibit where our professional representativeswill welcome the opportunityto discuss and answer any questions regardingour product Bystolic® (nebivolol)tablets. Please visit our website atwww.bystolic.com.HoMedics, Inc.Booth Number: 1126Founded in 1987, HoMedics prides itselfon over 20 years of devotion and dedicationto consumer wellness. HoMedicsoffers an innovative line of home healthcareand diagnostic products, includingstate of the art blood pressure monitors,thermometers, and more to help peopleproactively manage their health whileimproving their overall well being.INC ResearchBooth Number: 1406INC Research is a global contractresearch organization, with a TrustedProcess® for conducting PhaseI-PhaseIVclinical trials that ensures customersexperience trial excellence. With operationsin 40 countries, our process helps tominimize risk factors and leads to moreinformed and confident drug developmentdecisions. Whether your projectis a full-service international study orrequires select regional services, INCresearch can meet your needs.International Society onHypertension in Blacks, Inc. (ISHIB)Booth Number: 1006Founded in 1986, ISHIB is an non-profitorganization of healthcare professionsand leaders in cardiovascular diseaseand related disorders. Our mission is toimprove the health and life expectancy ofethnic minorities and eliminate racial andethnic health disparities in cardiovasculardisease through professional and publiceducation, targeted clinical research, andfacilitation of the delivery of higher qualitycardiovascular health care. We hostan annual conference, membership andother programs.Lippincott, Williams & WilkinsBooth Number: 1211Lippincott, Williams & Wilkins offersspecialized publications and softwarefor physicians, nurses, students andspecialized clinicians. Products includedrug guides, medical journals, nursingjournals, medical textbooks and medicalPDA software. LWW publishes thejournal Hypertension, the Journal ofthe American Heart Association, andThe Journal of Hypertension, the officialjournal of the International Society ofHypertension and the European Societyof Hypertension.Microlife Medical Home Solutions,Inc.Booth Number: 1207Microlife Medical Home Solutions is continuingto empower physicians and theirmedical practices with patient-centeredprograms that improve the evaluation,diagnosis and treatment of cardiovascular,pulmonary, and metabolic diseases.Our WatchBP monitors provide a uniquecombination of in-office and out-of-officeblood pressure measurements to advancehypertension diagnosis and treatment inaccordance with practice guidelines.National Kidney FoundationBooth Number: 1306How many of your patients with diabetes,hypertension and cardiovascular diseasehave undiagnosed chronic kidneydisease? One in nine US adults has CKD.Early detection of CKD can help preventprogression to kidney failure. Visit Booth1306 to learn how your patients and clinicianscan benefit from NKF’s educationaltools, resources and screening programs.Nature Publishing GroupBooth Number: 1818Nature Publishing Group brings leadingscientific and medical research to yourdesktop. The NPG portfolio combines thecontinued excellence of Nature, its associatedresearch, review journals and over45 leading academic and society journalsin the life, physical and clinical sciences.Visit Stand 1818 for free sample copies.NicOxBooth Number: 1005NicOx is a pharmaceutical companycommitted to developing nitric oxide–donating drugs that address importantunmet medical needs and targetingthe therapeutic areas of inflammatoryand cardiometabolic diseases. NicOx ismaximizing the value of its broad productportfolio through in-house developmentof drug candidates and partnerships withmajor pharmaceutical companies.Novartis PharmaceuticalsCorporationBooth Number: 1100Novartis Pharmaceuticals is dedicated todiscovering, developing, manufacturingand marketing prescription drugs thathelp meet our customers’ medical needsand improve their quality of life. Pleasevisit the Novartis exhibit where our salesrepresentatives will be available to discussour products.Omron HealthcareBooth Number: 1008Omron Healthcare, Inc. is a leadingmanufacturer and distributor of bloodpressure monitors for home use. OmronHealthcare markets clinically provenproducts that provide accurate healthinformation to consumers and physiciansand support positive lifestyle changes andhealth improvement.Philips RespironicsBooth Number: 1110Philips Respironics is passionate aboutimproving the quality of people’s liveswith solutions designed around the needsof our customers and their patients. Thetradition of innovation combined withour ability to anticipate market needs hasmade Philips Respironics a global leaderin the markets we serve.RESPeRATE (InterCure Inc)Booth Number: 1012RESPeRATE® is the only non-drugtherapy indicated for the adjunctivetreatment of hypertension, availableOTC. Clinically proven in 10 publishedstudies, RESPeRATE enables patientsto reduce sympathetic activity, decreaseperipheral resistance and lower BP. Usedfor 15 minutes a day, several times a week,RESPeRATE demonstrates a significantall-day BP reduction without any sideeffects. Find out how you can qualify for acomplimentary unit through our ProfessionalPrograms.Sanofi-aventisBooth Number: 1301Sanofi-aventis U.S. is an affiliate of sanofiaventis,a leading global pharmaceuticalcompany, discovers, develops and distributestherapeutic solutions to improve thelives of everyone. Sanofi-aventis is listedin Paris (EURONEXT: SAN) and in NewYork (NYSE: SNY).For more information, visit www.sanofiaventis.usor www.sanofi-aventis.com.SunTech Medical, Inc.Booth Number: 1004For over 25 years SunTech Medical hasprovided clinical grade non-invasiveblood pressure (NIBP) products andtechnology. We offer solutions for ambulatoryblood pressure monitoring, cardiacstress test blood pressure monitoring,and now a general-use, expandable bloodpressure device with temperature andSpO2 upgrades. Our series of OEM bloodpressure modules are trusted by over 75other medical device companies as theirNIBP provider.Takeda PharmaceuticalsNorth America, Inc.Booth Number 1120Based in Deerfield, Ill., Takeda PharmaceuticalsNorth America, Inc. and TakedaGlobal Research & Development Center,Inc. currently market oral diabetes,insomnia, rheumatology and gastroenterologytreatments and seek to bringinnovative products to patients througha pipeline that includes compounds indevelopment for diabetes, cardiovasculardisease, oncology, gastroenterology,neurology and other conditions. To learnmore about Takeda, visit www.tpna.com.Tiba Medical, Inc.Booth Number: 1402Tiba Medical provides state-of-the-artAmbulatory Blood Pressure Monitoring(ABPM) systems to clinicians and researchers.Our Ambulo 2400 ABPM systemsare reliable, accurate and affordable.They include advanced features as built-inactigraphy and provide a complete solutionfor better diagnosis and managementof hypertensive patients. We also providepharmaceutical and biotech companiesand their clinical research organizationsand core lab partners with tools and servicesfor conducting thorough BP analysisfor efficacy and cardiac safety trials.Wiley-BlackwellBooth Number: 1011Wiley-Blackwell meets the informationneeds of family practitioners, internists,and cardiologists in a wide variety ofways. Visit booth #1011 for the latest issueof Journal of Clinical Hypertension and topurchase books at a discount. Wiley-Blackwell is the scientific, technical, medical,and scholarly publishing business ofJohn Wiley & Sons.190

2010 ASH Exhibitors continuedCVRx Inc.Contact:Phyllis Skoglund9201 West Broadway Avenue, Suite 650Minneapolis, MN 55445763-416-2845 direct or (763) 416-2840 mainPhone:Fax: 763-416-2841E-mail: pskogland@cvrx.comWebsite: www.cvrx.comBooth Number: 1305CVRx, Inc. has developed for the treatment of hyper Rheos®System for the treatment of hypertension and heart failure. Itis the first and only implantable device that provides baroreflexactivation therapy for these conditions. The Rheos System is aninvestigational device and is currently in clinical trials in theUnited States and Europe.Daiichi Sankyo, Inc.Contact: Ann Marie Bermudez2 Hilton CourtParsippany, NJ 07054Phone: 973-944-2827Fax: 973-944-2425E-mail: jstiehl@dsi.comWebsite: www.dsi.comBooth Number: 1000Daiichi Sankyo, Inc., is the U.S. subsidiary of Daiichi SankyoCo. Ltd., a global leader in pharmaceutical innovation since1899. The U.S. organization, including commercial operationsand global clinical development, is headquartered in NJ. Afocus of R& D is cardiovascular disease, hypertension, diabetesand acute coronary syndrome. www.dsi.comElsevierContact:1600 JFK Blvd.Suite 1800Philadelphia, PA 19103Phone: 215-239-3490Fax: 215-239-3494Website: www.elsevierhealth.comBooth Number: 1308ELSEVIER, proud publisher of the Journal of the AMERICANSOCIETY OF HYPERTENSION, is dedicated to being yourintegral partner in delivering exceptional healthcare. TrustELSEVIER to offer superior resources that expand yourknowledge, foster communication, build insights, enableindividual and collective advancement in the healthcare field.191

2010 ASH Exhibitors continuedForest Pharmaceuticals, Inc.Contact: 13600 Shoreline DriveSt. Louis, MO 63045Phone: 800-678-1605Fax: 314-493-7450E-mail: info@forestpharm.comWebsite: www.forestpharm.comBooth Number: 1307Forest Pharmaceuticals, Inc welcomes you to New York!We invite you to visit our exhibit where our professionalrepresentatives will welcome the opportunity to discuss andanswer any questions regarding our product Bystolic®(nebivolol) tablets. Please visit our website atwww.bystolic.com.HoMedics, Inc.Contact: Stacey Krusac3000 Pontiac TrailCommerce Township, MI 48390Phone: 248-863-3000Fax: 248-863-3103Email: stacey.krusac@homedics.comWebsite: www.homedics.comBooth Number: 1126Founded in 1987, HoMedics prides itself on over 20 years ofdevotion and dedication to consumer wellness. HoMedicsoffers an innovative line of home healthcare and diagnosticproducts, including state of the art blood pressure monitors,thermometers, and more to help people proactively managetheir health while improving their overall well being.INC ResearchContact: Kyle McIntosh4700 Falls of Neuse Road, Suite 400Raleigh, North Carolina 27609Phone: 919-876-9300Fax: 919-876-9360Email info @incresearch.comWebsite: www.incresearch.comBooth Number: 1406INC Research is a global contract research organization, witha Trusted Process® for conducting PhaseI-PhaseIV clinicaltrials that ensures customers experience trial excellence. Withoperations in 40 countries, our process helps to minimizerisk factors and leads to more informed and confident drugdevelopment decisions. Whether your project is a full-serviceinternational study or requires select regional services, INCresearch can meet your needs.192

2010 ASH Exhibitors continuedInternational Society on Hypertension in Blacks, Inc. (ISHIB)Contact: Terry E. Jackson157 Summit View DriveMcDonough, GA 30253Phone: 404.880.0343Fax: 404.880.0347E-mail terry-jackson@ishib.orgWebsite www.ishib.orgBooth Number: 1006Founded in 1986, ISHIB is an non-profit organization ofhealthcare professions and leaders in cardiovascular diseaseand related disorders. Our mission is to improve the healthand life expectancy of ethnic minorities and eliminate racialand ethnic health disparities in cardiovascular disease throughprofessional and public education, targeted clinical research,and facilitation of the delivery of higher quality cardiovascularhealth care. We host an annual conference, membership andother programs.Lippincott, Williams & WilkinsContact: Jeff Thompson (914) 400-9664Professional Sales Representative —New York CityAddress: 530 Walnut Street Suite 8WPhiladelphia, PA 19106 USAPhone: 916-425-1254Fax: 800-882-9237E-mail:jeff.thompson@wolterskluwer.comRepresenting Lippincott Williams and Wilkins,Thieme, McGraw-Hill, Springer, Humana, andBC DeckerWebsite: www.LWW.comBooth Number: 1211Lippincott, Williams & Wilkins offers specialized publicationsand software for physicians, nurses, students and specializedclinicians. Products include drug guides, medical journals,nursing journals, medical textbooks and medical PDAsoftware. LWW publishes the journal Hypertension, theJournal of the American Heart Association, and The Journal ofHypertension, the official journal of the International Society ofHypertension and the European Society of Hypertension.193

2010 ASH Exhibitors continuedMicrolife Medical Home Solutions, Inc.Contact: Kevin Priest2801 Youngfield St., Suite 241Golden, CO 80401Phone: 800-968-1378Fax: 303-274-2244E-mail: kevin.priest@mimhs.comWebsite www.MiMHS.comBooth Number: 1207Microlife Medical Home Solutions is continuing to empowerphysicians and their medical practices with patient-centeredprograms that improve the evaluation, diagnosis and treatmentof cardiovascular, pulmonary, and metabolic diseases. OurWatchBP monitors provide a unique combination of in-officeand out-of-office blood pressure measurements to advancehypertension diagnosis and treatment in accordance withpractice guidelines.National Kidney FoundationContact: Doreen Mallard30 East 33rd StreetNew York, NY 10016Phone: 212-889-2210Fax: 212-889-2310E-mail: info@kidney.orgWebsite: www.kidney.orgBooth Number: 1306How many of your patients with diabetes, hypertension andcardiovascular disease have undiagnosed chronic kidneydisease? One in nine US adults has CKD. Early detection ofCKD can help prevent progression to kidney failure. VisitBooth 1306 to learn how your patients and clinicians canbenefit from NKF’s educational tools, resources and screeningprograms.194

2010 ASH Exhibitors continuedNature Publishing GroupContact: Aimee Gladysiewicz—Marketing Manager75 Varick Street, 9th floorNew York, NY 10013Phone: 212-726-9200Fax: 212-696-9006Webstie www.nautre.comBooth Number: 1818Nature Publishing Group brings leading scientific and medicalresearch to your desktop. The NPG portfolio combines thecontinued excellence of Nature, its associated research, reviewjournals and over 45 leading academic and society journals inthe life, physical and clinical sciences. Visit Stand 1818 for freesample copies.NicOxContact:Tina MagillPrint address: (for print items only)Les Taissounières – 1681 Route des Dolines –Bat HB4B.P. 31306 906 Sophia Antipolis CedexFrancenicox@nicox.comTel: +33 (0)4 97 24 53 00 +33 (0)4 97 24 53 00Fax: +33 (0)4 97 24 53 99Correspondence address : (contact address)15 Independence Blvd, Suite 430Warren, NJ 07059Office: +1 908 991-3003Mobile: +1 732 773-7524Fax: +1 908 604-1076Email: magill@nicox.comWebsite: www.nicox.comBooth Number: 1005NicOx is a pharmaceutical company committed to developingnitric oxide–donating drugs that address importantunmet medical needs and targeting the therapeutic areasof inflammatory and cardiometabolic diseases. NicOx ismaximizing the value of its broad product portfolio throughin-house development of drug candidates and partnershipswith major pharmaceutical companies.195

2010 ASH Exhibitors continuedNovartis Pharmaceuticals CorporationContact: Becca BaileysOne Health PlazaEast Hanover, NJ 07936Phone: 862-778-1899Fax: 973-781-5488E-mail: rebecca.baileys@novartis.comWebsite: www.novartis.comBooth Number: 1100Novartis Pharmaceuticals is dedicated to discovering,developing, manufacturing and marketing prescription drugsthat help meet our customers’ medical needs and improve theirquality of life. Please visit the Novartis exhibit where our salesrepresentatives will be available to discuss our products.Omron HealthcareContact: Dan Aske1200 Lakeside DriveBannockburn, IL 60015Phone: 847-680-6200Fax: 847-680-6269Website: www.omronhealthcare.comBooth Number: 1008Omron Healthcare, Inc. is a leading manufacturer anddistributor of blood pressure monitors for home use. OmronHealthcare markets clinically proven products that provideaccurate health information to consumers and physicians andsupport positive lifestyle changes and health improvement.Philips RespironicsContact: Jackie TerranovaAddress: 1740 Golden Mile HighwayMonroeville, PA 15146Phone: 724-387-7708Fax: 724-387-7402E-mail: jackie.terranova@philips.comWebsite: www.respironics.comBooth Number: 1110Philips Respironics is passionate about improving the qualityof people’s lives with solutions designed around the needs ofour customers and their patients. The tradition of innovationcombined with our ability to anticipate market needs has madePhilips Respironics a global leader in the markets we serve.196

2010 ASH Exhibitors continuedRESPeRATE (InterCure Inc)Contact: Judy ChodirkerAddress: 589 8th Ave. 6th FloorNew York, NY 10018Phone: 1-800-509-2403Fax: 212-967-5060Email: hcp@resperate.comWebsite: www.resperate.com/mdBooth Number: 1012RESPeRATE® is the only non-drug therapy indicated for theadjunctive treatment of hypertension, available OTC. Clinicallyproven in 10 published studies, RESPeRATE enables patientsto reduce sympathetic activity, decrease peripheral resistanceand lower BP. Used for 15 minutes a day, several times a week,RESPeRATE demonstrates a significant all-day BP reductionwithout any side effects. Find out how you can qualify for acomplimentary unit through our Professional Programs.Sanofi-aventisAddress: 55 Corporate DriveBridgewater, New Jersey 08807Phone: 908-981-5000Website: www.sanofi-aventis.comBooth Number: 1301Sanofi-aventis U.S. is an affiliate of sanofi-aventis, a leadingglobal pharmaceutical company, discovers, develops anddistributes therapeutic solutions to improve the lives ofeveryone. Sanofi-aventis is listed in Paris (EURONEXT: SAN)and in New York (NYSE: SNY).For more information, visit www.sanofi-aventis.us orwww.sanofi-aventis.com.SunTech Medical, Inc.Contact: Karen DiOrio-Inside Sales504 Airport Blvd., Suite 117Morrisville, NC 27560Phone: 919-654-2300 or Toll Free: 1-800-421-8626Fax: 919-654-2301E-Mail sales @suntechmed.comWebsite: www.SunTechMed.comBooth Number: 1004For over 25 years SunTech Medical has provided clinicalgrade non-invasive blood pressure (NIBP) products andtechnology. We offer solutions for ambulatory blood pressuremonitoring, cardiac stress test blood pressure monitoring, andnow a general-use, expandable blood pressure device withtemperature and SpO2 upgrades. Our series of OEM bloodpressure modules are trusted by over 75 other medical devicecompanies as their NIBP provider.197

2010 ASH Exhibitors continuedTakeda Pharmaceuticals North America, Inc.Address: One Takeda ParkwayDeerfield, IL 60015Phone: 877-872-3700Website: www.tpna.comBooth Number: 1120Based in Deerfield, Ill., Takeda Pharmaceuticals NorthAmerica, Inc. and Takeda Global Research & DevelopmentCenter, Inc. currently market oral diabetes, insomnia,rheumatology and gastroenterology treatments and seekto bring innovative products to patients through a pipelinethat includes compounds in development for diabetes,cardiovascular disease, oncology, gastroenterology, neurologyand other conditions. To learn more about Takeda, visit www.tpna.com.Tiba Medical, Inc.Contact: Merat Bagha2701 NW Vaughn Street, Suite 470Portland, Oregon 97210 U.S.A.Phone: 1-503-222-1500US/Canada Toll Free Phone/Fax: 1-800-985-TIBA (8422)E-Mail: info@tibamedical.comWebsite: www.tibamedical.comBooth Number: 1402Tiba Medical provides state-of-the-art Ambulatory BloodPressure Monitoring (ABPM) systems to clinicians andresearchers. Our Ambulo 2400 ABPM systems are reliable,accurate and affordable. They include advanced features asbuilt-in actigraphy and provide a complete solution for betterdiagnosis and management of hypertensive patients. We alsoprovide pharmaceutical and biotech companies and theirclinical research organizations and core lab partners with toolsand services for conducting thorough BP analysis for efficacyand cardiac safety trials.Wiley-BlackwellContact: Amanda Banner350 Main StreetMalden, MA 02148Phone: 781-388-8250Website: www.wiley.com/go/cardiologyBooth Number: 1011Wiley-Blackwell meets the information needs of familypractitioners, internists, and cardiologists in a wide variety ofways. Visit booth #1011 for the latest issue of Journal of ClinicalHypertension and to purchase books at a discount. Wiley-Blackwell is the scientific, technical, medical, and scholarlypublishing business of John Wiley & Sons.198

Author IndexAAbaunza, Ricardo, 122Abdala, Antonio D., 158Abraham, Saji, 158Abram, Sara, 139Acelajado, Maria Czarina, 60Achouba, Assya, 118Acquafresca, Manlio, 121Adamopoulos, D., 87Adams, Robert J., 122Adgey, Jennifer, 119Adiyiah, Jeffery, 134Adler, Gail, 57, 161Agatston, Arthur, 121Aggiusti, Carlo, 84, 119, 140Aiba, Naomi, 88Akinboboye, Ola, 120Aksut, Baran, 142Alegría, Eduardo, 137Ali, Quaisar, 159Alonso, Ana, 109Alonso, Ignacio, 129, 131, 143Alonso, Pablo López, 148Altieri, Chiara, 133Alviar, Carlos, 110Alviar, Carlos L., 60, 88AlZoby, Muneer, 113Amdur, Richard, 84, 142Anastasiou-Nana, Maria, 118, 122Andersen, Ulrik B., 60Andrade, Helena M., 155Andrews, L. A., 111Andrikou, E., 147Andrikou, I., 147Angelici, Laura, 139Angelini, Luca, 137Angell, Sonia Y., 58, 161Anunciato, Iara F., 121, 129Aonuma, Takanori, 139Apostolakou, Filia, 147Appel, Lawrence J., 87, 161Arango, Juan Luis, 106Aranda, Pedro, 136Araujo, Salustiano Pereira, 134Araújo, Salustiano Pereira, 134Arellano-Mendoza, Monica, 155Arellano, Said, 146Armando, Ines, 76, 135Armstrong, Scott, 156Aronne, Louis J., 94Arsena, Rosalia, 146Arvaniti, Chrysa, 118, 122Asche, Stephen E., 131Asferg, Camilla, 60Asico, Laureano, 135Asico, Laureano D., 76Aslam, Farhan, 149Astor, Brad C., 54, 161Athanasiadis, Ioannis, 149Aurigemma, Gerard P., 125Axon, R. Neal, 149, 150Ayala, Diana E., 78, 105, 124, 129,130, 131, 132, 143Azevedo, Elsa, 154Aziz, Emad F., 110BBabayan, Zaruhi V., 132Babazadeh, Simon, 105Bachman, David L., 122Baek, InYoung, 119Bagmanova, Nazilya, 138Bahl, Vinay, 158Bailey, Kent R., 94, 148Bakris, G., 94Bakris, George, 142, 145Bakris, George L., 70, 79, 89, 93, 94,95, 161Bakris, G. L., 145, 146Balbarini, Alberto, 148Balek, Mark, 120Balkestein, Elisabeth J., 135Baltatzi, Maria, 137, 150, 154Banegas, Jose Ramón, 149Bangalore, Sripal, 54, 112, 160, 161Baou, Katerina, 82Barbato, Antonio, 76, 133Baroni, Marcos A., 116, 126, 135Barrettova, Lenka, 156Bartels, Valerie, 147Barzilay, Joshua, 67, 161Baschiera, Fabio, 106, 115Basile, Jan, 105Basile, Jan N., 62, 80, 161Basu, Sanjib, 125Batson, Bryan, 139Bautista, Rocio, 146Bayorh, Mohamed A., 134Belardinelli, Luiz, 109Belchior, Helena, 140Bellet, Marc, 110Belletti, Daniel A., 83Bell, Lashonda, 132Bellido, Claudio A., 74, 146, 161Belo, Adriana, 136Belojevic, Goran, 155Ben-Dov, Iddo Z., 60Bendersky, Mario, 116, 126, 135Benjo, Alexandre, 110Benjo, Alexandre M., 60, 88Bennett, Edward S., 132Ben-Shlush, Lior, 140Berenson, Gerald S., 125Berlowitz, Dan R., 101, 161Berra, Elena, 139Bertacchini, Fabio, 119Bertoquini, Susana, 87Bertorello, Alejandro M., 86Beschi, Fabio, 119Bestermann, Bill, 83Bijarnia, Mahendra, 106Birkenhäger, Willem H., 145Biskupiak, Joe, 113Bisognano, John, 95, 145Bisognano, John D., 69, 84, 97, 161Blacher, Jacques, 153Black, H., 106, 110, 114Black, Henry, 107Black, Henry R., 56, 70, 79, 92, 94,106, 159, 161Blaha, Michael, 148Blaha, Michael Blaha, 121Bleske, Barry E., 77Bloch, Michael J., 62, 161Bloom, Frederick J., 77Bluemke, David A., 119199

Author IndexBlumenfeld-Katzir, Tamar, 115Blumenthal, Roger, 121, 148Blumenthal, Roger S., 77, 161Boan, Andrea D., 122Boaz, Mona, 118Boddi, Maria, 121Boerrigter, Guido, 86, 94Bolla, Manlio, 147Bonacho, Eva Calvo, 149Bonartseva, Garina A., 107Bonartsev, Anton P., 107Bordicchia, Marica, 76, 116, 133, 154Bostrom, Susan, 116Botha, Jaco, 105, 115Boutouyrie, Pierre, 118Bracho, Mayela J., 152Braun-Dullaeus, Rüdiger C., 107Braunwald, Eugene, 70, 161Braver, Jose D., 146Bravi, Elena, 130Brede, Yvonne, 107Breton, Cristian F., 143Bridges, William, 122Brook, Robert D., 68, 161Brown, Angela L., 62, 161Brown, Michael, 147Brown, Michael D., 133Brumback, Lyndia, 119Brunel, Patrick, 115Brunson, Domonique, 134Brunson, Greg, 152Budoff, Matthew, 148Bullock, Gwen, 132Burnett, John C., 94, 148, 162Burnett, Jr., John C., 86, 97Burnier, Michel, 107Burns, Trudy L., 153Bursztyn, Michael, 60Butler, Robert, 128CCabrerizo, L., 137Caceres, Anthony, 126Cain, Van, 125Calara, Federico B., 151Calhoun, David A., 60, 62, 155, 162Callejas, Pedro A., 131Calmon, Gustavo E., 152Calvo, Carlos, 111, 112, 113Calvo, Gaila, 78, 88, 111, 112, 113,126Calvo-Gomez, Carlos, 116, 133Calvo-González, Gaila, 116Campbell, Patrick T., 130Campo, Alfredo del, 139Cañas, Juan, 108Cannom, David S., 69, 162Cannon, Ann, 126Cannone, Valentina, 94Cantarin, Maria P. Martinez, 153Cao, C., 144, 145, 146Cao, Charlie, 142Cardoso, Filomena, 140Carletti, María Inés, 151, 152Carlson, Linda E., 144Carnelutti, Alessia, 146Carrizo, Lidia, 151, 152Carrothers, Timothy J., 108Cassis, Lisa A., 59, 162Castanheira, Liliana, 144Castellani, Sergio Franco, 121Castelo-Branco, Miguel, 144Castiñeira, Maria C., 131Castro, Pedro, 154Cataliotti, Alessandro, 94, 148Catena, Cristiana, 146Cavalli, Ricardo, 94Cawley, Jacquelyn B., 126Cernes, Relu, 87Cha, Eunme, 151Chanda, Craft, 122Chang, Alexander R., 148Chang, Hyuk-Jae, 121Chang, Kyoung-sig, 108Chaparro, Miguel ÁngelSánchez, 149Chatterjee, Arka, 139Chayan, Luisa, 129, 131, 143Chen, Aihua, 98, 162Chen, Wei, 125, 159Chen, Yiu-Fai, 142, 156Chen, Yu-Hong, 117Cheruvu, Madhavi, 156Chhatwal, Jiwanjot K., 138Chinali, Marcello, 125Chintala, Raghu, 130Choi, Dong Hoon, 144Choi, Dong-Hyun, 108Choi, Sang-il, 121Chow, Vincent H., 152Chrysant, Steven G., 108, 109, 111,138Chua, Nanette, 113Chun, Eun-Ju, 121Chung, Joong-Wha, 108Churilla, James R., 149Cilvetti, Angel, 136Clavell, Emilio S., 152Cobelo, Carmen, 136Coca, Antonio, 78, 88, 111, 112, 113Cockcroft, John R., 89, 105, 119, 162Coffman, Thomas M., 59, 162Cohn, Jan N., 73Cohn, Jay, 150Cohn, Jay N., 137, 162Coleman, Corey, 156Colhoun, Helen, 95Colussi, GianLuca, 120, 146Conway, Barbara, 121Cordero, Diego J., 158Corry, Dalila, 76Costello-Boerrigter, Lisa C., 94Coulson, James, 119Coulson, James M., 105Crespo, Juan J., 130, 132Crikelair, N. A., 109Crikelair, Nora, 109Crikelair, Nora A., 155Cunha, Danny Alves, 134Cushman, W., 110, 128Cushman, William C., 54, 67, 95,162Calvo, Carlos, 78, 88, 126Carretero, Oscar A., 57, 86Cassi, Antonino, 130200

Author IndexCastellano, Maurizio, 119Cataliotti, Alessandro, 86Catena, Cristiana, 120Cavallotti, Pietro, 130Cerasola, Giovanni, 133, 146Chen, Horng H., 86Chugh, Atul R., 54, 139, 162Cloutier, Lyne, 130Coelho, Eduardo B., 121Cooper, Richard, 148Corradi, Luca, 78, 109Cortez-Dias, Nuno, 136Cottone, Santina, 146Crippa, Giuseppe, 130Cruz, Mariana A., 116, 126, 135Cutler, Jeffrey A., 67, 95, 162Cziraky, Mark, 111DD’Abate, Fabrizio, 121Dahlöf, Björn, 159Dalmar, Ahmed, 126Daniels, Stephen, 155d’Anzeo, Marco, 76, 116, 133Daroca, Ana, 151, 152Dattani, Dan, 108Dawn, Buddhadeb, 139Day, Wesley W., 94Dede, Jennifer, 152Deedwania, Prakash, 95Defeo, Holly, 159de la Fuente, Salvador Ruiz, 148de Lis, Jesus Perez, 130Dellamora, Alfredo, 116, 126, 135Deloach, Stephanie, 153Denekamp, Lynn, 143Denina, Ruslana Valentunivna, 133DeRosa, MariaLeonarda, 143Dessì-Fulgheri, Paolo, 76, 133Dessì-Fulgheri, Paolo Lorenzo, 132,137, 154Davidson, Michael H., 101, 162Davis, Barry R., 67, 162Davis, Harry, 132Destro, Maurizio, 78, 109Devarapally, Santhosh, 60, 88, 112Derosa, Giuseppe, 78, 109, 136Diaz-Benito, Jose, 136Diaz, Keith M., 133, 147DiBona, Gerald, 162DiBona, Gerald F., 86, 90Dijian, J., 78Dijian, Jacques, 124Dingemanse, Jasper, 110Dion, Zappe H., 116Divisón, Juan Antonio, 139Dima, Ioanna, 82Dimitriadis, K., 86, 120Djordjevic, Dragan D. D. J., 129Dolan, Larry, 155Doleh, Tarick, 128Dominguez, Manuel, 132Dominiczak, Anna F., 59, 82, 162Dong, Fang, 143Donnini, Debora, 146Dorsch, Michael P., 77Doumas, Michael, 120, 142Doumas, Michalis, 121, 150Doumas, Mihail, 149Dominguez, Manuel, 131DuBard, Annette, 116Dubovsky, Steven L., 102Duarte, Mariano, 146Dulmen, Manfred van, 144Duprez, D., 110, 128, 158Duprez, Daniel A., 119, 137Duquesroix, B., 78Durazo-Arvizu, Ramon, 148EEatman, Danita, 134Ebling, William, 115Efthymiou, Elias, 137Egan, Brent M., 58, 96, 149, 150, 162Eguchi, Kazuo, 84, 109, 124, 129Ehrmann, David A., 87, 90, 163Eiroa, Peregrina, 131Eisner, Gilbert M., 151Eliseyeva, Marietta, 153Elkayam, Amitay, 138Elliott, William J., 125, 163Elmore, Julius B., 139Elliott, William J., 62, 70, 77Enciso, Jorge Silva, 112Entcheva, Miglena, 150Epstein, Murray, 66, 77, 163Erickson, Steven R., 77Ernst, Michael, 163Ernst, Michael E., 84Ertel, Adam, 153Escalante, Bruno, 155Escano, Crisanto, 76Escano, Crisanto S., 135Espeland, Mark, 67, 163Esper, Ricardo J., 158Espinosa, Emma, 132Eto, Masahiko, 139Eugen-Olsen, Jesper, 148Evans, Gregory W., 95FFabio, Alessandro Di, 120, 146Fabregate, Martin, 109, 135, 156Fabregate, Rosa, 109, 135, 156Fagard, Robert, 145Fagard, Robert H., 142Falkner, Bonita, 153Fang, Christy, 111Fan, Pang-Yen, 125Fares, Maria Luisa, 130Faria, Joao, 87Farms, Phyllis, 60, 82Farms, Phyllis K., 156Faselis, Charles, 84, 120, 121, 142,149, 150Feairheller, Deborah L., 133, 147Fedecostante, Massimiliano, 132Fedorowski, Artur, 82Feig, Daniel I., 91, 163Feig, Peter, 110, 163Feig, Peter U., 102Felder, Robin A., 151Ferdinand, K., 158Ferdinand, Keith C., 58, 66, 111,159, 163Fergus, Icilma V., 132Fernández, Angelica, 156201

Author IndexFernandez-Garcia, Jose Carlos, 136Fernandez, Jose R., 78, 105, 124, 129,131, 143Fernández-Labandera, Carlos, 149Fernandez, Sandra, 149Fernandez, Victor, 108, 109, 110,111, 113Ferrari, Ilaria, 136Ferrario, Carlos M., 83, 163Ferrario, Carlos M., 65, 68, 100Ferreira-Filho, SebastiaoRodrigues, 120Ferreira-Filho, SebastiãoRodrigues, 134Ferrioli, Eduardo, 129Ferriolli, Eduardo, 121Filatova, Elena A., 107Filho, Sebastiao RodriguesFerreira, 134Finkelstein, Joseph, 151Fink, Gregory D., 57, 76, 156, 157,163Fisher, Edward A., 71, 163Fisher, Naomi D., 146, 154Fisher, Naomi D. L., 148Fitzig, Lorenzo, 158Fiuza, Manuela, 136Flack, John M., 60, 69, 96, 163Fleites, Aldo Martinez, 121Fleming, Rosanna, 124Fletcher, Ross, 121, 150Fletcher, Ross D., 84, 142Florea, Natalia, 137Fogari, Roberto, 78, 109, 136Fontao, Maria J., 78, 129, 131, 143Foody, JoAnne, 149Ford, Earl S., 149Forker, Alan, 158Forman, John P., 148, 154Fortina, Paolo, 153Fortunati, Marco, 137Foster, Clyde, 152Francis, Charles K., 54, 163Franco, Martha, 146Franklin, Stanley S., 152Frayssinet, H., 78Freitas, Declan de, 157Freitas, Joao P., 138, 154Fresco, David M., 144Friedman, Jeffrey M., 92Frusca, Tiziana, 140Frutos, Miguel Angel, 136Fuat, Ahmet, 121Fujisawa, Tomomi, 135Fulesdi, Bela, 83Fulgheri, Paolo Dessì, 116Fung, Maple M., 83Fujita, Toshiro, 66, 163GGaldamez, Ana Maria, 107Galeazzi, Sara, 116Gale, Nichola, 119Gamez-Mendez, Ana, 155Gando, Yuko, 116Gao, Guichan, 148Garber, Jeffrey R., 56, 163Garcia, César Bertoldo, 134García, Javier Román, 149Garcia-Puig, Juan, 112Garrido, Patricio, 139Gasparinatos, Gerasimos, 118Gathercole, Susan E., 121Gatti, Giorgia, 140Gaurav, Kumar, 156, 157Gavish, Benjamin, 60, 126Gavish, Leah, 126Gbarayor, Confidence, 152Gelpi, Guido, 147Gemmel, David, 113Gensini, Gian Franco, 121Gerber, Linda M., 151, 152Gerlach, Raquel, 94Germino, F. Wilford, 62, 163Ghuman, Nimrta, 130Gialernios, T., 118, 142Giammarresi, Gaia, 133Gilderman, Larry, 106Giles, T., 77, 112, 113, 150Giles, Thomas, 128Giménez, Francisco J., 148Giovas, Periklis, 132Girish, M. P., 158Gavras, Haralambos, 163Giles, Thomas D., 69, 81, 164Glazer, Robert, 155Glik, Zehava, 131Godoy, Enrique, 139Gomara, Sonia M., 131Gomes, Manuel João, 149Gomes, Marcos Alvinair, 120Gomez-Sanchez, Celso E., 100, 164Gomez, Vicente, 156Goncalves, Francisco Rocha, 154Gonen, Ohel, 153Gonen, Ron, 153Gong, Kaizheng, 142Gonzalez, Alicex C., 152Gonzalez, Santos Julian, 107Gonzalez-Segura, Diego, 137Goodin, Thomas, 159Gopalakrishnan, Kathirvel, 60, 82,156Gorelick, Philip B., 70, 164Goto, Aya, 151Gradman, Alan H., 60, 69, 81, 164Graff, A., 159Graham, Garth, 148Graham, Jove, 77Grandits, Gregory, 137Grantham, Cassandra C., 126Greenland, Philip, 119Green, Michelle, 108Grim, Carlene M., 126, 129, 131,138, 143Grim, Clarence E., 126, 129, 131,138, 143, 150Grimm, Richard H., 68, 95, 96, 164Grodzicki, Tomasz, 145Grossman, Ehud, 78, 88, 138, 147,164Guerra, Federico, 132, 137, 154Guerri, Asuncion, 109, 135, 156Guevara, Gabriela, 151, 152Gulati, Martha, 54, 90, 101, 164202

Author IndexGuarneri, Marco, 146Guo, Yuan, 98, 164Gupta, Alok K., 87Gutiérrez, Juan Carlos Sainz, 149Gutierrez, Kati, 143Guttmann, C., 122HHaesler, E., 119Hage, Fadi, 142Hage, Fadi G., 156Halbert, James, 132Hamsten, Anders, 86Handler, Joel, 33, 92, 164Haque, Tahir, 111, 157Haralambos Gavras, 57Häring, Dieter A., 107Harshfield, Gregory, 132Hasegawa, Eri, 112, 139Hasselstrøm, Jan, 151Ha, Sung-Il, 108Hatzitolios, Apostolos, 150, 154Hatzitolios, Apostolos I., 137Haugaard, Steen, 148Hausberg, Martin, 147Hayoz, Daniel, 119Heagerty, Anthony M., 157He, Ben, 133Hegde, Laxminarayan G., 156Heistad, Donald, 31Heistad, Donald D., 92, 164Hennessy, Sean, 77Hermida, Alvaro, 78, 88, 111, 112,113, 126Hermida-Ameijeiras, Alvaro, 116,133Hermida, Ramon C., 78, 105, 124,129, 130, 131, 132, 143Hernandez, Domingo, 136Herzog, Eyal, 110Heshmat, Ramin, 152, 155Heublein, Denise M., 94Heyrman, Reinilde, 108, 109, 110,111, 113Higuchi, Mitsuru, 116Hilkert, R., 77, 106, 107, 110, 112,113, 114, 128, 150Hillebrand, Uta, 147Hill, Jeffrey C., 125Hirai, Yuji, 117Hochman, Judith, 88, 102, 164Hoke, Lynn, 137Holick, Michael F., 100Hollenberg, Norman K., 92, 146, 164Holzhauer, Bjoern, 94Homami, Mohsen Rezai, 152, 155Hong, Bum Ki, 144Hong, Soon-Pyo, 108Hong, Yongqiang, 98Hoppe, Uta, 108Hoshide, Satoshi, 84, 109, 124, 129Howard, DeLeonardo, 152Hristoskova, Sashka, 107Hseuh, W., 159Hsueh, Willa A., 82, 100Hughes, Joel W., 144Hull, Pamela, 125Hu, Lufei, 109Husaini, Baqar, 125Hussain, Tahir, 159Hua, Tsushung, 94Hygia Project Investigators, 130,131, 132IIannaccone, Andrea, 139Iaria, Pierre, 153Iavicoli, Oscar R., 146Iglesias, Francisco J., 130Ingaramo, Roberto A., 74, 151, 152,164Ioakeimidis, Nikolaos, 82Ishikawa, Joji, 84, 129Israel, M., 106, 107, 110, 114Iwasaki, Jun, 117, 121Izzo, J., 106, 107, 114Izzo, J. L., 109, 110, 128Izzo, Joseph L., 164Izzo, Jr., J. L., 128Izzo, Jr., Joseph L., 58, 109, 110JJacobs, Jr., David, 119Jadhav, Uday, 158Jakovljevic, Branko, 155Jakovljevic, Branko B. J., 129Jamerson, Kenneth A., 159Jansen, Susan, 147Jardim, Paulo César B. V., 124Jardim, Thiago S. V., 124Jatte, Fernanda G., 129Javed, Fahad, 60, 88, 110Jennings, Phillip, 143Jeon, Dong Woon, 144Jeppesen, Jørgen, 60, 148Jiang, Lisheng, 133Jin, Yu, 117Jironda, Cristina, 136Joe, Bina, 32, 60, 82, 92, 156, 164Johnson, W., 144Johnson, Wallace, 136, 152Johnson, William D., 87Joly, M. P., 119Jones-Burton, Charlotte, 110Jones, C., 159Jones, John E., 76Jones, Ronald Jones, 84Jose, Pedro A., 76, 135, 151Josephson, Richard, 144Joshi, Nomita, 122Joyner, JaNae, 83Jr, 162Jr., 95, 164, 168Juhasz, Maria, 83Julius, Stevo, 94Juncos, Luis, 74, 164KKabutoya, Tomoyuki, 109Kagelidis, Giannis, 137Kahan, Thomas, 151Kahler, Kristijan, 111Kajii, Eiji, 139Kalinoski, Andrea, 60Kallikazaros, I., 120Kamat, Siddhesh, 111Kamide, Kei, 86Kamran, Haroon, 116, 117, 120203

Author IndexKandra, Albert, 119Kang, Hyuensok, 60, 88Kantola, Ilkka M., 136Kaplan, Norman M., 125, 164Kaplan, R., 122Kapuku, Gaston K., 132Karimova, Barno, 153Kario, Kazuomi, 84, 109, 124, 129Karlafti, Eleni, 150Karlafti, Evangelia, 137Karpanou, E., 87, 118, 142Karumanchi, S. Ananth, 92, 164Kasiakogias, A., 147Katayama, Yusuke, 117Katona, Eva M., 83Katsiki, Niki, 150, 154Kattamis, Antonios, 147Kawakami, Ryoko, 116Kawamoto, Kenji, 117Kawano, Hiroshi, 116Kawano, Yuhei, 86Kawata, Reiji, 117Kawecka-Jaszcz, Kalina, 145Keefe, Deborah L., 115Keefe, Deborah, 111Kerby, Tessa J., 131Kereiakes, Dean, 111Kereiakes, Dean J., 144Kershaw, Glenn, 125Kevorkov, Amayak, 111Khalid, M. Rizwan, 132Khalid, Muhammad Raza, 132Khan, Bobby V., 111, 157Khandelwal, Priyank, 117Khan, Shahzeb, 110Khashayar, Patricia, 152, 155Khoo, Chee Wah, 117, 146Khoury, Philip, 155Kifnidis, Konstantinos, 149Kihara, Yasuki, 154Kimball, Thomas, 155Kim, Cheol-Ho, 150Kim, Eun Ju, 160Kim, Jin Won, 160Kim, Sungeun, 160Kisaka, Tomohiko, 154Kjeldsen, Sverre, 94Kjeldsen, Sverre E., 79, 165Kleinpeter, Myra, 63, 165Kliche, Katrin, 147Kobalava, Zhanna, 138, 148Kobori, Hiroyuki, 133Kobzev, Ruslan, 148Koenig, Wolfgang, 112Koh, Young-Youp, 108Kokkinos, P., 84Kokkinos, Peter, 120, 121, 142, 149,150Kokubo, Yoshihiro, 86Koliakos, George, 154Kollias, Anastasios, 131, 132Komonyi, Eva, 83Kontsas, Konstantinos, 118, 122Koren-Morag, Nira, 88Kostanyan, Sofya, 120Kostis, John B., 68, 70, 165Kotovskaya, Yulia, 138, 148Kounanis, Andreas, 150Kouraklis-Symeonidis,Alexandra, 147Kowey, Peter R., 88, 90, 165Komori, Takahiro, 84, 129Kountz, David S., 96, 165Krakoff, Lawrence R., 124, 165Kramer, Holly, 148Kribben, Andreas, 106Krishnamoorthy, Suresh, 117, 146Kronmal, Richard, 119Kumada, Maki, 139Kumarasamy, Sivarajan, 60, 82, 156Kumar, Parag, 116, 117Kumar, Rahul, 153Kumar, Soumitra, 158Kumar, Sunil, 160Kupfer, S., 144, 145, 146Kupfer, Stuart, 142Kurbanova, Dilorom, 153Kuritzky, Louis, 62, 63, 165Kurtz, Theodore W., 82, 135, 165Kuznetsova, Tatiana, 135, 145Kuznetsov, Sofya, 139Kyritsi, Fiorina, 121, 150Kyvelou, Stella-Maria, 87, 118, 142LLackland, Daniel T., 60, 65, 122, 165Lacourciere, Yves, 155Lacy, Peter S., 115Ladis, Vassilios, 147Laflamme, Annik K., 105, 106Lahr, Brian, 94Landa, Rafael Gil, 107, 108Langer, Robert D., 77Lapeira, Margarita, 136Lara, Pedro Aranda, 139Larijani, Bagher, 152, 155Laurent, Stéphane, 118Lawrence, Kayode, 134Lawrence, William, 116Lazar, Jason, 120Leblanc, Marie-Ève, 130Lee, Hae-Young, 129, 144, 150Lee, J., 106, 107, 110, 114Lee, James, 108, 109, 110, 111, 113Lee, Jong Y., 156Leeuw, Peter W. de, 145Lemes, Helton Pereira, 134Lengyel, Szabolcs, 83Lerman, Lilach O., 54, 165Lesogor, Anastasia, 108Levine, Robert, 125Levy, Andy P., 153Levy, Drew, 111Lewin, Andrew J., 159Ley, Ludwin, 159Liao, Weichi, 107Lieber, Ari, 153Lillestol, Michael, 105Lima, Nereida K. C., 121, 129Lim, Hoong Sern, 117, 146Li, Peng, 142Lip, Gregory Y. H., 117, 146Li, S., 116Lakatta, Edward G., 62, 71, 165Lazar, Jason, 116, 117204

Author IndexLekakis, John, 118, 122Leone, Aurelio, 148Lerman, Jorge, 146Levy, Daniel, 83, 98, 124, 165Littlejohn III, Thomas W., 130, 145Littlejohn, T., 159Littlejohn, Thomas, 111Littlewood, Elizabeth, 121Liu, Lijun, 60Liu, Tianhu, 98, 165Liu, Yan-Ping, 117Li, Yan, 117Lijnen, Paul J., 142Lima, Leandra G., 129Ljungman, Charlotta, 151Lobo, Romulo R., 121Lohmeier, Thomas, 165Lohmeier, Thomas E., 69Longlade, Pascal, 124Lopez, Jose Enrique, 112Lopez, José Enrique, 78, 88, 126López, José Enrique, 113López-Paz, Jose E., 116, 133Lopez-Paz, José Enrique, 112López-Paz, José Enrique, 111Loughran, John H., 139Lovic, Branko B. L., 129Lovic, Dragan, 155Lovic, Dragan D. L., 129Lovic, Milan M. L., 129Lowy, Adam, 107Lucas, Caridad Turpin, 108Lucas, Jason, 142Luke, Amy, 148Lukic, Tanya, 159Luo, Jianfang, 98, 165Lutsey, Pamela L., 119Lucas, Caridad Turpin, 107Lyn, Deborah, 134Lyngbæk, Stig, 148MMacedo, Mario E., 138Machado, Rogelio, 158Macheret, Fima, 148Maciel, Maria Julia, 154Maciosek, Michael V., 131MacManus, C., 84Magkou, Dimitria, 137Mahata, Manjula, 83Mahata, Suskil K., 83Mahina, Tatiana K., 107Mai, Yabing, 110Makani, Harikrishna J., 112Malatino, Lorenzo S., 148Malyar, Viola, 147Mancia, Giuseppe, 79, 159Mancinelli, Lucia, 137, 154Manhem, Karin, 151Mann, Samuel J., 63, 152, 165Manoharan, Ganesh, 119Manolis, Athanasios, 121, 149, 150Marai, Ibrahim, 147Margolis, Karen L., 68, 101, 131, 165Marín, Elena, 156Mark, Allyn L., 54, 82, 165Marshall, Micheal, 138Martin, Aaron, 130Martinez-Castelao, Alberto, 137Martins, Suzana R., 136Marzano, Luigi, 120Maslanik, Tom, 109Mason, Terry, 58Massie, Barry M., 84, 166Matas, Zipora, 118Matsumoto, Sachiko, 86Mazaraki, A., 86, 147Mazzolai, L., 119McClelland, Marilyn K., 134McCoy, Connie, 155McCrory, Mark, 156McDonnell, Barry J., 119McEniery, Carmel M., 89, 119, 166McGlone, Meghan, 87McInnes, Gordon, 94McKie, Paul M., 86, 148McLaughlin, Jim, 119McManus, Christopher, 84Melander, Olle, 82, 86Melino, Michael, 108, 109, 110, 111,113Mellen, Philip B., 139MELODY Study GroupInvestigators, 137Menchi, Ilario, 121Mendioza, Ricardo, 146Merchant, Nadya, 111, 157Merlo, Pablo M., 158Merritt, Marcellus, 120Messerli, Franz H., 110, 112, 160,166Messineo, Frank C., 132, 158Meybodi, Hamid Reza Aghaei, 152,155Meyer, Peter M., 125Meyers, Peter J., 131Miglietta, Daniela, 147Mikheyev, Vyacheslav, 120Milan, Alberto, 139Milazzo, Valeria, 139Miliou, A., 86Miller, James J., 139Miller, Jerry, 83Miller-Lotan, Rachel, 153Miralles, J. M., 137Miyachi, Motohiko, 88, 116Miyaji, Tsuyoshi, 117Miyata, Toshiyuki, 86Mohmand, Asad K., 156, 157Mojon, Artemio, 78, 105, 124, 129,130, 131, 132, 143Molnar, Csilla, 83Moore, Helen, 108Moore, Michael, 83, 166Moore, Michael A., 65Morgado, Manuel, 144Morgan, Eric, 60Moriguti, Julio C., 129Morillas, Carlos, 137Morita, Akemi, 88Morrison, Kathy, 119Moscufo, N., 122Motro, Michael, 88Mousa, Tarek M., 76, 120Moya, Ana, 132205

Author IndexMakris, T., 147Mann, Samuel J., 62, 91, 151Marcucci, Pierfrancesco, 116Marinho-da-Silva, Antonio J., 155Mason, R. Preston, 81Materson, Barry J., 92, 166Matsui, Yoshio, 124Messerli, Franz, 60, 78, 88Mitchell, Gary F., 89, 166Monteduro, Cristina, 84, 119Moriguti, Julio C., 121Moser, Marvin, 62, 166Moya, Ana, 131Muiesan, Maria Lorenza, 140Mugellini, Amedeo, 78, 109, 136Muiesan, Maria Lorenza, 84, 119Mulè, Giuseppe, 146Müller, Dominik N., 59Munk, Veronica C., 107Munnery, Ian, 119Munnery, Margaret, 119Muñoz-Garde, Luisa, 136Murakami, Haruka, 116Murphy, Jeremy J., 121Murphy, John C., 119Murray, Alexander, 108, 112Myerscough, Rodney, 144Myshkina, Vera L., 107NNadim, Mitra, 95, 145Nadkarni, Girish N., 60, 88Najarian, Thomas, 94Nakamura, Yoshikazu, 139Namana, Vinod, 117, 120Narayanan, Arumugam, 125Narayan, Puneet, 150Narkiewicz, Krzysztof, 79, 166Nascimento, Daniella Diniz, 134Nasir, Khurram, 121, 148Natac, Iulian, 95Nawrot, Tim, 135Nelimarkka, Lassi, 136Nesbitt, S., 159Nesbitt, Shawna D., 54, 166Neutel, J., 159Neutel, Joel M., 130, 138, 144, 145,159Newton-Cech, Christopher, 82Neyko, Yevgen M., 115Nijhawan, Vinay, 134Nitzan, Meir, 131Nixon, Jeremy S., 156Nakhoul, Farid, 153Navar, L. Gabriel, 86, 97, 166Nobre, Fernando, 121Nora, Crikelair A., 116Norman, Nicole, 152Nozell, Susan E., 142Nyby, Michael D., 76Nylen, Eric, 121, 150OO’Brien, Eoin, 145Ocello, Alessandra, 146O’Connor, Daniel T., 83O’Connor, Patrick J., 131Ofili, E., 77, 112, 113, 128, 150Ohmori, Yumi, 88, 116Okamura, Tomonori, 86Okayama, Masanobu, 139Olsen, Michael Hecht, 148Olson, Timothy M., 94Olsufka, Rachael, 156Onuigbo, Macaulay A., 134, 152Onuigbo, Nnonyelum T., 134, 152Oparil, S., 77, 113, 115, 128, 150Oparil, Suzanne, 60, 79, 80, 94, 109,112, 113, 125, 142, 156, 166Ortiz, Eduardo, 166Orynchak, Mariya A., 135, 137Orynchak, Mariya Andriivna, 135Otero, Alfonso, 130, 131Ogedegbe, Gbenga, 58, 166Ohta, Yuko, 112, 139Otero, Alfonso, 132Ozono, Ryoji, 154PPablo, Pedro, 137Padovan, Paulo R., 129Padron, Julio, 147Paini, Anna, 84, 119, 140Palacios, Fernando Aguirre, 106Palatini, Paolo, 94Palei, Ana, 94Pall, Denes, 83Papademetriou, V., 84Papademetriou, Vasilios, 72, 84, 120,121, 142, 149, 150, 166Papagiannis, John, 132Papassotiriou, Ioannis, 147Papastergiou, Natalia, 137Papst, Cheraz Cherif, 158Paragano, Antonio J., 158Paragh, Gyorgy, 83Paran, Esther, 140Park, Chang-Kyu, 144Park, Jung-Bae, 129Park, Timothy, 156Parthasarathy, Sampath, 157Passi, Neha, 157Patel, Maninee, 137, 144Patel, S., 115Patel, Samir, 108, 112Paunovic, Katarina, 155Pavenstädt, Hermann, 147Pearlson, G., 122Pêgo, Guilherme M., 155Peixoto, Aldo J., 54, 167Peleg, Edna, 138, 147Pena, Marta, 78, 88, 111, 112, 126Pereira, Cristiane N., 156Perez, A., 144, 145, 146Perez, Alfonso, 142Perfumo, Federico, 140Periard, D., 119Periera, Cristiane N., 157Peroz, Julie, 153Petri, Cristina, 120Pfahl, Kyle William, 139Phillips, Robert A., 88, 101, 125, 167Pietri, P., 87Piller, Linda B., 67, 167Pittaras, Andreas, 121, 150Pitt, B., 77, 112, 113, 128, 150Pitt, Bertram, 54, 57, 167206

Author IndexPittaras, Andreas, 149Plato, Craig, 109Pocognoli, Antonella, 116Poggi, Alessandra, 147Pohl, Marc A., 128Pointer, Mildred A., 134Polak, Joseph, 119Pollin, Irene, 149Polonia, Jorge, 87, 140Popolo, Mario Del, 151, 152Popov, Sergej, 86Poulimenos, Leonidas, 149Prat, Lorenzo Iogna, 146Preti, Paola, 78, 109, 136Previti, Antonio, 133Prieto, Minolfa C., 133Protogerou, Athanase, 131, 153Providência, Luis A., 155Psianou, Konstantia, 137Pujara, Kuntal, 112Pu, Jun, 133Punzi, Henry A., 159Purkayastha, D., 106, 107, 110, 114,128, 158Pushilin, Sergei, 120QQian, C., 159Qian, Chunlin, 130, 137, 138, 144Queiroz, Vinícius de Souza, 134Quintela, Arturo González, 149Qvarnström, Miriam, 151RRabbia, Franco, 139Rafey, Mohammed A., 128Raggi, Paolo, 148Rahman, Mahboob, 67, 167Rahman, Syed T., 157Raij, Leopoldo, 61, 66, 167Rajagopalan, Sanjay, 157Rajagopal, Desikan, 157Rajzbaum, Gerald, 153Rakugi, Hiromi, 135Ramaswamy, Krishnan, 113Ramírez, Juan Pablo López, 148Ram, Venkata, 113Ram, Venkata S., 137, 145Rands, Vicky F., 133Rao, Fangwen, 83Rappelli, Alessandro, 133Rappelli, Allessandro, 76Rasgon, Scott A., 151Rebelo, Irene J., 138Redón, Josep, 145Reiermann, Stefanie, 147Reiner, Ed, 113Renner, Travis, 156Rey-Meier, M. A., 119Richardson, Carrie, 156Richart, Tom, 117, 135, 145Ricks, Z., 114Rios, Amelia, 155Rios, Maria T., 131Rivera, Juan, 121, 148Ram, C. Venkata, 80Ram, C. Venkata S., 66, 71, 91, 167Rappelli, Alessandro, 116, 132, 137,154Reisin, Efrain, 74, 167Riccobene, Raffaella, 146Roberti, Laura, 154Roccella, Edward J., 65, 167Rocha, Ricardo, 111Rodeheffer, Richard J., 94, 148Rodrigues, Dina T., 155Rodriguez, Arantxa, 109, 135, 156Rodriguez, Gloria, 156Rohatagi, Shashank, 108Rollins-Hairston, Aisha, 134Roman, Mary J., 89, 167Romero, Jorge, 60, 88, 110Romero, Luisa, 78, 111, 112, 113Romero, María Luisa, 88, 126Romero-Miguez, Maria L., 116Rosei, Claudia Agabiti, 84, 119, 140Rosei, Enrico Agabiti, 84, 119, 140Rosendorff, Clive, 71, 167Rosenthal, Talma, 115Roussias, Leonidas, 132Roussos, D., 120, 147Ruan, Litao, 125Rubino, Joseph, 110Rughani, Govind, 122Ruilope, Luis M., 149Ruilope, Luis Miguel, 149Ruiz, Santiago Garcia, 107, 108Rumberger, John, 148Rumpelt, Patricia, 158Rusak, Eduardo J., 146SSabán-Ruiz, Jose, 156Sabuhi, Rifat, 159Sachson, Richard A., 137, 144, 145Saban-Ruiz, Jose, 109, 135, 156Safar, Michel E., 153Saikumar, Jagannath, 82Sakamoto, Daisuke, 117Sakuragi, Satoru, 117Sala, Jose P., 116, 126, 135Salazar, Daniel E., 108Salciccioli, Louis, 116, 117, 120Saldaña, Manuel Aguilera, 107, 108Salgado, Cláudia M., 124Salgado, Jose L., 131Salvadeo, Sibilla, 136Salvetti, Guido, 76Salvetti, Massimo, 84, 119, 140Samad, Zahid, 125Sammour, Rami, 153Sampson, U., 125Samuel, Preethi, 159Samuel, R., 77, 110, 112, 113, 128,150, 158Sanada, Hironobu, 151Sanada, Kiyoshi, 116Sanchez, Fabio, 86Sanchez, Luis, 95, 145Sanchez, Olivia, 109Sanchís, Carlos, 139Sandberg, Kathryn, 54, 167Sandrim, Valeria, 94Sandu, Oana, 95Sangaralingham, S. Jeson, 86Santini, Ferruccio, 76Santos, Mafalda, 149207

Author IndexSantos, Rosa M., 138, 154Sarac, Erdal, 113Sarangapani, Ramesh, 115Sarzani, Riccardo, 76, 116, 132, 133,137, 154Saunders, E., 144Saunders, Elijah, 78, 152, 159, 167Savary, Isabelle, 130Savola, Heljä, 136Savopoulos, Christos, 137, 150, 154Saxena, Naveen, 122Schmid, Dorothee, 116Schnackel, William, 82Schnitzer, T., 78Schnitzer, Thomas, 124Schreiber, Jr., Martin J., 128Schuster, Richard, 83Scott, Kathryn, 153Sechi, Leonardo A., 120, 146Segers, Patrick, 135Segura, Julian, 149Seifu, Y., 77, 112, 113, 128, 150Seijo, Marta Pena, 113Seog, Hong Seog, 160Seredyuk, NestorMyckolayovych, 133Sergienco, Ruslan, 140Shabtay, Zehava, 138Shafton, Asher, 156Shahawy, Mahfouz El, 150Shaheen, Iffat, 110Shan, Peiren, 133Sharabi, Yehonatan, 138, 147Shargorodsky, Marina, 87, 118Sharma, Arya M., 91, 167Shaw, Leslee, 148Shaya, Fadia T., 152Shaya, Gabriel E., 136Shechter, Michael, 147Sheiner, Eyal, 140Shemesh, Joseph, 88Sheng, Chang-Sheng, 117Sheremeta, Oleg M., 135Shi, Jiaxiao M., 151Shimada, Kazuyuki, 84, 109, 124,129Shindo, Nobuyasu, 135Shinoda, Masahiro, 117Shoham, David, 148Shojaee, A., 159Shojaee, Ali, 130, 145Shrive, Nigel G., 120Sica, D., 94, 144, 145, 146Sica, Domenic, 142Sica, Domenic A., 73, 75, 95, 97, 116,145, 167Sierra, Alejandro de la, 137, 149Sierra, Cristina, 111, 112, 113Sierra, Martha Cabrera, 149Silva-Carvalho, Joao, 140Silva, Egle R., 152Silva, Jose A., 87, 140Silveira, Angela M., 86Sim, John J., 151Simmons, Debbie, 83Simons, Rob, 113Sineiro, Elvira, 131Singh, Kanwar, 72, 75, 167Skrypnik, Nadia V., 137Smith, David H. G., 144Smith, William, 139Smutko, Victoria, 76Soardo, Giorgio, 146Soboleva, Galina M., 107Sole, Ricardo M. Cabrera, 107, 108Soler, Rita, 129, 131, 143Solomon, Henry A., 83Solomon, Scott D., 97, 167Song, SaeHeum, 108Sos, Thomas A., 72, 75Souridis, Vasilios, 118Sovtus, Volodymyra I., 113Sowers, J., 77, 112, 114, 128, 150Sowers, James, 113Sowers, James R., 54, 167Spanos, P., 87Sperl-Hillen, JoAnn M., 131Srinivasan, Sathanur R., 125Srivastava, Vinita, 122Srojidinova, NigoraZaynutdinovna, 135Staessen, Jan A., 117, 135, 145Stassaldi, Deborah, 119Stefanadis, C., 84, 86, 87, 118, 120,142, 147Stefanadis, Christodoulos, 82Steigerwalt, Susan, 138Stell, Lance K., 56, 168Stepanavage, Michael, 110Stergiou, George S., 131, 132Stoakes, Kathy A., 137, 138, 145Stojanov, Vesna, 155Stojanov, Vesna V. S., 129Stone, Neil J., 87, 92, 168Stossel, Thomas P., 56, 168Strazzullo, Pasquale, 76, 133Strollo, Jr., Patrick J., 102Strollo, Patrick J., 168Struijker-Boudier, Harry A., 135Sturgeon, Kathleen, 147Sturgeon, Kathleen M., 133Suarez, Daniel H, 158Suarez, Daniel H., 158Suárez, Fernando, 151, 152Sundström, Anders, 151Suryadevara, Ramya, 110Sugimoto, Ken, 135Suwelack, Barbara, 147Suzuki, Hideyuki, 117Svintsova, Galina, 138Syrseloudis, D., 86Syvänen, Ann-Christine, 86Szalai, Alexander J., 156Szpuner, Susanna, 138TTabata, Izumi, 116Taddei, Stefano, 106Taler, Sandra J., 72, 168Tanus-Santos, Jose, 94Taroni, Giorgio, 130Tatsis, H., 120Taylor, Addison A., 100, 168Tehrani, Mohammad RezaMohajeri, 152, 155208

Author IndexTello, Susana, 109, 135, 156Teresa, Rodrigues, 149Testa, Elisa, 139Textor, Stephen C., 54, 62, 168Thacker, Hemant, 158Thangavel, Jayakumar, 60, 82Thibodeaux, Harold, 156Thijs, Lutgarde, 117, 135, 145Thomopoulos, C., 84, 86, 147Tiago, Pedro, 140Tighe, Dennis A., 125Tiwana, Simrandeep K., 131Tobian, Louis, 156Toland, Edward J., 82Tolbert, Shanita, 132Tomizawa, Hidenori, 84Toprak, Ahmet, 125Tornese, Francesca, 133Torre, Nuria de la, 109, 135, 156Totaro, Silvia, 139Toth, Phillip, 111Tousoulis, D., 86Touyz, Rhian M., 59, 76, 100, 168Townsend, Raymond R., 54, 73, 75,77, 89, 158, 168Trappe, Lena, 147Triantafyllidi, Helen, 118, 122Trivedi, Dyuti, 125Trivilou, Paraskevi, 118, 122Tsiachris, D., 120Tsiamis, E., 120Tsioufis, C., 84, 86, 120, 147Tsioufis, Costas, 120, 142Tsuchihashi, Takuya, 112, 139Tuck, Michael L., 76Tyberg, John V., 120Tzamou, V., 87, 118, 142Tziomalos, Konstantinos, 137, 154Tziomalos, Kostas, 150Tzortzis, Stavros, 118, 122UUddin, Molla, 112Uehara, Ritei, 139Ugalde, Arturo, 135, 156Umer, Muhammed, 116, 117Umnikova, Marina, 138Umpierrez, Guillermo E., 111Ungar, Andrea, 121Urbina, Elaine, 155Uribarri, Jaime, 95VVaccaro, Francesco, 146Vagelos, P. Roy, 83, 168Vaidya, Anand, 154Vakaliuk, Igor Petrovich, 135Vakalyuk, Iryna Igorivna, 135Valeri, Marica, 120Vargas-Robles, Hilda, 155Varis, Juha, 136Varma, Deepti, 147Varona, Jose F., 137Varounis, Christos, 118Vassiliadou, Carmen, 82Vazquez, Sonia T., 146Veerabhadrappa, Praveen, 133, 147Veglio, Franco, 139Venkatesan, Bhuvaneshwasi, 116,117Ventura, Hector O., 74, 168Verde, Ignácio, 144Vergani, Barbara, 147Vesalainen, Risto, 136Viana, Jackeline Karoline Brito, 124Viera, Anthony J., 116Villasmil, Jose J., 152Vinisko, Richard, 159Vlachopoulos, C., 118Vlachopoulos, Charalambos, 82,89, 168Vyssoulis, G., 87, 118, 142WWågsäter, Dick, 86Wahi, Jessica E., 111Wakefield, D., 122Wakefield, Dorothy, 130Wang, Antonia, 108Wang, Hongyu, 98, 168Wang, Jian, 125Wang, Ji-Guang, 117Wang, Jiun-Jr, 120Wang, Thomas J., 82Wang, Xiaoyan, 135Wang, Xioayan, 76Wang, Yun, 149Watanabe, Shaw, 88Watanabe, Tsuyoshi, 151Watson, Ralph E., 156, 157Watts, Stephanie W., 156Waverczak, W., 159Weaver, Bessie M. B., 159Webb, R. Clinton, 59Weber, M., 159Weber, M. A., 78, 94, 144, 145, 146Weber, Michael, 94, 142Weber, Michael A., 54, 56, 61, 168Weder, Alan, 139Weder, Alan B., 77Weinberger, M., 106, 107, 110Weinberger, Myron, 114Weinberger, Myron H., 60, 168Weintraub, H., 110, 128Weintraub, Howard, 68, 102, 168Weir, M., 159Weiss, Awraham, 88Weitzman, Richard, 105Wettermark, Björn, 151Whaley-Connell, Adam, 114Whelton, Andrew, 61White, W. B., 78, 94, 122, 144, 145,146White, William B., 62, 73, 124, 130,142, 168Wiesel, Joseph, 158Wijesuriya, Janake, 76Wilcox, Christopher S., 76, 169Wilkinson, Ian B., 119Williams, Bryan, 115Williams, David, 151, 152Williams, Gordon H., 102, 169Williams, Jonathan S., 148, 154Williamson, Sheara, 133Williamson, Sheara T., 147Wilson, Peter F., 101, 169209

Author IndexWithers, Sarah, 157Wiznitzer, Arnon, 140Wogen, Jennifer, 83Wolak, Talya, 140Wolfson, L., 122Wolfson, Leslie, 130Wolfson, Ninel, 118Wong, Ken, 152Wong, Nathan D., 152Woolson, Robert F., 149, 150Wright, M., 115Wright, Melanie, 105, 106, 108Wright, Richard, 158XXaplanteris, Panagiotis, 82Xing, Dongqi, 142, 156YYadao, A., 114, 115, 158Yadao, Anthony, 158Yakovlev, Sergey A., 107Yamamoto, Kenta, 116Yancy, Clyde W., 54, 169Yang, Qinglin, 142Yang, Yu, 76Yan, Xia, 152Yarows, Steven A., 62, 115, 132, 169Yasumura, Seiji, 151Yatsyshyn, Natalya G., 115Yatsyshyn, Roman I., 115Yen, Joseph, 155Yerga-Woolwine, Shane, 60, 82Yokokawa, Hirohide, 151Younis, Firas M., 115Yow, Angie, 116Yuan, Ancai, 133Yu, Cecile, 156Yu, Jin, 135Yurkovic, Carol, 105ZZacker, Christopher, 83Zakariaei, Robin, 117Zambianchi, Sergio, 151, 152Zanchetti, Alberto, 94, 149Zappe, D., 110, 128Zappe, D. H., 109Zappe, Dion, 94, 109Zappe, Dion H., 119Zarrinkoub, Ramin, 151Zerebeckyj, Mykolai, 109Zervopoulos, Georgios, 137Zhang, J., 115Zhang, Jack, 107, 108, 112Zhang, Yanrong, 76Zhang, Yi-Fei, 117Zhan, Wei-Wei, 117Zhang, Yi, 153Zhao, Yumin, 149, 150Zhong, Wei, 137Zhou, Ning, 133Zhu, Ying, 117Zimlichman, Reuven, 87, 118Zoppi, Annalisa, 136Zucker, Irving H., 76210

Hilton New York Floor PlansSecond Floor211

Hilton New York Floor PlansThrid Floor212

Hilton New York Floor PlansFourth Floor Concourse213

Notes214

Are You 1in 3?Get the facts. Know your risks. Help spread the word byvisiting 1in3people.comAs per the National Health and Nutrition Examination Survey,33% of U.S. adults suffers from high blood pressure.